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Abstract 
Understanding the structural, dynamical and energetic basis of protein-protein 
interactions (PPIs) is key for a number of research disciplines. Predicting which sites in 
PPIs show potential for modulation with binding free energy (∆G) calculations allows 
experimental work to be targeted and inhibitors to be rationally designed. However, 
PPIs remain a challenging target for computational free energy calculations due to their 
large and complex interfaces. 
A number of different methods for predicting ∆G from molecular dynamics simulations 
have been developed, yet each suffers from unique problems in its potential for 
widespread implementation across PPIs. This thesis initially evaluates the efficacy of the 
existing MM-PB/GBSA free energy calculation techniques and notes a niche for the 
improvement of the methods’ predictive power. This is followed by the development of 
a new computational method for predicting the effects of any PPI interface mutation, 
which we term Mutational Locally Enhanced Sampling (MULES). 
MULES generates atomistic molecular dynamics trajectories of native and mutant 
protein complexes simultaneously. These trajectories are then used to calculate relative 
binding free energies (∆∆G) between the two complexes, investigating both structural 
and energetic effects of individual amino acids at an interface. In principle MULES allows 
the effect of any mutation to be calculated. Initially tested against a prototypical set of 
mutations with experimentally measured ∆∆G, MULES showed significantly improved 
accuracy in ∆∆G prediction and high precision and speed compared to existing methods. 
The approach was further validated on a large and diverse dataset of approximately 60 
individual mutations, comparing results to experimental data and other computational 
predictions. Validation provided additional evidence for the improved accuracy, 
precision, speed and particularly versatility of the technique, but also identified areas 
for improvement. The successes and limitations of MULES discovered here will be of 
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interest to the protein design, drug discovery and computational chemical biology 
communities. 
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1 Protein-protein interactions 
1.1 Roles in the cell 
Proteins are the molecular machines of our cells, designed individually to carry out 
countless unique tasks and for the regulation of countless unique biological processes at 
sub-cellular levels. To carry out these tasks individual proteins often come together and 
form complexes as part of the regulatory process or mechanism. These complexes may 
be homo- or heterodimers, -trimers or higher order multimers, proceeding all the way 
to huge macromolecular complexes such as the ribosome, consisting of 79 individual 
protein units.1, 2 
Protein-protein interactions (PPIs) are therefore ubiquitous in biology and crucial for 
almost every cellular process. Determining the overall number of PPIs in humans 
remains a challenging goal3 and estimates of the scale of the interactome vary, but are 
consistently on the order of hundreds of thousands of individual binary associations.4, 5 
The sheer number and breadth of interactions mean that PPIs are of interest across 
research disciplines, and determining interaction sites, mechanisms and strengths is of 
importance for the understanding of basic biological processes and disease pathways 
alike. 
This study describes the development and evaluation of computational methods for 
investigating protein-protein interfaces in atomistic detail. For the reader to better 
understand the context of this research, this chapter provides an introduction to the 
field of PPIs as a whole. Sections will cover the identification and detection of PPIs, their 
classification and key characteristics, and how these characteristics have posed 
problems for the ultimate aim of much PPI research - drug discovery and development. 
The chapter will also include a discussion of the potential of protein interaction design, 
which has been the objective of many of the computational methods developed over the 
past decade and is of clear relevance for our novel method introduced in later chapters. 
Firstly however, the broad importance of PPIs across biology cannot be emphasised 
enough. The following section introduces some of the diverse roles of PPIs and 
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highlights some with particular relevance for the mechanisms of human health and 
disease. 
1.1.1 Involvement in cellular processes 
As already mentioned, the ribosome is one of the largest examples of a multi-unit 
complex controlled by the cooperative interactions of proteins and shows that PPIs play 
a key part in the fundamental process of translation and protein synthesis. However, 
PPIs are also found in equally important cellular processes but in much smaller 
complexes, often simply between two individual protein partners. It is the specificity 
and high affinity of these interactions that make some PPIs targets for drug discovery. 
Some roles of PPIs are exemplified below. 
1.1.1.1 Signal transduction 
The process of mediating a signal from the outside of a cell to the inside, inducing a 
response, is known as signal transduction. Extracellular signals can start or stop a 
variety of intracellular signalling pathways, inducing many different responses in a cell.1 
Misregulation of these signalling pathways is the cause of numerous diseases including 
cancers, diabetes, asthma and neurodegenerative disorders amongst others.6-9 They are 
therefore often key targets for drug discovery. 
G-protein coupled receptors (GPCRs) are transmembrane proteins involved in signal 
transduction that comprise the largest superfamily of proteins in the human genome 
and are targets for up to 40% of all successfully marketed drugs.10 Their signalling 
mechanism involves a change in conformation on binding to an extracellular signalling 
molecule, which induces binding to an intracellular G-protein, which in turn activates an 
intracellular signalling cascade. PPIs are involved in this process at every stage - many 
neurotransmitters and hormones are peptides or proteins, the G-protein coupling to the 
receptor after conformational changes is a classic example of a PPI, and the downstream 
signals may be further modulated by separate interactions with other proteins.11, 12. All 
points provide potential opportunities for drug discovery, although some have seen 
more success than others. 
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1.1.1.2 Immune response 
Antibody/antigen interactions are the basis of molecular recognition in our immune 
response systems. Protein antibody families have similar structures but are required to 
bind specifically to unique protein antigens. The specific, high-affinity nature of these 
PPIs tags foreign proteins for removal as part of our immune response system, but has 
also been manipulated for research and therapeutic uses - indeed, the ‘gold standard’ 
method for biochemically determining partners in protein-protein interactions is 
through co-immunoprecipitation. Given a known protein partner and a known antibody 
specific to that partner, the whole complex can be isolated and purified from a mixture 
in order to identify the second, as yet unknown, partner with further immunoblotting.1, 
13 
Determining the molecular basis of antibody/antigen interactions is important if the 
design of new or improved functionality is required. Whether this design is performed 
in vitro14 or in silico,15 a detailed knowledge of the interface location, structure and 
dynamics is a useful tool for the design process. 
1.1.1.3 Enzyme/inhibitor interactions 
Enzymes catalyse specific chemical reactions and may act on either small molecule 
ligands or macromolecules such as proteins or nucleic acid chains. In both cases, their 
action may be regulated through the presence of complementary inhibitors, which again 
may be ligand-like or large and proteinic in nature. Numerous examples of these 
proteinic enzyme/inhibitor complexes exist and play significant regulatory roles in 
humans and other organisms. 
The function of many enzymes, such as proteases or ribonucleases, would be so 
destructive if left unregulated that their inhibitors must reliably stop all enzyme activity 
if and when desired. As an example of how this is achieved, the bacterial ribonuclease 
barnase interacts with its complementary inhibitor barstar with one of the strongest 
(i.e. highest affinity) PPIs known.16 Likewise, a similar ribonuclease/inhibitor PPI 
system in humans has similarly tight binding, demonstrating the importance of these 
regulatory mechanisms across organisms.17 
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Additionally, some inhibitors, such as those of proteases, must be resistant to 
degradation by the enzymes they inhibit or those in their surroundings. The cyclotides, 
for example, are a family of cyclic miniproteins with well-defined ‘cysteine-knot’ 
topologies.18, 19 Their rigid structure, cyclic peptide backbone and multiple disulfide 
linkages provide resistance to hydrolysis but have also provoked their investigation as 
scaffolds for designing new specificity and affinity, or in drug development.20-22 
The roles of PPIs discussed above are by no means exhaustive and merely provide a 
selection of the reasons why PPIs are the focus of research, and some of their potential 
uses in investigating the mechanisms of health and disease and in developing new 
therapeutics. Before any in-depth evaluation of this potential however, the first stages of 
investigating any PPI are the identification and characterisation of the interacting 
partners and, ideally, of the interface between them. Some possible techniques for this 
are explored below. 
1.1.2 Methods of PPI detection 
As mentioned above, co-immunoprecipitation remains the most reliable way of 
verifying a PPI if one of the interaction partners is already known. For large scale 
screening purposes however, other methods are more appropriate. Phage display, first 
described by Smith in 1985,23 is one such technique that has become commonplace in 
PPI screening.24, 25 
Briefly, phage display allows the synthesis and display of a library of proteins on the 
surface of bacteriophages, using additions to the DNA of the phage itself. The displayed 
proteins (and attached phages) are then allowed to interact with a target protein 
immobilised on a surface. The protein partners that interact remain attached to the 
surface after washing, and after further rounds of enrichment and purification the DNA 
of the bound phages is sequenced, allowing the determination of the sequence of the 
protein partners. In this way, a large number of random protein sequences displayed on 
the surface of phages can be quickly screened for some level of binding activity to a 
target protein, identifying possible PPIs.24 
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A second experimental approach is the yeast two-hybrid assay.26 In this case, successful 
PPIs are determined by the activation of a reporter gene in yeast. Successful activation is 
determined by a change in the yeast cell’s phenotype - if the reporter gene is crucial for 
survival then the only cells that survive are those in which a successful PPI has been 
formed. If libraries of random protein sequences are used as one of the potential 
partners then this selection of live yeast cells allows the identification of novel protein 
partners to the other, known, protein. 
These experimental methods rely on the selection of individual PPIs from a large library 
of potential interactions, and their success therefore depends on the size and 
composition of the library. They also provide little information on the identified 
interactions themselves beyond the sequence of the interacting partners. Further 
studies on the identified PPIs would be carried out if structural or dynamical 
information were required. 
Computational techniques may also be used for the prediction and investigation of PPIs. 
Bioinformatics methods for predicting interactions, even based simply on sequence 
information, have been developed and used for over a decade but vary in their accuracy 
and usefulness.27-29 Computational docking studies using structural information are also 
available and have been consistently and repeatedly assessed in the ongoing CAPRI 
(Critical Assessment of the Prediction of Interactions) process for the past decade.30-32 In 
the absence of experimental X-ray crystallography or NMR structures of a complex, 
protein-protein docking provides an alternative method of obtaining structural 
information on the PPI interface. Knowledge of the site and structure of the protein 
interface allows further, more in-depth analysis of the binding interactions and 
mechanism. 
1.1.3 Methods of PPI analysis 
Having determined that two protein partners form a complex, the next stages in the 
analysis of a PPI may be the determination of where they interact and what precisely 
makes them interact. Many of the predominant forms of PPI analysis therefore revolve 
around the measurement of the binding free energy of the interaction. The binding free 
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energy, ∆G, is related to the equilibrium dissociation constant of the interaction, KD, the 
inverse of the association constant, by the following equation: 
            ( 1-1 ) 
Both KD and ∆G are measurements of the affinity of the protein partners for each other 
and are determined by the interactions of the residues at the interface. Understanding 
the binding free energies of PPIs, combined with structural data, provides valuable 
atomistic-level information for determining novel drug targets or molecular 
mechanisms. Either KD or ∆G of interactions can be measured directly using a number of 
different techniques. 
For example, Surface Plasmon Resonance (SPR) can be used to determine the 
adsorption of molecules to a surface. It is highly sensitive to small changes in adsorbed 
mass, such as the change upon complexation of two protein partners to one another. By 
immobilising one protein to a surface and passing a second partner protein across the 
same surface, the association and dissociation rate constants and association and 
dissociation equilibrium constants for the interaction can all be determined 
independently.33 SPR has been widely used for the study of many protein-protein and 
protein-ligand interactions as it provides both thermodynamic and kinetic data for the 
interaction under investigation.34-36 
Isothermal titration calorimetry (ITC), an alternative technique, is a highly quantitative 
method of determining the heat evolved when a ligand binds to its protein partner. It 
allows the determination of the equilibrium association constant, stoichiometry and 
enthalpy of binding (∆H) for the PPI under investigation.37 Since          , the 
entropic contribution to binding, ∆S, can also be extracted separately from ITC 
experiments, giving further information on mechanisms of binding and allowing 
comparison between different PPIs, including, with careful experiment design, the 
extent of enthalpy/entropy compensation for related ligands.38 Again, ITC remains a 
widely used experimental technique for measuring binding free energies of 
protein-protein and protein-ligand interactions with a high degree of accuracy and 
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precision, and is often used to validate computational predictions.39-41 Many 
computational approaches may also be used to investigate PPIs, and the evaluation and 
improvement of one of these approaches, the use of molecular dynamics simulations, is 
the focus of this study. However, given the importance of a full evaluation of available 
computational methods, these are discussed separately in chapter 2. 
The methods outlined above represent only a small selection of available techniques for 
identifying and investigating PPIs but have been amongst the most widely used. The 
thorough study of protein interfaces over the past 20 years has resulted in the 
identification of numerous properties and trends that have come to define PPIs. These 
will be examined in the following section. 
1.2 Key characteristics 
1.2.1 Interface size and type 
Although part of the reason for the advance of research focus on protein-protein 
interactions has been the development of novel investigatory techniques such as those 
outlined above, there has also been a renewed focus on PPIs as drug targets due to their 
role in a number of human diseases.42-44 Small molecule drugs have traditionally 
targeted protein-ligand interactions such as enzyme active sites, with tight, deep 
binding pockets. 
Protein-protein interfaces have been found to share a number of characteristics, many 
of which differ from those desirable for protein-small molecule interactions.45, 46 In 
terms of size, PPIs bury an interface area of 1000 - 1600 Å2 on average, far larger than 
the average of 300 - 1000 Å2 determined for protein-ligand interactions.45 Likewise, in 
contrast to the traditional model of small molecules (such as enzyme-substrate 
interactions) binding to proteins within deep, solvent excluded pockets with specific 
electrostatic or covalent interactions, PPI interfaces are broad, shallow, have 
hydrophobicity intermediate between that of the surface and buried domains and 
average between 0.7 - 1.4 hydrogen bonds per 100 Å2 of interface.45, 46 
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Residue frequencies at interfaces also vary from those found in whole proteins. Multiple 
studies comparing the propensity of individual amino acids to be found at interfaces 
compared to the rest of the protein have found that large, hydrophobic and aromatic 
residues such as tryptophan, phenylalanine and tyrosine are overrepresented at 
interfaces, while small, often polar residues such as serine, threonine, alanine and 
glycine are particularly underrepresented.47-49 Larger interfaces tend to have more 
hydrophobic residue-residue contacts, while smaller tend towards the polar or charged 
interfaces of protein-ligand interactions,50 suggesting that the hydrophobic effect plays 
an important role in protein complexation as it does in protein folding. Equally, each 
individual interface type has been linked to unique prospective roles of the PPI, with 
weaker, transient interactions tending to have more polar and planar interfaces and 
with stronger interactions inclined to undergo greater conformational changes on 
complexation and have less planar and occasionally more hydrophobic interfaces.51 
Targetting a full PPI interface with small molecule drugs would therefore be a greatly 
challenging proposition. One potential mechanism for blocking interactions would be to 
target “molecular triggers” or “anchor residues” at PPIs. These are individual, 
structurally conserved residues that provide the starting points for an induced fit 
mechanism of binding for some interactions, reducing the need for greatly unfavourable 
interface rearrangements prior to binding.51, 52 However, more importantly and 
providing a larger range of potential targets, binding strength at PPIs is not uniform 
across the whole interface. Instead, affinity is affected mostly by “hot-spots” of stronger 
interactions, which provide more realistic opportunities for drug discovery. 
1.2.2 Hot-spots 
A “hot-spot”, a term first coined by Clackson and Wells in 1995,53 is a residue or group of 
residues at a protein-protein interface that contributes disproportionately to the 
binding free energy, ∆G, of the complex. Binding of the protein partners as a whole is 
therefore mostly controlled by the presence of hot-spots. Modifying or interfering with 
their interactions is likely to cause a large change in affinity and possibly abolish binding 
entirely. 
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The hot-spot model was very rapidly accepted as being the predominant mechanism of 
PPI binding and many subsequent PPI research projects and drug discovery efforts have 
focussed on determining and modulating hot-spots at interfaces. Just as with PPI 
interfaces as a whole, the propensity of individual amino acid types to be found as 
hot-spot residues is far from random. Generally, large hydrophobic residues are more 
likely to be hot-spots, whereas small, polar or charged ones are less likely to be, but 
there are notable exceptions to this rule.54, 55 Figure 1.1 demonstrates the results of one 
of the first widespread analyses of hot-spot residues by Bogan and Thorn, which 
evaluated the enrichment of amino acid frequencies in hot-spots over and above their 
approximate naturally occurring frequencies in proteins.54 
 
Figure 1.1 – Enrichment of amino acid frequencies in hot-spots compared to in bulk protein, 
created using results of Bogan and Thorn.54 A value of 1 denotes no enrichment, i.e. a residue 
type is equally likely in hot-spots as it is in bulk protein. Values > 1 and < 1 denote enrichment 
and depletion of residue likelihood in hot-spots respectively. No data for alanine residues was 
generated as hot-spots were identified using alanine scanning mutagenesis. 
Tryptophan, tyrosine and arginine residues are significantly overrepresented in 
hot-spots whereas smaller residues such as valine, serine, threonine and cysteine are 
underrepresented. The larger residues have multiple different methods by which they 
can enhance binding, which clearly favours their potential as hot-spots; their size 
promotes solvent exclusion at the hydrophobic interfaces, aromatic sidechains can be 
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involved in π-stacking interactions and charged residues or polar functional groups can 
participate in electrostatic interactions or act as both donors and acceptors for 
hydrogen bonding interactions with complementary residues on the partner protein. 
As well as their large contribution to binding, PPI hot-spots have other characteristics 
that are beneficial for their potential as drug targets.42, 44 In particular, dynamical 
motions of PPIs in some cases allows transient grooves and pockets to open up at the 
interface.56 These transient pockets provide new opportunities for the design of small 
molecule inhibitors,44 and there has been some success in exploiting these dynamical 
changes for inhibitor design in a number of cases.56-59 Beyond this, recent work has 
suggested that identifying hot-spots with conformational flexibility may be a conserved 
mechanism for determining the druggability of a particular interaction site, which could 
improve the efficiency of ligand design and discovery.59 
Identifying hot-spot residues therefore remains an important part of understanding any 
PPI and is particularly important if any manipulation of the interface specificity or 
binding properties is desired. Predicting and determining hot-spots either 
computationally or experimentally is therefore an area of great research interest, 
discussed in further detail in the next section. 
1.2.3 Determining contributions to binding 
We have already seen how and why hot-spots control binding at protein interfaces, but 
have not yet discussed in any detail how the contribution of any individual residue to 
binding can be quantified. Experimentally, and often (but not always) computationally, 
this is done via alanine scanning mutagenesis (ASM). ASM mutates each interfacial 
residue individually to alanine and measures the effect of the mutation on binding free 
energy of the complex, conceptually measuring the energetic contribution of each 
residue interface separately to compare their importance. The idea of these relative 
binding free energies on mutation to alanine, ∆∆G, is discussed further in section 2.2.1. 
Alanine is one of the simplest naturally occurring amino acids, with a sidechain 
consisting of a single methyl group. The small, apolar nature of this sidechain means that 
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alanine is considered to have relatively neutral structural and energetic effects. The only 
amino acid with a smaller sidechain, glycine, introduces flexibility in protein structures 
and so changes in free energy on glycine mutation may include undesired artefacts of 
structural rearrangements too. 
The concept of ASM was introduced during early investigations of protein-protein 
interfaces60 but has since been widely extended to become a standard technique for 
measuring and comparing residue effects at protein interfaces. High throughput 
methodologies for scanning large interfaces and families of proteins have been 
developed,61-63 and databases of thousands of individual mutations collated.54, 64-67 
Computational predictive methodologies have also been developed for identifying 
hot-spots, with the aim of directing experimental work towards the most interesting or 
important residues. The accuracy and computational expense of these methods varies 
greatly, with the quickest approaches using only sequence or structural information and 
empirically determined features to identify probable hot-spot sites.68-71 Slightly more 
computationally costly are the popular Rosetta protein design software suite and online 
Robetta alanine scanning server, which both use empirically weighted energy functions 
and single sets of complex structural coordinates, for example from X-ray crystal 
structures.72 Finally, the most expensive methods use fully physical energy functions 
and dynamical information from simulations to evaluate ∆∆G values for the required 
mutations. 
The evaluation and development of the latter computational approaches has been the 
focus of the study presented here. The theoretical background and reviews of the 
successes and failure of these techniques are therefore described in detail in the next 
chapter. However, to conclude the current discussion of the biological relevance of PPIs, 
the final section below discusses potential uses of computational, and experimental, 
methods in developing ways to exploit protein-protein interactions for research or 
therapeutic advantage. 
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1.3 Designing and exploiting PPIs 
1.3.1 Designing PPI modulators 
1.3.1.1 Peptidic molecules 
Given the vast array of important cellular processes they are involved in, it is no 
surprise that there is much research interest in developing ways to interfere with 
protein-protein interactions. This development of modulators is not necessarily 
restricted to traditional small molecule drug discovery. Peptidic inhibitors and high 
affinity probes are also of interest for many interactions and provide alternative routes 
to understanding recognition mechanisms or eventually drug discovery.57, 73 
Because PPI interfaces by definition involve the interaction of proteins, the simplest 
starting point for a potential inhibitor of a target protein is its binding partner. A peptide 
mimic of the sequence and/or structure of one of the partners at a protein interface 
should competitively inhibit the PPI complex. This concept of developing inhibitory 
peptides based on the sequences of the protein partners themselves is now a 
well-established approach that has long been demonstrated with both experimental74, 75 
and computational76, 77 methodologies. 
The peptidic mimic approach comes with two caveats however. Although the majority of 
affinity at an interface is contributed by hot-spot residues, which may be included in the 
copied epitope, residues at the periphery can play important contributory roles in 
determining specificity and cumulatively add to the interaction binding free energy. 
Generating high affinity peptide inhibitors therefore often requires further optimisation 
of residue contacts. Again, this can be done computationally and with identical 
methodology to the initial peptide assessment, such as during the molecular 
dynamics-based study of Liang et al.,77 or experimentally and subsequent to an initial 
rapid screen, as suggested in the Rosetta-based work of London and coworkers.76 
Secondly, the structure of the copied binding epitope may be equally important as its 
sequence and hence binding epitope mimics must usually be displayed on a rigid surface 
of another, larger protein, rather than simply as their short peptide oligomer. This 
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‘grafting’ of the epitope to another protein again requires additional optimisation. 
Computational investigations performing this optimisation have again generally 
focussed on the use of fully physical molecular dynamics-based techniques.77, 78 
Despite these complications, the use of peptidic binding epitope mimics can still provide 
useful starting points for the development of PPI inhibitors. The requirement for 
structure at the interface has also led to the idea of protein ‘scaffolds’: peptides79 or 
small miniproteins80 amenable to easy chemical synthesis and modification, with rigid, 
defined structures and surfaces suitable for protein binding. The surfaces of these 
scaffolds may be modified as wished to probe new binding interactions or specificities 
without the need for time consuming biochemical protein synthesis.81 The cyclotides, 
mentioned first in section 1.1.1.3, are one such family of proteins that have successfully 
been redesigned to show new specificities and activities.19, 22, 80 
Given that the sole purpose of scaffolds, and in fact of PPI inhibitors generally, is to 
present residue functional groups and structural motifs to the target protein, there is no 
reason why the scaffold must be peptidic in nature. In fact, non-natural molecules may 
be more specific and more resistant to proteolysis than their natural counterparts; 
properties that are particularly advantageous for drug discovery. There has therefore 
also been much interest in the use of modified peptides and peptidomimetics as PPI 
inhibitors. 
1.3.1.2 Peptidomimetic molecules 
Stabilising the secondary structure motifs of small oligopeptides can be achieved in 
many different ways synthetically, without grafting the sequence to a protein scaffold.82, 
83 The synthetic methods used depend mainly on the secondary structure required. 
α-helices, for example, may be ‘stapled’ by crosslinking residue sidechains on the same 
face of the helix (the i, i+4 and i+7 residue positions) to force the peptide into a helical 
conformation. Non-natural amino acids may be used to achieve the same result. Both 
methods have been successfully used to generate highly potent inhibitors of greatly 
functionally relevant interactions.84-86 Similar methods also exist for the stabilisation of 
ß-sheet and ß-turn structures.87 
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The stabilisation of existing secondary structure has two main advantages. Firstly, the 
pre-organisation of conformation reduces the entropic penalty of binding and so can 
result in peptides of higher affinity than their unstabilised counterparts. Secondly, the 
use of non-natural residues and covalent linkages between sidechains reduces the 
susceptibility of the peptides to proteolysis, an important consideration for studies in 
vivo.84 
Beyond the adaptation of peptides, the use of peptidomimetics, small molecules 
designed to display the key functional groups of the desired peptide in the correct 
conformation, has also been widely investigated.83 Again, α-helical mimetics have seen 
the most widespread developments, in particular by Hamilton and coworkers, and 
multiple potential small molecule scaffolds for helices now exist.88-90 Nevertheless, 
mimetics of other structural motifs have also been developed, including macromolecules 
designed to mimic entire surfaces.91, 92 
It should be noted that the approaches detailed above focus on the direct inhibition of 
the protein-protein interaction by blocking of the interface completely or in part. 
Allosteric inhibitors of PPIs, which inhibit interactions indirectly by changing structure 
or dynamics of the interfacial region, preventing binding, are not discussed. Although 
allostery is clearly an important mode of action for many inhibitors,43 it remains difficult 
to predict or design using conmputational free energy calculations such as those 
described here. 
Nevertheless, clearly there is much scope for computational modelling to aid the 
development of PPI modulators, from determining the initial hot-spots and binding 
mechanism of the interface through to rationally designing new peptidomimetic 
inhibitors. The usefulness of many techniques for the latter is hindered by the focus of 
the majority of models on the interactions of proteins and specifically the 20 naturally 
occurring amino acids. Many techniques were simply not designed to handle small 
molecule interactions or non-natural sidechains, although there are increasing efforts to 
broaden the functionality of simulations, particularly for the more computationally 
expensive dynamics-based methods.93 However, the faster, more empirical approaches 
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such as Rosetta have still seen successes in the design of entirely new protein-protein 
interactions using only natural amino acids. 
1.3.2 Designing new PPIs 
Protein-protein interaction design can refer to a number of different research 
objectives, of differing complexity. Firstly, existing interfaces may be optimised to 
enhance binding affinity. In this case the evaluation of relative binding free energies 
through alanine scanning mutagenesis may point towards residues whose contribution 
to binding is less than might be expected, or even negative, indicating their potential for 
improvement. Secondly, existing interfaces may be designed to show new or broadened 
specificity. This is a more complex proposition, as it involves the positive selection of 
desirable protein interaction states simultaneously to the negative selection against 
undesirable interactions with similar or related proteins.94 
Finally, models may be used to create entirely new protein interfaces where no 
interactions previously existed. The computational design of entirely novel PPIs has 
been a key goal of many labs, but the Baker group and the Rosetta team have been 
predominant in this area for many years.95 Starting with the development of an energy 
function and computational alanine scanning methodology of the Robetta online 
server,96, 97 the functionality of the Rosetta suite of software has been broadened over 
many years. Success in redesigning PPI specificity followed,98 before very recent 
successes in the design of entirely new protein binding partners for an existing protein99 
and in the design of a novel protein binding pair.100 
Despite these impressive successes, the dream of individual researchers being able to 
computationally design and redesign high affinity, specific PPIs at will has not yet 
become a reality. In particular, it should be noted that the Rosetta computational PPI 
design protocol has so far only generated potential leads for novel interactions. These 
leads have then been followed by extensive experimental optimisation in order to create 
the final, high affinity interfaces seen. This extensive optimisation by no means detracts 
from the achievements of the computational design protocol, which, in the case of the de 
novo binding pair, achieved affinity many orders of magnitude greater than ever 
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designed before.100 However it does mean that PPI design is still a greatly labour 
intensive, time consuming and expensive process, not suitable for all potential 
interactions. New computational methodology may therefore have broader potential 
and greater therapeutic impact if focussed instead on understanding PPI mechanisms 
and designing PPI modulators, as discussed in the previous sections of this chapter. 
1.4 Summary 
This chapter has highlighted the vast importance of PPIs in both health and disease in 
human biology. PPIs have been the subject of much research interest and many 
techniques to investigate them have been developed, both experimental and 
computational in nature. Identifying, understanding, modulating and designing PPIs are 
all targets for research efforts that may be particularly enhanced by the use of 
computational approaches to complement experimental findings. 
Existing simulation methods vary in their computational cost and in the information 
they provide. Methods based on molecular dynamics, the approach developed in this 
study, are amongst the most costly but also most versatile techniques. Despite previous 
successes of existing methods, there is clearly still an unmet need for computational 
investigations of PPIs that are rapid enough for routine use, give accurate enough 
predictions for quantitative agreement with experiment and that can model the 
interactions of peptides, non-natural peptide modifications and peptidomimetic small 
molecules. 
The assessment and development of such a technique is the focus of this study, but first 
requires a discussion of the theoretical background to molecular dynamics, its usage in 
biomolecular simulations and advantages and disadvantages of investigating PPIs with 
molecular dynamics methods. These will be the subject of the next chapter. 
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2 Molecular Dynamics – theory and 
applications 
2.1 Introduction to Molecular Dynamics 
Molecular dynamics (MD) simulations are, at their heart, simply a way of modelling the 
complex physical motions and interactions of molecules. The underlying concepts of MD 
simulations can be applied to any system, chemical or otherwise, of interest – a simple 
internet search will reveal applications across physics, chemistry, the life sciences, 
materials sciences and engineering. Whilst the concepts are uniformly applicable, each 
discipline generally has its own interpretation of how and where MD can be best 
implemented. The focus of this project is on the simulation of biomolecules, particularly 
proteins, and therefore this chapter will deal specifically with MD in the context of its 
usefulness within chemical biology. 
The next few sections will initially explain the theory and process behind simulating 
biomolecular motion with MD, including questions on how the biomolecule and its 
cellular environment may be best represented within a computational model. The idea 
of using MD simulations in free energy calculations will also be explored and explained, 
as this was one of the key aims of the research undertaken. Finally, examples of current 
work in studying PPIs within the MD community will also be given, and the objectives of 
this project in contributing to the area will be highlighted. Throughout, the focus will be 
on an explanation of the current successes and limitations in applying MD to biological 
systems, rather than a theoretical look at the potential of computational simulation. If a 
more detailed explanation of MD in a wider sense is required, the reader is referred to 
Frenkel and Smit’s handbook “Understanding Molecular Simulation”,101 which explains 
the underlying physics and mathematics of many different forms of computational 
simulation in great detail. 
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2.1.1 Simulating motion 
2.1.1.1 Quantum mechanics 
During the late 19th and early 20th centuries, a vast number of experiments changed the 
way in which we understood the world at the atomic level. Observations from double 
slit experiments, the photoelectric effect,102 black body radiation,103 and of electrons 
behaving as waves104 could not be explained with classical Newtonian mechanics. These 
experiments, amongst others, led to the development and confirmation of the ideas of 
quantum theory. Our understanding of the physical sciences changed fundamentally, 
and the development of quantum theory is recognised as one of history’s most 
important scientific achievements, not least by its contribution to the awarding of many 
Nobel prizes. 
The interactions of atoms, and therefore molecules, proteins, cells and whole organisms, 
could in theory be completely described with quantum mechanics (QM). However, as 
early as 1929, Dirac already foresaw the problem with this approach: 
“The underlying physical laws necessary for the mathematical theory of a large part of 
physics and the whole of chemistry are thus completely known, and the difficulty is only 
that the exact application of these laws leads to equations much too complicated to be 
soluble.”105 
This is still true today. Although technology for performing calculations and evaluating 
wavefunctions (the underlying quantum mechanical descriptor of the instantaneous 
state of a molecule) has clearly vastly improved since the early 20th century, quantum 
mechanical calculations are still a hugely intensive task and hence their scope is limited. 
In order to extend this scope as far as possible, the past eighty years has seen the 
development of many different methods for calculating the energies and properties of 
molecules via quantum mechanics. Each of these methods has its own set of inherent 
assumptions and approximations, leading to differences in calculation intensity, speed 
and chemical accuracy. Most are suited to particular applications and not to others. 
Examples of these methods and their relative computational cost are given in table 
2.1.106 
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Table 2.1 – Examples of computational methods currently used to perform quantum mechanical 
calculations and comparison of their formal scaling relative to basis set size. Formal scaling may 
be improved by the use of approximations in certain methods, though these affect accuracy to 
variable extents. 
Technique Formal scalinga ‘Real-world’ scalingb 
Hartree-Fock N4 N - N4 
Density Functional Theory N4 N - N4 
Möller-Plesset Perturbation Theory ≥ N5 N5 - N8 
Configuration Interaction ≥ N5 N6 - N10 
Coupled Cluster ≥ N5 N6 - N10 
a Where N is number of basis functions. b Range of scaling factors for realistically applied 
techniques, which often include approximations to improve speed or require additional 
calculations to improve accuracy 
The size of system that can be realistically investigated with QM methods therefore 
varies greatly. Proteins also vary greatly in size, although are generally on the order of 
thousands of atoms even before accounting for any solvating water molecules or 
ligands. Even the ‘Trp cage’ miniprotein,107 often used as a benchmark in computational 
simulations as one of the smallest proteins with a defined tertiary structure and folding 
pathway, consists of 304 atoms and is out of reach of the more costly methods described 
in table 2.1. 
There is clearly a great interest in the enhancement of computational efficiency of 
existing methods in order to make the evaluation of proteins with QM methods 
tractable. Linear-scaling Density Functional Theory (DFT) approaches may be of future 
potential here, as computational effort scales linearly with the number of atoms 
evaluated rather than cubically or higher as with standard DFT.108 One such technique 
with successful use on biomolecules is ONETEP (Order-N Electronic Total Energy 
Package), developed primarily by Skylaris and coworkers over the past decade.109 It has 
been successfully used to evaluate energies and investigate protein-protein interactions 
across numerous systems, all with sizes in the thousands of atoms.110-112 
However, despite advances in technology and method development, quantum 
mechanical calculations are still effectively only performed on static, single structures of 
biomolecules. If we wish to simulate the dynamics of a protein, following its motion and 
changes in structure, this requires evaluating the energies and interactions of multiple 
sequential structures over a period of time. Quantum mechanical calculations are simply 
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unable to do this, and thus a simpler model of atomic energetics and interactions is 
required. 
2.1.1.2 Molecular mechanics 
Molecular Mechanics (MM) is a method of modelling atomic interactions that 
fundamentally differs to QM. Rather than using quantum mechanics to describe the 
energy and interactions of a system, it makes the approximation that these interactions 
can be fully described by classical Newtonian mechanics. The equations required to 
evaluate energies, interactions and forces on atoms are therefore far simpler than those 
involved in QM, and so MM calculations are many orders of magnitude faster. As such, 
MM can be used to quickly calculate energies of many structural snapshots propagating 
over a period of time. This is the concept of a molecular dynamics simulation. 
In order to study the potential of a protein system with classical mechanics, MM 
calculations represent atoms as charged spheres with appropriate Van der Waals radii 
and make use of the Born-Oppenheimer approximation (that nuclear and electronic 
motion can be considered separately) to neglect the individual contribution of 
electrons.1 These atoms may then have numerous interactions with one another, the 
basic forms of which are described in figure 2.1. 
                                                             
1 Although electrons are not represented directly in MM calculations, their effect on the potential 
is, through charge or polarisability parameters. 
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Figure 2.1 – Schematic representation of the basic forms of interactions in a system modelled 
with molecular mechanics or molecular dynamics. Interactions between atoms are divided into 
bonded (bonds, angles & dihedrals) and non-bonded (electrostatic and Van der Waals) terms. 
Atoms in molecules are assigned a set of parameters to describe the interactions 
between them. For non-bonded interactions each atom is given a fixed point charge to 
describe its electrostatic attraction or repulsion to others and a radius and well depth to 
describe its Van der Waals interactions. Bonds between atoms are represented as 
harmonic oscillators with appropriate equilibrium distances and force constants. Angles 
and dihedrals are similarly represented. To calculate the potential the parameters and 
atomic coordinates are used in an energy function such as that of equation ( 2-1 ). 
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This typical function has five terms corresponding to the five sets of parameters 
proposed in figure 2.1. The first two terms describe bonds and angles with harmonic 
potentials, with force constants k, current length l and angle , and equilibrium 
lengths/angles leq and θeq respectively. The third describes dihedral angles, as they are 
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periodic about the rotation, as a Fourier series with periodicity n, torsion angle ω, offset 
γ and a barrier height of VN. The fourth and fifth terms are combined and correspond to 
a Lennard-Jones potential for non-bonded Van der Waals interactions and a Coulombic 
electrostatics term (charges qi and qj, vacuum permittivity constant 0 and distance 
between charges of rij). 
The set of parameters used to describe atoms is known as the molecular mechanics 
force field. Force fields are parameterised to accurately represent molecules in specific 
environments, thus there are numerous different force fields for use in different 
applications – a force field for proteins will differ to one for carbohydrates, which will 
differ to one for inorganic chemistry, for example. Energy functions may also differ 
between applications and often include additional terms to those above in order to 
account for additional interactions. Within proteins, these terms may include 
parameters for improper torsions for planar functional groups, polarisabilities of atoms 
or explicit terms to describe hydrogen bonding. The Amber software package, used 
throughout this study, also has its own set of associated force fields for biomolecular 
simulations – these are subject to further discussion in section 2.1.3. Further details of 
the connections and information flow between various standard modules of the Amber 
suite of programs (many of which have been used extensively in this research) can be 
found in appendix 1, figure S1. 
2.1.1.3 Molecular dynamics 
With a MM force field and a set of atomic coordinates the potential of the system at an 
initial timepoint can be calculated. For a molecular dynamics simulation we wish to 
follow how the atomic positions, velocities and accelerations change over time. The 
initial forces on the system can be calculated as the negative derivative of the potential 
with respect to position; the initial accelerations of each atom can then also be 
calculated, and the integration of Newton’s laws of motion leads to a trajectory 
describing the variation of the atomic positions, velocities and accelerations with 
respect to time. The integration of Newton’s laws of motion cannot be performed 
analytically for such a complex potential function, but this can be performed numerically 
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with a number of algorithms. Amber uses a variant of the Leapfrog algorithm,113 the 
derivation of which will be described in the next few paragraphs. 
The first step is in recognising that position, velocity and acceleration are all related to 
each other by differentiation: velocity is the first derivative of position with respect to 
time, and acceleration the second derivative with respect to time. It is therefore possible 
to express position, r, as a Taylor series expansion to generate a new set of positions at 
time t + δt. 
 
 (    )   ( )     ( )  
 
 
    ( )  
 
 
    ( )    ( 2-2 ) 
Generating a second Taylor series at the previous set of positions, r(t – δt), gives 
equation ( 2-3 ). 
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Summing the two equations ( 2-2 ) and ( 2-3 ) and neglecting the contributions of terms 
including δt4 or higher (valid for a short enough timestep) gives an expression free of a 
velocity calculation. 
  (    )    ( )   (    )      ( ) ( 2-4 ) 
This is the Verlet algorithm,114 which is also commonly used in MD simulations. The 
Leapfrog algorithm is an adaptation of the Verlet algorithm to explicitly calculate 
velocities, important from both an information perspective and a simulation 
perspective, as velocities can be acted upon by a thermostat to regulate temperature. 
The Leapfrog algorithm equally uses a Taylor expansion to relate position to velocity 
and acceleration, but starts and uses a half timestep, δt/2. 
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As with the Verlet algorithm, repeating the same series half a timestep back gives: 
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Subtracting equation ( 2-6 ) from ( 2-5 ) and neglecting terms of higher order leaves: 
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Therefore positions at time t + δt can be calculated if velocities at the half timestep are 
known. To calculate these, velocities can also be represented by a Taylor series 
expansion as in equation ( 2-8 ). 
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By using a half timestep and an equivalent expansion for half a timestep back (similar to 
equation ( 2-6 )) followed by subtraction of the two series, an expression for 
  (     ⁄ ) is obtained: 
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In this way, the calculated velocities are used to calculate a new set of positions, which 
are used to calculate a new set of velocities and so on. As the positions and velocities are 
calculated at half timestep offsets, the positions are said to ‘leap’ over the velocities, 
followed by the velocities ‘leaping’ over the positions. If velocities at time t are desired, 
they can be simply approximated by linear interpolation between velocities at      ⁄  
and      ⁄ . 
The length of an MD simulation is therefore determined simply by the number of steps 
for which the equations of motion are integrated multiplied by the timestep between 
these steps. For example, calculating a trajectory consisting of a million (106) steps, with 
a timestep of 1 fs (10-15 s) between those steps results in a simulation of the dynamics of 
a protein over 1 ns (10-9 s). However, each step taken requires additional computational 
expense. Therefore, when determining how long a simulation needs to be, or even if MD 
is a suitable simulation technique, there are two main issues that are considered. 
 44 
Firstly, proteins are dynamic across a number of timescales.115 This results from a 
complex energy landscape in which the rate of transition between conformational 
substates is inversely proportional to the barrier height separating them.116 Smaller 
transitions, such as sidechain rotations, occur on shorter timescales, whilst large 
changes, such as domain motions, occur over much longer timescales. Examples of these 
timescales are shown in figure 2.2 (adapted from Henzler-Wildman and Kern115). 
 
Figure 2.2 – Dynamics of proteins across multiple timescales. Whilst standard molecular 
dynamics simulations can access most local conformational changes with smaller barrier heights, 
the majority of larger motions require other techniques in order to be simulated effectively. 
The length of MD simulations is only limited by the technology with which they are 
performed. The past five years has seen multi-microsecond length MD simulations 
become routinely available, whether through the use of commercially available Graphics 
Processing Unit (GPU) hardware,117-119 or through dedicated specialist MD software and 
supercomputing resources.120, 121 These technologies allow MD to access a larger 
number of protein conformational substates and probe a wider range of protein 
dynamics than ever before. Nevertheless, standard MD is still currently limited to the 
microsecond timescale. Dynamics on the longest timescales, such as large domain 
motions or protein folding, are more efficiently investigated with enhanced sampling 
MD approaches,122, 123 to the extent that hundreds of nanoseconds of enhanced sampling 
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MD may provide a similar probing of dynamics to a millisecond of standard 
simulation.124 These enhanced sampling methods generally either apply a bias to the 
overall potential to direct the simulation in a certain fashion, or accelerate the 
transitions between conformational substates. They will be discussed with further 
reference to one method in particular, locally enhanced sampling, in section 4.1.1. 
The concept of sampling is also important when determining the length of a simulation 
for another reason. For a system containing n atoms, 3n values define the coordinates of 
the system and 3n values describe the components of momentum for each atom. A 
combination of 3n positions and 3n momenta therefore describes a single configuration 
of the system. This configuration can be thought of as a point in ‘phase space’, a 6n 
dimensional space that describes all possible configurations of the system. An MD 
trajectory can therefore be said to trace out a path in phase space, with the successive 
configurations generated by the trajectory connected by time. 
In statistical mechanics, average values of free energies, for example, are defined as 
ensemble averages. Ensemble averages are calculated across all possible states of the 
system. To calculate an ensemble average from an MD simulation therefore, the system 
must visit all points in phase space. This is physically impossible - even for the very 
smallest systems the time required to sample every point in phase space would be 
longer than the age of the universe.125 Instead, MD calculates a time average – an 
average of a series of configurations connected by time. 
Because a simulation would visit all points in phase space if it continued indefinitely, the 
ergodic hypothesis states that the ensemble average and the time average are 
equivalent, given sufficient sampling. To calculate time averages reliably, an MD 
simulation should visit enough representative configurations so that the ergodic 
hypothesis is correct. The answer to “how many is enough?” is one that depends on a 
number of variables, including the size of the system, the conditions of the simulation 
and the thermodynamic average that is to be calculated. In practise the reliability of 
measurements is tested by ensuring that the system is at equilibrium – that the value of 
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the time average does not change by lengthening or shortening the simulation, i.e. by 
sampling more or less phase space. 
So far we have seen why MM and MD are used to investigate biomolecules, how they are 
implemented, the limits of their use and some of the caveats of simulations – that they 
should neither be too long (for computational efficiency) nor too short (for sufficient 
sampling). However, there are also questions of how best to represent biomolecules 
within the simulation, and these will be answered in the next sections, beginning with 
solvation and how best to represent the cellular environment. 
2.1.2 Explicit and implicit solvation 
2.1.2.1 Explicit solvation 
The interior of a cell is a crowded environment.126 The cytoplasm may contain proteins, 
cellular organelles, RNA, small molecule ligands, cofactors, lipids, solvent, salts and 
many other biomolecules. This macromolecular crowding can and does have effects on 
protein interactions and dynamics. However, the complexity of these effects means that, 
despite some efforts to model crowded environments with advanced MD techniques,127-
129 simulations are more usually performed as single proteins or protein complexes 
surrounded by solvent (usually water) and an appropriate concentration of salt. As an 
approximation, this may be thought of as the equivalent of an in vitro rather than in 
cellulo experiment - in vitro studies are performed with dilute solutions of isolated 
proteins in a dedicated buffer in order to eliminate complexities from competing 
interactions. In silico work may be performed in much the same way. 
The simplest way to conceive the solvation of an atomistic molecular model is to 
surround it with an appropriate number of atomistic water molecules. This is ‘explicit’ 
solvation. The protein complex can be neutralised with ions as part of the bulk solvent 
and an effective salt concentration can be similarly modelled if desired. In addition, any 
solvent can be modelled if appropriate parameters are generated. For water, a number 
of solvent models are available, but the TIP3P model130 is among the most commonly 
used for this purpose. It is a three point, rigid body water model, consisting of one 
oxygen and two hydrogen atoms, both bonded individually to the oxygen and also to 
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each other with an artificial H-H bond. Charges are centred on the three atoms, whilst 
only the oxygen has Lennard-Jones parameters that are designed to encompass both 
hydrogens too. Unlike higher order models, TIP3P does not contain any extra points to 
attempt to improve the electrostatic distribution around the molecule, however this 
does enhance the efficiency of its simulation. Likewise its rigidity with the artificial H-H 
bond allows the model to be used with algorithms that constrain bonds involving 
hydrogen to enable the use of longer timesteps. 
The main disadvantage of explicit solvation is in the computational cost associated with 
modelling thousands of atoms extra to those of the protein solute of interest. Hence 
further adaptations of basic molecular dynamics are implemented to enhance 
computational efficiency as much as possible. Firstly, it is impossible to model an 
(effectively) infinite number of water molecules required to fully solvate an individual 
protein. Periodic boundary conditions are used to approximate this solvation instead. 
Within a simulation, the system is contained within a periodic box, a 3D shape that 
tessellates infinitely. When a water (or protein) molecule exits one side of the box it is 
wrapped around and enters the opposite side - thus the system as a whole can be seen 
as an infinite series of repeating periodic boxes, each containing a single copy of a 
protein and solvent system (figure 2.3). 
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Figure 2.3 – Schematic 2D representation of periodic boundary conditions. Solute represented 
by solid circle, solvent and directions of motion represented by arrowed circles. As a molecule 
exits one side of the periodic box, its image enters the opposite side, thereby representing 
solvation infinitely in all dimensions. 
The use of periodic boundary conditions allows realistic solvation to be modelled with 
relatively few solvent molecules. However, it also imposes a maximum length at which 
non-bonded interactions may be evaluated explicitly as per equation ( 2-1 ). Because 
each periodic image is an exact replica of the original box, if non-bonded interactions are 
evaluated at infinite range a molecule may interact explicitly with an image of itself in an 
adjacent box. In order to avoid this, non-bonded interactions are limited to a cutoff 
length of less than half the length of the shortest side of the periodic box. In practice this 
length is usually between 8 – 16 Å. 
Although Van der Waals interactions tail off rapidly towards zero at long distances, 
electrostatic interactions may still have large non-zero components at ranges of 8 - 16 Å. 
To avoid inaccuracies and generate stable trajectories these long range interactions are 
therefore evaluated with the Particle Mesh Ewald (PME) approach.131, 132 This has the 
added advantage that PME is a far more computationally efficient way of dealing with 
large numbers of interacting pairs than explicitly calculating pairwise Coulombic 
energies. 
Explicit solvation under periodic boundary conditions is now a standard way of 
performing MD simulations. Explicitly representing solvent molecules allows 
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biomolecules to interact with bulk solvent both physically and energetically identically 
to the way they do experimentally. Bulk properties such as density, pressure and 
electrostatic screening are modelled correctly. Solute-solvent hydrogen bonds are 
represented explicitly, and structurally important solvent molecules can be included and 
exchange with bulk solvent as appropriate. Nevertheless, where speed or size of 
simulation is more important than exact solvation of the solute there are alternatives to 
explicit solvation. 
2.1.2.2 Poisson-Boltzmann solvation 
A solvent does not have to be modelled explicitly in order to include its effects in a 
simulation. ‘Implicit’ solvation is a second commonly used method for taking account of 
the effects of the environment on the solute. Here solvent is modelled with an equation 
and takes the form of a structureless continuum, rather than the individual molecules of 
explicit solvation. 
For implicit solvation techniques, the effects of solvation are divided into electrostatic 
and non-electrostatic based terms. The non-polar term is typically estimated to be 
proportional to the solvent accessible surface area (SASA) of the solute, whereas there 
are two classes of commonly used methods for calculating the electrostatic component 
of solvation for biomolecules. The first class is based on solutions of the 
Poisson-Boltzmann (PB) equation:133-135 
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Where  refers to the three dimensional gradient,  is the dielectric constant,  the 
electrostatic potential,  the solute charge, c the concentration of ion i at infinite 
distance from the molecule, z its valency, q the proton charge, kB the Boltzmann 
constant, T temperature and (r) describes the accessibility to ions of point r. Assuming 
the potential is small (which may not be accurate for highly charged biomolecular 
systems),136 the PB equation can also be simplified to a linearised form for ease of 
computation: 
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Solving the PB equation for  gives the electrostatic potential throughout space. This can 
then be additionally used to calculate molecular properties such as the polar 
contribution to solvation free energy. Within Amber, PB solvation is typically controlled 
by the pbsa module, which uses a finite difference method to iteratively calculate  at 
each point on a lattice.137, 138 Briefly, the biomolecular system consists of a solute of low 
dielectric (~2 to 4) and atomic point charges, and structureless solvent of high (~80) 
dielectric. A cubic lattice is superimposed onto the system, and initial values for all 
terms in the PB equation assigned individually to each point of the lattice. Crucially, the 
potential at each point is affected by the potential of the surrounding points, so the 
equation must then be solved iteratively for  until convergence is achieved. 
The PB equation is therefore a computationally intensive way of calculating electrostatic 
potential and modelling solvation, particularly for large systems that may require large 
cubic lattices to contain them. The accuracy of the technique is also clearly affected by 
the spacing of the grid points on the lattice - finer spacing results in better accuracy but 
at greater cost. Due to its cost, PB is primarily used for the evaluation of static 
structures, although efficient implementations for use in dynamic simulations are 
available.139, 140 
The primary advantage of the PB method is in its accuracy. Despite the inherent 
limitations of implicit solvent methods, PB has often been successfully used to calculate 
electrostatic solvation energies for biomolecules, with good accuracy compared to both 
experiment and other models, both implicit and explicit.134, 141-143 PB methods also 
remain a benchmark by which other solvation methodologies may be judged.144 
Nevertheless, the desire for faster computation of solvation effects that is more suited to 
dynamical simulations has led to the development of alternative techniques. 
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2.1.2.3 Generalised Born solvation 
The second notable class of implicit solvation techniques use the Generalised Born (GB) 
equation.145 GB methods are typically far less computationally costly than solving the PB 
equation, and so have found favour in dynamical simulations where speed and efficiency 
of computation may be more important than absolute accuracy.119, 146, 147 The GB 
equation as it is implemented in Amber takes the following general form: 
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Where ∆Gel is the electrostatic contribution to free energy of solvation, qi and qj are the 
partial charges of atoms i and j,  is the Debye screening parameter (inverse of the 
Debye length) used to account for the effects of salt,  is the solvent dielectric and fGB is a 
function of the distance rij between atoms and the effective Born radii Ri and Rj. A typical 
example of this function is that first developed by Still and coworkers:145 
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For a single ion in pure water, this expression leads the Generalised Born equation to 
correspond to the Born equation for the solvation free energy of a single ion,148 whilst 
for a system of two ions separated by very large distances, the equation tends towards 
point charges obeying Coulomb’s law. Accurately interpolating between these two 
extremes clearly depends on the calculation of the effective Born radii. 
The effective Born radius can be defined as:125 
“…the radius that would return the electrostatic energy of the system according to the 
Born equation if all other atoms in the molecule were uncharged (i.e. if the other atoms 
only acted to define the dielectric boundary between the solute and the solvent).” 
For the limit of a single ion in bulk water the effective Born radius is equal to the Van der 
Waals radius of the ion, hence resulting in the GB equation equalling the Born solvation 
free energy as stated above. Highly solvent exposed atoms on a protein surface will also 
tend towards this limit, as they are closely, if not completely, surrounded by solvent of 
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high dielectric. Deeply buried atoms in the interior of a protein however, surrounded by 
solute of low dielectric, have Ri much larger than their VdW radii to account for the 
effects of the solute. Effective Born radii can therefore be seen as a measure of burial 
within a molecule. 
As effective Born radii depend upon the instantaneous shape of the solute and solvent 
they must be recalculated with every change of conformation. In order to be used for 
MD simulations a GB model must therefore compute Born radii as efficiently as possible, 
as well as accurately recreate solvation free energies. There are a number of GB models 
within Amber, developed and tested for use with different biological macromolecules. Of 
particular importance for proteins are the Onufriev, Bashford and Case (OBC) models, 
variants of which are implemented using either the igb=2 or igb=5 options.147, 149 The 
OBC models have seen widespread use and validation in protein simulations and free 
energy calculations (see also section 2.2.4).150-153 
GB models come with similar caveats to their usage as PB models. As stated above, the 
Poisson-Boltzmann method is the ‘gold standard’ form of implicit solvation by which the 
accuracy of more approximate methods is judged. Comparisons of GB with PB and 
explicit solvation show that GB models still come with some limitations regarding 
accuracy of calculated values to experiment141, 147 and in conformational sampling.154, 155 
These caveats notwithstanding, the computational efficiency of GB means it remains the 
favoured methodology for dynamical simulations with implicit solvent. 
For each simulation the choice of implicit versus explicit solvent, which sub-model to use 
within either of the two options, whether to account for salt, and so on, is far from 
straightforward. The suitability of an approach varies greatly depending on the goals of 
the study and the MD methods used to achieve those goals – where the enhanced 
conformational sampling of GB may be desirable in a protein folding study, for example, 
it may not be useful for studying the free energy of binding of a ligand to a receptor in a 
pocket containing many water-mediated hydrogen bonds. This section has detailed 
some of the considerations of how best to represent solvent in a biomolecular 
simulation, and these will be further referred to, with importance for free energy 
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calculations, in section 2.2.4. For general MD simulation however, the next question is 
how best to model the biomolecule itself, which requires a set of parameters from a 
force field. 
2.1.3 The Amber force fields 
As previously discussed, ‘force field’ is a term used for both a collection of MM 
parameters used to describe a class of molecules and the equation accounting for the 
possible interactions of atoms within a model. Conceptually, a force field therefore 
relates atomic positions to potential energy - the first step in the process of MD 
explained in section 2.1.1.3. 
Force fields can be parameterised to accurately represent one class of molecules or to be 
more general. This section will solely examine the Amber force fields for biomolecular 
simulation and their modern development and usage. For details of the early 
development of Amber and the development of other biomolecular force fields the 
interested reader is referred to an introductory review by Ponder and Case.156 
The potential function of the Amber force fields has some minor modifications to the 
example given earlier as equation ( 2-1 ). Most notably these include a term accounting 
for improper torsions (i.e. out-of-plane motions for planar functional groups such as the 
peptide bond and aromatic rings), the exclusion of 1-2 and 1-3 non-bonded terms (to 
avoid clashing of atoms connected by bonds or angles) and the scaling of 1-4 
non-bonded terms (an empirical scaling incorporated during early force field 
development). Traditionally, Amber force field developers have paid particular attention 
to the correct description of these torsional and non-bonded (particularly electrostatic) 
terms as they contribute greatly to the stable secondary and tertiary structures of 
proteins that the force fields are designed to simulate. This focus is apparent in the first 
modern Amber force field, developed by Cornell et al. and also known as ff94.157 
The ff94 force field was the first attempt by the Amber developers to invoke a defined 
and repeatable methodology for obtaining electrostatic point charges from the QM 
electrostatic potential. The RESP (Restrained Electrostatic Potential) algorithm158, 159 
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was designed to be generally applicable to any class of molecules rather than specific for 
amino and nucleic acids, and has since been repeatedly used in the development of new 
parameters.160, 161 Other parameters for bonds, angles and dihedrals, were either fitted 
to experimental data such as vibrational frequencies or more quantum mechanical 
calculations of rotational barrier heights. 
The advance of computer technology meant that by 1999 the force field could be further 
developed and compared with more and higher level QM calculations. The Amber ff99 
force field162 development started from ff94 as a basis, but in particular included 
additional and adapted torsional terms which were shown to more accurately recreate 
QM energies and experiment where possible. From a biomolecular point of view the key 
changes were in  and  torsions for the peptide bond, which are of great importance 
for the correct representation of secondary structure. 
Nevertheless, by 2006 further advent of technology resulted in further development of 
the ff99 force field. MD simulations over timescales far beyond those accessible during 
the original parameter development showed that both ff94 and ff99 had a propensity to 
overstabilise -helical structures. The resulting correction of this bias, known as the 
ff99SB force field,163 again adapted  and  torsions for the peptide backbone, but in this 
case took advantage of improved computational hardware to perform nanosecond 
timescale MD simulations comparing multiple Amber force fields old and new. Thus the 
adaptations could be validated against dynamics from experimental NMR relaxation 
studies or structural data from the Protein Data Bank (PDB). 
Other Amber force fields are available, including those with polarisable rather than fixed 
point charges on atoms. In addition further changes to ff99SB have been suggested to 
adapt the torsions of certain sidechains to better reflect dynamics in long timescale 
simulations.164 Notwithstanding the potential benefit of alternative force fields for 
specific applications, ff99SB has been the most widely used in recent studies and 
remains the most current version of the Amber force fields for general simulation of 
proteins. The ff99SB force field has therefore been used throughout this project. 
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The previous sections have given a brief introduction to the concept and development of 
MD, some issues concerning how best to represent a model of a protein in solvent and in 
the condensed phase, and the development and validation of the current Amber force 
fields for protein simulation. This has described the basic process of designing and 
setting up a simulation. However, more important for any study is the question of how 
best to use a simulation to gain relevant information on the system being investigated. 
In the case of PPIs, the free energy of binding of the complex is the desired property, and 
there are numerous ways to obtain this computationally. 
2.2 Free energy calculations 
2.2.1 Calculating free energies from MD 
As with other properties, the accurate calculation of either the Helmholtz or Gibbs free 
energy of a system (denoted by ‘A’ and ‘G’ respectively) from MD requires an ergodic 
trajectory, or at least for the ergodic hypothesis to be true. Unfortunately, whilst many 
high-energy regions of phase space contribute greatly to a system’s free energy, a 
standard MD trajectory will mostly sample low energy regions, and hence estimates of 
total free energies may be inaccurate and imprecise. 
Fortunately, from the point of view of comparison with experimental data, the total free 
energy of a system is rarely of interest. What is more often measured is a change in free 
energy from one system to another. Binding free energies - the absolute change in free 
energy, ∆G, on binding of a ligand to a receptor to form a complex - are one such 
example. For comparison of multiple ligands of one receptor this concept can be taken a 
stage further to measure the relative change in binding free energy, ∆∆G, between one 
ligand and another. Assuming that the phase space of the two states overlaps, MD 
simulations may be used to calculate these quantities. 
One way to conceptualise the difference between these absolute (∆G) and relative (∆∆G) 
changes in free energy is with thermodynamic cycles,165 and these are often made use of 
in MD-based free energy calculations. Beginning with relative free energy differences, 
the simplest difference between two states would be the difference between the binding 
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of one ligand to a receptor and a second, mutated, ligand to the same receptor. This can 
be represented by the thermodynamic cycle of figure 2.4. 
 
Figure 2.4 – Thermodynamic cycle for the calculation of ∆∆G. As the sum of the cycle is zero, ∆G3 
- ∆G4 = ∆G1 - ∆G2. The experimentally determined ∆∆G value, ∆G3 - ∆G4, may therefore be 
replicated using computational transformations of the ligand, ∆G1 and ∆G2, which have no basis 
in experiment. 
In figure 2.4 the experimental binding free energies of ligands 1 and 2 are represented 
by ∆G3 and ∆G4 respectively. The difference between the two gives the ∆∆G - the 
indication of which ligand binds more strongly to the receptor. The absolute binding 
free energies of both ligands are difficult to calculate computationally, as the binding 
partners may undergo significant conformational changes that require extensive 
sampling to ensure a suitable overlap of phase space for results to be converged. 
Instead, the computation of ∆G1 and ∆G2, the free energy change when one ligand is 
transformed into the other, may be much simpler. The ∆∆G can then be calculated as 
∆G3 - ∆G4 = ∆G1 - ∆G2. These ligand transformations, although they have no physical basis 
in reality, may be simply performed in a simulation. The methods used to do so are 
known as ‘pathway’ or ‘alchemical’ free energy methods, as they transform one species 
into another via a pathway of non-physical, alchemical intermediates. 
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If the absolute binding free energy between a solvated receptor and ligand is desired, 
this may also be represented by a thermodynamic cycle, shown in figure 2.5. 
 
Figure 2.5 – A thermodynamic cycle for absolute binding free energy calculations. The sum of 
the thermodynamic cycle is zero, therefore the lower value, ∆Gbind,sol, can be calculated provided 
that the other values are known. 
In this case the value of interest is ∆Gbind,sol, the ∆G of binding in a solvated system. As 
stated above, this value is difficult to obtain directly from simulation, as extensive 
sampling is required to obtain converged values, particularly in solvent. If the other 
values are known or calculated however, the ∆Gbind,sol can be obtained as: 
                                                                    ( 2-14 ) 
The values on the right hand side of equation ( 2-14 ) can be calculated using pathway 
methods if desired, with transformations to zero (i.e. ‘disappearing’ the molecule) in 
solution phase and gas phase providing routes to solvation and gas phase binding 
energies. However if a swifter method is desired then, assuming that the sampled phase 
space of the receptor, ligand and complex overlap, the individual solvation free energies 
and gas phase binding free energy can be calculated directly from simulations. Free 
energy methods with this approach are known as ‘endpoint’ techniques, as they only 
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require the simulation of the endpoints of transformations, rather than a pathway 
through alchemical transformations. Of course, endpoint free energy techniques can also 
calculate relative free energies, simply by performing two absolute free energy 
calculations and taking the difference between them. 
Numerous pathway and endpoint free energy methods have been developed, primarily 
because there is no standard approach to calculating free energies for all systems and 
the accuracy and suitability of a particular method is determined by a number of factors. 
Free energy calculations are primarily estimates - given a particular set of parameters, a 
particular set of starting conditions, a particular ensemble sampled by MD and a 
particular set of assumptions, free energy calculations will provide an estimate of the ∆G 
associated with a process. Thus this calculated ∆G may not always be expected to agree 
with an experimentally determined one, depending on the exact implementation of the 
method. Despite this, free energy calculations are often used to compare computational 
predictions to experimental data, either for drug design purposes, or to rationalise 
biological interactions and observations. Examples of some potential methods to do this, 
and their successes and limitations, will be explored in the following sections. 
2.2.2 ‘Alchemical’ free energy methods 
There are many differences between states that have an associated free energy that may 
be of interest from a biological perspective. In this section the focus will be on free 
energy changes associated with a biomolecular process, such as binding or solvation. To 
measure the free energy of conformational changes, which may also be of interest, other 
techniques such as potential of mean force calculations and/or umbrella sampling are 
required, which are not covered here. 
Nevertheless there are also multiple methods for calculating binding free energies. 
Alchemical free energy methods in particular have a long history in this regard.166 The 
late 1980s and early 1990s saw an explosion in the use of two related techniques to 
calculate free energy differences: Free Energy Perturbation (FEP)167-170 and 
Thermodynamic Integration (TI).171-173 
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The Free Energy Perturbation approach to calculating free energy differences was first 
described by Zwanzig:174 
 
           〈   [ 
(     )
   
]〉  ( 2-15 ) 
Here, ∆GXY is the free energy change in transforming from state X to state Y, kB the 
Boltzmann constant, T temperature,    and    the respective Hamiltonians (or 
potentials) of states X and Y, and 〈 〉  denotes an ensemble average over all 
configurations of state Y. If these configurations are from the isobaric-isothermal (NPT) 
ensemble, equation ( 2-15 ) gives rise to the Gibbs free energy, otherwise with 
configurations from the canonical (NVT) ensemble the Helmholtz free energy is 
produced. As ever, the requirement for exact calculation of ∆G is that the ensemble 
covers all configurations of the molecule. 
This is impossible for MD simulations, as we have already discovered. Instead, for 
equation ( 2-15 ) to reliably converge the configurations representative of states X and Y 
should overlap in phase space, such that an MD simulation of one state samples 
configurations that are relevant for the second. The validity of this assumption can be 
assessed simply by reversing the reference and final states X and Y - in this case the ∆G 
calculated should be of equal magnitude and opposite sign. For all but the simplest 
transformations this phase space overlap is unlikely given the configurations sampled 
by MD (figure 2.6a). However, convergence can be improved by the addition of multiple 
intermediate states, coupled between X and Y by means of a coupling parameter,  
(figure 2.6b). 
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Figure 2.6 – A) MD-based configurational ensembles in phase space of two states, X and Y. In this 
case, lack of overlap between the states means that equation ( 2-15 ) is unlikely to converge and 
hence ∆G estimates are inaccurate. B) In the FEP approach, the two final states are coupled by 
multiple, overlapping, intermediate alchemical states, each assigned a coupling parameter  to 
denote the stage of transformation between X and Y. 
As the coupling parameter is slowly varied between 0 and 1, so the reference state is 
slowly transformed into the final state through multiple intermediates, defined as 
weighted linear combinations of the potential energy functions for the two states. These 
intermediates are chosen to overlap better in phase space, so that the individual 
calculations of ∆G for 01, 12 etc. converge more quickly and are more accurate. 
The overall ∆G for the full transformation is then simply the sum of the individual ∆G 
along the transformation pathway. This is the FEP approach. 
Thermodynamic Integration (TI) is a related technique, which rather than calculating 
the average difference in potential between neighbouring  windows, calculates the 
average derivative of the potential with respect to  at each window, and then integrates 
to find ∆G: 
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In this case the concept is similar in that intermediates corresponding to  values 
between 0 and 1 overlap well in phase space and so provide a smooth transformation 
from reference to final state. However, rather than  values being simulated stepwise 
and the energy difference from each step summed, as with FEP, TI performs 
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independent simulations at each  window, calculates the derivatives of potential w.r.t. 
 at each, and then integrates to obtain ∆G once all simulations are complete. The 
advantage of this method is that additional  windows can be added at any time, in case 
better overlap in phase space (and hence convergence) is needed for any particular part 
of the transformation. Equally, as the overall ∆G for the transformation is not dependent 
on the path taken to achieve it, the transformation can be decoupled into multiple 
distinct steps, each with their own  windows, if desired – for example beginning by 
removing electrostatic charges of state A, followed by transformation of the neutral 
state A into state B, followed by the reinstatement of charges in state B.175 This may 
again lead to better convergence due to more closely overlapping intermediates and is 
far easier to achieve with TI than with FEP. 
Whilst both TI and FEP are still commonly used,176-180 the accuracy and precision of their 
calculations is fraught with problems.181, 182 These have resulted in numerous 
adaptations and improvements to the techniques over time. Notable solutions have 
included softcore VdW potentials to avoid instabilities and poor convergence at very 
low or very high  values (i.e. where atoms are just appearing or just disappearing),183, 
184 enhanced sampling techniques to improve overlap between neighbouring 
windows,178, 185 the use of multiple trajectories to improve precision of calculations186 
and methods to account for and understand the effects of conformational changes 
during binding.187, 188 Although attempts have been made to compare and quantify the 
respective accuracy, precision and robustness of FEP, TI and other free energy 
calculation methods189 the large number of potential adaptations to the underlying 
techniques, as well as the inherent variability of biomolecular systems, mean that all 
alchemical free energy calculations still require careful design and implementation in 
order to generate meaningful results. 
With thoughtful application alchemical free energy methods can provide very precise 
results and good agreement with experiment (in cases where this is warranted). The 
problem in putting them into routine practice is not in their accuracy, but rather in the 
time they take to complete. Carrying out these free energy calculations is not a trivial 
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task and may rely on the availability of high performance or distributed computing.176 
For drug discovery or large scale screening purposes the use of such computationally 
intensive methods is currently unfeasible, hence there has always been a great interest 
in the development and application of quicker free energy calculation techniques, which 
may rely on greater approximations. As mentioned in section 2.2.1, one major 
approximation that can be made is that only the endpoints of a transformation require 
simulation rather than the whole pathway. 
2.2.3 ‘Endpoint’ free energy methods 
As with alchemical methods, there are a number of endpoint techniques that have been 
developed over the past two decades. Two of these have risen to particular prominence 
in the literature and will be discussed here, as they are relevant for investigations of 
protein-protein interactions and for large scale virtual screening. 
The first is the Linear Interaction Energy (LIE) approach developed and propagated 
since 1994 by Åqvist and coworkers.190 It is one of a class of methods based on the 
Linear Response Approximation (LRA): the approximation that the electrostatic 
contribution to binding free energy is approximately linear with respect to the ligand 
charge. 
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Here,    
    refers to the electrostatic energy between the ligand and its surroundings 
(both the protein and solvent) and the angular brackets again indicate ensemble 
averages from MD simulations; the subscripts RL and L refer to normal simulations of 
the receptor-ligand complex and ligand respectively whilst RL’ and L’ are simulations in 
which the ligand charges have been set to zero. 
Whilst the LRA can be used to calculate the electrostatic contribution to free energy, an 
extension of the approximation is required to account for non-polar, hydrophobic 
effects. Similarly to the electrostatic contribution, LIE uses a simple linear 
approximation of the VdW interaction energies between the ligand and surroundings (in 
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both complexed and free ligand forms) to calculate the non-polar contribution to ∆G. 
Removing electrostatic interaction energies where ligand charges are zero, the L’ and 
RL’ simulations, leaves the ∆G of binding with the LIE method as: 
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In this case,  and  are now parameterised scaling factors that may be defined 
empirically. A value of 0.5 for  is theoretically justifiable given the accordance with the 
LRA, but the value of  has no such theoretical basis and is chosen to maximise 
correlation with experiment. In early studies values of 0.16 – 0.18 were seen as an 
appropriate choice across multiple systems. 
The LIE method and associated techniques based on the LRA have become popular as 
rapid, approximate methods to generate binding free energies over the past two 
decades. Agreements with experimental binding free energies have been on the order of 
~1.0 kcal mol-1,191 even tested across multiple force fields.192 However, the main 
problem with the LIE approach is that this accuracy and agreement with experiment 
clearly depends upon the appropriateness of the two scaling factors,  and . The VdW 
scaling factor, , is the more variable of these and has been hypothesised to depend 
upon a function of how hydrophobic the binding site is,193 or simply the type of 
interaction being probed, with drug-like ligand and PPI studies requiring different 
coefficients.194 
The parameterisation of the  coefficient was always known to be important for LIE 
accuracy.190 However, early studies with LIE rapidly identified that the electrostatic 
parameter, , should also vary from its theoretical value of 0.5 in order to improve 
correlation with experiment.195 In addition, some results were also improved with the 
addition of a third coefficient, , to equation ( 2-18 ) to shift calculated ∆G by a constant 
based on the change in solvent accessible surface area (SASA) on binding.196 These 
additional changes greatly increase the complexity of generating accurate and reliable 
LIE free energies for a novel system. As may be expected, recent evaluations and 
comparisons with alternative methods have shown that the accuracy of LIE calculations 
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depends greatly on the coefficient set chosen, and that the appropriate coefficient set 
depends greatly on the type of system investigated.197, 198 
LIE remains a popular method for estimating binding free energies, but its use for PPI 
studies in particular is limited by the careful parameterisation required.194 Using a 
training set of ligands to first choose coefficients may be suitable for small drug-like 
binders, but for large PPIs this approach is unfeasible. Other endpoint free energy 
methods are therefore more appropriate for investigating PPIs. The MM-PB/GBSA 
techniques are commonly used instead for this purpose. 
2.2.4 MM-PB/GBSA 
2.2.4.1 Theoretical basis 
MM-PBSA (Molecular Mechanics – Poisson Boltzmann Surface Area) and MM-GBSA 
(Molecular Mechanics – Generalised Born Surface Area) are two related endpoint free 
energy calculation methods for calculating absolute binding free energies. Originally 
developed by Srinivasan and coworkers in 1998199 the two methods have been used to 
calculate absolute binding free energies for almost 15 years. 
Both methods make use of the thermodynamic cycle described by figure 2.5 and 
equation ( 2-14 ) to calculate ∆G. This requires structures of the complex, ligand and 
receptor in both solvated and vacuum environments. The Gibbs free energy for each 
state may then be calculated as follows: 
 〈 〉  〈   〉  〈     〉   〈 〉 ( 2-19 ) 
Where EMM is the molecular mechanical energy of the species, Gsolv the solvation free 
energy, T temperature and S the entropy. This may be seen as equivalent to the famous 
definition of the Gibbs free energy, 〈 〉  〈 〉   〈 〉. In MM-PB/GBSA the solvation free 
energy may be further broken down into electrostatic and non-polar constituents. 
 〈     〉  〈          〉  〈       〉 ( 2-20 ) 
Both methods use implicit solvation to calculate the electrostatic contribution to 
solvation free energy for speed, but whereas MM-PBSA uses theoretically exact 
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Poisson-Boltzmann solvation (section 2.1.2.2), MM-GBSA uses the more approximate 
Generalised Born technique (section 2.1.2.3). In both cases the non-polar contribution is 
estimated with a function of the solvent accessible surface area, SASA, and the solvent 
surface tension, . In this study, the nonpolar solvation free energy was calculated 
directly as SASA ( = 0.0072 kcal mol-1 Å-2).145 
Following calculation of the Gibbs free energy of each state, the overall ∆G of binding is 
calculated by taking the difference of the complex and combined receptor and ligand 
free energies. The free energies of MM-PBSA and -GBSA are therefore calculated using a 
fully physical energy function, dependent only on the MM force field and the parameters 
of the PB or GB solvation method used. Unlike LIE there are no empirical weightings 
used to enhance correlation with experiment, nor (in theory) does the method have to 
be adapted and parameterised to be accurate for different types of protein-ligand 
complexes. Nevertheless, there are a number of potential variations of MM-PBSA 
and -GBSA that have been investigated and should be considered when designing a free 
energy study. 
2.2.4.2 Technical considerations - sampling 
MM-PB/GBSA use structural snapshots from MD simulations to calculate an ensemble 
average ∆G of binding. As discussed above, the calculation requires separate snapshots 
for the receptor, ligand and complex. There are two approaches to obtaining these 
snapshots, known respectively as the ‘three trajectory’ and ‘single trajectory’ methods. 
The three trajectory method is conceptually simple - separate MD simulations are run 
for the receptor, ligand and complex in solvent. Representative structural snapshots are 
taken from each simulation and used to calculate the respective MM energies, solvation 
free energies and overall ∆G. This simple approach allows the conformational ensembles 
of the receptor, ligand and complex to differ, in theory accounting for structural and 
entropic changes that may occur to both partners on ligand binding. 
The problem with this approach is similar to one of the inherent challenges of MD 
described in section 2.1.1.2 - namely, how can we be certain that the individual receptor, 
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ligand and complex simulations are all sampling suitable conformational ensembles that 
overlap significantly enough in phase space for an endpoint free energy method to be 
appropriate? Theoretically the three trajectory approach should accurately account for 
the free energies of both the unbound and bound states and hence give good agreement 
with experiment. In practice this may be combined with a loss of precision due to the 
inherent variability in sampling between the three simulations, leading to large 
uncertainties in ∆G estimates.200 
The single trajectory approach, in contrast, only requires a single MD simulation of the 
solvated complex structure. Coordinates of the receptor and ligand are then extracted 
separately from each structural snapshot of the complex. The single trajectory method 
assumes that any structural reorganisation that takes place upon binding is negligible. 
Although this assumption may not be valid for every system, it maintains two 
advantages over the three trajectory approach. Firstly, it is a much faster way of 
generating ensembles as it requires only one MD simulation rather than three. Secondly, 
because the dynamics of the receptor, ligand and complex are identical, errors and 
fluctuations in the free energy calculation cancel, leading to greater precision in 
estimated ∆G.201 As the statistical precision of a ∆G estimate is related to the number of 
snapshots used to obtain it, the single trajectory method requires fewer snapshots (and 
hence less simulation time) than the three trajectory method to obtain a given level of 
statistical convergence, providing a further speed advantage. 
2.2.4.3 Technical considerations - entropy 
A further technical consideration relates to the treatment of the entropic term in 
equation ( 2-19 ). Until now the discussion of ∆G calculation has incorporated the 
‘enthalpic’ (EMM and Gsolv) and entropic (TS) terms together. Entropy changes are well 
known to make significant contributions to some protein activities and ligand binding 
affinities38, 202, 203 and the accurate calculation of the extent of this contribution is 
valuable for ligand design. The configurational entropy is traditionally estimated in 
MM-PB/GBSA in one of two ways; using Normal Mode Analysis (NMA) or a 
quasiharmonic (QH) approximation. 
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The QH approximation method, first proposed by Karplus and Kushick in 1981,204 is a 
rapid technique that can calculate entropies directly from MD simulations. Although 
fast, its accuracy is inherently linked to the MD simulation from which it is calculated 
and thus may be similarly limited. Significantly, accurate QH calculations require 
simulations that not only correctly sample representative conformations, but which also 
correctly sample the relative populations of these conformations.205 Convergence of QH 
entropic estimates therefore needs extensive sampling, either from long timescales or 
multiple simulations.205, 206 This reduces its computational efficiency. 
The alternative of NMA entropic estimates is normally a far more computationally 
costly, but more theoretically accurate, approach. The vibrations of a molecule are given 
by its normal modes, which can be calculated from energy minimised snapshots of MD 
simulations. These vibrational frequencies are then used to calculate the vibrational 
contribution to entropy. To calculate accurate vibrational modes the NMA approach 
requires extremely well minimised structural snapshots, which are computationally 
expensive to obtain. In addition, like QH analysis, accuracy and convergence of the 
estimates is related to the sampling of the underlying MD trajectory. Long trajectories 
and large numbers of minimised snapshots are unfeasible from a computational 
perspective however. 
As such, numerous methods for improving NMA convergence and reducing 
computational costs have been investigated, often specifically for use with 
MM-PB/GBSA. The most simple of these is the use of the single trajectory approach. Just 
as the precision of the MM and solvation energy terms is enhanced by the cancellation of 
errors that a single trajectory for complex, receptor and ligand provides, so is the 
precision of the entropic calculation. Single trajectory entropy estimates converge far 
faster than their three trajectory equivalents, albeit with the same caveats for 
accuracy.200 
Large fluctuations in the entropic term can have adverse effects on the accuracy of the 
whole ∆G calculation, even if the entropy as a whole is converged.207, 208 Reducing the 
complexity of the system studied, thereby reducing the differences between minimised 
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snapshots and reducing the possibility of spikes in the vibrational entropies, is one way 
of avoiding these fluctuations. This may be done simply by truncating the size of the 
calculation to only include protein residues within 8 Å of the ligand.209 Alternatively, 
Ryde and coworkers have been proponents of an improvement to this method that 
includes a ‘buffer’ region of both solute and solvent extended beyond the 8 Å region of 
entropy calculation.210 This fixed buffer zone reduces undue variations in structure for 
the minimised snapshots, thereby improving the precision of entropy estimates further 
without significant additional cost.210, 211 
Despite improvements to the efficiency and precision of both NMA and QH calculations, 
the entropy term remains the source of much of the error and computational cost of 
absolute free energy calculations with MM-PB/GBSA.212 Careful choice of method is 
required to obtain estimates that are both realistic and helpful for predictions. If only 
relative free energies are required, the assumption is often made that the entropic 
contributions to free energy of both ligands are identical. This would mean that the 
entropies cancel in the ∆∆G calculation, and as such entropy could be completely 
neglected. 
This assumption results in an ‘effective’ ∆∆G, as only the MM and solvation energy terms 
are considered to contribute to the difference in binding free energy. Although the 
validity of this is clearly highly system dependent, neglecting entropy can remove a 
large proportion of computational expense and a large potential source of error. The 
decision whether to include or neglect entropic contributions is therefore likely to 
depend on individual circumstances and study objectives. 
MM-PBSA and -GBSA have been used across a huge variety of systems and the exact 
implementation of the method in each study varies. The technical considerations 
discussed above are relevant to all possible uses of MM-PB/GBSA in binding free energy 
calculations, however there are many other considerations that may be taken into 
account for specific studies. The following section summarises the successes of 
MM-PB/GBSA, the areas in which they are still limited, and the key lessons that have 
been learned from the past ten years of simulation. 
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2.2.5 Successes & failures of MM-PBSA and MM-GBSA 
Binding free energy calculations in all their forms have seen some significant successes 
over the past two decades but remain far from universally applicable. Perhaps the most 
useful result of their occasional failures is the discovery of recurring themes in their 
mistakes – areas of underperformance that may be tackled with specific adaptations to 
methodology.213, 214 The previous section discussed the importance of two of these areas, 
sampling and entropy, for accuracy and precision. The following section discusses 
further advantages and disadvantages identified from 20 years of binding free energy 
calculations. 
2.2.5.1 Evaluations of MM-PB/GBSA 
The use of MM-PBSA and -GBSA has been widespread, but attempts have been made to 
evaluate and review its progress more thoroughly. Each of the problems identified from 
the long experience of MM-PB/GBSA work falls into one of two categories: a problem 
with accurate representation of the system, or a problem with precise estimation of a ∆G 
value. These recurring themes are examined in detail below. 
One of the first negative results with the approaches came from David Pearlman in 
2005,215 in a study which compared predictions of relative binding free energies from 
MM-PBSA and other methods for a series of related ligands of p38 MAP kinase. 
MM-PBSA performed poorly compared to both more costly (TI) and less costly (ligand 
docking) techniques. Further work by Page and Bates, investigating ligand binding to 
many different kinases,208 expanded on this. It was suggested that the source of poor 
agreement with experiment was primarily due to the numerous assumptions and 
approximations imparting a large error on each individual component of the free 
energy. This could eventually result in a large error in the final ∆G value, given that the 
fortuitous cancellation of errors that is desired may not be realistic for all systems. 
Page and Bates therefore suggested that MM-PBSA would be more usefully deployed to 
extract information about the mode or mechanism of binding, rather than ordering 
binding free energies, as there was no consistent way of identifying which free energy 
technique would be appropriate prior to carrying out the simulations. It is worth noting 
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that broader studies on larger numbers of ligands have not seen such poor performance 
of MM-PBSA, but perhaps this merely reinforces the above conclusion.216 Consistent 
with this, MM-PB/GBSA have also taken on an alternate role in drug discovery, 
becoming secondary methods used to rescore and validate binding free energies and 
poses from more rapid virtual screens.217-219 
Notably, the above studies that showed poor performance of MM-PBSA in replicating 
ligand binding affinities were based on relatively short, individual simulations. Given the 
fact that relative binding free energies between ligands may be small, on the order of 
0 - 4 kcal mol-1, small error bars on predictions are crucial for reliable ordering of 
results. One way of obtaining statistical precision in predictions is to repeat the 
calculation for multiple independent trajectories of the same complex, gaining an 
understanding of ∆G variation between predictions as well as within them.220 Recent 
studies have used this approach with great success, both with MM-PBSA and TI.186, 221-223 
The increasing ability to simulate complicated systems for long timescales has also led 
to the identification of further issues with free energy calculations. As introduced in 
section 2.1.1.2, proteins are dynamic across multiple timescales. Conformational 
changes occur on the ps to ms scales, and only some of these will be effectively sampled 
by MD. Many proteins are known to change conformation on ligand binding,224 and 
changes in dynamics are known to play important roles in protein function.115, 225-227 
This includes affecting binding free energies.188, 228 
Correctly dealing with conformational changes may be key for the accuracy of a free 
energy calculation. In practice this simply requires effective sampling of the change. For 
pathway free energy methods some groups have investigated the use of biased or 
enhanced sampling in order to ensure that the system does not remain trapped in a 
metastable state on mutation, affecting the accuracy of ∆∆G between native and 
mutant.178, 188 For endpoint free energy methods it is simply a case of ensuring the 
underlying MD simulation effectively samples any relevant conformational changes. 
Multiple simulations may be one way of doing this as long as they are independent 
enough to sample different (but still related) areas of phase space.229 Depending on the 
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size of the change, long timescale simulations may also be required – whilst small 
sidechain rotations may be sampled by multiple short simulations, a loop motion may be 
better represented by a single long simulation of equivalent computational cost.230 
Finally, MM-PB/GBSA in their standard implementation can be an overly simplistic way 
of calculating contributions to binding. As solvation free energies are generated with 
either the PB or GB equations, all explicit water molecules and counterions are stripped 
from the structural snapshots prior to analysis. However, water molecules in binding 
sites can clearly play important structural and energetic roles.231-233 Where these waters 
are known or can be observed to play a role in binding they may be included in the free 
energy calculation. This is yet another way of improving the biological relevance of the 
system and may be used to obtain information on binding mechanism or improve the 
accuracy of predictions.234 
2.2.5.2 Lessons for effective MM-PB/GBSA 
The previous sections have shown how effective MM-PB/GBSA calculations must 
maintain a balance between ensuring biological realism, and hence accuracy, and 
statistical relevance of predictions, brought about through precise estimations. There 
are three key lessons of the past decade’s studies with MM-PBSA and -GBSA. 
Firstly, the increase in available computing power has led to a vast expansion of 
simulation possibilities. For free energy calculations this has led to a trend of improving 
estimates by performing multiple independent simulations. Multiple simulations allow 
the evaluation of whether a system is equilibrated, enhance the sampling of 
conformational changes that may be of interest, identify how much variation is inherent 
in the methodology and allow statistical precision of the results to be calculated. These 
effects can improve accuracy and precision to varying degrees dependent on the system 
under investigation. 
Secondly, where assumptions can be made to simplify calculations the precision of 
estimates can be greatly improved. The single trajectory approach has advantages over 
three trajectory MM-PB/GBSA, assuming that entropic contributions can be neglected 
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has major speed advantages and removes a source of large errors, and the 
approximation of calculating solvation free energies with either the PB or GB equation is 
one of the cornerstones of the method itself. All assumptions come with caveats for their 
effects on accuracy however, as their validity varies from one system to the next. 
Finally, accurate representation of the system and the changes the system undergoes on 
binding is important for accuracy of predicted free energies. Here MM-PB/GBSA have 
the advantage of flexibility. Pathway free energy methods require extensive additional 
computation or the development of new protocols to deal with changes between states. 
However, the effects of conformational changes, solvation changes, protonation state 
changes and others can all be estimated rapidly with MM-PB/GBSA. The ability to do 
this is not only important for predicting ∆G and ∆∆G accurately, but also allows the 
extraction of detailed information on the molecular mechanisms of binding interactions. 
MM-PBSA and MM-GBSA have become popular as fast, efficient and flexible ways to 
calculate free energies compared to more theoretically accurate but expensive 
alchemical methods. These strengths suggest they have potential for use in the 
widespread probing of binding at protein-protein interfaces, with all the implications for 
drug and protein design that implies. The goal of the following study is therefore to 
investigate this potential and to further develop MM-PB/GBSA free energy calculations 
to improve upon the weaknesses identified from over ten years of existing work. 
2.3 Summary 
This chapter has shown how computational chemistry has become a powerful tool for 
investigating biomolecular interactions. With tools that stretch from highly accurate 
energetic, molecular orbital and reaction pathway calculations based on quantum 
mechanical principals, through to rapid and approximate techniques for scoring ligands 
binding to protein targets, it is clear that computation has had a broad impact across 
disciplines. This section will summarise the main points of the chapter, followed by 
detailed aims of the research carried out in this project. 
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2.3.1 Computational biological chemistry 
Quantum mechanics describes the fundamental basis of chemical interactions. Despite 
huge advances in our understanding of QM concepts and huge advances in technology, 
performing theoretical calculations based on QM is still a hugely challenging and time 
consuming task. QM calculations on molecules the size of proteins are generally 
unfeasible, particularly if information on the dynamics of a molecule over time is desired 
rather than its instantaneous interactions. 
Molecular mechanical force fields represent biomolecules as hard spheres connected by 
springs, with specific parameters describing the interactions of atoms through bonds, 
angles, dihedrals and non-bonded VdW and electrostatic terms. The simplicity of these 
models and the fact they are based on classical mechanics allows them to be used to 
propagate the movement of molecules through time, by integration of the Newtonian 
laws of motion. This is the overall concept of a molecular dynamics simulation. 
MD simulations of proteins and other biomolecules usually attempt to accurately 
portray a biological environment, with a biomolecule solute surrounded by an 
appropriate solvent and salts. The solute is represented using a force field with 
parameters specifically developed and tested to recreate the experimental energetics, 
interactions and dynamics of that biomolecule as accurately as possible. The solvent and 
salts may be defined explicitly, with atoms connected by springs and again represented 
by a specific MM model, or implicitly, with a structureless continuum based on a 
theoretical representation. 
Each representation, force field and MD method has its own advantages and 
disadvantages, and careful design of simulation protocol is required in order to generate 
a reliable and realistic model of the biomolecular dynamics. As well as simply recreate 
dynamics however, MD simulations can be used to extract other information about the 
system. Most notably for studies of PPIs, there are various techniques for performing 
binding free energy calculations that make use of MD trajectories. 
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Binding free energy calculations can be divided into two main subsets. The first 
calculates the absolute ∆G of binding, for example of a protein-ligand complex. The 
second calculates the relative ∆∆G of binding between two different states, for example 
between one complex and a second complex in which a residue has been mutated. Both 
types of calculation can give valuable information on binding mechanisms, determining 
how and why specific interactions contribute to binding free energy. 
Techniques for carrying out free energy calculations can be divided into ‘alchemical’ (or 
‘pathway’) and ‘endpoint’ categories. Alchemical methods, including FEP and TI, 
evaluate changes in free energy through slow perturbation of one state into another, 
through a series of alchemical intermediates. Although they are, in theory, highly 
accurate, they require vast amounts of computation and very carefully designed 
protocols in order to obtain reliable, repeatable and precise estimates of free energy. 
Endpoint methods, such as LIE, MM-PBSA and MM-GBSA, only simulate the endpoints of 
a transformation and so require far less computational expense. However, they also rely 
on more assumptions and approximations in order to do this, and so are generally 
considered less accurate than the ‘gold standard’ alchemical methods. 
Endpoint free energy methods are more appropriate for investigating the binding of 
PPIs as their relative speed is useful when the effects of changes across large interfaces 
must be probed. The MM-PBSA and MM-GBSA techniques are two related popular and 
well-studied methods for calculating ∆G and ∆∆G. They differ only in their treatment of 
solvation free energy (using either the Poisson-Boltzmann or Generalised Born 
equations) during their calculations. Both methods have been widely used since they 
were first proposed in 1998 and have seen success in estimating binding free energies 
across a wide variety of systems. 
Nevertheless, weaknesses remain in the MM-PB/GBSA approaches. For predictions to be 
useful they should be both accurate and precise. MM-PB/GBSA studies must therefore 
balance two facets: including enough identity and phase space overlap between 
calculations to ensure repeatable results with small error bars, and allowing enough 
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variability between simulations to correctly account for all biologically relevant 
dynamical changes.  
Finally, this balancing act requires careful study design and validation and has led to the 
development of new adaptations and new methodologies for the approaches, each 
useful in specific cases. Studying the binding free energies of PPIs poses different 
challenges to studying protein-drug or protein-ligand interactions. Therefore PPIs are 
an area with opportunities for adapting MM-PB/GBSA to improve the efficacy of 
predictions. 
2.3.2 Study aims and objectives 
The overall aim of this research is to evaluate the potential of MM-PBSA and MM-GBSA 
for probing protein-protein interfaces. The screening of PPIs and the identification of 
the determinants of protein binding is a research area of great importance, as discussed 
in chapter 1. A rapid, adaptable and accurate computational approach to calculating 
binding free energies would be of enormous benefit. MM-PB/GBSA have been used on 
multiple occasions and show potential in regard to probing PPIs.77, 200, 235-237 Calculations 
of relative binding free energies are of particular interest, as reliable ∆∆G predictions 
would invite the use of MM-PB/GBSA in protein interaction design or drug discovery. 
The objectives of this study are therefore as follows: 
 To assess the current uses of MM-PB/GBSA for probing protein-protein 
interfaces. Calculating ∆∆G with MM-PB/GBSA is currently performed with one 
of two protocols. The first allows full independence of the MD trajectories of the 
native and mutant protein complexes, while the second assumes that the 
dynamics of the mutant complex can be approximated using those of the native. 
The advantages and disadvantages of both protocols will be appraised through 
comparison of theoretical predictions with experiment, using a prototypical PPI 
that has been previously investigated within the department. 
 To investigate the use of Locally Enhanced Sampling to generate trajectories for 
MM-PB/GBSA analysis. As known from literature studies, accurate free energies 
may require dynamical changes during the binding process to be realistically 
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represented. This is equally applicable to relative binding free energies, as 
differences in the binding process may occur between native and mutant 
structures. The Locally Enhanced Sampling (LES) MD technique (explained 
further in section 4.1.1) may be used to generate multiple MD trajectories of 
identical systems that have different dynamics only in a specified local region. 
 To adapt LES to generate MD trajectories of non-identical systems. This leads to 
trajectories of, for example, a native and mutant protein complex, that 
dynamically differ only in the specified local region. These trajectories may then 
be used for ∆∆G calculations. This adaptation, known as Mutational Locally 
Enhanced Sampling (MULES) will initially be tested using the same prototypical 
PPI used to evaluate existing MM-PB/GBSA ∆∆G methodologies. 
 To validate the MULES approach across a wide dataset. Having established the 
potential of the technique many MULES parameters will be varied and tested, 
including size of the region in which dynamics are allowed to differ, simulation 
length and solvation. This will develop a protocol for the further standard use of 
MULES. The method will then be further developed to assay its performance 
across a much wider range of PPIs. The objective of this is to gain statistical 
information on the accuracy and precision of MULES that can be compared 
directly with alternative techniques for calculating ∆∆G, thereby validating the 
approach not only against experiment, but also against existing methods. 
 To evaluate MULES as a general probe of any mutational change. An ideal 
computational predictor of ∆∆G at interfaces should be able to handle mutations 
of any residue to any other, whether natural or non-natural amino acids. 
However, the prevalence of natural amino acids in the vast majority of PPIs and 
the standard use of alanine scanning60 to discover the contributions of individual 
residues to binding has led most computational protocols to concentrate only on 
the effects of alanine mutations. The final objective of this research is therefore 
to develop MULES into a tool that may be used to perform any desired mutation. 
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3 Comparing computational alanine 
scanning techniques 
3.1 Introduction 
As discussed in the previous chapter, the MM-PBSA and -GBSA techniques have been 
used to calculate binding free energies for numerous protein-protein interactions, often 
with tight correlation of theoretical and experimental values. The techniques calculate 
the absolute binding free energy of a complex, ∆G, from underlying MD trajectories. The 
calculation of ∆∆G between one complex and another requires two individual ∆G 
calculations and hence two underlying trajectories – MM-PB/GBSA do not calculate ∆∆G 
directly within a single simulation as alchemical free energy methods can. 
Studies of PPIs often make use of alanine scanning to identify the contributions of 
individual residues to binding (this concept has been discussed extensively in section 
1.2.3). Alanine scans result in the calculation of ∆∆G between a native complex and a 
complex where one or more residues have been mutated to alanine. Computationally, 
MM-PB/GBSA analysis therefore requires a trajectory of the native complex and a 
trajectory of a mutant complex in which one or more residues have been mutated to 
alanine. 
There are currently two methods commonly used to generate these MD trajectories. The 
first performs separate simulations for each complex. The second only performs a single 
simulation of the native complex, which is used to create the second, alanine mutant, 
trajectory by removing the sidechain of the desired residue down to the C atom. The 
aim of this chapter is to compare the relative accuracy, precision and speed of the two 
techniques, both to experiment and to the popular online Robetta alanine scanning 
server, which also calculates ∆∆G.96, 97 
Multiple independent simulations were used in order to gain information on the 
variance and statistical confidence intervals of each of the methods. Attempts to account 
for entropic contributions to free energy are also described. The chapter concludes with 
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a summary of the problems identified with each method and notes a niche for the 
development of a novel method of generating trajectories for MM-PB/GBSA calculations. 
The majority of work in this chapter has been published as Bradshaw et al., 2011.238 
3.1.1 A prototypical PPI 
Computational methods are usually evaluated by comparison of theoretically predicted 
values to experimentally measured ones. As most computational predictions are 
designed to reduce or better focus experimental efforts, correctly recreating 
experimental results is the goal of many computational models. The use of MM-PBSA 
and -GBSA in calculating ∆∆G is no exception. However, as discussed in chapter 1, 
measuring binding free energies of PPIs experimentally is not a trivial task. 
A prototypical PPI was required in order to obtain a set of experimental ∆∆G that were 
known to be accurate and robust enough to test the accuracy, precision and speed of the 
existing MM-PB/GBSA ∆∆G methods. Rather than extract ∆∆G from literature studies, 
this prototype would ideally be analysed in-house, in order to gain a better 
understanding of the source and magnitude of potential experimental errors. An ideal 
prototype should have a simple practical method of measuring its binding, numerous 
binding residues to ensure ∆∆G cover a wide range of free energies, and available 
structural data to allow ease of simulation for the native complex and its mutants. 
The Bowman-Birk inhibitors239, 240 (BBIs) are a family of peptidic serine protease 
inhibitors found in many plants.241 They are known to have a range of specificities, 
although inhibition is controlled predominantly by the presence of short, well-defined 
peptide loops, cyclised through the disulfide crosslinking of two cysteine residues. 
Mimics of these peptide loops retain the inhibitory properties of the full protein, 
facilitating the study of inhibition mechanisms.242-246 BBIs have also been investigated 
for their medicinal properties247 and their potential for redesign to show new 
specificities and affinities.248-251 
The inhibition loops of Bowman-Birk inhibitors are well suited to being probes of PPIs. 
They are small (9-11mer) peptides amenable to solid-phase peptide synthesis (SPPS), 
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they have well-defined rigid structures that allow facile MD simulation thanks to 
conserved cysteine and proline residues,252, 253 and their activity as protease inhibitors 
lends itself well to simple determination of binding affinity and binding free energies via 
functional assays. BBIs are also a well-established research interest of the group. In 
particular, practical investigations of a synthetic version of the nine residue inhibition 
loop of the Mung Bean Trypsin Inhibitor (MBTI) had already been performed, 
generating a series of experimental ∆∆G between the native MBTI inhibitor (figure 3.1) 
and a number of alanine mutants.254 
 
Figure 3.1 – Native sequence and structure of the synthetic MBTI inhibition loop. The loop is 
cyclised by the oxidation of the two terminal cysteine residues to form a disulfide bridge, giving 
the loop its characteristic structure and function. Residues are labelled according to 
Schechter-Berger nomenclature,255 and the scissile bond denoted by an asterisk. 
Conveniently for computational studies, the crystal structure of the MBTI loop in 
complex with trypsin is also available as PDB accession code 1SMF.256 The crystal 
structure (figure 3.2) shows the very close interaction of the P1 lysine (hereafter 
referred to as P1Lys) residue of the inhibitor with the S1 aspartic acid residue of trypsin. 
Given the specificity of trypsin for large, basic amino acids, this is to be expected. The 
crystal structure also shows that the protein-peptide interface extends from the P3 
cysteine (P3Cys) to the P2’ isoleucine (P2’Ile) residue. The P3’ – P6’ residues are 
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predominantly solvent exposed, but are also capable of interacting with the receptor. 
Overall the interface has a buried surface area, calculated with the online EBI PISA web 
server,257 of approximately 500 Å2. This places it at the lower end of the size range for 
PPIs, but its ease of simulation and the presence of existing experimental ∆∆G data 
outweigh this. 
 
Figure 3.2 – A) Cartoon representation of MBTI (red) – trypsin (blue) crystal structure from PDB 
entry 1SMF. Synthetic inhibitor loop is cyclised by the presence of a disulfide, and interacts 
predominantly via a salt bridge between the P1 lysine and S1 aspartate residues (shown in 
orange). B) Surface representation of the 1SMF structure, showing the interface region extends 
beyond the specificity pocket, although some residues remain solvent exposed. Images created 
with UCSF Chimera.258 
Within the MBTI scaffold the two cysteine residues are required for cyclisation of the 
peptide and the two prolines maintain structure and rigidity of the loop. Therefore the 
existing experimental data covers five alanine mutations of the native structure, at the 
P2Thr, P1Lys, P1’Ser, P2’Ile and P5’Glu positions. Although the number of mutants was 
low, the changes in binding affinity associated with the mutations spanned several 
orders of magnitude, corresponding to ∆∆G between 1 - 5 kcal mol-1. Taking all of the 
above features into account, the trypsin-MBTI loop complex was chosen as a 
prototypical PPI for the study of existing MM-PB/GBSA methods for calculating relative 
binding free energies. 
3.1.2 Previous experimental data 
As stated above, the determination of experimental ∆∆G between the synthetic MBTI 
loop and its alanine mutants had been previously carried out within the group by 
Bhavesh Patel.254 The below experimental work and measured ∆∆G values are therefore 
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not submitted for assessment as part of this study, but are repeated here to clarify the 
experimental process and determination of ∆∆G values for comparison to predictions. 
Briefly, the native peptide and single alanine mutants at the P2, P1, P1’, P2’ and P5’ 
positions were synthesised by SPPS, cyclised through the intramolecular formation of a 
disulfide, purified and identified using high performance liquid chromatography (HPLC) 
and mass spectrometry (MS). Competitive inhibition assays of each peptide were then 
carried out against the enzyme trypsin, using a fluorogenic substrate in order to 
determine relative enzyme activity levels at different concentrations of inhibitor. This 
provided an IC50 value for each peptide; the inhibitor concentration at half maximal 
inhibition. IC50 values are not absolute and depend upon assay conditions. However, 
they may be related to the inhibition constant (which is absolute) using the 
Cheng-Prusoff equation: 
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( 3-1 ) 
Where [S] is the substrate concentration in the assay and KM is the substrate 
concentration at half maximal enzyme activity. The inhibition constant, Ki (identical to 
the Kd for a non-inhibitory binding interaction) is then related to the binding free energy 
as follows: 
        (  ) ( 3-2 ) 
Where R is the gas constant and T temperature. The combination of the above two 
equations implies that accurate calculation of absolute binding free energy (∆G) from 
IC50 requires a further measurement of the KM of the enzyme/substrate complex. 
However, this may not be the case, for two reasons. Firstly, under conditions where 
[ ]    , the denominator of the Cheng-Prusoff equation approximates to one, and 
hence       . More importantly for our purposes however, if relative free energies 
(∆∆G) between two mutations assayed with the same experimental conditions are 
desired then the effect of the Cheng-Prusoff equation is simply to scale both IC50 by a 
constant. The ∆∆G between the two mutants is identical whether or not this scaling is 
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performed as it depends merely on the relative strength of binding – the ratio of Ki – of 
one mutant to another. Therefore if only ∆∆G measurements are required then the Ki 
can be approximated to be equal to the IC50 under all conditions. 
The measured ∆∆G for the synthetic MBTI inhibitor and its mutants are shown in table 
3.1. To reiterate, these measurements were not performed in this study and are taken 
from previously performed work,254 but are repeated here for clarity as they have been 
used to validate the computational predictions performed in this research. 
Table 3.1 – Experimentally determined Ki values (measured as IC50 for calculation of ∆∆G) and 
associated binding free energies for native trypsin/MBTI complex from PDB entry 1SMF and 
alanine mutants thereof. Binding free energies calculated at 300 K for direct comparison to 
computational values. 
Mutation Ki (µM) ∆G (kcal mol-1) ∆∆G (kcal mol-1) 
Native (1SMF) 0.304 ± 0.03 -8.94 ± 0.06 0 
Glu(P5’)Ala 1.68 ± 0.12 -7.92 ± 0.04 1.02 ± 0.07 
Ser(P1’)Ala 7.51 ± 0.46 -7.03 ± 0.04 1.91 ± 0.07 
Thr(P2)Ala 9.61 ± 0.48 -6.88 ± 0.03 2.06 ± 0.07 
Ile(P2’)Ala 114 ± 27.50 -5.41 ± 0.14 3.53 ± 0.16 
Lys(P1)Ala > 4500a > -3.22 > 5.72 
a Less than 10% inhibition at 500 µM, which suggests Ki > 4500 µM 
3.1.3 Computational alanine scanning techniques 
As briefly mentioned in section 2.3.2 there are currently two commonly used methods 
for calculating ∆∆G with MM-PB/GBSA. These differ only in the way that the native and 
mutant MD trajectories are generated. As discussed, the simplest technique is to carry 
out separate MD simulations of the native and each mutant structure. This will hereafter 
be referred to as the ‘Full MD’ approach. 
The full MD approach requires only initial structures for the native and mutant 
complexes. These can both be taken from X-ray or NMR structures, if both exist, or 
alternatively the structure of the mutant can be obtained by a simple point mutation and 
minimisation of the structure of the native. The two resulting MD simulations allow 
complete variation in structure and dynamics between the two complexes, but 
obviously at twice the computational cost of a single simulation. 
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An alternative technique for generating the trajectory of an alanine mutant was first 
proposed by Massova and Kollman in 1999.259 This approach is often known in the 
literature simply as ‘computational alanine scanning mutagenesis’, but is referred to 
here at the ‘post-processing’ method in order to differentiate from the full MD approach 
to alanine mutations. Post-processing requires only one simulation of the native 
complex. Each of the structural snapshots in the native trajectory is then copied and 
truncated in order to generate an alanine at the desired mutation point. The rest of the 
structure is left unchanged - thus the structure and dynamics of the alanine mutant are 
assumed to be identical other than at the mutated residue. Figure 3.3 gives an example 
of this process. 
 
Figure 3.3 – Example of the post-processing alanine scanning method. A) A snapshot of initial 
structure with the desired residue (here P2’Ile) present in its native form. B) The equivalent 
P2’Ala snapshot in the mutant MD trajectory. Sidechain beyond the Cß atom has been 
transformed into hydrogen atoms, with no perturbation to the surrounding structure. 
The Ile to Ala mutation shown in figure 3.3 is carried out by first deleting the 
coordinates of the sidechain atoms beyond the Cß of the initial Ile residue. This leaves a 
residue with a sidechain consisting of a single carbon atom, Cß and a single hydrogen 
atom, Hß1. Two additional hydrogen atoms are then inserted at the standard C-H bond 
length and along the vectors of the previous Cß-Cγ bonds, resulting in an alanine residue. 
The post-processing method has been used to perform alanine scanning on many PPIs, 
often successfully identifying hot-spots at interfaces and with impressive correlation of 
∆∆G to experiment.55, 259-261 However, the lack of structural rearrangement on mutation 
has led to the overestimation of ∆∆G in some cases, particularly those involving 
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mutations of charged residues.260 The caveats of post-process alanine scanning will be 
discussed further in section 3.4.4, with reference to the results of this study. 
Despite a wealth of studies involving either post-process or full MD alanine scanning 
there was no direct comparison of the accuracy, precision and speed of both methods, 
using a consistent set of mutations and with statistical analysis of results, at the 
beginning of this research. Here these properties are compared for the first time, using 
the 1SMF complex as a prototypical PPI, the set of five alanine mutations of table 3.1 as a 
validated experimental dataset, and sets of ten independent simulations to calculate 
statistical confidence levels in the observed results. 
3.2 ‘Full MD’ approach 
3.2.1 Methods 
Full details of all simulations and analysis performed are available in chapter 8, but are 
summarised here to enable comparison with the post-processing approach. All MD 
simulations were performed with the PMEMD (Particle Mesh Ewald Molecular 
Dynamics) module of the Amber 10 suite,262 using the ff99SB forcefield.163 The full MD 
approach simulated a set of ten individual MD trajectories for the native trypsin/MBTI 
complex and each of the P2Ala, P1Ala, P1’Ala, P2’Ala and P5’Ala mutants thereof, giving 
a total of 60 individual simulations. Initial protein structures (taken or modified from 
the X-ray crystal structure of PDB entry 1SMF)256 were charge neutralised, solvated, 
energy minimised, heated to 300 K, equilibrated at constant pressure of 1.0 bar and 
finally simulated at constant temperature and pressure for a period of 10 ns. Structural 
snapshots were saved at intervals of 10 ps, giving a total of 1000 snapshots for each MD 
trajectory. Independence of the trajectories was ensured by the use of a different seed 
for the random number generator of the Langevin thermostat for each run.263 
MM-PBSA and MM-GBSA free energy calculations were then performed using the 
mm_pbsa perl scripts in Amber. All 1000 snapshots from each trajectory were analysed, 
resulting in a mean ∆G for each simulation. Each of the 10 runs of the native complex 
were then compared with each of the 10 runs of each mutant, giving a total of 100 ∆∆G 
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for each mutation and each of the PB and GB solvation methods of the free energy 
calculation. The mean ∆∆G and associated standard deviation were calculated from 
these 100 individual values. 
3.2.2 MD simulations 
For both the full MD and post-processing protocols, the ten MD trajectories of the native 
1SMF structure were taken from a previous study.264 All MD simulations, free energy 
calculations and analyses of the mutant complexes were performed entirely within the 
scope of this project, however. 
The initial stage of any MD study is to check the equilibration and stability of the 
performed simulations. Total, potential and kinetic energy, temperature, pressure, 
periodic box volume and density data were extracted from output files for both the 
equilibration and production sections of each trajectory and plotted to ensure the 
stability of each measure. Example plots are shown in appendix 2, figures S1 to S10. 
Following validation of trajectory stability, the dynamics of each run were evaluated by 
visual inspection of the trajectory structures and calculation of the backbone root mean 
square deviation (RMSD) and residue-based root mean square fluctuations (RMSF) for 
each simulation. Respectively, these provide measures of how far a complex structure 
deviates from its initial conformation and which domains of the complex fluctuate more 
(on average) during a trajectory. Typically backbone RMSD remained below 2.0 Å across 
all simulations, with average fluctuations of individual residues varying between 
0.5 - 3.0 Å. Example plots are shown in figure 3.4. 
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Figure 3.4 – Example plots of complex RMSD (top) and by-residue RMSF (bottom). Internal 
Amber numbering used: trypsin corresponds to residues 1-223, MBTI to residues 224-232. The 
first simulation of the 1SMF native complex is used as a typical trajectory. 100-point running 
average is shown in blue for the RMSD plot. 
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Typically, the backbone RMSD of the complex rose rapidly as the complex first moved 
away from the initial conformation and then settled around a mean value. Large 
backbone movements were seen as step changes in RMSD, such as the one seen in the 
last 400 ps of figure 3.4. Trajectories with any of these step changes were further 
checked by visual inspection to ensure binding of the complex remained unaffected. 
figure 3.4 also shows that residues 9 to 10, 56 to 61 and 221 to 223 had higher than 
average fluctuations. These corresponded to largely solvent exposed regions of the 
trypsin receptor, which are expected to have greater range of motion. Importantly, 
residues 224 to 232, corresponding to the synthetic MBTI loop, remained with average 
or lower than average fluctuations, indicating that the complex remained stably bound 
throughout. 
Equivalent analysis of all runs showed that all trajectories were equilibrated and all 
complexes remained stably bound throughout. MM-PB/GBSA calculations were then 
performed using snapshots from each trajectory. 
3.2.3 Free energy calculations 
MM-PBSA and MM-GBSA ∆G calculations were carried out for every complex using the 
‘single trajectory’ method to generate receptor and ligand structures from the parent 
complex trajectory. To further evaluate the equilibration of each trajectory and the 
effects of conformational changes on binding, the fluctuation of ∆G during the course of 
each trajectory was also plotted. Figure 3.5 shows a typical example of these plots. 
Although instantaneous snapshots of ∆G may vary wildly across the trajectory, the mean 
value should remain relatively constant to indicate the sampling of a single equilibrium 
conformational ensemble. Although this is seen to be the case in figure 3.5, some 
trajectories showed larger fluctuations in mean ∆G across the course of the simulation. 
These trajectories were further analysed to investigate the cause of these changes in 
binding, particularly whether they were correlated to any conformational changes at the 
protein-inhibitor interface. The effects of these changes are further explored in section 
3.4.1.2, in comparison to the effects of conformation in post-processing calculations. 
 88 
 
Figure 3.5 – Variation in the calculated MM-PBSA (black) and -GBSA (blue) free energies across 
the course of the first native 1SMF trajectory. 200-point running averages (solid lines) are shown 
for clarity as individual results fluctuate greatly. 
Comparison of the 10 mean ∆G of the native complex simulations with the 10 mean ∆G 
of each of the mutant conformations gave 100 individual ∆∆G for each complex and 
solvation method in the calculations. Full results are shown in appendix 2, tables S1 to 
S5, but ∆∆G results are summarised here in table 3.2. 
Table 3.2 – Mean ∆∆G calculated using the full MD method. Results include associated standard 
deviations and 95% confidence interval of the mean across ten independent trajectories. 
Experimental ∆∆G (from table 3.1) also included for reference. 
Mutation Expt. ∆∆G 
/kcal mol-1 
Solvation Mean ∆∆G 
/kcal mol-1 
Std. Dev. 95% C.I. 
/kcal mol-1 
Glu(P5’)Ala 1.02 ± 0.07 PB 2.59 5.59 ± 1.11 
Ser(P1’)Ala 1.91 ± 0.07 PB 2.88 5.74 ± 1.14 
Thr(P2)Ala 2.06 ± 0.07 PB 3.43 5.46 ± 1.08 
Ile(P2’)Ala 3.53 ± 0.16 PB 6.57 5.62 ± 1.12 
Lys(P1)Ala > 5.72 PB 9.04 5.87 ± 1.16 
Glu(P5’)Ala 1.02 ± 0.07 GB 2.43 4.04 ± 0.80 
Ser(P1’)Ala 1.91 ± 0.07 GB 3.40 4.26 ± 0.85 
Thr(P2)Ala 2.06 ± 0.07 GB 5.33 4.18 ± 0.83 
Ile(P2’)Ala 3.53 ± 0.16 GB 7.98 4.34 ± 0.86 
Lys(P1)Ala > 5.72 GB 11.22 4.94 ± 0.98 
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The full MD approach correctly recreated the ordering of the experimental ∆∆G whether 
MM-PBSA or MM-GBSA was used. In terms of accuracy, excluding the P1Ala mutation 
(for which an experimental ∆∆G was not unambiguously determined), the mean 
unsigned error (MUE) to experiment was 1.76 kcal mol-1 for the PB method and 
2.66 kcal mol-1 for GB. 
Despite the correct ordering of the mean ∆∆G predictions, individual ∆∆G results 
covered a wide range of values (appendix 2, tables S1 to S5). The 100 individual ∆∆G of 
the P1Ala mutation, for example, ranged from 24.50 to -3.32 kcal mol-1 with MM-PBSA, 
and 24.33 to 2.11 kcal mol-1 with -GBSA. Given that the P1Ala mutation is greatly 
detrimental to inhibition and shows a large positive ∆∆G experimentally, the presence of 
such over- and underestimated ∆∆G in individual computational predictions results in a 
lack of confidence that any individual result correctly represents the computationally 
predicted ∆∆G on mutation. Multiple repeat simulations, such as the ten performed here 
for each mutant, generate a mean ∆∆G value and associated statistical confidence 
interval, which can be used to better assess the accuracy of full MD. 
The large standard deviations and confidence intervals also result in a lack of statistical 
confidence in predictions. Using MM-PBSA, none of the observed differences between 
the P5’Ala, P1’Ala and P2Ala ∆∆G are statistically significant. MM-GBSA performs with 
slightly greater precision, due to the lower variance observed, but at the cost of accuracy 
as detailed above. To investigate whether allowing the system to equilibrate for longer 
affected the precision of results, free energy calculations were repeated after excluding 
the first 2 ns of each trajectory as additional equilibration time. Results are summarised 
in table 3.3.  
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Table 3.3 – Full MD mean ∆∆G calculated after excluding the first 2 ns of each trajectory as 
equilibration. Results include associated standard deviations and 95% confidence interval of the 
mean across ten independent trajectories. Experimental ∆∆G also included for reference. 
Whilst the results of tables 3.2 and 3.3 are very similar overall, there were two effects of 
increasing equilibration time to 2 ns and hence reducing production MD time to 8 ns. 
Firstly, the P5’Ala and P1’Ala predictions swapped order when a shorter analysis time 
was used in conjunction with MM-PBSA. This was unsurprising, given the errors in the 
predictions, but was also joined to an increase in mean unsigned error to experiment to 
2.06 and 2.93 kcal mol-1 for PB and GB solvation respectively. Secondly, analysing fewer 
snapshots in the free energy calculations resulted in an increase in standard deviations 
and errors. Although this reassuringly suggested that the MD trajectories used were 
suitably equilibrated, it also pointed to far longer simulations being required for 
statistical precision of the results. 
It should be remembered at this stage that all computational calculations had been of 
‘effective’ ∆∆G - structural changes between mutants were assumed to be small enough 
to make entropic contributions negligible. Given the large variation in individual ∆∆G 
calculations this clearly may not have been the case. Therefore further investigations 
into the effects of specifically calculating entropic contributions for the ∆G and ∆∆G 
results were carried out. 
3.2.4 Entropic considerations 
Including estimates of entropy in MM-PB/GBSA free energy calculations has been shown 
to have either positive265 or negative221 effects on the correlation of results to 
Mutation Expt. ∆∆G 
/kcal mol-1 
Solvation Mean ∆∆G 
/kcal mol-1 
Std. Dev. 95% C.I. 
/kcal mol-1 
Glu(P5’)Ala 1.02 ± 0.07 PB 3.09 6.13 ± 1.22 
Ser(P1’)Ala 1.91 ± 0.07 PB 2.89 6.83 ± 1.36 
Thr(P2)Ala 2.06 ± 0.07 PB 3.41 6.33 ± 1.26 
Ile(P2’)Ala 3.53 ± 0.16 PB 7.35 6.47 ± 1.28 
Lys(P1)Ala > 5.72 PB 9.25 6.38 ± 1.27 
Glu(P5’)Ala 1.02 ± 0.07 GB 2.74 4.66 ± 0.92 
Ser(P1’)Ala 1.91 ± 0.07 GB 3.52 4.96 ± 0.98 
Thr(P2)Ala 2.06 ± 0.07 GB 5.39 4.86 ± 0.96 
Ile(P2’)Ala 3.53 ± 0.16 GB 8.58 4.98 ± 0.99 
Lys(P1)Ala > 5.72 GB 11.74 5.53 ± 1.10 
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experiment, depending on the system investigated. In this study, it was hoped that the 
inclusion of entropy would improve the accuracy of ∆∆G predictions and remove some 
of the large error to experiment seen with the full MD method. 
As explained in chapter 2 there are two commonly used methods for estimating entropy 
from MD simulations. In this case, quasiharmonic analysis was used to calculate a single 
estimate of entropy for each mutant. All 10000 snapshots from the 10 trajectories were 
used in each QH analysis, as previous studies had shown poor convergence with smaller 
numbers of snapshots.200, 206 Although normal modes calculations could have provided 
individual entropy estimates for each trajectory, the computational cost of carrying this 
out for 600 ns of simulation (60 individual trajectories of the native and mutant 
structures) was deemed prohibitive. 
The entropies calculated for each mutant and their effects when included in ∆∆G are 
shown in table 3.4. Although including entropy improves accuracy to experiment 
somewhat for the P2’Ala and P1Ala mutations, the overall effect is to remove the 
predictive power of the full MD method, as ∆∆G are no longer ordered correctly 
compared to experiment. 
Table 3.4 – Entropic contributions to free energy at 300K calculated with quasiharmonic 
analysis across all ten independent trajectories for each mutant. Effect on MM-PBSA ∆∆G 
included for reference. 
To summarise, the full MD method was shown to successfully recreate experimental 
ordering of ∆∆G, albeit with relatively large errors to experiment and large uncertainties 
in the results, hampering statistical confidence. Increasing the length of time set aside 
for trajectory equilibration made little difference to accuracy and at the expense of 
precision - suggesting that even longer trajectories are needed to improve predictions 
Complex SCOM / cal 
mol-1 K-1 
SREC / cal 
mol-1 K-1 
SLIG / cal 
mol-1 K-1 
∆S / cal 
mol-1 K-1 
-T∆∆S / 
kcal mol-1 
∆∆GPB / 
kcal mol-1 
Native 11545.2 11134.1 556.9 -145.8 0 0 
Glu(P5’)Ala 11484.9 11085.4 545.4 -145.9 0.03 2.62 
Ser(P1’)Ala 11586.9 11160.9 576.2 -150.3 1.35 4.23 
Thr(P2)Ala 11590.1 11141.5 610.8 -162.2 4.92 8.35 
Ile(P2’)Ala 11498.0 11093.3 541.3 -136.6 -2.76 3.81 
Lys(P1)Ala 11625.3 11210.2 558.3 -143.3 -0.74 8.30 
 92 
further. Finally, given some of the caveats of QH entropy estimates, the possibility that 
the poor accuracy of the full MD method to experiment is partly caused by neglecting 
entropy cannot be completely discounted. However, at the very least, including entropy 
‘correctly’ (for each individual trajectory) would require multiple costly normal modes 
analyses. All of these results will be compared with those of the post-processing method 
in the following section. 
3.3 ‘Post-processing’ approach 
3.3.1 Methods 
The post-processing method only requires MD simulations of the native complex, which 
had already been performed in the previous full MD analysis. For the sake of 
consistency, the ten previous simulations of the native 1SMF complex were therefore 
used as the basis for the post-processing free energy calculations. 
Post-process alanine scanning as described by Massova and Kollman259 is fully 
integrated into the mm_pbsa perl scripts in Amber, requiring no additional scripting or 
modifications. These scripts were used to carry out the free energy calculations for all 
five alanine mutants. As each alanine free energy calculation is specific to a single native 
free energy calculation, the ten trajectories led to ten ∆∆G values for each mutant. Mean 
values and associated statistics were again calculated from these ten individual ∆∆G. 
3.3.2 Free energy calculations 
As the structural equilibration of the simulations had already been verified for the full 
MD method, no further analysis of this was required. Calculated ∆∆G results for each 
mutant are summarised in table 3.5, full results are available in appendix 2, tables S6 to 
S10. 
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Table 3.5 – Mean ∆∆G calculated with the post-processing method. Results include standard 
deviation and 95% confidence interval of the mean across ten independent trajectories. 
Experimental ∆∆G also included for reference. 
Again, calculated ∆∆G correctly recreated the ordering of the experimentally measured 
results, except for the switch of the P2Ala and P2’Ala ∆∆G calculated with MM-GBSA. 
However, the difference between these two mutants was not statistically significant 
(p = 0.91) and was thus disregarded. Mean unsigned error to experiment was 
0.84 kcal mol-1 for PB solvation and 1.19 kcal mol-1 for GB, indicating much greater 
accuracy than the full MD approach. This level of accuracy also compares similarly to 
other post-processing studies, suggesting robustness of the method across systems.259, 
260 Furthermore, error in the mean results (as measured by confidence intervals) was 
much smaller than that seen in full MD. The post-processing approach showed 
significant improvements over full MD in terms of both accuracy and precision. 
Interestingly, the improvement in precision was not equal across all mutations and both 
solvation methods. The P1Ala mutation showed larger error than other mutations, and 
much larger for the MM-PBSA calculation than the MM-GBSA. As shown in figure 3.2, the 
P1 lysine residue forms a highly stable salt bridge with the S1 aspartate residue of 
trypsin. The post-processing method has been known to overestimate the effects of 
alanine mutations where partners are salt bridged, presumably as, in reality, disruption 
of a salt bridge would result in large structural rearrangements that are not accounted 
for when using post-processing. PB results are also known to suffer from this more 
greatly than GB results.260 This explains the varied nature of the P1Ala MM-PBSA ∆∆G. 
Ways to overcome this variation are discussed in section 3.4.1.3. 
Mutation Expt. ∆∆G 
/kcal mol-1 
Solvation Mean ∆∆G 
/kcal mol-1 
Std. Dev. 95% C.I. 
/kcal mol-1 
Glu(P5’)Ala 1.02 ± 0.07 PB 0.45 0.27 ± 0.19 
Ser(P1’)Ala 1.91 ± 0.07 PB 0.93 0.46 ± 0.33 
Thr(P2)Ala 2.06 ± 0.07 PB 3.02 0.69 ± 0.49 
Ile(P2’)Ala 3.53 ± 0.16 PB 4.39 0.61 ± 0.44 
Lys(P1)Ala > 5.72 PB 9.45 3.44 ± 2.46 
Glu(P5’)Ala 1.02 ± 0.07 GB -0.07 0.19 ± 0.14 
Ser(P1’)Ala 1.91 ± 0.07 GB 0.65 0.13 ± 0.09 
Thr(P2)Ala 2.06 ± 0.07 GB 4.00 0.32 ± 0.23 
Ile(P2’)Ala 3.53 ± 0.16 GB 3.98 0.47 ± 0.34 
Lys(P1)Ala > 5.72 GB 6.55 0.58 ± 0.41 
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For full comparison to the full MD approach, the post-processing results were also 
reanalysed after discarding the first 2 ns of simulation as equilibration time. Results are 
summarised in table 3.6. 
Table 3.6 – Mean ∆∆G calculated with the post-processing method after excluding the first 2 ns 
of each trajectory. Results include standard deviation and 95% confidence interval of the mean 
across ten independent trajectories. Experimental ∆∆G also included for reference. 
Discarding the first 2 ns of simulation made little difference to accuracy and precision, 
and no difference to the overall ordering of predictions. This reiterated the robustness 
of post-processing to changes in protocol, suggesting that efficiency of predictions could 
be further improved by further reducing the length of MD simulation. It has been 
suggested that ∆∆G values could be calculated most efficiently using single 
protein-ligand structures for MM-PB/GBSA, rather than ensembles from MD 
simulations.265, 266 This is also the methodology of the online Robetta alanine scanning 
server,97 although that makes use of an empirically scaled MM energy function rather 
than the fully physical method used by MM-PB/GBSA (see section 8.4.1).96 
The advantage of such single-structure approaches is clear, as they take seconds or 
minutes to perform compared to the hours required for multiple snapshots. To 
investigate the accuracy of these methods three sets of individual structures were 
analysed to produce three sets of ∆∆G; the 1SMF structure compared with its 
post-processing alanine mutants, the energy-minimised 1SMF structure compared with 
its post-processing alanine mutants, and the energy-minimised 1SMF structure 
compared with its energy-minimised alanine mutants. All three sets were analysed with 
Mutation Expt. ∆∆G 
/kcal mol-1 
Solvation Mean ∆∆G 
/kcal mol-1 
Std. Dev. 95% C.I. 
/kcal mol-1 
Glu(P5’)Ala 1.02 ± 0.07 PB 0.42 0.29 ± 0.21 
Ser(P1’)Ala 1.91 ± 0.07 PB 0.88 0.54 ± 0.39 
Thr(P2)Ala 2.06 ± 0.07 PB 2.88 0.84 ± 0.60 
Ile(P2’)Ala 3.53 ± 0.16 PB 4.32 0.77 ± 0.55 
Lys(P1)Ala > 5.72 PB 8.97 3.89 ± 2.78 
Glu(P5’)Ala 1.02 ± 0.07 GB -0.09 0.20 ± 0.14 
Ser(P1’)Ala 1.91 ± 0.07 GB 0.63 0.14 ± 0.10 
Thr(P2)Ala 2.06 ± 0.07 GB 3.96 0.39 ± 0.28 
Ile(P2’)Ala 3.53 ± 0.16 GB 3.91 0.60 ± 0.43 
Lys(P1)Ala > 5.72 GB 6.59 0.74 ± 0.53 
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both MM-PBSA and MM-GBSA. The 1SMF crystal structure was also submitted to the 
Robetta server for comparison - submission of other structures was deemed 
unnecessary as Robetta includes its own sidechain rotamer optimisation protocol 
during mutation. ∆∆G results are summarised in table 3.7. 
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Table 3.7 - ∆∆G for alanine mutants of single structures, calculated with the MM-PBSA, -GBSA and Robetta methods. 
 aCalculations performed on 1SMF crystal structure stripped of water and ions, and post-process alanine mutants thereof 
bCalculations perfomed on minimised 1SMF crystal structure stripped of water and ions, and post-process alanine mutants thereof 
cCalculations perfomed on minimised 1SMF crystal structure stripped of water and ions, and minimised alanine mutants thereof 
dCalculations performed on 1SMF crystal structure, analysed with the online Robetta server. Solvation methods not applicable. 
 
 
 
 
Mutation Solvation Cryst. Struct. ∆∆Ga 
/kcal mol-1 
Minimised 1 ∆∆Gb 
/kcal mol-1 
Minimised 2 ∆∆Gc 
/kcal mol-1 
Robetta ∆∆Gd 
/kcal mol-1 
Glu(P5’)Ala PB -3.28 1.14 -0.59 0.47 
Ser(P1’)Ala PB 2.56 1.68 4.28 1.37 
Thr(P2)Ala PB 7.76 6.84 11.77 2.69 
Ile(P2’)Ala PB 4.39 6.58 9.88 2.02 
Lys(P1)Ala PB 20.52 26.25 15.86 6.94 
Glu(P5’)Ala GB -6.46 -0.59 -0.76 N/A 
Ser(P1’)Ala GB 0.45 1.50 -0.83 N/A 
Thr(P2)Ala GB 5.25 5.83 8.57 N/A 
Ile(P2’)Ala GB 2.86 5.66 4.75 N/A 
Lys(P1)Ala GB 8.90 11.61 12.94 N/A 
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Neither MM-PBSA nor MM-GBSA performed well when only single structures were 
analysed, no matter which minimisation protocol is used. Ordering of the predicted ∆∆G 
was consistently wrong. Although the Robetta server generated ∆∆G of a more realistic 
magnitude, this was to be expected given that its energy function is empirically 
weighted. Additionally, Robetta also incorrectly ordered the P2Ala and P2’Ala mutants, 
through a combination of overestimating the effect of the former and underestimating 
the latter. The overestimation of ∆∆G for the P2Ala mutant was systematic across all 
methods used, perhaps indicating that the P2Thr residue in the crystal structure adopts 
a particularly favourable conformation, and thus its contribution to binding is only 
correctly sampled by MD simulation. In summary it is clear that, for this system, 
single-structure techniques did not reliably generate ∆∆G and that ensemble approaches 
were more appropriate, despite their additional cost. 
3.3.3 Entropic considerations 
The major assumption made in calculating ∆∆G with post-processing is that no 
structural rearrangement of the interface occurs on mutation. The overall ∆∆G consists 
of both enthalpic and entropic contributions, however, as seen with the full MD protocol, 
entropic contributions are difficult and time consuming to calculate, and may also 
adversely affect the correlation of results with experiment. For the post-processing 
method, trajectories of the native and mutant complexes are almost identical. Entropies 
calculated from these trajectories should therefore also be almost identical. Inclusion of 
an entropic term in post-process alanine scanning would seem to be counterproductive, 
as any minor improvements in accuracy or precision of ∆∆G would be outweighed by 
the huge increase in computational cost of the free energy calculation. As such, no 
entropy calculations were performed for the post-processing method. 
3.4 Discussion and conclusions 
3.4.1 Accuracy and precision 
3.4.1.1 Correlations to experiment 
The aim of this study was to compare and contrast the full MD and post-processing 
protocols and identify the advantages and disadvantages of each. Although the 
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prototypical PPI and associated dataset of alanine mutants used here are relatively 
small, their results are consistent with previous studies, and hence some general 
conclusions can be drawn as to the suitability of each approach for PPI research. 
Overall, both methods performed well in recreating the ordering of experimental 
results, and with reasonable errors to experiment. Figure 3.6 shows the correlation of 
both techniques and solvation methods to experiment. 
 
Figure 3.6 – Correlation between calculated and experimental ∆∆G values for both post-process 
(above) and full MD (below) protocols, and PB (crosses/solid line) and GB (squares/dashed line) 
solvation methods. P1Ala mutation excluded as experimental ∆∆G was not determined 
unambiguously. 
All methods tested gave good to excellent correlations to experiment, although slopes of 
the regression lines were consistently > 1, indicating a consistent overestimation of ∆∆G. 
This might be expected for the post-processing approach, as including structural 
rearrangement would likely compensate for some of the unfavourable effects of 
truncating a sidechain, but is slightly more surprising for the full MD protocol. 
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3.4.1.2 Dealing with conformational changes 
In theory, the full MD approach should be able to represent all the potential effects of an 
alanine mutation as it takes into account changes in protein structure and dynamics. 
This should result in a far greater accuracy to experiment than the post-processing 
approach, with its inherent assumption of no structural changes beyond the mutated 
residue. In practice, this is not seen to be the case. The full MD approach requires 
averaging of results from several independent trajectories to maintain experimental 
ordering of ∆∆G, and, although it is likely that longer simulations would result in greater 
accuracy and precision, this comes at great computational expense. 
The post-processing method conversely benefits from the lack of structural 
rearrangements because of the cancellation of errors this provides in the free energy 
calculation. This leads directly to the high precision of the results. As noted during the 
initial tests of trajectory stability and equilibration, some trajectories sampled different 
conformational changes to others. Conformational changes, particularly at binding 
interfaces, may have dramatic effects on binding free energies. To investigate this, 
overall ∆G for each simulation of the 1SMF native complex were decomposed into 
by-residue contributions. Changes in MBTI residue contribution were then correlated 
with changes in 1 dihedral angle (representing sidechain rotation about the Cα-Cß 
bond). Figure 3.7 shows an example of one such change, the rotation of the P2’Ile 
sidechain, that was shown to correlate directly with a change in its contribution to 
binding. 
All ligand residues had differing rotamer populations across the ten native trajectories, 
but the P2’Ile differences were particularly pronounced. Across the full dataset of 
10 000 snapshots, the P2’Ile had a 1 dihedral of -60˚ in 7571, -180˚ in 1519, and +60˚ in 
910. As shown in figure 3.7, these populations varied greatly both within and between 
runs. Runs 1 and 7 are shown as they show differences in dynamics most clearly, but 
similar effects were observed during other simulations, and to a lesser extent for other 
sidechains. 
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Figure 3.7 – Variation in contribution to ∆G (below) and 1 dihedral angle (above) for P2’Ile over 
the course of native runs 1 (solid lines) and 7 (dashed lines). A change in sidechain rotamer 
observed in run 7 corresponds to a significant change in residue contribution to ∆G. Both 
measures shown as running averages for clarity (20-point window for dihedral angle, 100-point 
window for ∆G). Dihedral angles above +120˚ are shown as ‘negative’ dihedrals (< -180˚) for ease 
of visualisation. 
The ∆G contribution remained relatively stable for run 1, where the P2’Ile consistently 
has a dihedral of -60˚. Run 7 however showed a switch in dihedral angle after 
approximately 200 snapshots, which corresponded to an immediate increase in ∆G of 
approximately 1 kcal mol-1. 
As previously discussed, sampling of different conformational substates is one of the 
advantages of performing multiple independent simulations, as trajectories cover a 
wider area of equilibrium phase space. However, if the native and mutant trajectories 
cover significantly different areas of phase space, as is possible with the full MD method, 
the conformational changes in one partner may not be equally represented in the 
second. This leads to large errors in individual ∆∆G predictions, as shown in figure 3.8. 
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Figure 3.8 – Comparison of ∆G 100-point running averages over the course of runs 1 (above) 
and 7 (below) and native (solid lines) and P2’Ala mutant (dashed lines) complexes, using the full 
MD approach. Difference between native and mutant lines corresponds to ∆∆G. 
The variation in individual ∆G across runs, caused by the differential sampling of 
conformational substates indicated by dihedral angle changes, led to asynchronously 
fluctuating ∆∆G with the full MD approach. These large fluctuations, even varying from 
+10 to -5 kcal mol-1 just for the two runs shown in figure 3.8, were the source of the 
large error bars in the full MD predictions and the requirement for averaging results 
across several trajectories. Post-processing, despite being based on the same native 
simulations, did not see the same variation in ∆∆G (figure 3.9). 
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Figure 3.9 - Comparison of ∆G running averages over the course of runs 1 (above) and 7 (below) 
and native (solid lines) and P2’Ala mutant (dashed lines) complexes, using the post-processing 
protocol. Difference between native and mutant lines corresponds to ∆∆G.  
The post-processing ∆∆G remained roughly constant at around 4 kcal mol-1 both during 
and between trajectories. This was a direct consequence of the cancellation of errors 
derived from not allowing structural differences between native and mutant 
trajectories. This eliminated much of the variation in both the enthalpic and entropic 
contributions to ∆∆G, enhancing the repeatability and precision of the technique, and 
allowing the results of a single run to be treated with far greater confidence than with 
the full MD approach. 
3.4.1.3 Charged residue mutations 
The post-processing approach is not without its limitations. Where structural 
rearrangements are likely on mutation, the full MD method may perform better. This is 
seen in the P1Ala mutation, which disrupts a highly favourable salt bridge and also 
involves a large change in sidechain volume from lysine to alanine. With full MD, the 
variation in individual ∆∆G and hence precision of the mean result is consistent with 
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that of other mutations. With post-processing however, and particularly with MM-PBSA, 
the precision is noticeably worse than for the other estimates. 
The variability and often overestimation of ∆∆G for charged mutations has been a well 
known problem for the post-processing method since Huo, Massova and Kollman’s first 
widespread validation of the technique, using the human growth hormone-receptor 
complex as an example PPI.260 Since then the problem has been observed in other PPIs, 
and again here. To improve correlations with experiment, Ramos and coworkers have 
suggested the use of different solute dielectric constants in the free energy calculations 
depending on the type of residue mutated.267-269 They make use of higher dielectric 
constants for polar and charged residues than non-polar ones, arguing that the resulting 
increased electrostatic screening approximates the greater degree of reorganisation that 
may take place on mutation. Although their results have seen some success in improving 
correlation to experiment, their choice of dielectric constant for each type of residue 
was completely empirical in nature. The inclusion of different dielectric constants may 
introduce more complexity and sources of error than the simpler, and theoretically 
more rigorous, single dielectric constant used here. 
3.4.2 Timings 
The comparison of single-structure free energy calculations in section 3.3.2 indicates 
that accurate MM-PB/GBSA predictions require, at the very least, the averaging of 
results from a conformational ensemble generated by a MD simulation. Nevertheless, 
there are still noteworthy differences in cost between the methods. Typical timings for 
single predictions with full MD or post-processing are shown in tables 3.8 and 3.9. 
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Table 3.8 – Representative timings for analysing a single mutation of 1SMF, from a single 
trajectory, using the full MD method. 
Calculation Time / hra Cumulative time / hr 
Structure setup 1 1 
Native MD simulation 45 46 
MM-PBSA 6 52 
MM-GBSA 1 53 
Mutant MD simulation 45 98 
MM-PBSA 6 104 
MM-GBSA 1 105 
Table 3.9 – Representative timings for analysing a single mutation of 1SMF, from a single 
trajectory, using the post-processing method 
Calculation Time / hra Cumulative time / hr 
Structure setup 1 1 
Native MD simulation 45 46 
Native MM-PBSA 6 52 
Native MM-GBSA 1 53 
Mutant MM-PBSA 6 59 
Mutant MM-GBSA 1 60 
aSee methods (chapter 8) for exact computational hardware and protocol 
There were numerous points of note in these computational timings. Firstly, 
post-process alanine scanning saved ~40% over its full MD equivalent, even for a single 
prediction. Secondly, the savings for the total investigation performed here (perhaps a 
more realistic comparison for PPI work, given the multiple trajectories used and 
multiple mutations investigated) were even greater: the full MD protocol required 
around 22 000 CPU hours for simulation and analysis, whilst the post-processing 
approach required only 4000. Although the efficiency of MD has increased dramatically 
with the advent of GPU simulations since this research was carried out, full MD remains 
the costlier technique. Thirdly and finally, the MM-PBSA calculations only had a minor 
speed disadvantage compared to MM-GBSA. Generally, the PB calculations showed slight 
improvements in accuracy at the slight loss of precision compared to GB. However, as 
discussed above, PB may also be more sensitive to structure and fluctuate more when 
investigating charged residues. Therefore, a preference for each solvation method likely 
depends on the system under investigation. However, given that the free energy 
calculations are a relatively minor component of the overall simulation cost, both 
MM-PBSA and -GBSA ∆G values should continue to be evaluated for each mutation to 
avoid an a priori arbitrary choice between them. 
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3.4.3 Entropic considerations 
Whether or not to even attempt to include an entropy term in the calculation of relative 
binding energies is a difficult question. The magnitude of ∆S clearly makes an important 
contribution to absolute free energies. However, for similar ligands the entropic 
contributions to binding may be of similar magnitudes. Therefore, ∆∆S, the contribution 
of entropy to ∆∆G, may be negligible for similar ligands. In such a case the inaccuracy of 
computational entropy calculations may actually be harmful to the accuracy of ∆∆G 
estimates – as seen here with the inclusion of a quasiharmonic entropy estimate in the 
full MD ∆∆G. 
Despite requiring careful (and time consuming) implementation to ensure accuracy, 
entropy calculations may nonetheless be necessary. Very similar ligands, that bind 
overall with similar affinities, can have markedly different enthalpic and entropic 
contributions due to enthalpy/entropy compensation.39, 270 This clearly poses problems 
for computational ligand and PPI design, as extensive long-timescale sampling and 
theoretically rigorous, yet expensive, normal modes analysis would be required to 
accurately account for entropy using the full MD method and MM-PB/GBSA. 
Enthalpy/entropy compensation is still poorly understood, but is not a mechanism 
universal to all systems. Indeed, some recent widespread studies suggest that the extent 
of entropic compensation for enthalpic changes (as opposed to neutral or reinforcing 
effects) has been overestimated, partly due to the inherent error in experimental 
methodologies for estimating ∆S.38, 271 Whether it is worthwhile to include entropy at all 
is again likely to be system dependent. In any case, the post-processing protocol 
provides a simple solution to calculating ∆∆S - with little structural difference between 
native and mutant snapshots, the calculated entropy difference is likely to be negligible, 
and so the problem never arises in the first place. Even for full MD, the MBTI work 
shows that more theoretically rigorous methods than MM-PB/GBSA, such as TI, may be 
required to account for entropic changes accurately. This is consistent with current 
literature opinion.271 
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3.4.4 Limitations 
For the trypsin/MBTI system the post-processing method shows good correlation with 
experiment and accuracies within 1.0 kcal mol-1 on average. It is also far faster and 
generates more precise estimates than the equivalent analysis with the full MD 
approach, despite its inherent assumptions. However, two key limitations remain that 
prevent its effective use as a widespread PPI probe. 
Firstly, the lack of structural flexibility on mutation means that predictions cannot be 
accurate in all cases. It is possibly fortuitous that such good correlation (r > 0.75) is 
observed for the mutations carried out here, and it is possible that accuracy and 
correlations may have worsened if an exact experimental ∆∆G for the P1Ala mutation 
had allowed it to be included in analysis. In any case, the variation between trajectories 
in the estimation of the P1Ala mutation is consistent with previous studies of residues 
involved in salt bridges, and this is a clear weakness of post-processing. In addition, the 
overall slope of the fit of computational to experimental results is greater than y = x, and 
closer to y = 2x. This is also sub-optimal when accurate predictions are desired. 
Secondly, the post-processing methodology of truncating the sidechain of a native 
structure residue is currently only implemented for alanine or glycine mutations in 
Amber. Although the method can be extended to other mutations (discussed further in 
the following chapter), mutated residues must be smaller than their native parents. 
Sidechains can only be truncated, not extended, as to do so would introduce 
energetically unfavourable steric clashes. This limits the number of possible mutations 
for each residue, particularly for small residues such as serine or cysteine. 
These limitations give rise to the hypothesis that combining some of the advantages of 
the full MD method and post-processing together will improve the predictive power of 
the MM-PB/GBSA techniques as PPI probes. Exactly how this may be performed will be 
discussed in the next chapter. 
  107 
3.5 Summary 
The work described in this chapter has compared the ability of two simulation methods, 
full MD and post-processing, to perform computational alanine scanning mutagenesis at 
protein-protein interfaces. To the best of our knowledge, this is the first study that has 
made use of multiple independent trajectories to provide a comparison of the statistical 
precision of estimated ∆∆G. 
The results of this chapter clearly indicate the post-processing method to be the more 
preferable technique of the two, in terms of accuracy, speed and precision. 
Post-processing benefits from a cancellation of errors in its free energy calculations, 
caused by the inherent similarity in native and mutant structures analysed by 
MM-PB/GBSA. Although the full MD method resulted in the correct ordering of ∆∆G for 
the series of mutations investigated here, this was at a much greater computational cost, 
and with much lower reproducibility of ∆∆G than those observed for post-processing. 
Both disadvantages were inherently due to the independent and non-overlapping areas 
of phase space sampled by independent trajectories in the full MD method. The 
imprecision of full MD is primarily a sampling issue therefore. However, before any 
simulation is carried out, it is difficult to determine how many simulations of what 
length would be required before full MD predictions could be deemed reliable. 
Post-processing has its own disadvantage, being limited to making mutations to smaller 
residues as it cannot adapt the interface through simulation to avoid structural clashes. 
In principle, a technique that allowed a small area of local conformational differences 
between native and mutant complexes, but that maintained identical cancellation of 
errors for free energy calculations throughout the majority of the complex, would 
combine the advantages of both methods. The possibility of such a technique will be 
explored in the following chapter. 
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4 Development of Mutational Locally 
Enhanced Sampling 
4.1 Introduction 
The previous chapter focussed on existing methods of generating native and mutant MD 
trajectories for use with MM-PB/GBSA ∆∆G calculations and clearly identified a niche for 
the development of a new method that combines the varied advantages of those that 
already exist. Allowing some degree of dynamical flexibility between the two complexes 
was deemed to be important for accuracy, but maintaining some structural identity 
between trajectories also improved the precision and repeatability of the free energy 
calculations. Combining these two conflicting needs, a method is required that generates 
native and mutant trajectories that are mostly identical, but contain appropriate local 
structural rearrangements surrounding the site of mutation. 
The previous chapter showed that the post-processing method is currently the most 
suitable MD-based way of rapidly probing a PPI interface. However, as well as better 
accounting for the dynamical effects of a mutation, a method with structural flexibility 
would also (in principle) allow any mutation to be made, as potential structural clashes 
could be avoided during the simulation. This could be far more useful as a probe for PPI 
design and/or modulation than any existing method. 
The Locally Enhanced Sampling (LES) method is a simulation technique in which a 
defined area of the system is duplicated into multiple non-interacting copies. The 
concept (explained further in section 4.1.1) is that these multiple copies explore 
different areas of phase space within the same simulation, without the additional 
computational cost of running completely separate simulations. At the end of a LES 
simulation, a trajectory for each of the copies can be extracted separately if desired. 
Each of these trajectories will differ only within the defined copied LES region. 
Until now, LES has only been performed with multiple identical copies, i.e. 
homogeneously. This chapter describes the idea behind, and initial development of, a 
protocol that will be referred to as Mutational Locally Enhanced Sampling (MULES), in 
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which a LES simulation is performed using copies of both native and mutant structures, 
i.e. heterogeneous LES. Multiple independent MULES simulations are performed on a 
series of related natural and non-natural mutations, ∆∆G are calculated with 
MM-PB/GBSA, results are compared with a post-processing approach to generating the 
same mutations and validated against experimentally determined binding free energies. 
MULES is shown to have the potential to quantitatively predict the structural and 
energetic effects of mutations at protein-protein interfaces. The majority of work in this 
chapter has been published as Bradshaw et al. 2012.272 
4.1.1 Locally Enhanced Sampling 
The LES methodology, first developed by Elber and Karplus in 1990,273 was initially 
designed as a way of improving computational efficiency by allowing multiple copies of 
a small molecule ligand to interact with a single protein receptor simulataneously. It 
was subsequently used as a method of lowering energy barriers for conformational 
transitions in a localised area of a structure in order to increase the rate at which a 
system reached equilibrium.273, 274 During MD simulations, conformational sampling of 
the desired region is enhanced, while the rest of the simulation sees the average of the 
interactions of all conformations in the multiply copied LES region. 
The theoretical basis for LES is derived from the time-dependent Hartree approximation 
applied to classical dynamics. In this approximation, it is assumed that the overall phase 
space probability density of a system can be approximated as a product of the phase 
space probability densities of subsets of coordinates of that system. Equation ( 4-1 ) 
demonstrates this concept as used in the work of Elber and Karplus; a small CO ligand 
present within a large myoglobin protein: 
  (     )     (         )    (           ) ( 4-1 ) 
Here, (P,Q,t) refers to the overall phase space probability density (of a state with 
momenta P and coordinates Q at time t) and the subscripts CO and myo refer to the 
subsets of coordinates for the CO ligand and myoglobin receptor respectively. In the 
case of LES, multiple coordinates of the CO subset are present within a single, averaged 
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coordinate of the large myoglobin receptor. The initial individual phase space 
probablility densities can then be represented by a series of ∂-functions: 
     (             )   (         
 ( )) (         
 ( )) ( 4-2 ) 
    (           )   (       
 ( ))∑  
 
(        
 ( )) ( 4-3 ) 
Here,    
 ( ) is the initial set of coordinates of the myoglobin structure and    
 ( ) 
the initial set of momenta assigned by Boltzmann distribution. However, with multiple 
copies of the CO ligand, the representation for the ligand (equation ( 4-3 )) is more 
complex. A single set of initial coordinates may be used for all copies (   
 ( )), whilst 
the initial momenta of each copy are assigned randomly from a Boltzmann distribution, 
and hence overall corresponded to a Boltzmann weighted (w) sum of the momenta of all 
copies. 
Equations of motion for the two subsets can be derived separately from equation ( 4-2 ) 
and ( 4-3 ). The derivation of these is provided as an appendix to the original study of 
Elber and Karplus for the interested reader, but importantly they allow the calculation 
of many different trajectories of the CO ligand within the presence of a single trajectory 
of the myoglobin protein. This means that the trajectory of each individual CO copy is 
exact, moving within the field of a single set of protein coordinates, whilst the trajectory 
of the protein is approximate and influenced equally by a factor of 1/n by the presence 
of each of n copies: 
  
  
    
   
 
 
∑
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 ( 4-4 ) 
What this means in practice is that within a given molecular structure, a LES simulation 
creates multiple copies of atoms in an individual region. These virtual copies do not 
interact with one another, but do interact individually with the rest of the structure 
outside the LES region. Importantly, the parameters for each of the atoms inside the LES 
region are scaled by   ⁄ , where n is the number of individual copies. In this way, the 
rest of the system interacts in an averaged manner with all of the individual copies in 
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the LES region, summing to a total interaction strength of   
 
 
, i.e. exactly 1. Interactions 
solely inside the region require a further correction factor; an atom with parameters 
  ⁄ , interacting with a second atom also with parameters   ⁄ , will result in an 
interaction strength scaled as    ⁄ . Within the LES region, interactions are therefore 
scaled up by a factor of n to make sure that energies and forces correspond correctly. 
LES is an established technique that has seen successful use across a range of MD 
studies. While it has not been used as widely as some other enhanced sampling 
techniques, such as replica exchange MD, its concept is simpler and computational cost 
much lower. One limitation of LES that has perhaps prevented its more widespread use 
is the requirement for careful choice and testing of simulation parameters. The LES 
conditions, including number of separate regions (as more than one is possible), size of 
each region and number of copies in each region, can have a large effect on the efficacy 
of the enhanced conformational sampling and utility of the resulting MD trajectories.275 
LES simulations have been used to ensure adequate conformational sampling of small 
functional groups to allow free energy calculations of conformational transitions,276 
rapidly optimise loop structures to native conformations for both RNA275 and peptide 
chains,277 and evaluate the mechanism of ammonia transfer through an intramolecular 
channel.278 LES has delivered new insights into molecular mechanisms and provided 
alternatives to existing, often more costly or less suitable, enhanced sampling 
methodologies. 
The idea of sampling multiple conformations in a localised area of interest whilst 
keeping the dynamics of the remainder of the complex identical is clearly of importance 
for the free energy calculation studies herein. LES simulations would have a 
performance benefit over multiple independent trajectories as they essentially only run 
multiple simulations of a small desired area, rather than the whole complex. Separate 
LES simulations of native and mutant complexes, followed by MM-PB/GBSA 
calculations, may be a faster alternative to full MD for calculating ∆∆G. 
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However, if the simulation of the native structure and its mutant could be combined into 
a single LES trajectory, there would be no difference between the coordinates of both 
trajectories beyond the LES region surrounding the mutation. Just as with 
post-processing in the previous chapter, this would massively improve the precision of 
∆∆G estimates by cancelling errors in the free energy calculations - allowing the 
calculation of ∆∆G that take into account rearrangements at the interface without the 
confounding variables of rearrangements elsewhere in the complex. This is the concept 
behind MULES. 
4.1.2 Concept of MULES 
Mutational Locally Enhanced Sampling (MULES) is a term coined here to describe the 
heterogeneous version of LES in which copies of native and mutant structures are 
combined in the same MD simulation. At the end of the simulation, the trajectories of the 
two complexes are extracted separately, providing two sets of structural snapshots for 
MM-PB/GBSA calculations, and a ∆∆G derived between them. Although conceptually this 
is a simple development of the LES approach, to the best of our knowledge this study 
represents the first time that a heterogeneous version of LES has been attempted. 
The MULES approach to generating trajectories is described pictorially in figure 4.1 and 
contrasted to the post-processing method. Whilst post-processing does not allow any 
structural rearrangement of the interface on mutation, MULES allows relaxation and 
conformational changes in a small surrounding region, which can be defined 
individually for each complex or simulation as desired. 
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Figure 4.1 – Schematic comparison of the post-processing and MULES approaches. Figures 
represent the treatment of a mutation at an interface between two protein partners. Mutation is 
desired at residue X of one of the partners. A) A snapshot of the native protein-protein 
interaction. B) Mutation by simple truncation of the sidechain (the post-processing approach). 
C) The starting point of a MULES simulation consisting of one copy of the native and one copy of 
the mutant structure. MULES region is defined as the area around the mutation, in blue for the 
native and red for the mutant complex. D) The MULES simulation allows independent dynamics 
for native and mutant complexes within the MULES region, allowing small conformational 
changes to accompany mutation. The remainder of the complex (grey) has identical dynamics 
between native and mutant. 
The   ⁄  scaling of interactions in LES results in enhanced sampling and lowering of 
energy barriers to conformational transitions. These are not the direct aims of MULES, 
rather for MULES to function as desired the native and mutant copies should each 
sample conformations as close to their own equilibrium state as possible. In fact, 
extensively enhanced sampling may be problematic, as unrealistic conformational 
transitions may occur that bias binding free energy measurements. For this reason, only 
MULES simulations with two copies - one native and one mutant - have been 
investigated. Interactions are then scaled by ½, the minimal scaling possible for a 
MULES simulation. 
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There are two further variables in a MULES simulation that may affect the validity of the 
approach. Firstly, for the ∆∆G between native and mutant to be accurate, the MULES 
region should be large enough to encompass all relevant structural and dynamical 
changes caused by the mutation. Because the complex outside the region sees both 
copies, its dynamics should ideally be unaffected by the presence of ‘half’ a native and 
‘half’ a mutant structure. How large is ‘enough’ to ensure this happens is likely to be 
system dependent, and so should be investigated in the development of a MULES 
protocol. 
Secondly it is important to note that MULES should represent dynamical differences 
between native and mutant complexes at equilibrium. Rearrangements in the MULES 
region are not due to instantaneous energy minimisation or other optimisations and 
therefore take time to propagate. Additionally, when a copy of a region is first made, 
both copies have identical coordinates; it is only through simulation that the structure 
and dynamics of the two diverge. MULES simulations should therefore be of an 
appropriate length to encompass all relevant rearrangements. Again, how long is 
‘appropriate’ is a question that requires analysis during the development of a protocol. 
Initially though, the concept of MULES must be tested for its ability to generate stable 
trajectories suitable for MM-PB/GBSA analysis, and how accurate and precise the free 
energy estimates are compared to the existing post-processing method and to 
experimentally measured values. To do so, this chapter describes the development of 
MULES and testing on a series of related natural and non-natural mutations of an 
interface, again using the trypsin/MBTI system as a prototypical PPI. 
4.2 Experimental data 
4.2.1 Experimental mutations 
As discussed in chapter 3, experimental measurements of ∆∆G for many alanine 
mutations of the trypsin/MBTI complex (PDB entry 1SMF) already existed prior to this 
research. For the current study, however, one of the major aims was to gauge the 
applicability of MULES to mutations other than alanine, both natural and non-natural. 
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This required new experimental ∆∆G values, the generation of which is described briefly 
below. Full experimental methods can be found in section 8.2.1. 
The P2’Ile residue (see figure 3.1 for the native sequence) was mutated to a series of 
other amino acids. This residue was chosen firstly because it was already known to be a 
hot-spot of binding free energy (and thus ∆∆G were expected to span a wide range) and 
secondly because the isoleucine could be mutated easily to numerous related residues. 
The mutant residues chosen are shown in figure 4.2. 
 
Figure 4.2 – Mutant residues at P2’ position of synthetic MBTI loop in series of trypsin/MBTI 
complexes. Native residue is an isoleucine. Nva is norvaline, Abu is α-aminobutyric acid. All 
amino acids are natural L-isomers, excluding glycine, which does not possess a stereogenic 
centre. 
The chosen residues have two advantages. Firstly, they cover both natural and 
non-natural amino acids, testing the ability of MULES to be an effective tool in PPI 
design where mutation to any residue, no matter if naturally present in the cell, may be 
required. Secondly, they are all smaller, related variants of isoleucine, meaning their 
∆∆G may also be calculated with an adapted version of post-processing for comparison 
purposes (described further in section 4.3.1). 
4.2.2 Experimental inhibition assays 
Full details of experimental procedures are available in section 8.2.1, but are 
summarised here for clarity. 
Linear peptides of the desired sequence (each with a different amino acid present at the 
P2’ position) were synthesised using standard Fmoc-protected SPPS. After synthesis, 
peptides were washed, dried and cleaved from the synthesis resin. Sidechain protecting 
groups were also removed at this stage. Crude linear peptides were then re-washed and 
dried overnight under vacuum, yielding white solids. 
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Prior to cyclisation the linear peptides were analysed and purified by LC-MS. For each 
mutant, fractions containing pure peptide were combined, concentrated under vacuum 
and freeze dried. Pure linear peptides were obtained as white solids. Cyclisation by 
crosslinking of the terminal cysteine residues was then performed using 
dimethylsulfoxide (DMSO)-mediated oxidation.279 Crude cyclised peptides were again 
freeze dried to obtain white solids, followed by analysis and purification as above. 
Cyclised peptides with purity > 95% by HPLC and molecular masses verified by 
MALDI-TOF MS were obtained as white solids. Analytical HPLC chromatograms for each 
peptide are available in appendix 3, figures S1 to S6. Yields and characterisation data are 
shown in table 4.1. 
Table 4.1 – Yields and characterisation data for synthesised cyclic peptides. R.T. is the retention 
time of the product peak on reverse phase HPLC under the conditions described in section 8.2.1. 
IC50 values for each peptide were generated from fluorescence-based inhibition assays 
as follows (again, see section 8.2.1 for full details). Prior to assays, bovine ß-trypsin 
concentration was standardised by active site titration.280 Competitive binding assays 
were then carried out in 96-well plate format, in triplicate. Serial dilutions of each 
peptide were incubated with trypsin for 40 minutes at 37˚C. Following incubation, a 
fluorogenic substrate was added to each well, mixed, and measurement of fluorescence 
was begun. The initial rate of substrate hydrolysis for each peptide concentration was 
monitored by the release of a fluorescent hydrolysis product from the substrate. Initial 
rate data were fitted to determine IC50 for each peptide using the GraFit software 
package.281 Figure 4.3 shows an example of such a plot. 
Peptide Sequence Mr 
/g mol-1 
Overall yield 
/% 
MALDI-TOF 
peak / m/z 
R.T. 
/min 
Ile CTKSIPPEC 975.15 2.4 976 [M+H+] 9.1 
Nva CTKS(Nva)PPEC 961.12 3.9 962 [M+H+] 8.6 
Val CTKSVPPEC 961.12 1.5 962 [M+H+] 8.5 
Abu CTKS(Abu)PPEC 947.10 1.5 948 [M+H+] 7.9 
Ala CTKSAPPEC 933.07 2.4 934 [M+H+] 7.3 
Gly CTKSGPPEC 919.04 3.4 920 [M+H+] 6.6 
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Figure 4.3 – Example plot used to determine IC50 values of peptide inhibitors. Plot of activity 
(measured as initial rate of substrate hydrolysis) against inhibitor concentration for the native 
peptide with Ile at the P2’ position. IC50 were first estimated using a full 4-parameter fit of the 
equation   
     
  (
 
    
)
   , where s is a slope factor, c is a non-zero background constant and 
Range is the maximum y range of activity. Plots of background corrected (   ) and unit slope 
factor (       ) fits are also included. The close agreement of the fits shows the robustness 
of the data. Final IC50 values were taken from the background corrected fits as data from blank 
assays showed negligible background values. 
As this study only required relative rather than absolute free energies the Cheng-Prusoff 
correction for Ki was again not required. As discussed in section 3.1.2, the IC50 values 
may be approximated to be equal to Ki in cases where only relative free energies are 
needed. ∆G, and hence ∆∆G between native and mutant peptides, were then calculated 
as        (  ). Results are shown in table 4.2. 
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Table 4.2 – Experimentally determined ∆∆G between native peptide and mutants at the P2’ 
position.2 
P2’ Residue Ki / µM ∆Gb / kcal mol-1 ∆∆Gb / kcal mol-1 
Ile 4.74 ± 0.28 -7.31 ± 0.04 0 
Nva 29.1 ± 0.6 -6.22 ± 0.01 1.08 ± 0.04 
Val 18.9 ± 0.8 -6.48 ± 0.03 0.82 ± 0.04 
Abu 61.4 ± 2.6 -5.78 ± 0.03 1.53 ± 0.03 
Ala 246 ± 21 -4.95 ± 0.05 2.35 ± 0.04 
Gly ~4000a ~-3.3 ~4 
aGlycine mutant showed ~10% inhibition at 500 µM, Ki estimated as ~4000 µM. bBinding free 
energies calculated at 300 K for comparison to computational results. 
The glycine mutation resulted in an inhibitor far less potent than the others, showing 
only ~10% inhibition of activity at 500 µM, the highest concentration assayed. As with 
the P1Ala mutation of the previous chapter, identifying mutations that have significant 
effects on binding is of great practical importance, therefore the Ki of the glycine mutant 
was estimated as 4000 µM in order to allow comparison with the other results. The 
above set of experimental ∆∆G is used to validate computational predictions throughout 
the following sections. 
4.3 Post-processing predictions 
4.3.1 Adaptations to standard post-processing 
Chapter 3 showed that the existing post-processing method was a rapid and reliable 
method for calculating ∆∆G, particularly for the trypsin/MBTI system. It was therefore 
chosen as a comparison tool to assess the relative accuracy and precision of the newly 
developed MULES approach. If MULES could perform better than post-processing for an 
identical dataset, then further development and testing of the technique would be 
worthwhile. 
Post-processing as implemented in the Amber MM-PB/GBSA package can only perform 
alanine and glycine scanning however. The concept of post-processing has nevertheless 
been extended to other mutations in the past. Similar techniques, basing point 
                                                             
2 The ΔΔG value for the P2’Ala mutation performed here differs from that obtained from the 
previous study detailed in section 3.1.2. This is due to a difference in the way assay data were 
fitted to generate Ki values; previous data were treated as a tight binding inhibitor rather than 
the non tight-binding fit used here. In the absence of evidence refuting previous results, both 
values are reported in this study. 
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mutations on a single MD trajectory, have been used to perform computational fluorine 
scanning of small molecules,282 or mutate functional groups in druglike ligands.283, 284 In 
the latter case, the area around each mutation was also reorganised through energy 
minimisation, allowing effects on both solvation and sidechain packing to be accounted 
for. This is associated with additional computational cost however, and, as seen for the 
single structure evaluations of section 3.3.2, simple minimisation may not always 
improve correlation with experiment. For sake of identical comparison with the 
post-process alanine scanning methods detailed in the previous chapter, we do not 
attempt to include any energy minimisation or structural rearrangement in this study 
either. 
In post-process alanine scanning extraneous atoms are deleted from the trajectory and 
the remaining residue is reassigned the parameters of alanine rather than the original 
amino acid. In this study, the deletion of atoms is instead performed stepwise, 
selectively mutating the original isoleucine to norvaline, valine, alanine, glycine and one 
of two α-aminobutyric acid rotamers (see figure 4.4). Although these rotamers may 
interconvert during a dynamical simulation, in post-processing they are created by 
selective deletion of different parts of the original sidechain, and so must be treated 
separately. Original stereochemistry is preserved throughout the mutation process. 
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Figure 4.4 – Mutations performed with the post-processing technique. Starting from isoleucine, 
mutations to five different residues are possible by simple stepwise deletion of the sidechain. The 
position of deleted atoms is indicated by grey dashed bonds. Abu 1 and Abu 2 are two rotamers 
of α-aminobutyric acid created by deletion of either the Cγ1-Cδ1 chain or the Cγ2 chain. The 
selective deletion of atoms in the post-processing method means that these two conformations 
give different energies. Stereochemistry is retained throughout. As MULES allows structural 
flexibility on mutation only one case need be considered. 
In principle the original Ile residue could also have been mutated to any other smaller 
residue, such as threonine, cysteine or serine, through selective deletion of atoms and 
judicious choice of atom types. However, given the known preference for hydrophobic 
residues at the P2’ position244 and the difficulty of accounting for hydrogen bonding 
and/or rotamer populations correctly when mutating residues with post-processing, 
further mutations were not performed. Methods and results of the post-processing ∆∆G 
estimates are discussed in the following sections. 
4.3.2 Methods 
Full computational details are available in section 8.2.2.1 but are again summarised here 
for clarity. Ten independent MD simulations of the native 1SMF structure had been 
previously generated for the initial investigation of post-process alanine scanning 
detailed in chapter 3. These simulations were reused for this study. All 1000 snapshots 
of each 10 ns trajectory were used in the MM-PB/GBSA free energy calculations that 
follow. 
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Trajectories of mutant complexes were generated from those of the native complex. For 
each mutation, excluding the alanine mutant that had previously been studied, the ptraj 
module of Amber 10 was used to remove the coordinates of the relevant surplus atoms. 
With this protocol the new C-H bonds formed on mutation of C-C bonds were not reset 
to standard length. The errors in ∆∆G this produced were expected to be minor, and 
systematic, due to the small bond length and character changes involved. Parameters for 
natural amino acid mutants were taken from the Amber ff99SB force-field.163 
Parameters consistent with the ff99SB force-field for norvaline285 and α-aminobutyric 
acid286 were taken from literature studies. MM-PB/GBSA calculations were then 
performed on each of the native and mutant trajectories, using identical methods to 
those detailed in chapter 3. Entropic contributions to ∆∆G were assumed to be negligible 
and therefore not evaluated. 
4.3.3 MD simulations and free energy calculations 
As the MD simulations of the native 1SMF structure had already been analysed for 
stability and equilibration in the previous post-processing study (section 3.2.2), further 
analysis was deemed unnecessary. Each trajectory was subjected to the series of 
post-processing mutations and free energy calculations described above, leading to ten 
individual ∆∆G for each mutation. The full dataset of individual ∆∆G is available in 
appendix 3 table S1, but mean values and confidence intervals are summarised in table 
4.3. 
Table 4.3 – Comparison of mean ∆∆G calculated with the post-processing approach. All values in 
kcal mol-1. 
P2’ Residue Experimental ∆∆G MM-PBSA ∆∆G MM-GBSA ∆∆G 
Ile N/A 0 0 
Nva 1.08 ± 0.04 1.15 ± 0.10 0.62 ± 0.10 
Val 0.82 ± 0.04 1.89 ± 0.33 1.53 ± 0.21 
Abu 1a 1.53 ± 0.03 2.85 ± 0.16 2.23 ± 0.11 
Abu 2a 1.53 ± 0.03 3.63 ± 0.56 3.00 ± 0.45 
Ala 2.35 ± 0.04 4.39 ± 0.44 3.98 ± 0.34 
Gly ~4b 5.12 ± 0.36 5.39 ± 0.32 
Errors in computational values calculated as the 95% confidence interval of the mean of 10 
independent simulations. aUsing post-processing, two rotamers of Abu are possible by selective 
deletion of the sidechain (see figure 4.4). b~10% inhibition at highest concentration assayed, 
lower limit of ∆∆G estimated using Ki ≈ 4000 kcal mol-1. 
  122 
The post-processing predictions, excluding the glycine mutation, for which an 
experimental ∆∆G could only be estimated, had a mean unsigned error to experiment of 
1.32 kcal mol-1 using PB and 0.99 kcal mol-1 using GB solvation. Individual uncertainties 
in mean ∆∆G were also consistently low, with only the error in the Abu 2 prediction with 
MM-PBSA exceeding 0.5 kcal mol-1. The size of these errors to experiment and 
confidence intervals was consistent with those of the previous post-processing study 
where only alanine mutations were investigated. This suggests that the extension of the 
approach to other residues did not have any adverse effects on the accuracy or precision 
of the method, and as such it represents a useful addition to the computational PPI 
probing toolbox. 
Despite errors in accuracy to experiment of around 1.0 kcal mol-1, the post-processing 
method captured the trend of experimental results well. Correlation of experimental and 
theoretical ∆∆G, excluding the glycine mutation, was 0.90 for PB and 0.85 for GB. These 
excellent replications of the trend of experimental measurements were offset somewhat 
by the mis-ordering of the norvaline and valine ∆∆G, and the large differences in energy 
for the Abu 1 and Abu 2 rotamers. If a single estimate of ∆∆G were desired, as would be 
the case in a probe of interface residues, both rotamer ∆∆G would have to be averaged. 
Here the rotamers were instead treated separately for analysis, highlighting another 
difference of the post-processing and MULES approaches. 
Further discussion and analysis of the post-processing results takes place in section 4.7, 
with particular reference to their comparison with those of the MULES approach 
described below. 
4.4 MULES methodology 
4.4.1 The Addles program 
The concept of LES and its adaptation to MULES have already been explained in section 
4.1. However the method by which Amber prepares and simulates complexes with 
multiple copies has not yet been examined. Fortunately, LES is an established technique 
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in Amber and modules already exist to automate the preparation and simulation of the 
adaptations that LES requires. 
Initially, standard (non-LES) parameter and coordinate files of a given complex are 
created using Leap. The complex can be of any shape or size, but should be already 
solvated (explicitly or implicitly), as Leap cannot read LES parameter files to add solvent 
after multiple copies have been created. Once a suitable set of standard parameter & 
coordinate files is ready, the Addles module of Amber converts the two into LES-format 
parameter and coordinate files. 
Addles requires an input file that defines the initial parameter and coordinate files, the 
names of the final LES-format files, the atoms or residues that comprise each region to 
be copied and the number of copies desired in each region. The latter two of these 
options can act sequentially; regions may have subregions with multiple copies to 
enhance sampling further in an already enhanced area if desired. 
In every case the first step of the Addles program is to duplicate the atomic coordinates 
of the LES region(s) the appropriate number of times. All of the LES copies of a specific 
region initially occupy identical positions in space, but, since they should not interact 
with one another, the atoms of each copy are placed in the exclusion list of the atoms of 
the other copies. The exclusion list is used by Amber to define atoms that do not interact 
through non-bonded interactions. It is primarily used to define atoms connected by 
bonds or angles (which should not interact at all according to the constraints of the 
force field) or to scale 1-4 non-bonded interactions, however in LES it ensures that 
copies do not interact even if they occupy the same position in space. This is crucial both 
for the concept of LES and the stability of the MD simulation. 
Addles also scales the charges, VdW values and force constants of every atom inside the 
LES region by 1/n, where n is the number of copies. This scaling is the source of the 
lowered energy barriers and enhanced sampling of the LES regions. Atomic masses are 
also scaled by default, but may also be kept at their original values if desired. Masses are 
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not involved in the calculation of forces, but do affect kinetic energies and velocities. The 
consequences of scaling masses are discussed further in section 5.4.1. 
Once LES-format parameter and coordinate files have been created they are subject to 
the same simulation process (minimisation, heating, equilibration and production MD) 
as standard files. As mentioned in section 4.1.1, the interactions within LES regions 
require additional scaling in order to correctly recreate energies and forces. This scaling 
is performed with a modified version of the Sander MD engine, “Sander.LES”. The 
requirement for additional scaling, the increase in system size due to duplication of 
regions and the additions to the exclusion list mean that Sander.LES simulations have an 
additional computational cost over standard Sander simulations. The magnitude of this 
cost is entirely dependent on the system and parameters chosen for the simulation 
however. 
Fundamentally, MULES is very similar to LES. The first step of developing MULES 
simulations was therefore to use Addles to generate LES-format parameter and 
coordinate files of the native 1SMF complex with two copies of a defined region centred 
on the P2’Ile. For each desired mutation the parameter file was then further adapted to 
create a MULES parameter file consisting of one native and one mutant copy. 
4.4.2 Generating MULES parameter files 
4.4.2.1 Adaptations required 
The use of heterogeneous copies required many manipulations to the standard LES 
parameter files. For each desired mutation, one copy consisted of a sequence with 
parameters equivalent to an isoleucine at the P2’ position, whilst the other consisted of 
an identical sequence but with a norvaline, valine, α-aminobutyric acid, alanine or 
glycine as the P2’ residue. 
To create the MULES files, parameters of the atoms in the first (native) copy were left 
unchanged. Charges, masses, atom types (which determine VdW interactions) and force 
constants for bonds, angles and dihedrals of the second (mutant) copy were all adapted 
from their initial isoleucine to take on the parameters of the mutant residue, scaled 
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appropriately by ½ as they remained within a MULES region. Atoms not involved in the 
new mutant residue were left as ‘dummy atoms’ with zero parameters in the new 
MULES parameter file, as this avoided unnecessary manipulation of the LES coordinate 
file. Bonds, angles and dihedrals containing these dummy atoms were either set to zero 
force constant or deleted from the parameters list (see figure 4.5), and the atom types 
set to ‘HO’, a hydroxyl hydrogen, as this atom type has zero VdW interactions in the 
ff99SB force-field.157, 162, 163 
 
Figure 4.5 – Schematic of modifications to LES parameter files to generate MULES files. In 
standard LES, copy 2 is also an Ile residue. On adaptation to MULES, extraneous dummy atoms 
(grey) are modified to have zero parameters and zero interactions. The rest of the residue is 
assigned appropriate parameters and atom types of the mutant residue, here an alanine, 
including mutation of the two Cγ atoms to hydrogen. 
Two further adaptations to the original LES parameter files were required in some 
situations. Firstly, adding in and deleting bonds, angles and dihedrals from their 
associated lists in the parameter files often resulted in a change in the total number of 
bonds, angles or dihedrals. These totals are defined at the head of parameter files and 
used by Amber in assigning array lengths and associated memory sizes during 
simulation. These totals were therefore also adapted to reflect any changes made. 
Furthermore, if the connectivity of the mutant residue differed greatly from that of the 
native, any necessary changes to the exclusion lists were made to reflect the new 
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configuration of atoms. This is discussed further in the studies of more complex 
mutations in chapter 5. 
MULES is an entirely new technique and therefore, at the time of its development here, 
no automated methods for adapting a LES parameter file to a MULES parameter file 
existed. All modifications to parameter files were instead made by hand. This manual 
manipulation of large text-based files has clear potential for mistakes, which would 
adversely affect simulations and the interpretation of results if not identified and 
corrected. Therefore a systematic protocol, with in-built error checking, was developed 
to ensure the consistent generation of ‘correct’ MULES parameter and coordinate files. 
4.4.2.2 Protocol 
The following steps were followed for the generation of every set of initial MULES 
parameter and coordinate files. Examples of Addles input, unmodified LES files and 
modified MULES files are given in appendix 4. 
1. Create LES parameter and coordinate files of the native structure with 
appropriate region size and two copies of that region. 
2. Create a PDB file of the native LES complex for visualisation purposes. Note the 
atom numbers of the atoms to be modified in creating the mutant. 
3. CHARGES: Change the charge of each modified atom to that of the desired mutant 
residue in a LES parameter file. If necessary, use a LES parameter file of the 
whole mutant complex as a template. Change charges of dummy atoms to zero. 
4. MASSES: Change the mass of each modified atom to that of the desired mutant 
residue in a LES parameter file. Change masses of dummy atoms to zero. 
5. ATOM TYPE INDEX: Change the atom type index of each modified atom to that of 
the desired mutant residue. Change atom types of dummy atoms to HO 
(hydroxyl hydrogen). 
6. BOND TYPE INDEX: Add a new bond type to the bonds index, with zero force 
constant and unit equilibrium length. Note the index of the new entry. 
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7. ANGLE TYPE INDEX: Add a new angle type to the angles index, with zero force 
constant and unit equilibrium angle. Note the index of the new entry. 
8. DIHEDRAL TYPE INDEX: Note the index of a dihedral with zero force constant. If 
unavailable, add a new dihedral with zero force constant, unit periodicity and 
unit phase. 
9. BONDS: Modify, insert and/or delete relevant bonds to change the connectivity of 
the atoms in copy 2 from a native to a mutant residue. Reference relevant 
equilibrium lengths and force constants from the bonds index. Bonds between 
dummy atoms may remain but are set to zero force constant. Bonds between 
dummy atoms and non-dummy atoms are deleted to avoid unintended effects 
during simulation. Ensure that bonds including hydrogen or excluding hydrogen 
are properly assigned for SHAKE purposes (see methods in section 8.2.2.2). Take 
note of the number of bonds added or removed from each list. 
10. ANGLES: Repeat above process for angles in mutant residue. 
11. DIHEDRALS: Repeat above process for dihedrals in mutant residue. 
12. EXCLUSION LIST: If necessary due to changing connectivity of atoms to form the 
mutant residue, adapt the exclusion list and number of excluded atoms for each 
atom to reflect the new connectivity and ensure the correct exclusion of 1-2 and 
1-3 and the correct scaling of 1-4 interactions. 
13. ATOM TYPE LIST: Change the atom type of each modified atom to that of the 
desired mutant residue. Change atom types of dummy atoms to HO (hydroxyl 
hydrogen). 
14. HEADERS: If necessary, change the summary at the head of the parameter file to 
reflect the new numbers of total bonds, angles and dihedrals (both including and 
excluding hydrogen), number of excluded atoms and number of bonds, angles 
and dihedral types. 
15. TEST: Run a short minimisation of the complex with the new MULES parameter 
file. The LES coordinate file should provide the initial set of coordinates. On 
minimisation the structure of the two copies should diverge as the individual 
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mutants interact separately. If modification of the parameter file has been 
performed correctly, the dummy atoms should experience no force at all and 
should maintain identical Cartesian coordinates before and after minimisation 
(within numerical error). 
This stepwise approach to creating MULES parameter files minimised the opportunity 
for errors during the modification process. Notably, due to the very detailed nature of 
Amber parameter files and the likelihood of even small transcription errors 
perpetuating large dynamical changes, any errors that were made would be quickly 
identified during the standard analysis of the equilibration and stability of the MD 
trajectory. 
4.4.3 Methods 
Full details and parameters for MD simulations and free energy calculations are given in 
section 8.2.2.2, but are also summarised here. MULES parameter and topology files 
containing one copy of the native P2’Ile structure and one copy of a P2’ mutant were 
prepared for each of the Nva, Val, Abu, Ala and Gly mutations using the protocol 
described in section 4.4.2.2. The residues included in the copied MULES region are 
defined in the following section. Ten independent simulations of each mutation were 
then performed using an equivalent minimisation, heating and equilibration at constant 
pressure protocol to previous simulations. 
Following equilibration to a pressure of 1.0 bar a further equilibration period of 1 ns 
was simulated for each trajectory in order to allow the MULES regions time to relax and 
diverge structurally. This was followed by 10 ns of production MD simulation with 
structural snapshots saved every 10 ps, resulting in a total of 1000 snapshots for free 
energy analysis and a total simulation time of > 11 ns for each trajectory. Ten 
independent standard LES simulations, consisting of two copies of the native P2’Ile 
complex, were also performed to act as controls and to gain an understanding of the 
inherent free energy variation between LES copies. 
On completion each of the MULES or control simulations was split into two 
sub-trajectories using the ptraj module of Amber. One of these trajectories contained the 
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dynamics of the native copy and one the dynamics of the mutant. MM-PB/GBSA 
calculations were then performed to evaluate ∆∆G between these two sub-trajectories. 
This led to a total of ten individual ∆∆G estimations for each of the P2’ mutations, as well 
as ten ∆∆G values for the null mutation of two Ile copies from the standard LES 
simulations. Entropic contributions to ∆∆G were again assumed to be negligible and 
hence not evaluated. 
4.5 Determining a MULES protocol 
As an entirely new methodology, a new protocol for MULES simulations had to be 
developed. This involved choosing parameters for the length of the structural 
equilibration, the length of the production run simulation, the number of independent 
simulations performed and the size and residues copied as part of the MULES region. 
Production run length and number of independent simulations should ideally be chosen 
to be consistent with the comparative post-processing simulations. Hence ten 
independent simulations of 10 ns length each were performed for each mutation. 
However, choice of equilibration length and the crucial parameter of MULES region size 
were not as easily defined. Test MULES simulations, performed with the P2’Ala 
mutation, therefore investigated the effects of region size and equilibration length on 
∆∆G. 
4.5.1 Choosing a MULES region 
4.5.1.1 Effects on binding free energies 
Any set of user-defined atoms or residues may be copied in a LES simulation. Within a 
MULES simulation the residues outside the copied MULES region share the same 
coordinates and interact averagely with the two individual copies. To avoid any 
unintended effects on dynamics this averaging of native and mutant interactions may 
have, the MULES region should ideally be large enough to include all the structural 
consequences of the mutation - meaning the dynamics outside the region should be 
identical whether or not the mutation takes place. 
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Clearly the validity of this assumption, and the size of the region required to ensure it is 
approximately true, depends on the individual system and mutation under investigation. 
At the edges of the MULES region both copies are bonded to a single atom and so must 
share very similar coordinates. As the region size increases so too does the potential for 
larger structural differences between native and mutant copies. However, increased 
MULES region size also brings with it an increased number of atoms to simulate, an 
increased exclusion list size, an increased computational cost and an increased 
likelihood of large structural differences adversely affecting the precision of results as 
observed with the full MD method. 
To evaluate the effects of changing MULES region size and define a suitable set of copied 
residues for the MULES study of all mutations presented here, the P2’Ala mutation 
(isoleucine in the native copy, alanine in the mutant) was initially tested using MULES 
simulations with different copied region sizes. These varied from only consisting of the 
P2’Ile residue, to all residues within a 10 Å radius of the mutation site. The MULES 
regions chosen are summarised in table 4.4. 
Table 4.4 – MULES region sizes investigated for the P2’Ala mutation. Smaller regions were 
defined by residue. Larger regions were defined by radius – if the Cα atom of a residue was within 
the defined radius of any P2’Ile atom, the residue was included in the MULES region. 
MULES region 
(residues within…) 
Residues copied Atoms copied % System sizea 
P2’ 1 19 0.57 
P1 - P4’ 5 80 2.4 
P3 - P6’ 9 132 3.9 
5 Å 12 197 5.9 
9 Å 26 399 12 
10 Å 37 544 16 
a Percentage of overall complex copied as part of MULES region, based on number of atoms. Total 
atoms in native complex = 3352. 
The chosen MULES regions varied from allowing small local changes in structure, solely 
on the ligand side of the complex, to large widespread changes throughout (up to)   ⁄ th 
of the whole complex. Ten independent simulations of each region size were performed 
using the protocol of heating, equilibration, 1 ns of structural equilibration and 10 ns of 
production MD defined in section 4.4.3. Trajectories were then split into native and 
  131 
mutant copies and analysed for ∆∆G using MM-PB/GBSA. A plot of the trend of the 
results is shown in figure 4.6, the full dataset of results is shown in table 4.5. 
 
Figure 4.6 – Effect of MULES region size on predicted ∆∆G for the P2’Ala mutation. Increasing 
the region size as a percentage of the overall system results in a small but consistent downward 
trend in ∆∆G estimates with both MM-PBSA and –GBSA. 
Table 4.5 – Effect of MULES region size on predicted ∆∆G for the P2-Ala mutation. Mean, 
standard deviation and 95% confidence interval of the mean are all presented as measures of 
variance and uncertainty for both MM-PBSA and -GBSA calculations. 
For both MM-PBSA and MM-GBSA techniques, increasing the size of the MULES region 
and enhancing the structural variation between native and mutant copies resulted in a 
decrease in ∆∆G estimates. This was to be expected - a MULES region consisting of only 
the P2’ residue is conceptually very similar to a post-processing method, whereby any 
structural effects of the mutation beyond the individual residue are ignored. As 
  MULES region – includes all residues within… 
  P2’ P1 - P4’ P3 - P6’ 5 Å 9 Å 10 Å 
 Residues copied 1 5 9 12 26 37 
 % System size 0.57 2.4 3.9 5.9 12 16 
∆
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 PB Mean 2.49 2.28 2.24 2.17 1.96 1.97 
PB St. Dev. 0.54 0.43 0.27 0.27 0.39 0.30 
PB 95% C.I. ± 0.39 ± 0.31 ± 0.19 ± 0.20 ± 0.28 ± 0.21 
GB Mean 2.25 2.26 2.24 2.18 2.11 2.13 
GB St. Dev 0.24 0.28 0.25 0.25 0.42 0.24 
GB 95% C.I. ± 0.17 ± 0.20 ± 0.18 ± 0.18 ± 0.30 ± 0.17 
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post-processing consistently overestimated ∆∆G, a similar effect was expected for the 
smaller MULES regions. Nevertheless, even the small degree of relaxation afforded with 
a MULES region of the P2’ residue improved the agreement with experiment over 
post-processing (Experimental ∆∆G = 2.35 ± 0.04 kcal mol-1, post-processing 
∆∆G = 4.39 ± 0.44 kcal mol-1 with PB, 3.98 ± 0.34 kcal mol-1 with GB solvation). 
The decrease in predicted ∆∆G was greater with MM-PBSA than -GBSA calculations. In 
fact, none of the mean MM-GBSA ∆∆G had differences that were statistically significant 
at the 95% confidence interval, whilst only the estimates for the largest and smallest 
MULES regions were significantly different with MM-PBSA. The fact that the influence of 
MULES region size was relatively small was somewhat surprising. Equally unexpected 
was the fact that variance in the results showed no specific trends linked to region size. 
Uncertainties in the estimates remained low throughout. 
In principle, greater structural flexibility between copies should have led to better 
agreement with experiment. Although this may be the case for large mutations that 
involve extensive restructuring of the interface, the region size made little difference to 
the predictions for the P2’Ala mutation. Increasing the size of the MULES region did 
make a small difference to the computational cost of the MULES simulations however, 
and efficiency is equally important in the performance of simulations. 
4.5.1.2 Effects on timings 
The computational cost of standard MD simulations is primarily a function of the 
number of atoms simulated. The cost of MULES simulations is also a function of system 
size but has additional factors. As mentioned in section 4.4.1, MULES makes use of a 
modified version of Sander, Sander.LES, that performs the scaling of interactions inside 
the MULES region. Larger MULES region sizes involve greater scaling and hence greater 
cost. Additionally, the MULES approach relies on excluded atom lists to avoid copies 
interacting with one another. Large MULES region sizes result in extremely large 
exclusion lists, which may additionally slow each simulation step. As a result, the 
increase in MULES cost may not be not linear with region size. 
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Representative timings (in ns of simulation achieved per day) for simulations of each of 
the MULES region sizes are shown in table 4.6 and compared to timings for standard 
MD. Precise computational details are available in section 8.2.3. 
Table 4.6 – Comparison of system size and computational timings for MULES region sizes and 
standard MD. More ns/day of simulation means greater computational efficiency. 
Overall, MULES simulations performed with Sander.LES clearly showed a large increase 
in cost compared to standard MD perfomed with PMEMD. This was previously known. 
Beyond this, increasing MULES region size did not seem to greatly affect the cost of the 
simulation, as there were no clear trends between system or exclusion list size and 
ns / day of simulation achieved. Indeed, as simulations were performed on a shared high 
performance computing cluster, much of the variation in efficiency could be prescribed 
to variations in instantaneous load on the system, or small variations between compute 
nodes. 
Despite variations in individual timings, on average, runs with larger MULES regions 
were slightly more costly than those with smaller regions. Combined with the fact that 
increasing region size above residues within a 5 Å radius did not greatly change the 
accuracy or precision of ∆∆G estimates, there were no clear reasons for choosing a 
larger MULES region for a validation protocol. Including residues within 5 Å radius of 
the desired mutation was a practical compromise between speed and allowing 
necessary structural rearrangement.  
Therefore, for each mutation performed in this initial study, the MULES region was 
defined as a region of 5 Å radius surrounding the P2’ residue. Using the final structure of 
the native 1SMF complex at 300 K after heating and equilibration as a template, all 
residues with Cα atom within 5 Å of the P2’Ile residue were identified and included in 
 Standard 
MD 
MULES MD region 
 1SMF P2’ P1-P4’ P3-P6’ 5 Å 9 Å 10 Å 
Simulation size 
/atoms 
19492 19511 19572 19624 19689 19891 20036 
Exclusion list 
/entries 
40047 40532 46927 58212 80018 201585 339080 
Time / ns day-1 6.45 3.53 3.48 3.24 3.51 3.29 3.11 
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the MULES region for simulation. This included a total of 12 residues on both receptor 
and ligand sides of the interface, as shown in figure 4.7. Full details of the specific 
residues chosen are given in section 8.2.2.2. 
 
Figure 4.7 – MULES region defined for series of mutations of the 1SMF P2’Ile residue. Residues 
outside the MULES region, with identical dynamics between native and mutant, are shown with 
VdW surface representation, in blue for receptor (trypsin) and red for ligand (MBTI). Residues 
inside the MULES region, where dynamical differences between native and mutant propagate 
during the simulation, are shown in licorice representation, in grey (trypsin) or red (MBTI). 
P2’Ile residue is shown in yellow. Image created with PyMOL.287 
As seen in figure 4.7, the MULES region covered the majority of interface residues on 
both sides of the complex. Given the similarity of the mutations being made, stepwise 
from isoleucine through other hydrophobic residues to glycine, this region was thought 
to be sufficient to account for the limited structural changes expected. 
4.5.2 Choosing a structural equilibration length 
The preparation process for MULES coordinate and parameter files is based on standard 
LES. At the start of a simulation, a MULES run consists of two copies with very similar 
atomic coordinates. Some degree of structural equilibration is therefore undoubtedly 
required to allow the dynamics of the two copies to diverge. Whether 1 ns, the structural 
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equilibration length chosen during the analysis of region size, was enough time for this 
to satisfactorily occur was unknown.  
The latter two portions of the simulation process, structural equilibration and 
production MD, were performed with identical parameters and simulation conditions. 
The distinction in simulation nomenclature was merely for ease of analysis. As such, the 
definition of how much of the overall 11.1 ns trajectories should be considered 
structural equilibration time was flexible. Equilibration time could be increased by 
reanalysing the binding free energies of each trajectory but discarding a proportion of 
structural snapshots at the beginning. No further simulation would be required. 
Likewise, by increasing the proportion of an 11.1 ns trajectory denoted as equilibration 
time, the proportion used as production MD to carry out free energy calculations was 
equally reduced. The effects of this were equally unknown. 
The P2’Ala MULES trajectories were reanalysed for ∆∆G at progressively increasing 
structural equilibration times. Following heating and pressure equilibration, structural 
equilibration times of 1 ns (corresponding to the original set of ∆∆G), 2 ns, 3 ns, 6 ns, 
8 ns, 9 ns and 10 ns were all investigated for their effect on ∆∆G estimates. Results are 
plotted in figure 4.8. 
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Figure 4.8 – Effect of structural equilibration length on mean ∆∆G for P2’Ala MULES mutations. 
Increasing equilibration length (and thereby decreasing production run length) shows little 
effect on accuracy of ∆∆G prediction but does increase uncertainty in results as fewer structural 
snapshots are included in free energy calculations at longer equilibration lengths. 
The P2’Ala result showed increased ∆∆G standard deviations across the ten 
independent trajectories (and hence increased uncertainty in the mean ∆∆G) at longer 
equilibration times. This was unsurprising. Increased equilibration time resulted in 
decreased production MD time for free energy analysis, for the reasons outlined above. 
Decreased production MD time, equivalent to fewer structural snapshots analysed by 
MM-PB/GBSA, was likely to lead to increased variation between trajectories and hence 
increased uncertainty in ∆∆G estimates. 
Beyond this effect, increasing equilibration time induced little change in either the 
accuracy of mean ∆∆G estimates, or the agreement of MM-PBSA and MM-GBSA 
calculation methods. As such, the minimum 1 ns of equilibration time was deemed 
sufficient for the investigation of the remaining P2’ mutations. 
4.6 MULES simulations and analysis 
4.6.1 Stability, equilibration and dynamics of MULES MD simulations 
The MULES approach of simulating heterogeneous copies had not been attempted 
before. The first objective of this study was therefore to verify that MULES did not 
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introduce instabilities into the simulation. Visual inspection of all 50 MULES runs and 
the ten LES runs of the native structure showed that the complex remained intact and 
did not dissociate in any of the trajectories. Backbone RMSD and by-residue fluctuations 
of the residues outside the MULES region were also monitored and no undue differences 
between MULES and LES dynamics were observed. Backbone RMSD remained below 2 Å 
on average throughout all runs. This suggested that the MULES approach did not cause 
any undue fluctuations in the complex outside the copied region and that simulations 
remained stable throughout. 
Inside the MULES region dynamics of the native and mutant copies should differ and be 
as independent as possible. Visual inspection verified that the dynamics of the two 
copies did diverge slightly in all the trajectories. Figure 4.9 shows a comparison of the 
structures of a native and P2’Ala mutant copy at the end of the 10 ns production MD 
simulation. 
 
Figure 4.9 – Structural difference between native and mutant MULES regions at the end of a 
10 ns simulation. Coordinates outside the MULES region (grey ribbons) are identical, whilst the 
native P2’Ile at residue 228 (blue) and mutant P2’Ala (red) MULES region copies show small 
structural differences that allow the mutated residue to be better accommodated by its 
surroundings. Image created with UCSF Chimera.258 
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Although the structural rearrangements shown in figure 4.9 were relatively small, this 
was expected for such similar mutations and did show the MULES technique to have 
functioned correctly. Additionally, any structural rearrangement was expected to better 
account for the true changes in binding that took place upon mutation, and hence 
improve the accuracy to experiment of predictions compared to that of the 
post-processing approach. 
4.6.2 Free energy calculations 
As discussed above, ∆∆G calculations were first performed between the two copies of 
the native P2’Ile complexes from the control LES simulations. Investigating this null 
mutation allowed the estimation of the inherent variation in binding between two 
identical copies and hence the inherent ‘error’ in the LES technique. The equivalent null 
mutation with the post-processing technique would necessarily give a ∆∆G of 
0.0 kcal mol-1 as the mutated Ile would replace the exact same atomic positions of the 
native Ile. Across the ten independent trajectories the mean ∆∆G between the two native 
LES copies was 0.02 ± 0.13 kcal mol-1 using MM-PBSA and -0.05 ± 0.09 kcal mol-1 using 
MM-GBSA. The small magnitude and tight confidence intervals of these mean ∆∆G for 
the null Ile mutation instilled a high level of confidence that observed differences in ∆∆G 
for MULES simulations were a result of the mutation under investigation, rather than 
any inherent fluctuation caused by the simulation method. 
MM-PB/GBSA calculations were then carried out for the series of MULES simulations. All 
individual ∆∆G values are available as appendix 3, table S2, results and associated 
confidence intervals in the mean are summarised below in table 4.7. 
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Table 4.7 – Comparison of mean ∆∆G calculated with the MULES approach. All values in 
kcal mol-1. 
P2’ Residue Experimental ∆∆G MM-PBSA ∆∆G MM-GBSA ∆∆G 
Ile N/A 0.02 ± 0.13 -0.05 ± 0.09 
Nva 1.08 ± 0.04 0.86 ± 0.24 -0.07 ± 0.18 
Val 0.82 ± 0.04 1.38 ± 0.19 1.63 ± 0.13 
Abu 1.53 ± 0.03 1.64 ± 0.28 1.50 ± 0.21 
Ala 2.35 ± 0.04 2.24 ± 0.19 2.24 ± 0.18 
Gly ~4a 3.18 ± 0.30 3.57 ± 0.27 
Errors in computational values calculated as the 95% confidence interval of the mean of 10 
independent simulations. a~10% inhibition at highest concentration assayed, lower limit of ∆∆G 
estimated using Ki ≈ 4000 kcal mol-1. 
The MULES results replicated the trend of experimental results equally well to 
post-processing (table 4.3), with Pearson r correlations (excluding the glycine mutation) 
of 0.96 for MM-PBSA and 0.80 for MM-GBSA calculations. Significantly though, unlike 
post-processing, the MULES procedure led to very high absolute accuracy to experiment, 
with mean unsigned errors of 0.25 kcal mol-1 for PB and 0.53 kcal mol-1 for GB. 
Confidence intervals in the results were also small and sometimes even lower than 
those obtained with post-processing. This indicated equivalent, or sometimes better, 
reproducibility of the results and robustness of the predictions to variations in 
dynamics. 
In this study the additional cost associated with the MULES process, including input file 
preparation, longer simulation times and greater verification of equilibration required, 
did not greatly improve the correlation of predictions to experiment. Indeed, MULES 
predictions also swapped the ordering of the norvaline and valine mutant ∆∆G, 
suggesting that the differences between these particular mutations were especially hard 
to predict. The key improvement in MULES was instead the near quantitative accuracy 
of the results, and the implications of this are further discussed below. 
4.7 Discussion and conclusions 
4.7.1 Accuracy and precision 
The aim of the work presented in this chapter was firstly to establish whether the 
MULES approach could be used for predicting ∆∆G, and secondly to evaluate its 
effectiveness compared to the post-processing approach that was deemed the method of 
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choice in the previous chapter. To ease this comparison, the MULES and post-processing 
results, already described in the above sections, are presented again side by side in 
tables 4.8 and 4.9, and a graphical plot of the predictions and correlations is shown in 
figure 4.10. 
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Table 4.8 – Comparison of post-processing and MULES ∆∆G predictions. All values in kcal mol-1. 
P2’ Mutation Experimental ∆∆G PP PB ∆∆Gc PP GB ∆∆Gc MULES PB ∆∆G MULES GB ∆∆G 
Ile N/A 0 0 0.02 ± 0.13 -0.05 ± 0.09 
Nva 1.08 ± 0.04 1.15 ± 0.10 0.62 ± 0.10 0.86 ± 0.24 -0.07 ± 0.18 
Val 0.82 ± 0.04 1.89 ± 0.33 1.53 ± 0.21 1.38 ± 0.19 1.63 ± 0.13 
Abu 1a 1.53 ± 0.03 2.85 ± 0.16 2.23 ± 0.11 1.64 ± 0.28 1.50 ± 0.21 
Abu 2a 1.53 ± 0.03 3.63 ± 0.56 3.00 ± 0.45 N/A N/A 
Ala 2.35 ± 0.04 4.39 ± 0.44 3.98 ± 0.34 2.24 ± 0.19 2.24 ± 0.18 
Gly ~4b 5.12 ± 0.36 5.39 ± 0.32 3.18 ± 0.29 3.57 ± 0.27 
Errors in computational ∆∆G are calculated as the 95% confidence interval in the mean of ten independent simulations. aTwo rotamers of Abu are possible by 
performing post-processing on the native Ile as described in section 4.3.1. MULES does not distinguish between them. b~10% inhibition at highest concentration 
assayed, lower ∆∆G limit estimated assuming Ki ≈ 4000 µM. cPP = Post-processing. 
Table 4.9 – Correlation of experimental and computational ∆∆G values.a 
 Post-processing MULES 
PB GB PB GB 
Excluding glycine mutation Slope 2.73 ± 0.78 2.37 ± 0.84 0.94 ± 0.16 0.94 ± 0.40 
Intercept -1.58 ± 0.99 -1.53 ± 1.11 0.13 ± 0.20 0.05 ± 0.42 
r 0.90 0.85 0.96 0.80 
Including glycine mutation Slope 1.51 ± 0.43 1.67 ± 0.42 0.83 ± 0.12 0.85 ± 0.26 
Intercept -0.12 ± 0.65 -0.66 ± 0.65 0.20 ± 0.19 0.10 ± 0.35 
r 0.87 0.89 0.96 0.85 
Data analysed by linear regression, weighted by the errors in the individual data points using a Tukey biweight function. Uncertainties in slopes and intercepts are 
standard errors derived from the data fitting. As the experimental ∆∆G of the glycine mutant could not be unambiguously determined, two sets of correlations are 
presented, either including or excluding the glycine mutant data. 
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Figure 4.10 – Correlations of the post-processing (left) and MULES (right) ∆∆G predictions to 
experiment. ∆∆G calculated with either MM-PBSA (above) or MM-GBSA (below). Glycine 
mutation values are indicated separately as filled data points due to the uncertainty in the 
experimental ∆∆G measurement. Three lines are shown on each plot: Solid line, linear regression 
excluding glycine data; dashed line, linear regression including all data; dotted line, line of unit 
slope as expected for perfect correlation. 
As discussed previously and clearly shown by the results in table 4.9, both methods 
showed extremely good correlation to experiment whether including or excluding the 
glycine mutation from analysis. These results reinforce the idea that post-processing as 
described by Massova and Kollman259 can be extended to mutations other than alanine. 
Moreover, they also show that the newly developed MULES methodology is a viable 
approach to predicting ∆∆G. The most significant difference between the two methods is 
in their accuracy to experiment. 
The post-processing method tended to overestimate the effects of mutation, leading to 
slopes of        for both PB and GB solvation methods (table 4.9 and figure 4.10). This 
reduced to        if the glycine mutation data was included, but these slopes were 
still much greater than those calculated for the MULES method. Figure 4.10 shows that 
both PB and GB methods resulted in regression lines very close to perfect     
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prediction no matter whether the glycine mutation data was included, highlighting the 
robustness of these results further. 
The obvious reason for this improved accuracy is the structural rearrangement allowed 
by MULES. The post-processing method of simple deletion of atoms may force the 
mutant complex to adopt more energetically unfavourable conformations, with a 
necessarily higher ∆∆G, than those seen experimentally. This overestimation of effects is 
well known for alanine scanning with MM-PB/GBSA and has resulted in proposed 
adaptations to the free energy calculation method to improve its ability to make 
quantitative predictions.215, 260, 267 MULES approaches this problem in an alternative 
way - knowing that conformational changes on mutation can have a large effect on 
binding free energies, allowing for these rearrangements in a controlled way has clear 
advantages for accuracy and maintains the precision of the post-processing method. 
The uncertainties in each of the ∆∆G estimates are similar for both techniques, 
indicating the increased structural variation between native and mutant trajectories in 
MULES does not adversely affect the repeatability of the simulations. Given the 
reduction in precision associated with the conformational flexibility of the full MD 
approach, the equivalent precision of MULES and post-processing is perhaps 
unexpected. It should be remembered, however, that outside the MULES region the 
dynamics of native and mutant trajectories are identical and subject to the same 
cancellation of errors as post-processing. This cancellation of errors also suggests that 
neglecting entropic contributions to ∆∆G is a valid assumption, as the vast majority of 
entropic contributions will be identical. In principle then, any mutation performed with 
MULES would see a similar improvement over the same mutation performed with 
post-processing. 
4.7.2 Versatility 
The post-processing approach had already been extended beyond the alanine mutations 
of Massova and Kollman prior to this study,282-284 but the work presented here provides 
more evidence that the technique has potential for more widespread use than it 
currently enjoys. However, without allowing any other forms of structural 
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rearrangement (such as energy minimisation), there is only one set of coordinates from 
which the structures of all mutants can be extrapolated. This limits mutations to smaller, 
similar residues such as those presented here. If the proposed mutation were to change 
the character of the residue (for example, non-polar to polar, or acidic to basic) it is 
likely that conformational changes would be necessary to provide a realistic 
representation of the mutant protein structure. Post-processing is likely to fail for these 
types of changes - the alanine mutations of charged residues are where the largest 
errors have been reported previously.260, 288 
By contrast, the possibility of accounting for structural and, importantly, dynamical 
changes with MULES greatly increases its versatility. In principle it means that MULES 
may be used to investigate any mutation within a protein. Because surrounding residues 
have the opportunity to relax around a mutation during simulation, MULES only 
requires a suitable initial structure for the mutant, no matter its size or character. 
This concept may also be extended to other changes that may take place on mutation. 
For example, intercalating water molecules at the interface play important structural or 
energetic roles in many PPIs. Standard MM-PB/GBSA calculations remove all water 
molecules and counterions prior to analysis, replacing the explicit solvation with 
implicit. Although defined water molecules may be included in the free energy 
calculations if desired,234 a post-processing approach cannot capture the effects of a 
change in solvation during a mutation. Fortunately in the P2’Ile case this was not 
deemed necessary, as the residue is deemed buried (<20% relative SASA calculated with 
STRIDE289 and DSSP servers,290, 291 normalised with Gly-X-Gly surface areas of 
Chothia292). 
With MULES, on the other hand, explicit water molecules could be included in the 
MULES region if necessary. Alternatively, solvent exposed residues may benefit from an 
implicit solvation method during the simulation, as this would solvate each of the two 
copies independently and uniquely. The reliance on existing Amber modules means that 
MULES is versatile enough to accommodate these changes in methodology. Anywhere 
that standard LES can be used, MULES may also be attempted. 
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These changes to MULES methodology require testing to evaluate their usefulness and 
will be extensively explored in later chapters. Given the amount of further development 
required a further advantage of MULES is that, for a single mutation, it has a relatively 
small increase in computational cost over post-processing. Both techniques have similar 
lengths of underlying MD simulation, but while the simple MD required for 
post-processing may be performed with the PMEMD module of Amber, MULES must 
make use of the less computationally efficient Sander module, as LES is currently not 
implemented within PMEMD. Despite this, across 8 CPU cores a standard MD trajectory 
was complete in roughly 45 hours, whilst a MULES run required 65 hours - an increase 
of ~50%. This also means that MULES continues to be a far less costly approach than 
pathway free energy methods. It should be noted that the time required for 
MM-PB/GBSA calculations and analysis is identical for both MULES and post-processing, 
and, given the improvements in correlation and reduction in mean unsigned error 
(MUE) over GB, PB is the preferred solvation method in the free energy calculations. 
This is consistent with the previous results of chapter 3. 
4.7.3 Limitations 
Despite the successful development of MULES and the improvements in ∆∆G predictions 
it has shown so far, the technique remains limited in its ability to be an all-purpose 
probe of PPIs. The mutations investigated in this chapter have all been of similar, 
structurally related, hydrophobic residues. The conformational changes induced by 
these mutations are likely to be small, particularly as the MBTI peptide has a well 
defined structure and trypsin binding mode. Although MULES has shown significant 
improvement over post-processing, a much wider validation of MULES must take place 
in order to assess its true potential in predicting ∆∆G. This validation should encompass 
a large dataset of mutations, include polar, non-polar, acidic and basic residues and 
cover a variety of complexes. 
Such a widespread validation would require a standard protocol for the use of MULES to 
ensure that results between residue types and complexes were fairly compared. The 
study of MULES presented so far provides little information as to the optimum 
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parameters for correctly predicting ∆∆G in the minimum possible time. The effects of 
mutating other residues, implementing MULES on PPIs of different sizes, changing 
production MD simulation length and changing solvation should all be thoroughly 
explored before a large scale validation takes place. These investigations will be the 
focus of the next chapter. 
4.8 Summary 
This chapter has presented the development and initial testing of a novel method for 
generating native and mutant MD trajectories for calculating ∆∆G with MM-PB/GBSA. 
The new approach, MULES, adapts the Locally Enhanced Sampling technique to include 
heterogeneous copies of a defined region of a simulation for the first time. It allows the 
local structural and dynamical effects of a mutation to be accommodated whilst 
cancelling errors due to changes distal from the interface. 
The predictive power of MULES has been tested using a series of mutations of a 
prototypical PPI; the trypsin/MBTI complex of PDB entry 1SMF. Native and mutant 
versions of the MBTI inhibitory loop were synthesised, assayed for their inhibitory 
activity and relative binding free energies for each mutation experimentally determined. 
MULES ∆∆G estimates showed a high degree of accuracy, precision, reproducibility and 
robustness, with impressive near-quantitative accuracy (mean unsigned error to 
experiment = 0.25 kcal mol-1 for MM-PBSA, 0.53 kcal mol-1 for -GBSA). 
Importantly, MULES is also a far more versatile technique than the post-processing 
alternative. Allowing structural variation means that MULES would lend itself well to 
investigating changes in solvation, protonation state or other experiments that may only 
currently be performed with time consuming pathway free energy methods. Success in 
these applications would secure MULES as a valuable tool for the protein engineer. 
However, the dataset investigated so far is too small to draw general conclusions as to 
the applicability of MULES and it is possible that the excellent agreement with 
experiment seen in this study may be fortuitous. The next stage of research therefore 
investigates the effects of changing simulation parameters and mutation types on 
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MULES, with the aim of identifying a standard protocol for a validation of the technique 
with much a wider dataset. 
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5 Further MULES testing 
5.1 Introduction 
The results of the work presented so far have clearly demonstrated the deficiencies of 
existing methods of calculating ∆∆G with MM-PB/GBSA free energy calculations. Noting 
a niche for the improvement of these methods, whereby a limited amount of structural 
and dynamical variation between native and mutant trajectories is allowed in a local 
area surrounding the mutation, the MULES approach has been developed and tested on 
a series of related natural and non-natural mutations of a prototypical PPI. MULES was 
shown to greatly improve the accuracy of ∆∆G predictions, achieving near quantitative 
agreement with experimentally determined values with no loss of precision and little 
additional cost compared to the existing method of choice, post-processing mutagenesis. 
Nevertheless, as discussed in the previous chapter, at this stage the MULES approach 
remained limited in its application. As MULES had never before been attempted, the 
main objective of the modest study presented in the previous chapter was simply to 
discover whether the concept of heterogeneous copies was in any way viable, or 
whether the changes to LES it required induced problems or instabilities in the MD 
simulations. As MULES successfully generated results for a series of natural and 
non-natural mutations, these questions were answered. However, no conclusions can be 
drawn as to whether the simulation conditions chosen were the best way to perform 
MULES under all circumstances and for all mutations. 
The MULES parameters, meaning mutations studied, simulation and equilibration 
length, were effective for the P2’ series of mutations, but may not be suitable for other 
mutations, even of the same trypsin/MBTI complex. The effects of changing these 
parameters must be investigated before any widespread evaluation of MULES is made. 
This chapter focuses on optimising these parameters with the aim of defining a standard 
MULES protocol to eventually validate the approach on a broad dataset of mutations. 
Initially, further mutations of different residues at the trypsin/MBTI interface are 
investigated, with particular focus on how well MULES treats the mutation of charged 
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residues. As previously discussed, the interactions and conformational rearrangements 
caused by the mutation of these residues are difficult to capture accurately with 
MM-PB/GBSA approaches, resulting in a consistent overestimation of their ∆∆G. 
Different ways of representing these large mutations will be presented and evaluated. 
Computational efficiency is a key goal in designing a validation protocol suitable for use 
across a wide dataset of mutations, hence the effects of reducing the number of 
independent trajectories performed, increasing complex equilibration time and/or 
reducing production MD time will be investigated for all mutations performed. These 
parameters are key to the efficiency of MULES - if similar accuracy and precision can be 
obtained with fewer repeats or shorter simulation times, the ability of the method to act 
as a rapid generic probe is improved. 
Finally, variations of MULES solvation (implicit or explicit) and in scaling of atomic 
masses during the simulation are investigated. Both are linked to the degree of sampling 
enhancement inside the MULES region. Reduction of energy barriers in the MULES 
region is not in itself a disadvantage of the method, as it allows conformational changes 
to take place more rapidly and an equilibrium state to be achieved more quickly. 
However, care must be taken to ensure that a suitable equilibrium conformational 
ensemble, sampling similar enough phase space to that of a standard MD simulation, is 
being simulated to generate reliable ∆∆G. As both implicit solvation and scaling of 
atomic masses can enhance the rate at which conformational transitions take place 
(albeit for different reasons) the effects of both are investigated here. 
The results of all of the above investigations are then collated to produce a suggested 
protocol for MULES that may be used across multiple mutation types and multiple PPIs. 
The accuracy and precision of ∆∆G predicted with this protocol will then be evaluated in 
the next chapter. 
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5.2 Other trypsin/MBTI mutations 
5.2.1 Around the MBTI ring 
The synthetic MBTI inhibitory loop that is complexed with trypsin in PDB entry 1SMF 
has nine residues (shown in chapter 3, figure 3.1). One of these, the P2’Ile residue, was 
extensively modified in the investigation of MULES in the previous chapter. However, 
experimental ∆∆G from measurements previously carried out within the group (not as 
part of this study) were available for mutations of four other residues around the loop: 
the P2Thr, P1Lys, P1’Ser and P5’Glu.254 The P3Cys and P6’Cys, P3’Pro and P4’Pro 
residues were all deemed to be too important for structure for the effects of mutation to 
be investigated. 
Of the four mutated residues, the P5’Glu and P1Lys were the more interesting for 
MULES study for numerous reasons. Firstly, their experimentally measured ∆∆G on 
mutation to alanine (chapter 3, table 3.1) were at the extremes of those determined for 
the MBTI residues - 1.02 ± 0.07 kcal mol-1 for P5’Ala and > 5.72 kcal mol-1 for P1Ala. 
These relatively small (P5’Ala) and very large (P1Ala) ∆∆G represented new challenges 
for MULES, which until now had only been performed on the P2’ series of mutations of 
intermediate size and ∆∆G. 
Secondly, the solvation of the P5’ and P1 residues differed greatly. While the P1Lys was 
deeply buried at the interface, with strong salt bridge interactions at the base of the 
trypsin specificity pocket, the P5’Glu residue was almost completely solvent exposed 
and had few direct interactions with trypsin at all (figure 5.1). Although the effects of 
solvation are further explored in section 5.4.2, the differences identified here were 
hoped to provide some initial suggestions as to whether MULES performed 
fundamentally differently for buried and solvent exposed residues. 
  151 
 
Figure 5.1 – Structure of complex between trypsin (cyan, surface representation) and synthetic 
MBTI loop (red, ribbon representation) from PDB entry 1SMF. Two sidechains of the MBTI loop 
are explicitly shown; the P5’Glu residue, which is solvent exposed and interacts only with the 
surface of the trypsin receptor, and the P1Lys, which is buried and interacts internally within the 
complex, inaccessible to bulk solvent. Image created with UCSF Chimera.258 
Thirdly, both the glutamic acid and lysine were ‘charged’ residues - that is, they are 
acidic or basic (respectively) and are represented in the simulation with ionised 
sidechains, respectively negatively or positively charged. As discussed extensively in 
previous chapters, MM-PB/GBSA free energy estimates are known to perform poorly for 
charged residues. Some attempts to improve this performance, particularly those that 
adapt solute dielectric constants, have used the increased conformational 
rearrangements proposed after the mutation of a highly charged interface to justify their 
differential treatment of these interactions.153, 267, 293 If MULES successfully improved the 
agreement of charged residue ∆∆G with experiment, this would suggest that structural 
rearrangement may be the predominant role in accuracy, and also that MULES may 
provide a more robust way of estimating charged residue ∆∆G, as it requires no a priori 
‘guess’ of a suitable solute dielectric. 
For these three reasons, MULES simulations of the P1Ala and P5’Ala mutations were 
chosen to be performed and analysed. Their results are dealt with in turn below. 
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5.2.2 P1Lys to P1Ala mutation 
5.2.2.1 Dealing with charge changes 
The mutation of a charged residue such as lysine to an uncharged one such as alanine 
introduced new challenges to the MULES protocol. In previous work, although partial 
charges of individual atoms were modified extensively on mutation of the P2’Ile to other 
residues, the overall charge of the residue (and hence the overall charge of the system) 
was not changed. In this new case the MULES simulation consisted of one copy of a 
structure with a positively charged lysine, and one of a neutral alanine. The residue in 
total therefore only had half a positive charge, rather than a full positive charge. This 
reduction left the system as a whole with half a negative charge, as the initial lysine 
complex had been neutralised with chloride counterions. 
The PME method for dealing with long-range electrostatic interactions requires that the 
system as a whole is neutral.131 Therefore the half-charge left by mutation of the lysine 
had to be neutralised. Across a parameterised biomolecular system, rounding errors 
mean that partial charges rarely sum to exactly zero anyway. As a matter of course 
during the simulation, Amber deals with this non-neutrality by scaling all partial charges 
by a small, yet finite, constant, in order that the ratio of partial charges is conserved but 
their sum is zero. However, these rounding errors usually result in overall charges 
< 0.001. The half-charge produced in this MULES simulation was several orders of 
magnitude larger, and could potentially have resulted in large changes to dynamics if 
spread out across the whole system. An alternative approach was required. 
Similar problems are encountered in mutations of charged residues performed with 
alchemical free energy methods. Where charge changes take place during the 
simulation, the usual approach of the PME method is to generate a uniform neutralising 
plasma to cancel the effects of the change in overall charge. However, as this 
neutralising charge does not take account of the position of the mutation (and hence the 
change in charge) it can introduce large errors into free energy estimates - another 
potential source of the historic poor agreement of charged residue estimates with 
experiment.294, 295 A more realistic protocol is to perform two simultaneous mutations of 
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oppositely charged residues such that the overall charge of the system does not change 
during the mutation.176, 177, 294, 296 Although this approach has had some success with 
alchemical free energy calculations, it requires the careful choice of partner residue to 
ensure that no significant change to ∆∆G is caused by the second mutation. Although this 
would have been possible in MULES, simply by including an additional, distal, oppositely 
charged residue in the MULES region, the additional preparatory work and validation 
required was deemed prohibitive given the aim of creating a standard MULES protocol. 
The simplest way to change the overall charge of a simulation is by adapting the 
counterions present in bulk solvent. In principle this is similar to a mutation of a distal 
residue - counterions are likely to be far from any point of interaction with the protein 
and are guaranteed not to affect free energy calculations as they are stripped from the 
trajectory during MM-PB/GBSA analysis. The native 1SMF structure had a positive 
charge overall and so chloride counterions were included to neutralise the system. 
During the MULES simulation of the P1Ala mutation, one of these counterions was 
included in the MULES region, thereby generating two copies each with charge of -0.5. 
The second of these copies, part of the P1Ala mutant MULES region, was ‘mutated’ to be 
a dummy atom with zero charge and zero VdW interactions. This resulted in the 
neutralisation of the overall simulation, as well as the neutralisation of each individual 
copy. 
5.2.2.2 Initial MULES simulations 
MULES simulations of the P1Ala mutation were performed similarly to the investigatory 
MULES simulations of the previous chapter. Residues with Cα atoms within 5 Å of the 
P1Lys residue were copied as part of the MULES region, along with a single Cl- 
counterion present in bulk solvent. The native copy was left unmodified and the mutant 
copy adapted to include an alanine and remove the parameters of the counterion. Ten 
independent MULES simulations were then performed, using the same procedure of 
heating, equilibration, further conformational equilibration for 1 ns and finally a 
production MD period of 10 ns. Following simulation, separate native and mutant 
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trajectories were extracted from the combined MULES trajectory and MM-PB/GBSA 
calculations performed to generate ∆∆G. 
Calculated ∆∆G values are presented in table 5.1. For reference, the experimental ∆∆G 
had been previously determined to be > 5.72 kcal mol-1. 
Table 5.1 – MM-PB/GBSA ∆∆G of the P1Ala mutation calculated with charge neutralisation 
performed by modification of bulk solvent counterion. Mean, standard deviation and 95% 
confidence interval of the mean are all presented as measures of variance and uncertainty. All 
values in kcal mol-1. 
Unexpectedly, both PB and GB solvation methods gave ∆∆G that were of the wrong sign 
and of non-negligible magnitude. According to the MULES simulations, the mutation of 
the P1 lysine to alanine should have been highly favourable and greatly improve binding 
affinity. This was clearly incorrect, and only run 2 gave an estimate roughly in line with 
expectations from experiment. The fact that MM-PBSA and -GBSA gave results of similar 
magnitude and variability suggested the cause was the underlying dynamics of the 
simulation rather than the free energy calculation. 
Visual inspection of the MULES trajectories showed a partial dissociation of the complex 
in the majority of runs, usually after 5 - 10 ns of simulation. Conformational changes led 
to shifts in the interactions of the P1Lys residue in the native copy, and in particular to 
the loss of salt bridges between the P1Lys and S1Asp at the base of the trypsin 
specificity pocket. To verify this was not normal behaviour perhaps accelerated by 
unduly enhanced sampling in the MULES region, a 100 ns standard MD simulation of the 
Run MM-PBSA ∆∆G MM-GBSA ∆∆G 
1 -7.43 -2.06 
2 3.25 3.66 
3 -9.30 -5.85 
4 -9.59 -5.14 
5 -12.40 -5.84 
6 -6.80 -3.05 
7 -1.79 -1.54 
8 -7.06 -3.97 
9 -6.81 -2.23 
10 -3.51 0.79 
Mean -6.14 -2.52 
St. Dev. 4.45 3.01 
95% C.I. ± 3.19 ± 2.16 
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native 1SMF complex was performed and its dynamics compared to those of the MULES 
trajectories. Hydrogen bonding analysis with the ptraj module of Amber was used to 
determine the number of salt bridges between the sidechain amino group of the P1Lys 
and the sidechain carboxyl group of the S1Asp at every snapshot of the simulations. 
Running averages of these analyses are shown in figure 5.2. 
The analysis of the interactions between the receptor and ligand showed that the salt 
bridge was stable under normal simulation conditions. Even when disrupted for a short 
period of time (snapshot 6250 - 7500, figure 5.2a) the salt bridge was eventually 
regained. However, during MULES simulations the salt bridges were rapidly lost as 
conformational changes disrupted the position of the P1Lys residue. Only run 2 saw the 
resurrection of the salt bridging interaction towards the end of the simulation. 
The loss of this large, highly positive contribution to ∆G may have been one of the major 
causes of a negative ∆∆G on mutation to alanine - without the large, positive, enthalpic 
contribution of a salt bridge, the lysine residue may have truly been less favourable due 
to the different solvation penalties of the alanine and lysine in the dissociated ligand. 
However, the reasons for this loss of binding were still unclear. Changes in P1Lys 
dynamics were specific to the MULES approach, but there were many possible reasons 
for these changes. 
Firstly, the structural differences between native and mutant copies were necessarily 
limited by the size of the MULES region. The coordinates of residues outside the region 
were common to both copies. If a mutation resulted in conformational changes that 
could not be accounted for inside the region, then either the native or mutant copy 
interactions would have been incorrectly represented. In this case it was possible that 
the large mutation of the alanine copy would have affected the conformations of 
residues outside the MULES region and thereby adversely affected the binding of the 
lysine copy. However, increasing the size of the MULES region to include all residues 
within 8 Å of the P1Lys made no difference to the trend or variability of predicted ∆∆G. 
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Figure 5.2 – Salt bridges between P1Lys and S1Asp residues on MBTI and trypsin respectively. 
At each snapshot a maximum of two salt bridges is possible, corresponding to an interaction with 
each of the two negatively charged oxygen atoms of the aspartate carboxyl group. A) 100-point 
running average of salt bridges across standard MD trajectory demonstrates preservation of 
interaction throughout. B) 100-point running averages across ten MULES runs show a uniform 
rapid loss of the salt bridge, with only run 2 regaining the interaction later in the simulation. 
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Secondly, the MULES process itself of scaling interactions inside independent copies 
may have induced unusual conformational changes in one or both copies that affected 
the overall binding free energy. This was difficult to assess from the simulations 
performed, but further evaluation of the effects of enhanced sampling in MULES is 
presented in section 5.4. 
Thirdly and finally, the most likely explanation was simply that the mutation performed 
was an overly simplistic representation of the actual experimental mutation. For 
example, the mutation of the lysine residue to alanine and corresponding loss of a salt 
bridge was unlikely to experimentally result in the preservation of a bare, ionised, 
negatively charged carboxyl group surrounded by a vacuum where the lysine sidechain 
used to occupy volume. However, this is exactly what was simulated as the starting 
structure of the MULES runs. Realistically, the mutation would result in a change of 
solvation in the specificity pocket and/or a change in protonation state of the partner 
aspartic acid residue. Not accounting for these changes may have led to the adverse 
conformational changes described in the first possible explanation above. 
5.2.2.3 Changing the S1Asp protonation state 
To verify this was the case, further MULES simulations of slightly different mutations 
were performed. The S1Asp residue (Asp171 in the 1SMF PDB structure with Amber 
residue numbering) was predicted to have a pKa shift of approximately +3 pK units on 
mutation of the P1Lys to alanine, calculated with version 3.0 of the H++ server.297 It is 
feasible that this shift could change the protonation state of the residue on mutation. To 
test whether this was the case, MULES simulations were carried out with a MULES 
region of 5 Å around the P1Lys residue, with a native copy consisting of P1Lys and 
S1Asp and mutant copies consisting of P1Ala and S1Ash, where Ash is the neutral, 
protonated state of aspartic acid. Notably, this neutralisation of the Ash residue in the 
mutant copy meant that no neutralisation of a counterion in bulk solvent was necessary, 
as the overall system remained neutral throughout. ∆∆G estimates are presented in 
table 5.2, and an analysis of the Asp-Lys salt bridges for the native copies is shown in 
figure 5.3. 
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Table 5.2 - MM-PB/GBSA ∆∆G of the P1Ala/S1Ash mutation. Mean, standard deviation and 95% 
confidence interval of the mean are all presented as measures of variance and uncertainty. All 
values in kcal mol-1. 
 
Figure 5.3 - Salt bridges between P1Lys and S1Asp residues (i.e. native copy) on MBTI and 
trypsin respectively. 100-point running averages of interactions across ten independent MULES 
trajectories in which the mutant copy is P1Ala and S1Ash - the neutral aspartic acid. 
The results of the MULES simulations with the neutral aspartic acid mutant were clear. 
Firstly, from figure 5.3, the lysine-aspartate salt bridges of the native copy were retained 
throughout all simulations, and were perhaps favoured even more than during the 
Run MM-PBSA ∆∆G MM-GBSA ∆∆G 
1 3.77 5.08 
2 2.50 5.57 
3 5.26 5.83 
4 2.25 4.10 
5 4.97 5.39 
6 1.73 4.33 
7 4.10 4.42 
8 2.14 4.64 
9 3.93 5.28 
10 1.49 4.38 
Mean 3.21 4.90 
St. Dev. 1.36 0.60 
95% C.I. ± 0.97 ± 0.43 
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standard MD simulation. This may have been a result of slightly different starting 
conformations after minimisation however. Secondly, the preservation of the salt 
bridges resulted in estimated ∆∆G of the correct sign and magnitude compared to 
experiment, and with far less variation between individual predictions. 
These results strongly suggested that the cause of the instabilities in the initial P1Ala 
MULES simulations was the unrealistic nature of the mutation being simulated. In this 
case the simultaneous change in protonation state of a partner residue, S1Asp, was seen 
as the most probable representation of the ‘correct’ mutation in the absence of any 
direct evidence for the presence of a defined hydroxonium ion. However, this did not aid 
attempts to create a generic MULES protocol. Often, charged residues may be involved 
in salt bridges with multiple partner residues, or may not be surrounded by other 
charged residues at all. In both cases the choice of whether a partner residue should be 
simultaneously mutated, and which partner residue should be chosen, could not be 
made automatically. This was unsuitable for a standardised protocol. 
5.2.2.4 Changing mutant solvation 
Changes in solvation as a result of mutation were much easier to standardise however. 
The change in sidechain volume on mutation of a lysine to alanine would accommodate 
at least one additional water molecule in the mutant structure. In addition, given the 
location of this additional water next to the S1Asp residue, and its buried nature, it is 
possible that the molecule would be ionised, forming a H3O+ hydroxonium ion in 
proximity to the aspartate. This would again simplify the MULES simulation by making 
sure that the system as a whole remained neutral without the necessity for copying and 
mutating a counterion in bulk solvent. 
To test this hypothesis, MULES simulations were performed with mutant copies 
consisting of the P1Ala mutation and an additional H3O+ molecule interacting with the 
S1Asp. For ease of mutation, the mutant hydroxonium ion was overlaid on the positions 
of the NH3+ group of the initial lysine (figure 5.4). MULES parameter files were created 
using the same protocol as in section 4.4.2.2, but with the additional task of changing the 
exclusion list for the mutant residue, as the alanine had to fully interact with the H3O+ 
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(and vice versa). Parameters for hydroxonium were taken from Baaden and coworkers, 
including an angle term for HW-OW-HW present in the ff99/ff99SB forcefield but not 
usually required for TIP3P water.130, 162, 298 
 
Figure 5.4 – Schematic of MULES mutation of P1Lys to P1Ala + H3O+. The hydroxonium ion 
replaced the charged amino group at the end of the lysine sidechain. Atom exclusion lists were 
adapted to ensure the correct interactions of the new molecule. Dummy atoms with zero 
parameters are shown in grey in copy 2. 
Visual analysis of the trajectories revealed that the hydroxonium ion remained in the 
trypsin specificity pocket during the simulations and did not exchange with bulk water. 
During MM-PB/GBSA analysis of the P1Ala mutant there were a variety of possible ways 
to deal with the presence of the hydroxonium ion. The simplest was to treat the 
additional ion as any other solvent molecule and strip it from the trajectory prior to 
analysis. However, the very specific interactions of the hydroxonium ion also meant it 
may be justified to include the molecule specifically in the free energy calculations; 
either as part of the receptor, or as part of the ligand. All three approaches were tested. 
∆∆G estimates are shown in table 5.3, and figure 5.5 shows the analysis of salt bridges 
between the P1Lys and S1Asp of the native copies. 
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Table 5.3 – MM-PB/GBSA ∆∆G of the P1Ala/H3O+ mutation. Mean, standard deviation and 95% 
confidence interval of the mean are all presented as measures of variance and uncertainty. All 
values in kcal mol-1. 
Run Strippeda 
PB 
Strippeda 
GB 
Lig sideb 
PB 
Lig sideb 
GB 
Rec sidec 
PB 
Rec sidec 
GB 
1 7.57 4.60 21.98 17.17 6.22 4.69 
2 5.44 4.65 21.11 18.31 3.93 4.74 
3 7.76 6.47 20.57 20.17 6.81 6.38 
4 5.40 3.73 20.44 17.27 3.15 3.83 
5 1.76 1.91 19.30 15.80 0.51 2.10 
6 7.14 3.56 21.11 17.25 4.63 3.63 
7 1.25 3.12 18.08 16.35 0.63 3.30 
8 7.26 4.88 21.78 18.36 5.80 4.98 
9 -0.15 1.78 18.34 15.23 0.02 2.00 
10 4.82 3.90 20.82 17.87 4.24 3.94 
Mean 4.83 3.86 20.35 17.38 3.59 3.96 
St. Dev. 2.89 1.41 1.35 1.42 2.47 1.33 
95% C.I. ± 2.07 ± 1.01 ± 0.97 ± 1.01 ± 1.77 ± 0.95 
a Hydroxonium ion has been stripped from the MD trajectory prior to free energy analysis. 
b Hydroxonium ion remains in the MD trajectory during free energy analysis, treated as part of 
the ligand. c Hydroxonium ion remains in the MD trajectory during free energy analysis, treated 
as part of the receptor. 
 
Figure 5.5 - Salt bridges between P1Lys and S1Asp residues (native copy) on MBTI and trypsin 
respectively. 100-point running averages of interactions across ten independent MULES 
trajectories in which the mutant copy is P1Ala plus a hydroxonium ion. 
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Figure 5.5 shows that the MULES runs with a hydroxonium ion present in the mutant 
copy showed similar salt bridge stabilities to the 100 ns standard MD run. Where the 
salt bridges were lost during simulation they were quickly recovered. However, the 
greater variability in salt bridging seen between trajectories, which translates to greater 
conformational differences, goes some way to explaining the greater variability in ∆∆G 
estimates compared to the MULES runs with the neutral aspartic acid mutant. 
The more realistic native copy dynamics resulted in ∆∆G estimates that agreed far better 
with experiment. No matter what the treatment of the hydroxonium ion in the 
MM-PB/GBSA calculations, the predicted ∆∆G on mutation were all large and positive, 
correctly indicating a large loss of affinity for the alanine mutant. Notably however, the 
three methods of treating the H3O+ ion did have significant differences in magnitude and 
uncertainty of the mean predicted ∆∆G values. 
The variant with H3O+ present as part of the ligand during free energy analysis showed 
markedly greater ∆∆G than either of the other two protocols. Analysis of the individual 
energetic components of the overall free energy showed that the majority of this ∆∆G 
emanated from the PB or GB solvation terms. As part of the ligand, the large positive 
charge of the hydroxonium was relatively unshielded and completely solvent accessible, 
leading to a large change in the solvation free energy, a large overestimation of the 
desolvation penalty of the alanine mutant, a large underestimation of the alanine mutant 
binding free energy and hence a large overestimation of ∆∆G. By contrast, as part of the 
receptor, the hydroxonium was relatively buried and its electrostatic charge was better 
shielded by the presence of surrounding residues. This led to much more realistic 
estimates of ∆∆G. 
In any case, the large increase in the magnitude of ∆∆G estimated with the ligand-side 
protocol did not result in a large increase in variability, confirming the systematic, 
rather than random, nature of the error. Table 5.3 shows that the stripped and 
receptor-side protocols had similar uncertainties. Variability in the stripped method 
was slightly higher than that of the other two approaches, but this was to be expected 
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given that the charge of the S1Asp residue was not shielded by the hydroxonium 
counterion during these calculations. 
Conceptually, the stripped protocol is the most uniform way of dealing with a charge 
change. The counterion introduced to represent the effects of changing solvation on 
mutation is treated like any other solvent molecule and removed from the trajectory 
during MM-PB/GBSA analysis. However, there may be cases in which the presence of 
the counterion during the free energy calculation would have significant effects on the 
predicted ∆∆G, as shown by the results of the ligand-side protocol above. Despite its 
overestimation of ∆∆G for this particular mutation, the ligand-side protocol is 
conceptually a more correct way to deal with the presence of a counterion than the 
receptor-side method. If a residue on one side of an interface is mutated and a new 
solvent molecule introduced, the additional solvent should ‘belong’ to the side of the 
mutation. An independent receptor structure should not be modified by the presence of 
a mutation on its opposing ligand. This is consistent with the assumptions of the single 
trajectory MM-PB/GBSA approach. 
Despite successfully identifying a variety of methods for predicting the effects of the 
P1Ala mutation, all of these methods required further evaluation. The investigation of 
charged residue mutations was therefore continued to the P5’ glutamate to alanine 
mutation. 
5.2.3 P5’Glu to P5’Ala mutation 
The P5’Glu residue is positioned very differently to the P1Lys residue. Figure 5.1 clearly 
shows its high degree of solvent exposure and few interactions with the trypsin 
receptor. Experimentally it has only a limited effect on binding, with a ∆∆G of 
1.07 ± 0.07 kcal mol-1 on mutation to alanine (chapter 3, table 3.1). As a solvent exposed 
acidic residue it was always modelled in its negatively charged, ionised form during MD 
simulations. Combined, these properties made the P5’Glu an attractive target for further 
analysis of how best to treat charged residues with MULES. 
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MULES simulations were therefore performed to calculate ∆∆G of the P5’Ala mutation, 
with MULES regions including all residues within 5 Å radius of the native P5’Glu residue. 
The previous section described five approaches to treating the mutation of charged 
residues to alanine: 
1. The ‘counterion’ approach. Mutates the desired residue to alanine, neutralises 
the overall system by mutation of a counterion in bulk solvent. 
2. The ‘partner residue’ approach. Mutates the desired residue to alanine, 
neutralises the overall system by mutation of an oppositely charged partner 
residue to a neutral protonation state. 
3. The ‘stripped’ approach. Mutates the desired residue to alanine and an ionised 
solvent molecule to replace the previous sidechain volume and neutralise the 
system. Solvent molecule is stripped from the trajectory prior to free energy 
analysis. 
4. The ‘receptor-side’ approach. Mutates the desired residue to alanine and an 
ionised solvent molecule to replace the previous sidechain volume and 
neutralise the system. Solvent molecule remains during free energy analysis and 
is treated as part of the receptor. 
5. The ‘ligand-side’ approach. Mutates the desired residue to alanine and an 
ionised solvent molecule to replace the previous sidechain volume and 
neutralise the system. Solvent molecule remains during free energy analysis and 
is treated as part of the ligand. 
Of these approaches, the ‘partner residue’ and ‘receptor-side’ methods (2 and 4) were 
deemed to be irrelevant, as the P5’Glu had no direct interactions with the receptor in the 
complex crystal structure. However, ten independent simulations using each of the 
‘counterion’, ‘stripped’ and ‘ligand-side’ protocols were all carried out and analysed for 
binding free energy. In contrast to the P1Ala mutation, the P5’Ala mutation involved the 
loss of a negative charge from a solvent exposed residue. The ionised solvent molecule 
chosen to replace this charge was therefore a hydroxide ion, restrained in its 
surroundings during the simulations using weak Cartesian restraints. Hydroxide 
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parameters were taken from Pang and coworkers.299 Table 5.4 shows the MM-PB/GBSA 
calculated ∆∆G for the mutations. For reference, the experimentally determined ∆∆G for 
P5’Ala was 1.07 ± 0.07 kcal mol-1. 
Table 5.4 – MM-PB/GBSA ∆∆G of the P5’Ala mutation performed with various protocols. Mean, 
standard deviation and 95% confidence interval of the mean are all presented as measures of 
variance and uncertainty. All values in kcal mol-1. 
Run Counteriona 
PB 
Counteriona 
GB 
Strippedb 
PB 
Strippedb 
GB 
Lig sidec 
PB 
Lig sidec 
GB 
1 0.07 -0.21 0.18 -0.20 0.43 1.12 
2 -0.51 -0.44 0.34 -0.25 0.35 1.20 
3 0.39 -0.20 -0.16 -0.37 0.72 1.71 
4 0.67 -0.13 0.33 -0.17 0.60 1.49 
5 0.59 -0.09 0.45 -0.19 0.72 1.41 
6 0.46 -0.21 0.17 -0.14 0.58 1.51 
7 0.56 -0.04 0.61 0.09 0.40 1.06 
8 0.45 -0.12 0.23 -0.40 0.25 1.18 
9 0.83 0.05 -0.45 -0.43 0.35 1.84 
10 -1.46 -0.60 0.83 0.11 0.32 1.10 
Mean 0.20 -0.20 0.25 -0.20 0.47 1.36 
St. Dev. 0.69 0.19 0.36 0.19 0.17 0.27 
95% C.I. ± 0.50 ± 0.14 ± 0.26 ± 0.13 ± 0.12 ± 0.19 
a Ala mutant system neutralised via addition of chloride counterion in bulk solvent. b Hydroxide 
ion present in mutant copy stripped from MD trajectory prior to free energy analysis. c Hydroxide 
ion remains in the MD trajectory during free energy analysis, treated as part of the ligand. 
Interestingly, the ligand-side approach showed best agreement with experiment for 
both PB and GB solvation methods. The reasons for this are unclear given that the 
likelihood of the mutation of a solvent exposed residue resulting in the replacement of a 
nearby water molecule with hydroxide is slim. However, despite the better accuracy of 
the ligand-side method, all protocols correctly identified the P5’Glu as a neutral residue 
with little contribution to binding. 
Each of the three methods represents a very different consideration of the effects of a 
mutation. The counterion approach assumes that the mutation has no effect on the local 
solvation of the residue. The stripped approach assumes that the mutation results in the 
replacement of the residue sidechain with an ionised water molecule, but that this 
molecule is primarily present for structural reasons, rather than to mediate new 
interactions. The ligand-side approach assumes the same change in solvation, but that 
the replacement solvent molecule should significantly influence the binding of the 
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mutant. The appropriateness of each of these protocols will differ for different systems, 
but it is difficult to determine which protocol is most suitable before a simulation is 
performed. This is amply demonstrated by the large differences in ∆∆G estimates for the 
P1Ala mutation of the previous section. 
The widened study of MULES mutations of charged residues so far suggests that 
mutations should be investigated with all three approaches unless there are specific 
known reasons why one approach should be favoured. As this would not be the case for 
a widespread validation of MULES across multiple systems, all three methods should 
form part of the proposed generic MULES validation protocol. 
5.3 Changing simulation parameters 
5.3.1 Multiple independent simulations 
Running ten independent repeats for each MULES mutation has allowed the effects on 
robustness and repeatability to be evaluated for every change made to the MULES 
process. This has provided useful information on the inherent variation of each of the 
methods and also allowed the calculation of statistical confidence intervals, providing a 
more useful description of the uncertainty in a given estimate than the simple standard 
deviation of the results. Nevertheless, the use of multiple independent trajectories has 
come at great computational cost. 
If equivalent results could be generated with fewer simulations, the throughput of the 
MULES technique would be greatly increased. Fortunately, due to the extensive datasets 
already available, the effects on predicted ∆∆G of running fewer simulations could be 
easily calculated simply by reanalysing existing results. 
∆∆G were reanalysed using fewer simulations for each of the mutations already 
performed. Starting with the full dataset of 10 individual relative free energies, mean 
∆∆G were recalculated using 9, 8, 7, 6, 5, 4, 3, 2 or 1 of the individual values. For each of 
the truncated datasets, every single combination of parent ∆∆G was evaluated. For 
example, there are 10 ways of choosing 1 ∆∆G value from a parent set of 10. Likewise 
there are 10 ways of choosing 9 ∆∆G values from a parent set of 10. However, there are 
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252 ways of choosing 5 ∆∆G values from a parent set of 10. The mean ∆∆G value of each 
of these combinations of parent individual ∆∆G was quantified. 
Because each truncated dataset had a number of combinations, each with its own mean 
∆∆G value, this gave a range of potential results generated with each truncated dataset 
(of size n). This represented the range of results that would be expected from a random 
sample of size n from the population of 10 individual parent ∆∆G. 
For each mutation performed this range of results was plotted as a Tukey boxplot, with 
associated median, interquartile range, full range and outliers (defined as individual 
values either greater than 1.5 times the interquartile range above the 3rd quartile, or 
greater than 1.5 times the interquartile range below the 1st quartile). Examples of these 
boxplots are presented in figure 5.6. 
To reiterate, assuming the mean of the ten independent ∆∆G is the true mean of the 
population, then the boxplots represent the range of mean ∆∆G results expected for 
datasets of different sizes. 
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Figure 5.6 – Example Tukey boxplots for various mutations. Plots of dataset size (choose 1 of 10 ∆∆G, 2 of 10 ∆∆G etc.) against mean ∆∆G (calculated with 
MM-PBSA). A) P2’Ala mutation. Dataset size barely affects mean ∆∆G result. B) P1Ala mutation, stripped of H3O+. Dataset size greatly affects range of mean ∆∆G, 
including potential for large outliers (denoted by crosses). C) P5’Ala mutation, stripped of OH-. Small range of potential results, centred on -0.2 kcal mol-1 average. 
D) P5’Ala mutation, including OH- on ligand side. Similarly small range of mean ∆∆G, centred around 0.5 kcal mol-1 average. 
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The boxplots highlighted dramatic differences between different mutations. For the 
P2’Ala mutation (figure 5.6a) choosing a smaller dataset size would have made little 
difference to the overall ∆∆G calculated. If only 5 independent simulations had been 
performed, this would have resulted in a mean ∆∆G of between 2.02 - 2.46 kcal mol-1. 
This was little different to the mean ∆∆G of 2.24 kcal mol-1 obtained with the full dataset, 
and still showed good agreement with the experimental value of 2.35 kcal mol-1. For the 
P1Ala mutation by contrast (figure 5.6b), a dataset of only 5 individual ∆∆G could have 
resulted in a mean value anywhere between 2.62 - 7.03 kcal mol-1. This large range of 
potential results was clearly unacceptable. In order to have the same level of statistical 
confidence in results, the inherent variation in ∆∆G estimates of the P1Ala mutation 
would require a greater number of repeat simulations than the P2’Ala. 
Figures 5.6c and 5.6d show two different mutation strategies for the same overall P5’Ala 
mutation. Interestingly in this case changing the dataset size resulted in similar trends 
in potential ∆∆G for both mutation protocols. The range of potential mean ∆∆G 
increased similarly for both methods, despite the fact they were centred around 
different ∆∆G magnitudes. This suggested that differences in numbers of independent 
simulations required were primarily due to differences in the mutations themselves, 
rather than differences in the mutation strategy. Similar effects were observed for the 
P1Ala mutation strategies, which confirmed this hypothesis. 
In summary, this reanalysis of results showed that a protocol using fewer independent 
simulations could have significantly affected the ∆∆G estimates for some of the mutants. 
In the absence of any consistent effects between mutations the number of independent 
simulations could not be reduced. Although performing ten repeat analyses for each 
mutation required a large computational expense, it allowed statistical confidence in all 
results, not just those with limited inherent variation. Decreasing the number of 
independent repeats would have broadened confidence intervals for all mutations, 
perhaps to the extent where differences in binding between individual mutants were no 
longer statistically significant. As such, reducing the number of independent simulations 
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would have been a false economy. A more appropriate way of improving computational 
efficiency was by reducing the length of simulation required for each repeat. 
5.3.2 System equilibration time 
Until now, all MULES runs had been performed using a standard set of simulations 
designed to, in turn, heat the complex to 300 K, equilibrate the system pressure at 1 bar, 
equilibrate the structures of the two copies by allowing changes to propagate, and 
finally provide a set of structural snapshots with which to perform MM-PB/GBSA 
calculations. The heating and pressure equilibration simulations were each performed 
over a timescale of 50 ps, whereas the structural equilibration and production MD 
simulations had been, respectively, performed for 1 ns and 10 ns. This gave a total 
MULES trajectory length of 11.1 ns per mutant, per independent simulation. 
The structural equilibration time of 1 ns had been shown to be sufficient for the P2’ 
series of mutations (section 4.5.2). However, the extension of MULES to larger residues 
and the introduction of new simulation protocols for charge changes required the 
re-evaluation of the length of structural equilibration simulation to ensure that all 
complexes were properly equilibrated prior to free energy analysis. As such, all MULES 
mutations and trajectories were reanalysed for ∆∆G at progressively increasing 
structural equilibration times (1, 2, 3, 6, 8, 9 and 10 ns of equilibration). The effects of 
equilibration time for example mutations can be seen in figure 5.7. These example 
mutations compare the effects of equilibration time between non-polar and charged 
mutations and between protocols for making mutations of the same charged residue. 
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Figure 5.7 – Effect of equilibration time on predicted ∆∆G for example mutations. A) P2’Ala mutation shows practically identical ∆∆G no matter the length of 
equilibration or free energy calculation. B) P1Ala mutation, stripped of H3O+ ion during free energy calculations, shows distinct downward trend in ∆∆G with 
MM-PBSA and increased uncertainty with increasing equilibration time. C) P5’Ala mutation, stripped of OH- ion, shows no significant change in mean ∆∆G due to 
equilibration length. D) P5’Ala mutation, including OH- ion on ligand side during free energy calculation, again shows no significant ∆∆G differences with increasing 
equilibration time. Error bars calculated as the 95% confidence interval of the mean for each point. 
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For the majority of mutations, increasing equilibration time had little effect on the mean 
estimated ∆∆G beyond the expected increase in uncertainty in the results as the number 
of structural snapshots analysed with MM-PB/GBSA decreased as equilibration time 
increased (section 5.3.3 specifically examines the effects of changing production MD run 
length). Figures 5.7a, 5.7c and 5.7d show no dependence of predicted ∆∆G on 
equilibration time, despite covering different mutations and mutation strategies. Figure 
5.7b however, corresponding to the P1Ala mutation with the H3O+ counterion stripped 
from the trajectory during the free energy calculations, shows a clear downward trend 
in ∆∆G estimated with MM-PBSA. Although all ∆∆G lay well within error, this trend was 
repeated across other P1Ala mutation strategies, suggesting a genuine correlation with 
the increase in equilibration time. 
This trend was worrying, as it implied that some mutations may not have been suitably 
equilibrated even after ten nanoseconds of simulation. The P1Ala mutation was the 
largest mutation investigated so far in terms of both volume and ∆∆G magnitude, but 
estimation of its ∆∆G had been successful with only limited changes to the initial MULES 
protocol. If this accuracy was fortuitous, every MULES simulation would have required 
much longer equilibration times, greatly decreasing the efficiency of the approach. 
Nevertheless, the cause of the downward trend in ∆∆G was still ambiguous. The other 
charged residue mutated, P5’Glu, saw no such changes as equilibration time increased, 
indicating the residue-specific nature of the observation. More importantly, as run 
length was simultaneously changed as equilibration time was increased, it was 
impossible to determine whether the ∆∆G change was equilibration or run time 
dependent. Further investigation, adapting run length independently, was therefore 
required. 
5.3.3 Production MD trajectory length 
A shorter MD run length results in less exploration of phase space and fewer structural 
snapshots available for performing MM-PB/GBSA calculations. Both attributes can 
increase the variation in ∆∆G estimates between independent runs, either because the 
two trajectories sample different areas of phase space, or because the analysis of fewer 
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snapshots statistically leads to greater uncertainty and variation in each of the 
individual means. The previous section observed an increase in the uncertainties in 
mean ∆∆G results as equilibration time increased; this was attributed to the 
simultaneous decrease in run length. 
To verify this was the case and to investigate the effects of run length further, 
particularly effects on the P1Ala mutation, the existing MULES trajectories were 
reanalysed for ∆∆G at different MD trajectory lengths. Following heating, pressure 
equilibration and the standard structural equilibration time of 1 ns, production MD runs 
were truncated and reanalysed for ∆∆G at simulation lengths of 1 ns, 2 ns, 3 ns, 5 ns, 
8 ns or the full unmodified 10 ns. Example results are plotted in figure 5.8. 
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Figure 5.8 – Effects of production MD run length on ∆∆G estimates. A) P2’Ala mutation shows little effect with increasing run length beyond improving precision of 
estimates. B) P1Ala mutation, stripped of H3O+ counterion during free energy calculations, shows decrease in mean ∆∆G with increasing run length for MM-PBSA, 
coupled with increasing uncertainty in MM-GBSA results. C) P5’Ala mutation, stripped of OH- ion, shows small decrease in ∆∆G with increasing run length before 
reaching plateau. D) P5’Ala mutation, including OH- on ligand side in free energy calculation, shows little change in ∆∆G but decreasing uncertainty in results. Error 
bars calculated as the 95% confidence interval of the mean for each point. 
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For the majority of mutations, decreasing run length had an adverse effect on the 
variation between individual runs and hence the confidence intervals of the mean ∆∆G. 
Figures 5.8a, 5.8c and 5.8d clearly show this effect, with greater uncertainties in results 
obtained with shorter run times. However, the continued use of ten independent 
trajectories ensured that errors did not increase excessively to the point where ranking 
of mutants could not be distinguished. The majority of mutants did not show any effects 
of run length on magnitude of mean ∆∆G. 
Some mutants and mutation strategies did show changes associated with run length 
however. Figures 5.8b and 5.8c, for the P1Ala and P5’Ala mutations respectively, both 
stripped of their solvent counterion during the free energy calculations, show significant 
decreases in free energy with increasing run length, followed by (in the case of P5’Ala) 
an eventual equilibration and plateau of predicted ∆∆G after around 5 ns of simulation. 
Where the solvent counterion was included in free energy calculations, the P1Ala 
mutation showed a similar downward trend, but no undue effects were observed for the 
P5’Ala mutation (figure 5.8d). Notably the P1Ala results calculated with MM-GBSA did 
not see a similar decline in ∆∆G with increasing run length, but did see an unexpected 
increase in confidence intervals, indicating a corresponding increase in variation 
between individual ∆∆G from separate trajectories. 
The decrease in mean ∆∆G with increasing run length, combined with the decrease in 
mean ∆∆G with increasing equilibration length, suggested that snapshots taken from the 
end of the production MD run had far lower ∆∆G between native and mutant than those 
at the beginning of the trajectory. This suggested a progressive loss of binding over the 
course of the trajectory. Worryingly, this loss had now been observed for both the P1Ala 
and the P5’Ala mutation, which had previously not seen any effects due to changes in 
equilibration time. 
The progressive decline in ∆∆G had one of two causes. Either the simulations required 
even more equilibration before both MULES copies were sampling their equilibrium 
phase space, or the MULES approach was adversely affecting the dynamics of some 
independent trajectories and falsely predicting individual ∆∆G. To determine which was 
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the most likely cause for both the P5’Ala and P1Ala mutations, individual ∆∆G calculated 
separately from the first and last nanosecond of each trajectory were compared. Table 
5.5 shows results for the P5’Ala mutation and table 5.6 results for the P1Ala mutation. 
Both tables only examine the stripped mutation strategy for ease of comparison. 
Experimental ∆∆G were 1.02 ± 0.07 kcal mol-1 for P5’Ala and > 5.72 kcal mol-1 for P1Ala. 
Table 5.5 – Comparison of individual ∆∆G calculated from the first and last nanosecond of 
MULES production MD trajectories for the P5’Ala mutation, stripped of its OH- counterion. All 
values in kcal mol-1. Mean, standard deviation and 95% confidence interval of the mean results 
presented for comparison. 
Table 5.6 – Comparison of individual ∆∆G calculated from the first and last nanosecond of 
MULES production MD trajectories for the P1Ala mutation, stripped of its H3O+ counterion. All 
values in kcal mol-1. Mean, standard deviation and 95% confidence interval of the mean results 
presented for comparison. 
 MM-PBSA ∆∆G MM-GBSA ∆∆G 
Run 1st ns 10th ns 1st ns 10th ns 
1 0.63 -1.57 0.18 -1.28 
2 -0.27 1.26 -0.80 0.40 
3 0.14 1.01 -0.13 0.30 
4 0.21 1.17 -0.10 0.30 
5 1.01 0.07 0.40 -0.46 
6 1.60 0.38 0.83 -0.56 
7 1.02 0.68 0.28 0.05 
8 0.34 0.43 -0.14 -0.84 
9 0.94 -0.60 0.05 -0.35 
10 0.74 0.62 -0.34 0.21 
Mean 0.64 0.34 0.02 -0.22 
St. Dev. 0.54 0.87 0.44 0.57 
95% C.I. ± 0.39 ± 0.62 ± 0.32 ± 0.40 
 MM-PBSA ∆∆G MM-GBSA ∆∆G 
Run 1st ns 10th ns 1st ns 10th ns 
1 7.57 6.77 4.52 4.51 
2 7.26 11.91 5.50 5.38 
3 10.69 11.85 7.82 9.63 
4 7.38 -0.70 2.63 4.22 
5 8.42 -5.71 4.85 -3.36 
6 3.97 7.69 2.84 4.41 
7 0.85 -0.27 2.53 3.82 
8 8.45 10.81 4.13 5.90 
9 2.58 -2.53 2.25 2.26 
10 7.79 -4.31 5.72 0.03 
Mean 6.50 3.55 4.28 3.68 
St. Dev. 3.03 6.96 1.78 3.49 
95% C.I. ± 2.17 ± 4.98 ± 1.27 ± 2.50 
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The P5’Ala results of table 5.5 show a similar spread of ∆∆G at the start and end of the 
trajectories. Although the standard deviation of the ten individual results does increase 
slightly, all but one of the individual ∆∆G lie within ± 1.0 kcal mol-1 of the mean during 
the last nanosecond of the simulations. Run 1 is the sole outlier. Figure 5.9a shows the 
magnitude of the ∆∆G changes between the initial and final nanosecond of each 
simulation. Run 1 again shows the largest change and the majority of other trajectories 
show differences < 1.0 kcal mol-1 between start and end, indicating mostly stable ∆∆G 
estimates. 
The P1Ala results of table 5.6 show large differences between the beginning and end of 
trajectories however. Standard deviation across the ten individual entries doubled for 
both free energy calculation methods, indicating a substantial increase in the variation 
between individual trajectories. Additionally, some runs had negative ∆∆G estimates 
during the last nanosecond of simulation. The presence of negative values for a mutation 
that should had had a large, positive ∆∆G suggested that the dynamics of these 
trajectories were not correctly representing either the native or mutant copy, just as had 
been seen in the initial investigations of the P1Ala mutation neutralised by the mutation 
of a counterion in bulk solvent (section 5.2.2.2). Figure 5.9b shows the magnitude of the 
∆∆G changes between the start and end of each trajectory. Although many trajectories 
show small (< 2.0 kcal mol-1) differences, runs 4, 5 and 10 show very large declines 
across the course of the simulation that cannot be explained simply by relaxation of the 
two MULES copies to their equilibrium state. 
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Figure 5.9 – Changes in ∆∆G between first and final nanoseconds of simulation. A) P5’Ala 
mutation, stripped of OH- ion during MM-PB/GBSA, has stable ∆∆G between start and end of 
trajectories aside from run 1 outlier. B) P1Ala mutation, stripped of H3O+ ion during 
MM-PB/GBSA, shows large decline in ∆∆G for runs 4, 5 and 10 amongst others. 
The presence of such large discrepancies between ∆∆G at the start and end of the P1Ala 
runs and the fact that by the tenth nanosecond of simulations many runs no longer 
predicted the ∆∆G with any level of experimental accuracy both suggested significant 
changes in the complex dynamics over the course of the MULES trajectory. Similar 
effects on accuracy had been previously observed for the P1Ala mutation and attributed 
to the MULES protocol itself, rather than any residue-specific issue. 
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In the previous study of the P1Ala mutation (section 5.2.2.2), the MULES protocol 
appeared to have enhanced the partial dissociation of the mutant copy, which also 
affected the dynamics of the native structure. An analogous effect was hypothesised 
here, albeit delayed due to the presence of the solvent counterion. LES, and therefore 
MULES, had multiple options for implementation that had not yet been investigated, 
some of which could be used to either increase or reduce the level of enhanced sampling 
that took place inside the MULES region. The effect of these options on the P1Ala MULES 
simulation dynamics is investigated in the following section. 
5.4 Other simulation options 
5.4.1 Scaling of atomic masses 
5.4.1.1 Concept 
The default options of LES are to scale atomic charges, masses, VdW interactions, bond, 
angle and dihedral force constants according to the number of copies in the LES region. 
In the Addles program, used to prepare LES parameter and coordinate files, the option 
exists to use the original atomic masses in the new LES parameter file, without any 
scaling factors. Masses are not used during the force calculations of MD trajectories, but 
are used in the calculation of atomic velocities. As such, when masses are scaled by   ⁄  
in the LES parameter file, velocities in the coordinate file are also scaled by √  such that 
the overall kinetic energy (  ⁄   
 ) remains correct. 
This scaling of velocities propagates through the LES trajectory. The higher velocities of 
atoms inside a LES region give rise to the concept of the LES region existing at a higher 
effective temperature than its surroundings. This is one of the ways in which sampling 
inside the LES region is enhanced. As the development of MULES had been based on 
existing LES methodology, all MULES runs until now had been performed with scaled 
atomic masses and hence scaled velocities during the simulations. 
In the P1Ala MULES simulations the increase in velocities could have, in principle, 
enhanced the rate of conformational changes that were unrealistic at the desired 
temperature of 300 K. This could have explained the dramatic loss of ∆∆G for some 
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trajectories over the relatively short production MD timescale of 10 ns. There were two 
ways to investigate whether this was true. Firstly, the MULES region could have been 
artificially coupled to a separate thermostat than the rest of the region, keeping the 
MULES region at a lower nominal temperature, but a similar effective temperature due 
to the scaling of velocities. Secondly, the scaling of masses inside the region could have 
been switched off, using the original atomic masses of the MULES atoms to calculate 
unscaled velocities instead. 
The former option is available in Sander.LES, but its implementation is problematic. 
Firstly, the choice of MULES region temperature is non-trivial. The effective MULES 
region temperature (i.e. the conformational ensemble that the MULES region samples) 
should be 300 K, equal to its surroundings. However the nominal temperature (i.e. the 
contribution of thermal energy from the thermostat) that corresponds to this cannot be 
known a priori. 
A robust way of estimating the nominal MULES region temperature required would be 
to run multiple MULES simulations at different region temperatures and compare the 
dynamics of the region to those of standard MD simulations at the desired temperature 
of 300 K. The MULES region temperature that best represented the dynamics of a 
standard MD simulation would be chosen for the MULES protocol. This analysis would 
be extremely costly however, requiring multiple long simulations of both MULES and 
standard MD trajectories. 
Secondly, the MULES region cannot be kept at an entirely separate temperature to the 
surrounding system as a whole, as thermal energy crosses into the MULES region from 
interactions with the residues immediately surrounding it. As the surrounding, 
non-MULES, residues are at a higher nominal temperature than their counterparts 
inside the MULES region, this sets up a temperature gradient through the system. The 
definition of effective temperatures for the MULES region and its surroundings is 
thereby complicated even more. 
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Compared to connecting regions of the simulation to different temperature baths, the 
use of original unscaled masses in MULES parameter files is a far simpler approach to 
reducing atomic velocities. As mentioned above, using original masses in LES is 
straightforwardly defined by using the keyword ‘omas’ in the Addles input file. With this 
option, potential energy surfaces inside the MULES region are still smoothed by the 
scaling of parameters, but atomic velocities resulting from forces are reduced. When 
masses are scaled by 1/n, velocities are inherently scaled up by √  in order to conserve 
overall kinetic energy. With original, unscaled masses, velocities also remain unscaled. 
Additionally, using original masses requires no extra computational expense in choosing 
simulation strategy, nor any mutation- or complex-specific simulation conditions. 
To evaluate the effects of using original masses on dynamics and ∆∆G estimates, the 
P1Ala MULES simulations were re-performed with original masses of atoms in the 
MULES region. 
5.4.1.2 Results 
The use of original masses required new MULES parameter files to be generated using 
the omas option in Addles, followed by ten new sets of independent MULES simulations 
with structural equilibration time of 1 ns and production MD time of 10 ns. The omas 
option itself has no additional computational overhead compared to scaled masses, 
neither in the Addles parameter file generation, nor in the Sander.LES simulation itself. 
The omas P1Ala MULES simulations were performed with a H3O+ solvent counterion 
present in the mutation pocket and MM-PB/GBSA free energy calculations performed 
both with and without this counterion present. For ease of comparison with the scaled 
masses results of section 5.2.2, only the P1Ala stripped protocol results are shown 
below in table 5.7. 
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Table 5.7 – MM-PB/GBSA ∆∆G estimated for the P1Ala mutation, stripped of a H3O+ counterion 
during free energy calculations. All values in kcal mol-1. Mean, standard deviation and 95% 
confidence interval of the mean are all presented for comparison. 
The estimated ∆∆G of table 5.7 clearly agreed well with the equivalent ∆∆G calculated 
without the omas option (4.83 ± 2.07 kcal mol-1 for PB solvation, 3.86 ± 1.01 kcal mol-1 
for GB, section 5.2.2.4) and with experiment (> 5.72 kcal mol-1). Notably, the omas 
option seemed to greatly reduce the variation between individual runs, thereby 
narrowing the confidence intervals of the mean ∆∆G. Although this improvement could 
have been due to a reduction in unrealistic conformational sampling during the 
simulations, it was difficult to ascertain the precise cause from such a limited dataset. 
As the omas option had correctly estimated ∆∆G over a period of 10 ns of production 
MD, the trajectories were reanalysed to determine the effects of equilibration time and 
run length on the results. Equilibration times and run lengths were analysed 
equivalently to those of the previous section, 5.3. Results for equilibration time are 
presented in figure 5.10 and run length in figure 5.11. 
Run MM-PBSA ∆∆G MM-GBSA ∆∆G 
1 3.25 5.11 
2 2.16 3.71 
3 3.05 3.96 
4 5.33 4.77 
5 4.08 3.33 
6 5.47 5.75 
7 6.58 4.38 
8 6.53 4.89 
9 6.77 5.21 
10 4.88 3.66 
Mean 4.81 4.48 
St. Dev. 1.62 0.79 
95% C.I. ± 1.16 ± 0.57 
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Figure 5.10 – Effect of equilibration time on ∆∆G for the MULES P1Ala mutation performed with 
original masses (‘omas’) and stripped of solvent counterion in free energy calculations. Error 
bars calculated as the 95% confidence interval of the mean for each point. 
Examining the effect of equilibration time first, the decline in mean ∆∆G that was seen in 
the previous P1Ala ∆∆G estimates was not apparent in the results from the omas 
trajectories. In fact, mean ∆∆G estimated with MM-PBSA increased as equilibration time 
increased, before reaching a plateau at ~6 kcal mol-1 after around 8 ns of equilibration. 
MM-GBSA results did not see a change in the magnitude of mean ∆∆G. Both methods saw 
a mild increase in inter-simulation variability as equilibration time increased and 
corresponding run length decreased, demonstrated by the increase in confidence 
intervals of the mean results. These trends were now consistent with those observed for 
the P2’ and P5’ mutations, shown previously in section 5.3.2, figure 5.7. 
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Figure 5.11 – Effect of run length on ∆∆G for the MULES P1Ala mutation performed with original 
masses (‘omas’) and stripped of solvent counterion in free energy calculations. Error bars 
calculated as the 95% confidence interval of the mean for each point. 
The effects of run length were also now consistent with those observed previously. 
Decreasing run length had little effect on the magnitudes of mean estimated ∆∆G for 
either MM-PBSA or MM-GBSA. Uncertainty in the mean values did increase, but this was 
previously expected and also agreed with the observations from other mutations. 
The use of omas therefore appeared to be an effective approach to reducing the 
velocities of atoms inside the MULES region and ensuring that a realistic conformational 
ensemble was sampled during the P1Ala simulations. One final validation of the 
approach (table 5.8) was to compare individual ∆∆G calculated from the first and last 
nanosecond of each simulation, identical to the analysis performed in section 5.3.3, table 
5.6. 
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Table 5.8 – Comparison of individual ∆∆G calculated from the first and last nanosecond of 
MULES production MD trajectories for the omas P1Ala mutation, stripped of its H3O+ counterion. 
All values in kcal mol-1. Mean, standard deviation and 95% confidence interval of the mean 
presented for comparison. 
Overall, the mean estimated ∆∆G show a mild increase between the start and end of the 
MULES trajectories. Uncertainty in the mean ∆∆G calculated with MM-GBSA had 
decreased by the 10th nanosecond of simulation, but that in the MM-PBSA mean had 
increased. This was predominantly caused by the presence of a single outlier ∆∆G in the 
final nanosecond of simulation of the 10th independent MULES run. Excluding this result 
led to a mean ∆∆G of 4.88 ± 2.38 kcal mol-1, more closely in line with both the accuracy 
and precision of mean ∆∆G obtained during the first nanosecond of simulation. 
Importantly, no negative ∆∆G predictions were seen, unlike the estimates obtained 
without the omas option (section 5.2.2.4), suggesting that the use of original masses had 
successfully adapted the dynamics of the MULES region to be more in line with those 
expected in a standard MD simulation. 
Finally, a plot of the changes in ∆∆G between the start and end of each independent 
trajectory (figure 5.12) shows that, despite the outlier of the run 10 MM-PBSA result, the 
majority of ∆∆G estimates were stable across the course of the MULES trajectories. 
MM-PBSA results showed greater variability in changes than MM-GBSA, but this was 
consistent with all previous results, and was attributed to the greater sensitivity of the 
PB solvation method to small changes in the positioning of atomic point charges. 
 MM-PBSA ∆∆G MM-GBSA ∆∆G 
Run 1st ns 10th ns 1st ns 10th ns 
1 5.71 4.51 3.74 4.11 
2 7.88 0.71 5.02 3.53 
3 0.48 3.45 2.65 4.81 
4 4.97 3.72 5.44 5.40 
5 3.99 0.75 2.98 2.47 
6 7.38 7.76 6.70 4.11 
7 4.95 8.70 4.10 5.05 
8 6.92 5.49 2.74 3.91 
9 3.34 8.81 3.41 5.54 
10 1.35 15.63 2.14 5.36 
Mean 4.70 5.95 3.89 4.43 
St. Dev. 2.47 4.48 1.44 0.98 
95% C.I. ± 1.76 ± 3.21 ± 1.03 ± 0.70 
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Figure 5.12 – Changes in ∆∆G between start and end of MULES trajectories of the P1Ala 
mutation performed with original atomic masses. Run 10 shows a large increase of ∆∆G, but 
other runs show (on average) far more stable ∆∆G estimates than those from simulations 
performed with scaled atomic masses (figure 5.9). 
The MULES simulations performed with original atomic masses therefore produced ∆∆G 
estimates that were demonstrably more accurate to experiment, had smaller 
uncertainties in their predictions, were more consistent across the course of trajectories 
and had fewer outliers than their counterparts performed with scaled masses. As this 
had been realised with no additional computational cost, the omas option should clearly 
be used for all future MULES simulations. 
With the success of the omas option, all mutations now produced consistent estimates of 
∆∆G across the course of MULES trajectories. At shorter run lengths (or longer 
equilibration times) the variability between individual ∆∆G increased, resulting in lower 
precision of estimates, but there were no significant effects of either run length or 
equilibration time on the magnitudes of mean ∆∆G. This suggested that future MULES 
runs could be performed with run lengths as short as 1 ns, following heating, pressure 
equilibration and the standard structural equilibration time of 1 ns. This would reduce 
the overall simulation time of each independent trajectory from 11.1 ns to 2.1 ns - a 
more than five-fold improvement in the efficiency of MULES. 
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Finally, the viability of using such a short run length opened up the possibility of using 
GB implicit solvation during the MULES MD trajectory itself, in place of the more usual 
explicit solvation. This had not been previously investigated since the use of GB 
solvation in Amber tends to be more computationally costly than its explicit 
counterpart, despite the inherent reduction in simulation size. Additionally, implicit 
solvation is often perceived to be too inaccurate to be used extensively in standard MD 
simulations, but it had a number of potential advantages for use with MULES that are 
explored in the following section. 
5.4.2 Implicit solvation 
5.4.2.1 GB + LES 
Until now, all MULES simulations had been carried out under explicit solvation 
conditions, with the 1SMF trypsin/MBTI complex surrounded by a truncated octahedral 
box of water molecules. This has become the standard way of performing molecular 
dynamics simulations and some of the advantages of explicit solvation over implicit 
have already been discussed in section 2.1.2. The use of explicit solvation in MULES 
simulations has two consequences that are not relevant for standard MD simulations 
however. 
Both consequences are a result of having multiple copies of an individual region of the 
simulation. As the system external to the MULES region interacts with all copies, solvent 
molecules also interact with all copies in the same way. This gives rise to two 
phenomena. Firstly, if the copies move apart during the course of the simulation, their 
effective volume, as seen by the rest of the system, increases. This requires the creation 
of a larger solvent cavity and so has an energetic penalty, resulting in a stronger 
tendency for the dynamics of the copies to remain correlated and structures to remain 
undiverged. Secondly, if the copies do move apart, each copy is solvated identically, with 
the same positions and interactions of the surrounding water molecules. 
These problems are exacerbated with the MULES approach compared to LES. As the 
concept of MULES is to allow native and mutant copies to have independent dynamics, 
anything that results in unnecessary correlation between native and mutant structures 
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inside the MULES region could adversely affect ∆∆G predictions. Additionally, as both 
copies are identically solvated, at least one of the two will be ‘incorrect’. This incorrect 
solvation could have a large effect on the structural and dynamical stability of that copy, 
potentially resulting in instabilities in the complex structure or simulation as a whole. 
Alternatively, for residues where solvation plays little role in binding, incorrect 
solvation may result in negligible differences in structure and energetics. 
One way of tackling this problem would be to include solvent molecules in the MULES 
region. The copying of all bulk solvent would be intractable due to the computational 
cost involved, however individual molecules could be copied provided that they did not 
exchange with bulk solvent during the course of the simulation. This would likely 
improve results for mutations that involved solvation changes, such as those of large or 
solvent exposed residues. In principal, this is what has already been observed for the 
P1Ala and P5’Ala mutations, where ionised solvent molecules were added to the mutant 
copy to account for the effects of differential solvation and neutralise the system 
simultaneously. It also explains why such an approach was not necessary for the P2’ 
series of mutations, as the interface residue was buried from bulk solvent and changes 
in residue volume were much smaller than that of the lysine to alanine mutation. 
Alternatively, Generalised Born implicit solvation replaces explicit water molecules with 
a structureless continuum. This allows the solvation of each copy individually, as the 
interactions of the continuum model are defined solely by the dynamics of the solute, 
and if the solute has two, non-interacting copies of a region, then the GB solvent model 
can interact separately with each of them. This means that, theoretically, a MULES + GB 
approach should better solvate the two copies individually and allow greater structural 
divergence between native and mutant copies as solvation energies are individually 
calculated. 
GB solvation is also known to be a method of enhancing conformational sampling in 
itself. The lack of physical friction between solute and solvent allows specific 
conformational changes to occur over shorter timescales than those observed with 
explicit solvation.300-302 When combining GB with LES, Simmerling and coworkers found 
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the two techniques together to be an effective way of enhancing the sampling efficiency 
of each individual method even further.303 Their work has led to GB solvation being 
natively supported by Sander.LES, with only minor modifications to allow the 
calculation of variable Born radii for the atoms within the LES region. The derivation of 
these modifications is detailed further in their original study.303 
To investigate whether GB solvation would improve the accuracy of ∆∆G estimates from 
MULES trajectories, simulations of the P1Ala mutation were performed with implicit 
solvation. The P1Ala mutation was chosen for two reasons: firstly because it was a large 
mutation known to require an accurate representation of a change in solvation, and 
secondly because, of the mutations performed so far, it had been shown to be the most 
sensitive to changes in simulation conditions. Therefore, any effects of solvation seen in 
the MULES P1Ala simulations could in theory have been extrapolated to other 
mutations. 
5.4.2.2 MULES + GB simulations and results 
Full computational details of all simulations and free energy calculations performed are 
available in section 8.3.1, but are summarised here to highlight differences with 
explicitly solvated MULES runs. 
In principle, Generalised Born solvation should greatly reduce the cost of a simulation. 
Computational cost is a function of the number of atoms simulated and the bulk of any 
biomolecular simulation is solvent, hence with far fewer explicit atoms to simulate GB 
should be orders of magnitude faster than explicit solvent simulations. However, this 
idea neglects two complications of using GB. Firstly, the GB solvation method itself does 
not have negligible cost – effective Born radii must be updated at every timestep and 
solvation forces calculated. The efficiency of the code used to do this is software 
dependent, and whilst GB has been optimised for speed in the PMEMD module of 
Amber, its implementation in Sander.LES is much less efficient, albeit with greater 
flexibility for simulation options. 
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Secondly, and more importantly, GB simulations are non-periodic and therefore cannot 
use the PME method for treating long-range electrostatic interactions. Long cutoffs for 
non-bonded interactions are therefore required in order to avoid inaccuracies in 
electrostatic energies and resulting instabilities in dynamics. All MULES + GB 
simulations were therefore performed with non-bonded cutoffs of 999 Å (such that all 
pairwise electrostatic interactions were explicitly calculated). As a result, the 
computational cost of implicitly solvated simulations was actually greater than their 
equivalent explicit runs. Production MD trajectories were therefore limited to a length of 
1 ns. 
Ten independent MULES + GB simulations of the P1Ala mutation were carried out as 
follows. Original atomic masses were used for atoms inside the MULES region and the 
region was coupled to a temperature bath nominally 100 K lower than the overall 
complex as a further measure to reduce the likelihood of abnormal conformational 
changes inside the MULES region. Due to the lack of physical friction with solvent the 
complex was heated and equilibrated in stages (see figure 5.13) with weak Cartesian 
restraints in order to avoid introducing instabilities into the dynamics of the system. 
Over a period of 500 ps the complex was first heated to 300 K whilst relaxing positional 
restraints from 10 kcal mol-1 Å-1 to 2 kcal mol-1 Å-1, followed by slow switching off of the 
positional restraints altogether. The MULES region was heated to 200 K identically to 
the rest of the system and was then coupled to a separate thermostat at 200 K and 
allowed to reach equilibrium in thermal transfer with the rest of the complex (a nominal 
temperature of ~220 K). 
After heating, a further 1 ns of structural equilibration was performed before a final 1 ns 
of production MD simulation, giving a total simulation time for each trajectory of 2.5 ns. 
Snapshots were extracted at 10 ps intervals from the production MD trajectory and 
analysed by MM-GBSA. MM-PBSA results were not analysed as this would have been 
illogical given that the simulation was performed with GB implicit solvation. Finally, as 
the system did not require neutralisation for PME purposes, no H3O+ solvent counterion 
was used as part of the mutant MULES copy. 
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Figure 5.13 – Heating and equilibration protocol for implicitly solvated MULES simulations of 
P1Ala mutation. System as a whole is slowly heated to 300 K but MULES region is separately 
coupled to a 200 K bath after 200 ps. Cartesian positional restraints are slowly reduced as 
temperature increases, before final 100 ps of equilibration time under normal MD conditions. 
Following simulation, all trajectories were analysed visually. The first expected 
consequence of using GB was that the independent solvation of the two copies would 
result in larger conformational changes and greater independence of dynamics within 
the MULES region. Comparison of the RMSD between native and mutant copies for 
implicitly and explicitly solvated MULES simulations showed larger conformational 
changes took place during implicitly solvated runs (figure 5.14). Visual analysis also 
confirmed that dynamics appeared more independent, including sidechain rotations 
previously unseen in explicitly solvated simulations. The degree of this behaviour was 
difficult to quantify however, and so should be taken as suggestive of an improvement 
with GB, rather than full evidence thereof. 
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Figure 5.14 – Comparison of structural differences observed between copies during runs. RMSD 
of MULES region residues is higher for implicitly solvated runs (blue) than explicitly (black) 
indicating greater structural flexibility between copies. 10-point running averages of RMSD 
values are shown as solid lines. 
MM-GBSA free energy calculations were performed using structural snapshots from the 
production MD trajectories. ∆∆G results from all ten trajectories are shown in table 5.9. 
Table 5.9 – ∆∆G calculated with MM-GBSA for MULES P1Ala mutations performed with implicit 
solvation. All values in kcal mol-1. Mean, standard deviation and 95% confidence interval of the 
mean are all given for comparison purposes. 
Run MM-GBSA ∆∆G 
1 8.68 
2 -0.96 
3 7.55 
4 7.01 
5 8.59 
6 9.76 
7 7.91 
8 5.07 
9 7.67 
10 7.67 
Mean 6.90 
St. Dev. 3.02 
95% C.I. ± 2.16 
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In comparison to the MM-GBSA ∆∆G of the explicitly solvated MULES P1Ala trajectories 
(4.48 ± 0.57 kcal mol-1 using original atomic masses, table 5.7), the mean ∆∆G of the 
implicitly solvated runs showed a significant increase in magnitude and error. Although 
the standard deviation (and hence uncertainty in the estimate) was likely affected by the 
presence of a single outlier in run 2, the mean ∆∆G was still 2-3 kcal mol-1 greater than 
any previously observed. In the absence of a precise experimental value for the P1Ala 
∆∆G it was difficult to determine the absolute accuracy of either the implicit or explicitly 
solvated estimates, although both gave estimated ∆∆G of the correct order of magnitude. 
That said, if the increase in uncertainty seen with implicit solvation were consistent 
across all mutations this would likely result in a reduction in the predictive power of the 
MULES technique. 
In summary, GB solvation has some advantages for MULES over explicit solvation. 
MULES regions have shown greater RMSD compared to equivalent regions explicitly 
solvated and there has been complementary anecdotal evidence that these 
conformational changes have given rise to greater independence between native and 
mutant dynamics. Additionally, the system did not need to be neutralised when dealing 
with the charged P1Ala mutation, meaning that the appropriateness of including an 
ionised solvent molecule as part of the mutant copy would not have to be evaluated for 
every mutation. 
Nevertheless, implicitly solvated MULES runs also had some significant disadvantages. 
Computational cost of the simulations was increased, partly due to the increased length 
of simulation required thanks to a more gradual and restrained heating and 
equilibration process, and partly due to the expensive lack of cutoff for non-bonded 
interactions. This increase in cost did not result in any obvious increase in accuracy to 
experiment, nor any improvement in the precision of estimates. Naturally these results 
may vary with other mutations, but the fact that implicit solvation gave no noticeable 
improvements for P1Ala, the most challenging mutation studied so far, did not invoke 
confidence that other mutations would be significantly improved with GB solvation. 
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Perhaps the most significant disadvantage of the GB solvation approach was its 
requirement for careful selection of conditions. Whilst the slow heating and 
equilibration protocol used here gave stable simulation dynamics, it may not be 
applicable across all systems. Likewise the concept of keeping the MULES region at a 
lower nominal temperature than its surroundings (already dismissed for explicitly 
solvated runs) may be a useful method for restricting the enhancement of dynamics 
caused by GB, but is also one that may require careful parameterisation and different 
implementation across different complexes. Due to the lack of physical friction with 
solvent, GB simulation dynamics are far more susceptible to changes in initial 
conditions. It is difficult to design a simulation protocol that would acceptably simulate a 
wide variety of potential mutations across different complexes. 
As such, although GB solvation could be foreseen to have advantages for specific 
mutations, it cannot be used in a generic protocol aimed to validate the use of MULES 
across a wide range of mutations and systems. Explicit solvation allows greater 
consistency in simulation conditions between individual mutations, along with the 
advantages in computational efficiency this provides. Implicit solvation should instead 
only be used in cases where explicit solvation has failed to adequately predict ∆∆G, or 
for solvent accessible residues known to undergo significant conformational changes on 
mutation. In the absence of this knowledge a priori, such as in a dataset used for a 
validation protocol, explicit solvation should be the method of choice. 
5.5 Summary 
5.5.1 Investigated extensions of MULES 
This chapter has detailed a more thorough investigation of the MULES approach than 
the initial development carried out in the previous chapter. Residues beyond the P2’ 
position of the MBTI ring were studied for the first time, presenting new challenges 
around dealing with charged mutations and solvent accessible residues. For the P5’Ala 
and P1Ala mutations studied (of glutamic acid and lysine respectively), the use of PME 
to calculate the effects of long range electrostatic interactions required the overall 
solute/solvent system to be neutral, meaning the mutation of the desired residue 
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sidechain had to be counterbalanced by a simultaneous mutation of another charged 
entity in the system. 
Numerous strategies for performing this neutralising mutation were devised and tested. 
The mutation of a chloride counterion in bulk solvent was found to be a sufficient 
neutralisation strategy for the P5’Ala mutation, but the equivalent approach led to 
instabilities and partial dissociation of the 1SMF complex during P1Ala MULES runs. 
Instead, the P1Ala mutation required the introduction of an ionised solvent molecule, a 
hydroxonium ion, to neutralise the charge change directly at the mutation site. This 
resulted in trajectories that were dynamically more stable and gave ∆∆G in much better 
alignment with experiment, at no detriment to the P5’Ala results. The observations for 
P1Ala suggested that this particular mutation had a broad effect on both protein 
structure and solvation at the interface, necessitating the replacement of some of the 
lysine sidechain volume with a hydroxonium ion. The wider appropriateness of this 
technique for a much larger set of mutations remains to be seen in the following chapter. 
One of the main aims of the work performed in this chapter was to determine the most 
efficient simulation parameters for generating accurate and precise MULES ∆∆G in the 
quickest possible way. In the study of P2’ mutations of the previous chapter, each mean 
∆∆G was estimated from ten independent simulations of 1 ns equilibration time and 
10 ns production MD time. This was a total of over 110 ns of simulation for each 
mutation - or roughly 30 days of simulation on a single 8-core node. In an effort to 
reduce this expense, the effects of run length and number of independent repeats on 
∆∆G were investigated in depth. Equilibration length was also re-investigated for the 
new mutations to ensure that 1 ns of simulation continued to provide a sufficient level of 
structural equilibration, as it did for the P2’ series of mutations. 
Of these three parameters, reducing the number of independent repeats had the most 
obvious detrimental effect on results. Mean ∆∆G calculated from fewer independent 
runs could vary greatly, even at very small reductions in trajectory numbers and 
particularly for the challenging P1Ala mutation. This lack of consistency in effects 
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between mutations led to the firm conclusion that no reduction in trajectory numbers 
should be made, in order to keep a high level of statistical confidence in all results. 
Variations in the effects of run length and equilibration time between mutations were 
also observed. Like the series of P2’ mutations, the P5’Ala mutation showed no 
significant effects of run length or equilibration time on the accuracy of predicted ∆∆G, 
and only minor reductions in precision as run length decreased and fewer structural 
snapshots were analysed in the free energy calculations. The P1Ala mutation however 
showed a clear decrease in estimated ∆∆G as equilibration time increased and, 
surprisingly, as run length increased. Comparison of the calculated ∆∆G at the start and 
end of each P1Ala trajectory showed large changes for a number of runs, suggesting that 
MULES continued to have problems representing the P1Ala mutation correctly. 
MULES simulations had until now scaled atomic masses of MULES region atoms 
identically to the scaling of other atomic parameters. The reduction in masses leads to 
an increase in atomic velocities to maintain kinetic energy of the system. It was this 
increase in velocities that resulted in changes in dynamics in the P1Ala mutation and the 
decrease in ∆∆G observed through many trajectories. When original atomic masses 
were used in simulations, P1Ala ∆∆G results showed identical trends in effects of run 
length and equilibration time to other mutations, i.e. no effect on accuracy and a limited 
effect on precision of estimates.  
Using original atomic masses in future simulations will allow production MD run length 
to be reduced to as little as 1 ns without large effects on the accuracy of mean ∆∆G 
estimates. This will result in an approximate five-fold increase in the efficiency of the 
MULES process, with each mutation now requiring only 21 ns of simulation compared to 
the previous 111 ns. 
Finally, implicit solvation of MULES simulations was also evaluated, again using the 
P1Ala mutation. While GB implicit solvation did not have any detrimental effects on the 
accuracy of ∆∆G predictions, uncertainty in the mean estimates did increase and at the 
cost of greater computational expense. GB solvation does allow independent solvation of 
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the native and mutant copies and hence more independent dynamics, which may 
enhance predictions for residues that are solvent accessible or that undergo large 
conformational changes on mutation. However, it also requires careful setup and 
selection of simulation conditions in order to avoid introducing dynamical instability 
due to the lack of specific interactions with water molecules. In the absence of 
pre-existing evidence to suggest that GB would be more appropriate for a specific 
mutation, explicit solvation remains the first choice method for MULES. 
This chapter has developed MULES beyond the limited set of results obtained for the 
series of P2’ mutations and shown that the approach can generate accurate and precise 
∆∆G for other mutations of the 1SMF complex, even from production MD simulations of 
only 1 ns in length. Despite these successful predictions the studies detailed here have 
also determined some potential weaknesses of MULES. In particular, the most 
appropriate strategy for performing mutations is not yet known. Some mutations may 
be best represented by a simple truncation of the sidechain, some may require a change 
in surrounding solvation on mutation, or some may be best represented with GB 
solvation methods. Likewise, the neutralisation strategies for charged mutations may 
also have different impacts from those observed here, depending on the residue and 
biomolecular system under investigation. 
These broader effects will be determined only through the wider validation of MULES in 
the following chapter. The validation will build on the work already presented and make 
use of the standard MULES protocol developed using the knowledge gained from all 
studies performed so far. This protocol is summarised below for reference. 
5.5.2 MULES validation protocol 
The efficient validation of MULES across a wide dataset of mutations requires a standard 
protocol for simulations and free energy calculations. The protocol used is summarised 
below: 
1. Every mutation performed as part of the validation process requires appropriate 
experimental data for its ∆∆G, if possible including an estimate of its error. 
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2. MULES parameter and coordinate files are prepared individually for each 
desired mutation using the Addles module of Amber. All relevant parameters are 
scaled by ½, excluding atomic masses, for which the ‘omas’ option of Addles is 
used to keep original atomic mass values. 
3. The MULES region includes all protein residues whose Cα atom is within a 5 Å 
radius of the desired mutation residue, on both sides of the protein interface 
(though in exceptional cases there may be cause to add to this further with 
specific interacting residues). 
4. Dynamics are then simulated using the following progression of trajectories. 
First, the complex is heated gently to 300 K over 50 ps, followed by pressure 
equilibration of a further 50 ps. Next, a structural equilibration period of 1 ns 
allowed native an mutant copies to diverge structurally, before a final 1 ns of 
production MD simulation, from which coordinates are saved every 10 ps, giving 
a total of 100 structural snapshots. 
5. MM-PB/GBSA calculations are performed using the 100 structural snapshots 
from production MD simulations for each mutation and each native or mutant 
copy. This gives ten individual ∆∆G for each mutation, from which a mean, 
standard deviation and confidence intervals of the mean can be calculated. 
6. For mutations involving charged residues, two neutralisation strategies result in 
three separate free energy calculations for each mutation. Simulations are 
carried out in which the system is neutralised by the appropriate mutation of an 
inorganic counterion in bulk solvent, and in which neutralisation is performed 
by the presence of an ionised water molecule (hydroxide for negatively charged 
residues and hydroxonium for positively charged) replacing sidechain volume in 
the mutant copy of the MULES simulation. During the free energy calculations, 
this solvent molecule can either remain as part of the ligand (i.e. the mutated 
partner of the complex) or be stripped from the trajectory entirely. This gives 
three potential ∆∆G for each charged mutation, based on the ‘counterion’, the 
‘stripped’, or the ‘ligand-side’ approach. 
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7. Having generated ∆∆G for every mutation, the full dataset will be compared to 
experimental ∆∆G values and analysed to determine potential advantages of 
MULES over existing methods and areas for improvement. 
This protocol will allow the validation of the MULES approach on a much wider dataset 
in a realistic timescale. This is crucial for evaluating the potential of MULES for 
implementation as a genuine tool for protein design, and is the focus of the next chapter. 
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6 Validating MULES 
6.1 Introduction 
The previous chapters have discussed the initial creation of the MULES method, its early 
near-quantitative success in predicting ∆∆G for the P2’ series of mutations, the 
challenges faced when transposing this success onto other mutations and finally the 
development of a standard MULES protocol that can be used for investigating a wide 
variety of mutations across a wide variety of systems. Such a protocol is necessary if 
MULES is to be validated as a useful tool for computational protein design. That 
validation is the aim of this chapter. 
Validation of a computational predictive technique requires widespread comparison 
with the experimental values it attempts to recreate. For methods such as MULES that 
calculate ∆∆G for protein design purposes the most widely available experimental ∆∆G 
are from alanine scanning mutagenesis experiments. This chapter performs MULES 
simulations for a range of mutations at PPI interfaces from the dataset used to validate 
the Robetta online alanine scanning server.96 In total nearly 60 individual MULES 
mutations are performed across seven complexes (including the 1SMF studies already 
performed) and compared with experimental ∆∆G. 
As well as comparison to experiment, this chapter also compares MULES results to other 
computational mutagenesis methods. The post-process alanine scanning method 
detailed in chapter 3 and the Robetta server (described below in section 6.1.1) are both 
evaluated for their own performance across the same dataset and in comparison to 
MULES. This provides valuable information on where MULES has advantages and 
disadvantages over existing methods. 
Finally, one of the major potential advantages of MULES over both post-processing and 
the Robetta server is the fact it is not restricted to alanine mutations and can perform 
mutation to any residue or any change in surroundings desired. For the MULES studies 
of previous chapters however, this advantage has remained theoretical. Although some 
natural and non-natural mutations of the P2’Ile residue have been investigated in 
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chapter 4, these relatively simple mutations were also accessible using only minor 
adaptations of the post-processing technique and have not showcased the full potential 
of MULES. As such, this chapter also performs preliminary investigations of mutations 
not involving alanine, using a complex between tripeptides and an oligopeptide binding 
protein (OppA) from E. coli for which extensive structural and thermodynamic binding 
data is available as a test system. 
After validation on the wider alanine scanning dataset, the MULES approach showed 
consistent improvement over the post-processing method and some improvement over 
Robetta. More promisingly, the OppA work allowed mutations to be performed that 
were simply not possible with existing computational methods. The results of this 
chapter provide evidence for the advantages of MULES and highlight areas for future 
uses that are inaccessible to other computational techniques of similar cost. 
6.1.1 Choosing a validation dataset 
The internet age has seen an explosion in the collation and sharing of raw scientific data, 
in principal making the identification of new trends in existing results or the validation 
of new methods against their previous incarnations easier than ever before. It is true 
that a huge number of online databases and tools dedicated to the biosciences exist and 
the extent and scope of these is well summarised in recent reviews.67, 291, 304 However, 
for MULES validation only databases that contain experimental data of binding free 
energies specific to PPIs were of interest. This narrowed the possible dataset sources 
greatly. 
One area of great experimental endeavour with regard to PPIs has been in the 
determination of hot-spot residues at interfaces, usually by performing alanine scanning 
mutagenesis and calculating the differences in binding affinity between native and 
mutant complexes. These experimental ∆∆G would potentially provide a useful dataset 
for MULES validation, consisting of multiple mutations across a single interface, ∆∆G 
covering a range of contributions to binding and usually including structural data of the 
native complex, if not one or more of the mutants. One of the first attempts to collate 
this experimental data was in the alanine scanning energetics database (aseDB) of 
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Thorn and Bogan in 2001.64 This was a continuation of their previous work analysing 
the properties of PPI hot-spots using experimental binding data54 and covered roughly 
3000 individual mutations, the majority with complementary structural data of either 
one or both of the binding partners. 
In later years more databases of PPI experimental data were developed, with 
information that complemented that present in the aseDB. The Binding Interface 
Database (BID)65 was a compilation of PPI hotspots predominantly for complexes 
without structural data, extending the coverage of PPI systems beyond that of aseDB but 
of little use for computational studies with MULES. Databases such as PINT 
(Protein-protein Interactions Thermodynamic database)66 and most recently SKEMPI 
(Structural, Kinetic and Energetic database of Mutant Protein Interactions)305 have 
expanded databases beyond hot-spot identification and included mutations to residues 
other than alanine, data of great importance to MULES. There have also been attempts to 
define benchmark datasets of PPIs and mutations thereof to aid the validation and 
comparison of both structural306 and free energy189 prediction methods. 
The most recent developments above, namely SKEMPI and the potential benchmark 
datasets, were unavailable when MULES validation work was first begun, but the 
breadth of the experimental data available in databases such as the aseDB still posed an 
important question of how best to choose a validation dataset. It was recognised that 
one of the most important objectives of MULES validation was to allow the comparison 
of MULES with existing and future computational methods. Validating MULES with a 
dataset of PPI ∆∆G that had already been used to validate a previous ∆∆G prediction 
method was one way of achieving this. 
Of the numerous online ∆∆G prediction tools, the FoldX server (first developed at the 
European Molecular Biology Laboratory in Heidelberg)307, 308 and the Robetta server 
(based on the Rosetta suite of the Baker group)96, 97 are two of the most widely 
referenced in literature. Both use energy functions to calculate free energies, developed 
and scaled using a training set of point mutations to accurately calculate ∆G and then 
validated using a separate set including PPIs for ∆∆G estimates. Of the two validation 
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datasets, the one used in validation of Robetta was larger, covered a wider variety of 
protein complexes, included many of the complexes and mutations of the aseDB set of 
Bogan and Thorn and has also recently been used as a benchmark dataset in the 
validation of another hot-spot prediction method, the KFC2 server.71 The Robetta 
dataset was therefore chosen as the most suitable set of experimental alanine scanning 
∆∆G for validating MULES. Its exact usage is defined below. 
6.1.2 The Robetta dataset 
In total, the dataset used for validation of Robetta covered 380 point mutations over 19 
protein complexes. MULES, as it involves MD simulations, is a far more costly method to 
implement than Robetta and so the use of the entire dataset for MULES validation was 
unfeasible. Instead, a subset of the data was chosen based on the following criteria: 
 Available PDB structures were assessed for ease of MD simulation. Those that 
required additional parameterisation (e.g. inclusion of glycosylated residues, or 
transition metal counterions) or simulation (e.g. incomplete structures) were 
discarded. Complexes with minor structural discontinuities such as missing 
individual residues or small flexible loop regions were kept. Missing residues 
were added and optimised using the Modeller 9v7 software package.309, 310 This 
left 11 of the original 19 complexes. 
 Complexes similar to the trypsin/MBTI PPI already investigated (e.g. 
trypsin/Bovine Pancreatic Trypsin Inhibitor (BPTI) and chymotrypsin/BPTI) 
were discarded as they did not add enough diversity to the dataset, leaving 9 of 
the original complexes 
 Individual mutations whose experimental ∆∆G corresponded to a more than 
1000-fold change in binding affinity on mutation (> 4.12 kcal mol-1 at 300 K) 
were discarded as potentially unreliable measurements. Evidence from the 
P1Ala mutation highlighted the difficulties in accurately calculating ∆∆G for 
mutations that greatly abolish binding affinity, and the vast majority of alanine 
mutations, even at hot spots, cover ∆∆G ranges < 4 kcal mol-1. 
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 Each of the remaining protein complexes was neutralised, solvated and 
prepared for MD simulation using the Leap module of Amber. Complexes were 
then ordered by system size (number of atoms) as a measure of their 
computational cost. The three smallest systems, summing to a total of 44 
individual mutations, were selected in full for analysis. Further mutations from 
the next two smallest complexes were chosen for MULES analysis as deliberate 
extensions of the dataset to include known challenging residues (explained 
below). 
The addition of ‘challenging’ mutations was designed to test the boundaries of the 
MULES methodology within the wider validation dataset. In total, six mutations from 
two complexes (PDB accession codes 1A22 and 1JRH) were chosen, detailed below in 
table 6.1. Choices were based on results from existing literature data from Robetta, 
post-processing and other ∆∆G prediction methods.96, 260, 311 
Table 6.1 – Additional residues included in MULES dataset designed to test boundaries of MULES 
methodology. 
Complex Mutationa Expt. ∆∆G 
/kcal mol-1 
Justification 
1A22 F25A -0.40 Favourable mutation, incorrectly estimated as 
hot-spot 
1A22 D171A 0.80 Neutral ∆∆G charged mutation, greatly 
overestimated as hot-spot 
1A22 I324A 2.13 Hot-spot mutation, underestimated as neutral 
1A22 K326A -0.02 Neutral charged mutation, correctly estimated 
1JRH Y91A 0.58 Large sidechain neutral mutation, correctly 
estimated 
1JRH K460A 3.60 Hot-spot charged mutation, greatly 
underestimated ∆∆G 
a Residues labelled with sequential Amber numbering system 
Overall, including the seven mutations of the 1SMF complex already investigated, a total 
of 57 mutations over 6 complexes were included as part of the MULES validation 
dataset. The complexes, PDB accession codes and primary references for the associated 
experimental data are summarised below in table 6.2. 
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Table 6.2 – Complexes and primary references for mutations included in MULES validation 
dataset. 
Partner A Partner B Accession 
code 
Number of 
mutations 
Structure 
reference 
∆∆G assay 
references 
Trypsin MBTI 1SMF 7 256 Chapter 3 
HGHa Single HGHa 
receptor 
1A22 4 312 312, 313 
Barnase Barstar 1BRS 8 314 16, 314, 315 
ZipA FtsZ 
fragment 
1F47 9 316 316 
Interferon γ Antibody A6 1JRH 2 317 317-319 
Antibody D1.3 HELb 1VFB 27 320 320-323 
a Human growth hormone, bHen egg white lysozyme 
Experimental data were generated using a variety of different methods, spanned almost 
a decade of technological progress, were recorded to different levels of precision and 
were often performed by different analysts even for mutations within the same complex. 
Determining the uncertainty in experimental results was therefore difficult, even where 
errors for individual mutations were available in the original literature. Overall, 
experimental ∆∆G were estimated to have errors of ± 10%, consistent with the largest 
errors estimated for individual values in the primary references. 
The MULES validation dataset included at least one mutation of every naturally 
occurring amino acid to alanine with the following exceptions. No cysteine or proline 
residues were included in the original Robetta validation set due to their potential for 
introducing large changes in protein backbone structure. No alanine or glycine were 
included as the Robetta technique did not allow growth of a residue sidechain from 
glycine, and the alanine is a null mutation. Finally, although the full Robetta dataset did 
include methionine mutations, the truncated version used for MULES excluded 
methionine by chance, simply due to its low abundance in protein structures as a whole 
and particularly its under-representation as a PPI hot-spot.54, 324 All individual mutations 
are available in appendix 5 as table S1. 
Having identified a suitable dataset, the first stage of MULES validation was to evaluate 
existing methods of ∆∆G calculation for their own ability to recreate the experimentally 
determined results. This is the focus of the following section. 
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6.2 Robetta and post-processing results 
6.2.1 Methods 
The MULES validation involved comparison of ∆∆G predictions with those of the existing 
Robetta and post-processing methods. Robetta predictions were taken directly from the 
original Robetta literature of Kortemme and Baker.96 When performing mutations, the 
Robetta method allows a small degree of local flexibility by performing a short localised 
Monte-Carlo energy minimisation. Sidechains of residues within a 5 Å radius of the 
mutation site are substituted from rotamer libraries and evaluated for their energetic 
favourability. The Monte-Carlo basis of this simulation means that it is possible, but 
unlikely, that re-performing the Robetta predictions of the original dataset would have 
resulted in different conformations of sidechain rotamers and hence different ∆∆G. (See 
section XXX for explanation of Robetta methodology). 
Post-processing predictions, as discussed in section 3.3, relied on MD simulations to 
generate series of structural snapshots for analysis. Full computational details for these 
simulations are available in section 8.4.4, but are summarised here for clarity. Each of 
the complexes in table 6.2 (excluding 1SMF, for which post-processing ∆∆G had already 
been calculated), previously solvated and parameterised, were heated to 300 K and 
equilibrated at 1 atm pressure over a period of 100 ps. A single production MD 
simulation of 20 ns was then performed for each complex. Structural snapshots were 
saved at 10 ps intervals, giving a total of 2000 snapshots in each trajectory. 
MM-PB/GBSA free energy calculations were then performed for each complex and each 
desired mutation using the post-process alanine scanning function of the mm_pbsa perl 
scripts in Amber 10. 
6.2.2 Correlations and regression analyses 
6.2.2.1 Robetta 
As already discussed, the results for the Robetta method had already been generated. In 
the original Robetta study, the full PPI dataset (of 380 mutations) calculated 
experimental ∆∆G with a Pearson correlation of 0.593 and a MUE to experiment of 
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0.83 kcal mol-1. The MULES validation subset of the overall Robetta results gave a 
Pearson correlation to experiment of 0.494 and MUE of 0.87 kcal mol-1 (figure 6.1). 
 
Figure 6.1 – Calculated versus experimentally measured ∆∆G for Robetta results with the MULES 
validation dataset of mutations. Linear regression (solid line) and line of perfect prediction 
(dashed) included for reference. 
Simple linear regression of the Robetta results gave a line of slope 0.66 and intercept 
0.43. This was below the slope of 1.0 and intercept of 0.0 expected for perfect 
prediction. Although the majority of Robetta estimates clustered below 2 kcal mol-1, 
there were some noticeable exceptions, particularly the point at (0.80,8.73), which 
corresponded to the D171A mutation of the 1A22 complex (residues numbered 
sequentially as per internal Amber numbering). 
Simple linear regression and associated correlations can potentially be greatly affected 
by outliers. To avoid this, results were refitted using a robust linear regression method 
based on a Tukey biweight function with the Grafit software.281 Individual datapoints 
were weighted based on their residual errors, with outliers defined statistically as 
points with residuals   (             ). Outliers were iteratively identified and 
excluded from the dataset until no further outliers could be distinguished. The effects of 
this robust linear regression are shown below in figure 6.2 and table 6.3. 
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Figure 6.2 – Calculated versus experimentally measured ∆∆G for the Robetta method, excluding 
the 1A22 D171A outlier. Linear regression (solid line) and line of perfect prediction (dashed) 
included for reference. 
Table 6.3 – Comparison of statistical metrics for Robetta results including and excluding outlier. 
The work of the previous chapters had highlighted the potential for inaccuracy in ∆∆G 
estimates for charged mutations. It was unknown whether this effect extended to 
Robetta, which, as it used an empirically scaled energy function, may have been more 
suited to this particular class of residues. To investigate this, the full dataset was broken 
down further into subsets of polar (His, Asn, Gln, Ser, Thr, Tyr), non-polar (Phe, Ile, Leu, 
Val, Trp) or charged (Asp, Glu, Lys, Arg) mutations (N.B. Histidine was modelled in its 
neutral protonation state during simulations and so was classified as a polar residue for 
all methods). Robust regression analysis was then repeated for each subset. Results, 
excluding any outliers, are detailed below in table 6.4. 
Metric Including outlier Excluding outlier 
Regression slope 0.66 ± 0.16 0.70 ± 0.11 
Regression intercept 0.43 ± 0.28 0.23 ± 0.19 
Pearson correlation 0.494 0.673 
Mean unsigned error 0.87 kcal mol-1 0.72 kcal mol-1 
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Table 6.4 – Comparison of robust statistical metrics for polar, non-polar and charged residue 
mutations performed with Robetta. 
Metric Polar Non-polar Chargeda 
Regression slope 0.65 ± 0.20 0.38 ± 0.27 0.80 ± 0.17 
Regression intercept 0.33 ± 0.27 0.74 ± 0.46 0.04 ± 0.33 
Pearson correlation 0.618 0.411 0.743 
Mean unsigned error 0.61 kcal mol-1 0.77 kcal mol-1 0.79 kcal mol-1 
a Outlier = 1A22 D171A mutation 
Comparing the regression metrics visually, for ease of analysis, leads to the plot shown 
in figure 6.3. 
 
Figure 6.3 – Comparison of robust linear regressions for full dataset and its polar, non-polar and 
charged residue components. Mutations performed and ∆∆G calculated with Robetta. Line of 
perfect prediction (y = x) shown as dashed line for comparison. 
Visual comparison of the different residue type subsets in figure 6.3 allowed a number 
of conclusions to be drawn. Firstly, all residue types, both individually and combined as 
the full dataset, have regression slopes < 1. This suggested that Robetta consistently 
underestimated ∆∆G. Secondly, the non-polar residue mutations had a particularly low 
slope and high intercept, implying particularly poor predictive accuracy for this subset 
of mutations. This is supported by the fact that non-polar residues showed the lowest 
correlation of all Robetta subsets, and amongst the highest error to experiment. 
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Nevertheless, mean unsigned errors to experiment were generally low. Both the full 
dataset and each subset had MUE < 1 kcal mol-1, indicating good accuracy given the 
estimated errors in experimental ∆∆G. The charged residue subset in particular showed 
very high correlation with experimental results (r = 0.743 for n = 21 mutations), despite 
having the highest overall error of the subsets analysed. This may have been directly 
due to the fact that the Robetta energy function neglects Coulomb electrostatics, instead 
accounting for charge interactions via a hydrogen bonding term.96 However, the charged 
mutation subset did also provide the only statistical outlier of the dataset as a whole, 
highlighting the potential for variability in individual results. 
In summary, Robetta generally performed adequately in its analysis of the MULES 
validation dataset, generating results with similar correlations and errors to the full 
dataset used in its initial validation by Kortemme and Baker. However, its systematic 
underestimation of ∆∆G may be an inherent weakness of the empirically scaled nature 
of its energy function. A fully physical, unscaled energy function such as that used in 
Amber MD and MM-PB/GBSA calculations may provide a better representation of 
energetic interactions, and this will be discussed with reference to both post-processing 
and MULES results in the following sections. 
6.2.2.2 Post-processing 
As post-processing required MD simulations to generate conformational ensembles of 
the native protein complexes, it was orders of magnitude more computationally costly 
than the Robetta investigations already performed. This cost would be justifiable if it 
generated ∆∆G that were quantifiably more accurate or had better correlation to 
experimental results. Figure 6.4 shows a plot of post-processing MM-PBSA and -GBSA 
results against experiment using simple linear regression, not excluding any statistical 
outliers. 
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Figure 6.4 – Calculated versus experimentally measured ∆∆G for the post-processing method 
with the MULES validation dataset of mutations. MM-PBSA (blue diamonds, solid line) and 
MM-GBSA (red cross, dotted line) show linear regressions with slopes >> y = x (dashed line). 
The post-processing results clearly showed a consistent overestimation of the effects of 
mutation, whether favourable or unfavourable, leading to regressions with slopes >> 1. 
Additionally, there were clear individual cases with vastly overestimated ∆∆G, such as 
the point (0.80,41.00), corresponding to the 1A22 D171A mutation. The simple linear 
regressions of figure 6.4 would clearly be greatly affected by the presence of such 
outliers and so outliers were robustly eliminated using an identical protocol to that 
described for the Robetta method above. Linear regressions and associated metrics for 
the full dataset and its polar, non-polar and charged subsets, after outliers had been 
eliminated, are compared in table 6.5 and figure 6.5. 
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Table 6.5 – Comparison of robust regression metrics for full dataset and polar, non-polar and charged residue mutation subsets, calculated with post-processing. 
 MM-PBSA MM-GBSA 
Metric Full Polar Non-polar Charged Full Polar Non-polar Charged 
Regression slope 1.12 ± 0.41 1.19 ± 0.69 0.59 ± 0.42 1.21 ± 0.87 1.38 ± 0.33 1.27 ± 0.53 0.23 ± 0.61 1.82 ± 0.57 
Regression intercept 0.70 ± 0.67 0.18 ± 0.96 1.92 ± 0.78 0.76 ± 1.56 0.91 ± 0.57 1.12 ± 0.73 3.00 ± 1.15 0.03 ± 1.12 
Pearson correlation 0.357 0.379 0.350 0.329 0.500 0.495 0.100 0.602 
Mean unsigned errora 2.15 1.82 1.65 2.83 2.15 1.78 2.11 2.52 
Outliers 1A22 D171A 
1VFB D207A 
1JRH K460A 
N/A N/A 1A22 D171A 
1VFB D207A 
1JRH K460A 
1A22 D171A N/A N/A 1A22 D171A 
a All values in kcal mol-1 
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Figure 6.5 - Comparison of robust linear regressions for full dataset and its polar, non-polar and 
charged residue components. A) Mutations performed and ∆∆G calculated with the 
post-processing method and MM-PBSA. B) Mutations performed and ∆∆G calculated with the 
post-processing method and MM-GBSA. Line of perfect prediction (y = x) shown as dashed line 
for comparison. 
Even after accounting for statistical outliers, post-processing consistently overestimated 
the effects of mutations, leading to regression slopes > 1. The non-polar subset of 
mutations (n = 16) differed from this trend, giving the regression lines with lowest 
slopes and highest intercepts similarly to the Robetta results of the previous section. 
This again highlights the known sensitivity of MM-PB/GBSA, and the post-processing 
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technique in particular, to the electrostatic components of ∆G calculated from atomic 
point charges. Non-polar residues, with low point charges and few electrostatic 
interactions or polar contributions to solvation, did not suffer from the same level of 
∆∆G overestimation as polar or charged residues. 
Unfortunately this did not lead to better predictive power for the non-polar subset of 
residues, or for post-processing as a whole. Correlations to experiment were 
considerably lower for both MM-PBSA and -GBSA predictions than for those of the 
Robetta method and MUE to experiment were consistently higher. Surprisingly, 
MM-GBSA results generally showed better correlations and lower errors than their 
MM-PBSA counterparts, despite the fact that GB solvation is a more approximate 
representation of the polar contribution to free energy. It is likely that the improvement 
observed with GB was a consequence of the fact it was less susceptible to wild 
overestimations of ∆∆G, as shown by the presence of fewer outliers in table 6.5 and 
figure 6.5, and particularly the lower errors in charged residue mutations. 
Nevertheless, mean unsigned errors to experiment were still high across the full dataset 
and all subsets, no matter the solvation method used in the ∆∆G calculations. Compared 
to the Robetta results, MUE were three to fourfold higher for all subsets. This loss of 
accuracy cast doubt on the reliability of post-processing across broad datasets. It was 
also likely to have influenced the poor correlations and low regression slopes observed 
for the non-polar subset of mutations - large errors in individual results could easily 
skew correlation coefficients and affect linear regressions, despite the statistical 
elimination of outliers. 
6.2.3 Summary 
Neither the Robetta method not post-processing performed exceptionally in their 
estimations of ∆∆G for the MULES validation dataset. Excluding the statistically 
determined outlier of the 1A22 D171A mutation, Robetta generated computational 
predictions with correlation coefficients and MUE broadly in line with those of the full 
dataset used by Kortemme and Baker.96 The post-processing approach, in contrast, 
generated results with consistently poorer correlation and accuracy to experiment and a 
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larger number of statistical outliers. This was not unexpected given the limitations of 
post-processing identified and discussed in previous chapters. 
The larger-scale investigation of post-processing and comparison with Robetta 
presented here did allow the identification of some trends in ∆∆G predictions. 
Post-processing consistently overestimated its ∆∆G predictions, whilst Robetta ∆∆G 
consistently underestimated the correct values. Between residue types the greatest 
regression slopes were observed for charged residues, with this trend being repeated 
across all methods of analysis. Likewise, charged residues consistently saw higher 
errors than other residue types or the dataset as a whole, and all identified statistical 
outliers involved the mutation of charged residues. 
As discussed previously, the inaccurate prediction of charged residue ∆∆G has been a 
known weakness of the post-processing method for a number of years. Its 
overestimation of ∆∆G is thought to be due to a combination of its lack of structural 
rearrangement and an inherent overestimation of charge-charge interactions by the 
Amber force fields. This has led to the suggested use of higher internal dielectric 
constants for charged residue MM-PB/GBSA calculations in an effort to compensate for 
both problems.267-269 However, the fact that Robetta showed similar trends in its ∆∆G 
predictions, despite its empirically scaled energy function, suggested that difficulties in 
accurately predicting the effects of charged residue mutations could not be completely 
ascribed to the Amber energy function. 
The local structural flexibility allowed with MULES has already been shown to improve 
the accuracy of ∆∆G estimates over post-processing by reducing the overestimation of 
predictions for the 1SMF P2’ series of mutations. A similar improvement in accuracy 
over a broader dataset would result in MULES predicting experimental ∆∆G with similar 
correlations as Robetta, but with linear regression slopes closer to unity. The extent to 
which this was the case is discussed in the following section. 
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6.3 MULES validation results 
6.3.1 Methods 
The choice of MULES validation dataset has already been discussed in the previous 
section; residues included in the set are shown in table 6.2. The validation of MULES 
required a separate simulation of each of the desired mutations. Each of these 
simulations was performed using the protocol developed in the previous chapter and 
summarised in section 5.5.2. Each simulation included heating and equilibration stages 
to 300 K and 1 atm pressure, 1 ns of structural equilibration and 1 ns of production MD 
from which structural snapshots were extracted every 10 ps for MM-PB/GBSA analysis 
using the mm_pbsa perl scripts of Amber 11. ∆∆G of the 1SMF series of mutations, which 
had previously been calculated using 10 ns of production MD simulation, were 
recalculated based on the first nanosecond of simulation in order to compare results 
fairly. Full computational details are available in section 8.4.2.2. 
The MULES validation protocol consisted of three separate ways of performing the 
mutation of charged residues. Again, these have been discussed in detail in the previous 
chapter and hence are only briefly explained here to clarify the following results 
sections. None involved changing the protonation state of a partner residue as this 
methodology could not be applied uniformly across all mutations, as described in 
section 5.2.2.3. The first technique, referred to as the ‘counterion’ method, neutralised 
the overall system by the complementary mutation of an inorganic counterion (chloride 
or sodium, depending on the individual mutation and overall charge of the system) in 
the bulk solvent of the mutant copy. The second, the ‘ligand side’ approach, involved the 
replacement of mutant residue sidechain volume with a hydroxide or hydroxonium ion, 
weakly restrained in its surroundings during the simulation. The ionised solvent 
molecule was then kept as part of the ‘ligand’ (the mutated protein partner) during the 
free energy calculations. Finally, the ‘stripped’ approach used the same neutralisation 
technique of including an ionised solvent molecule during simulation, but removed the 
hydroxide or hydroxonium ion from the structural snapshots during free energy 
analysis. All three techniques were evaluated for every charged residue mutation. 
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6.3.2 Correlations and regression analysis 
Linear regression, following elimination of statistical outliers and weighted by 95% 
confidence intervals in individual datapoints, was performed for each mutation as 
described in section 6.2.2. The following sections examine results for the full validation 
dataset and each of the polar, non-polar and charged residue subsets in turn. 
6.3.2.1 Full MULES dataset 
Linear regressions and their associated metrics for MM-PB/GBSA ∆∆G predictions of the 
whole MULES dataset are summarised in table 6.6. Figure 6.6 shows a visual comparison 
of MULES regressions with those of Robetta and post-processing. 
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Table 6.6 - Comparison of robust linear regression metrics for ∆∆G of the full MULES dataset calculated with either MM-PBSA or -GBSA. Each solvation method 
includes three results for the different neutralisation approaches for charged residues. 
 MM-PBSA MM-GBSA 
Method Counterion Ligand side Stripped Counterion Ligand side Stripped 
Regression slope 0.84 ± 0.22 0.80 ± 0.17 0.83 ± 0.29 0.73 ± 0.22 0.73 ± 0.18 1.05 ± 0.26 
Regression intercept 0.19 ± 0.24 0.06 ± 0.15 0.44 ± 0.28 0.31 ± 0.20 0.38 ± 0.19 0.44 ± 0.26 
Pearson correlation 0.458 0.552 0.367 0.404 0.479 0.478 
Mean unsigned errora 2.03 1.33 2.36 1.81 1.36 1.89 
Outliers 1BRS E71A 
1JRH K460A 
1JRH K460A 
1SMF K226A 
1JRH K460A N/A 1JRH K460A 
1SMF K226A 
N/A 
a All values in kcal mol-1 
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Figure 6.6 – Comparisons of robust linear regressions for ∆∆G calculated with MULES, Robetta 
and post-processing methods. A) Results calculated with MM-PBSA for MULES and 
post-processing techniques. B) Results calculated with MM-GBSA for MULES and post-processing 
techniques. MULES results consist of three identical datasets, each using a different approach to 
the mutation of charged residues. 
Comparing the linear regression of MULES results with those of the other investigated 
methods, MULES estimated ∆∆G with regression slopes, correlations and MUE 
intermediate between Robetta and post-processing. For MULES, the inclusion of 
structural flexibility between native and mutant coordinates reduced the overestimation 
of ∆∆G seen with post-processing, while the use of the fully physical, unscaled Amber 
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energy function in free energy calculations likely avoided the underestimation of ∆∆G 
observed with Robetta. This was consistent with the conclusions of the initial MULES 
investigations detailed in chapter 4. 
Differences between the MULES approaches used for simulating charged mutations 
were more nuanced however. Using MM-PBSA free energy calculations, little difference 
was observed between regression slopes and intercepts, but the ligand-side approach 
clearly generated results with the lowest mean unsigned error. This was also reflected 
in its comparatively high correlation to experiment, almost on a par with that of Robetta 
(r = 0.673). However, using MM-GBSA, the regression slope of the stripped protocol 
dataset clearly showed best agreement with the line of y = x and identical correlation to 
the ligand-side approach despite its higher MUE to experiment. 
Overall, the full dataset investigations provided further confirmation of MULES’ closer 
agreement with y = x than either of the alternative methods already investigated. 
Nevertheless, mean errors in results remained higher than those of Robetta, caused by 
the remaining presence of some incorrect estimations despite the elimination of 
statistical outliers. 
There was no discernible trend in regression slope, intercept or correlation between the 
charged mutation protocols. The differences in effect of the protocols observed between 
MM-PBSA and -GBSA results was therefore perhaps due to underlying differences in the 
contributing ∆∆G of polar and non-polar residues for both solvation methods. To 
eliminate these confounding variables and determine an optimal protocol for MULES 
mutations, each of the residue type subsets was investigated independently in turn and 
compared with the predictions of Robetta and post-processing identically to the above 
analysis. 
6.3.2.2 Polar residue subset 
The polar residue subset (n = 20) was analysed by linear regression, weighted by the 
errors in individual points and excluding statistical outliers identically to the analyses 
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above. Associated metrics are summarised in table 6.7, and regressions are compared 
with those of Robetta and post-processing in figure 6.7. 
Table 6.7 – Robust linear regression metrics for ∆∆G of the polar residue subset calculated with 
MULES and either MM-PBSA or -GBSA free energy calculations. 
Metric MULES MM-PBSA MULES MM-GBSA 
Regression slope 0.66 ± 0.50 0.66 ± 0.39 
Regression intercept 0.09 ± 0.32 0.25 ± 0.30 
Pearson correlation 0.296 0.374 
Mean unsigned errora 1.44 1.18 
Outliers N/A N/A 
a All values in kcal mol-1 
 
Figure 6.7 – Comparison of robust linear regressions for ∆∆G of polar residues calculated with 
MULES, Robetta and post-processing methods. Results calculated with either MM-PBSA or -GBSA 
for both MULES and post-processing. 
MULES again clearly reduced the overestimation of ∆∆G inherent to the post-processing 
method, to the extent that MULES regression slopes and intercepts were almost 
identical to those of Robetta. However, compared further with Robetta, MULES showed 
larger mean unsigned errors and poorer correlations, despite the similar linear 
regressions. 
This suggested that MULES results simply suffered from greater variability than those of 
Robetta. To examine this possibility further, the individual ∆∆G predictions of Robetta 
  222 
and MULES for each mutation were plotted and compared. Figure 6.8 shows all 20 
datapoints for each method compared to the line of perfect prediction, y = x. 
 
Figure 6.8 – Comparison of MULES MM-PBSA (dark blue), MULES MM-GBSA (red) and Robetta 
(light blue) ∆∆G results for individual mutations of polar residues. Perfect prediction (y = x) 
shown as dashed line. Mutations with particularly poor MULES performance are labelled with 
complex accession codes and residue numbers. 
Although the majority of experimentally measured ∆∆G and computational predictions 
were correctly clustered between 0 - 2 kcal mol-1 for all methods, MULES showed some 
significant underestimations of individual mutations, particularly when MM-PBSA was 
used for free energy calculations. Although not unusual enough to be judged as 
statistical outliers, the presence of these poorly estimated ∆∆G increased the variability 
of the MULES results, increasing mean errors to experiment and leading to worse 
correlations for MULES than Robetta, despite similar regression slopes and intercepts. 
Notably, three of the four mutations identified as being underestimated with MULES 
were of tyrosine residues. Although classified as a polar residue due to the presence of 
an alcohol group available for hydrogen bonding, tyrosine also consists of a bulky, 
hydrophobic phenyl group. The large loss of sidechain volume on mutation to alanine 
and differing contributions to binding of the individual functional groups suggest 
tyrosine mutations may be particularly challenging to accurately predict with MULES. 
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The use of methods which were less sensitive to small changes of structure, such as 
Robetta, with its empirically scaled energy function, or even simply MM-GBSA rather 
than MM-PBSA, with its lower sensitivity to point atomic charge position, improved ∆∆G 
estimates for tyrosine mutations. 
Further potential explanations for the mischaracterisation of some tyrosine mutations 
are investigated in section 6.4. However, from the results above it was clear that MULES 
combined with MM-PB/GBSA free energy calculations generated ∆∆G estimates that 
were generally consistent with those of Robetta but included a minority of poor 
predictions. Excluding the four mutations identified in figure 6.8, the MULES polar 
residue mutations had MUE of 0.91 kcal mol-1 with MM-PBSA and 0.97 kcal mol-1 with 
MM-GBSA; closer in line with Robetta and a large improvement over post-processing. 
Nevertheless, without the selective, subjective and post-hoc exclusion of poorly 
estimated residues, MULES combined with MM-GBSA free energy calculations was the 
more accurate and reliable MULES method for polar residue mutations. 
6.3.2.3 Non-polar residue subset 
The subset of non-polar residue mutations (n = 16) was analysed by linear regression, 
weighted by the errors in individual datapoints and excluding statistical outliers 
identically to the analyses described above. Regression metrics are described below in 
table 6.8, and figure 6.9 compares regressions with the equivalent subset of Robetta and 
post-processing mutations. 
Table 6.8 - Robust linear regression metrics for ∆∆G of the polar residue subset calculated with 
MULES and either MM-PBSA or -GBSA free energy calculations. 
Metric MULES MM-PBSA MULES MM-GBSA 
Regression slope 0.62 ± 0.33 0.77 ± 0.48 
Regression intercept 0.83 ± 0.61 0.61 ± 0.85 
Pearson correlation 0.447 0.397 
Mean unsigned errora 1.07 1.47 
Outliers N/A N/A 
a All values in kcal mol-1 
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Figure 6.9 - Comparison of robust linear regressions for ∆∆G of non-polar residues calculated 
with MULES, Robetta and post-processing methods. Results calculated with either MM-PBSA 
or -GBSA for both MULES and post-processing. 
MULES regression lines, with either MM-PBSA or –GBSA, showed far better agreement 
with the ideal prediction line of y = x than any of the Robetta or post-processing 
methods. All methods seemed to consistently underestimate ∆∆G slightly, although 
again, MULES regression slopes were far closer to perfect than those of the other 
techniques investigated. 
The initial MULES investigations of a series of non-polar mutations of the 1SMF P2’Ile 
residue had determined that MM-PBSA free energy calculations predicted ∆∆G with 
greater accuracy to experiment and slightly better correlations than their MM-GBSA 
equivalents. Although overall correlation and MUE were less impressive across the 
wider dataset investigated here, the same trend was observed, with MM-PBSA being the 
preferred analysis technique for mutations of non-polar residues. 
MULES and MM-PBSA results across the non-polar dataset had a mean unsigned error to 
experiment of 1.07 kcal mol-1, the lowest error observed for any of the polar, non-polar 
or charged residue MULES subsets in the previous and following sections. An error of 
this magnitude was comparable to that of the Robetta method for the same residue type 
subset (0.77 kcal mol-1) and similar to the 1 kcal mol-1 level generally agreed to provide 
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chemical accuracy in absolute free energy calculations. This has been accepted to be the 
current limit of MM-PB/GBSA ∆G calculations, as described previously in section 2.2.5. 
MULES correlations to experiment also compared favourably with those of Robetta and 
post-processing. MM-PBSA results showed the best correlation of all techniques, whilst 
MM-GBSA showed a large improvement over post-processing. 
Compared to other residue type subsets and the full dataset as a whole, non-polar 
residues consistently gave no better than average correlations, despite their 
comparatively low errors to experiment. As with the MULES polar residue results 
discussed in the previous section, this suggested again that variability in the accuracy of 
specific predictions was the source of much of the error in the overall dataset. By 
selectively excluding small numbers of specific poorly estimated mutations it is likely 
that correlations and MUE to experiment would have improved further. Likewise, 
further MULES validation across a much larger number of mutations in future may 
negate the skewing effects of individual mutations or even identify some as statistical 
outliers. 
In the absence of a reliable statistical definition of any outliers in the existing non-polar 
dataset however, no ∆∆G predictions could be selectively excluded without potentially 
introducing bias to the MULES validation. Instead, other methods for improving ∆∆G 
estimations for some residues will be discussed in section 6.4. For the non-polar 
mutations investigated here however, MULES and MM-PBSA was the most accurate and 
reliable predictive method, due to its comparatively good correlation, low MUE to 
experiment and improved agreement with the y = x line of ideal prediction than either 
Robetta or post-processing. 
6.3.2.4 Charged residue subset 
Each mutation of a charged residue had been performed with three separate approaches 
to neutralising the overall system on mutation. The ‘counterion’, ‘ligand side’ and 
‘stripped’ protocols were all investigated in turn for all charged residue mutations, each 
using both MM-PBSA and -GBSA free energy calculations. The charged residue subset 
(n = 21) therefore generated three ∆∆G for each mutation and free energy calculation 
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method. The results of each approach were analysed by linear regression, weighted by 
the errors in individual datapoints and excluding statistical outliers in an identical 
manner to all other datasets and subsets. Regressions and associated metrics are 
described below in table 6.9, and figure 6.10 shows a comparison of linear regressions 
with Robetta and post-processing results. 
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Table 6.9 - Comparison of linear regression metrics for ∆∆G of the MULES mutations of charged residues calculated with either MM-PBSA or -GBSA. Each solvation 
method includes three results for the different neutralisation approaches for charged residues 
 MM-PBSA MM-GBSA 
Method Counterion Ligand side Stripped Counterion Ligand side Stripped 
Regression slope 0.84 ± 0.85 0.34 ± 0.18 2.10 ± 1.05 0.40 ± 0.60 0.53 ± 0.28 1.93 ± 0.58 
Regression intercept 0.55 ± 0.67 -0.06 ± 0.11 1.09 ± 0.60 0.28 ± 0.36 0.62 ± 0.25 0.84 ± 0.47 
Pearson correlation 0.232 0.411 0.428 0.153 0.420 0.606 
Mean unsigned errora 3.67 1.57 4.42 2.67 1.59 2.89 
Outliers 1BRS E71A 
1JRH K460A 
1JRH K460A 
1SMF K226A 
1JRH K460A N/A 1JRH K460A 
1SMF K226A 
N/A 
a All values in kcal mol-1 
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Figure 6.10 – Comparison of robust linear regressions for ∆∆G of charged residues calculated 
with Robetta, post-processing and MULES with one of three different protocols. A) 
Post-processing and MULES results calculated with MM-PBSA. B) Post processing and MULES 
results calculated with MM-GBSA. 
Charged residue mutations were known to be particularly challenging targets for 
accurate prediction of ∆∆G. It was therefore unsurprising that the charged residue 
subset showed the largest mean unsigned errors to experiment of all the residue types, 
no matter the approach taken to neutralising the mutations. Although MULES MUE were 
significantly larger than the 0.79 kcal mol-1 obtained with Robetta, they were either 
better, or similar in magnitude to the errors observed with the post-processing method. 
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Comparing the linear regressions and associated correlations of the three MULES 
approaches to making charged mutations, it was clear that charged residue mutations 
generated results that were inconsistent with those of the other residue type subsets. 
While the counterion and ligand side methods both underestimated ∆∆G and gave 
regressions similar to those of the Robetta method, the stripped approach consistently 
overestimated ∆∆G and gave close agreement with regressions observed for the 
post-processing technique (figure 6.10). Despite this, the stripped approach showed the 
best correlation to experimental results with both MM-PBSA and -GBSA free energy 
calculations. 
The effects of each individual method could better be seen when examining individual 
∆∆G as opposed to linear regressions for the whole subsets. Figure 6.11 shows the 
individual ∆∆G calculated for each mutation and with each method, compared both to 
one another and to y = x. 
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Figure 6.11 – Comparison of individual charged residue ∆∆G calculated with the ‘counterion’ 
(dark blue) ‘ligand side’ (red) or ‘stripped’ (light blue) methods for neutralising MULES 
simulations. Line of perfect y = x prediction (dashed line) included for comparison. A) Free 
energy calculations performed with MM-PBSA. B) Free energy calculations performed with 
MM-GBSA. 
The comparison of individual datapoints immediately highlighted the increased 
variation in results observed for MM-PBSA compared to MM-GBSA. The spread of 
individual ∆∆G in figure 6.11a showed the greater over- or underestimations of ∆∆G 
values for some mutations with MM-PBSA compared to MM-GBSA estimates in figure 
6.11b. This was likely a result of the known sensitivity of Poisson-Boltzmann solvation 
to small changes in point charge and fluctuations in structure. MM-GBSA, less 
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susceptible to these large over- or underestimations, therefore appeared to be the 
favoured free energy calculation method. 
The favoured neutralisation approach was not as obvious and hence requires further 
discussion. The ligand side approach gave the lowest MUE to experiment in table 6.9, 
but with notably lower regression slopes than the other methods and at the cost of 
treating the greatest number of results as statistical outliers. Individual results also 
seemed to show a significant cluster around calculated ∆∆G of 0 kcal mol-1, i.e. a number 
of mutations were identified as completely neutral, more so than would be expected 
from experimental results. Given that the ligand side mutation protocol involved 
replacing one charged group (carboxylic acid, amine or guanidinium) with another 
(hydroxide or hydroxonium) during the simulation and free energy calculation, it was 
unsurprising that some of these replacements falsely resulted in no change in binding 
free energy. 
The stripped approach, in which the replacement hydroxide or hydroxonium ion is 
removed during the free energy calculation, resulted in much larger MUE to experiment 
than its partner ligand side approach, and regression statistics close in line with those of 
post-processing. In principle the stripped approach is similar to the post-processing 
method, as molecular volume that is present during the dynamical simulation (the 
replacement solvent ion) is removed during the free energy calculation, leaving a 
vacuum that may result in the overestimation of ∆∆G between native and mutant 
structures. 
Figure 6.11b shows that the majority of large errors in predictions were indeed from 
overestimations of experimental ∆∆G rather than underestimations, corroborating this 
hypothesis. Nevertheless, the stripped approach did generate linear regressions with 
the greatest correlations to experiment and was also consistent with the standard 
MM-PB/GBSA procedure of removing all solvent and counterions prior to free energy 
analysis. 
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Finally, the counterion approach replicated the trend of experimental results with 
regression slopes and MUE intermediate between those of the stripped and ligand side 
approaches. Errors for hot-spot residues (≥ 2 kcal mol-1 experimental ∆∆G) were clearly 
larger than those for neutral residues however. Based on the experience of the 1SMF 
P1Ala mutation during the MULES protocol development of chapter 5, the use of the 
counterion approach could introduce dynamical instabilities where the mutation of a 
charged residue greatly abolished binding or induced excessively large conformational 
differences between native and mutant complexes. 
Whether some of the mutations analysed here also suffered from these dynamical 
instabilities was unknown. Standard analyses of the MD trajectories had not identified 
any large changes in structure or dynamics (see chapter 8 for full computational 
methods), but the short length of production MD simulations used in the MULES 
validation protocol may have hidden dynamical changes that took longer to propagate 
fully, but nevertheless affected binding free energies quickly through minor changes in 
structure. 
Choosing a single mutation approach as reliably giving the most accurate results was 
therefore far from straightforward. All three methods performed well for some 
mutations and poorly for others, and it is likely that the optimum technique would differ 
depending on the protein complex and mutation under investigation. Realistically, many 
of the mutations included in the MULES validation dataset may result in changes of 
solvation or structure that have not been fully accounted for with the mutation 
approaches investigated here. This may have been the source of some of the larger 
errors in predictions. 
In principle, this potential for variation in methods of treating individual mutations may 
be a benefit of the MULES approach, as it would allow more accurate representations of 
mutations that could not be performed with other techniques, not least Robetta or 
post-processing. The potential of using unique protocols for each mutation is explored 
in later sections of this chapter. However, only a single technique could be chosen for 
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the validation of MULES in order to avoid introducing subjective bias into the validation 
process. 
Overall, the stripped mutation protocol, with free energy calculations performed with 
MM-GBSA, was the most logical choice for charged mutations. MM-GBSA calculations 
had been shown to be less susceptible to extremely large ∆∆G over- or underestimations 
than their MM-PBSA counterparts, and the stripped protocol was the logical extension of 
the standard MM-PB/GBSA protocol to a trajectory that included an ionised solvent 
molecule to account for the charge change of a charged residue mutation. 
6.3.3 Optimal MULES validation dataset results 
Having identified the most appropriate MULES mutation protocol and free energy 
calculation for each residue type subset, a combined full dataset of MULES ∆∆G 
estimates was generated. Based on the results of the above sections, this included polar 
residue mutations with ∆∆G calculated with MM-GBSA, non-polar mutations calculated 
with MM-PBSA and charged residue ∆∆G simulated using the stripped protocol and 
calculated with MM-GBSA. Linear regression of the summarised results, weighted by the 
errors in individual points and excluding any outliers, was performed identically to 
previous analysis. The summarised results are available in table 6.10 and plotted in 
figure 6.12, while table 6.11 compares the optimal MULES results with those of Robetta 
and post-processing directly. 
Table 6.10 - Comparison of linear regression metrics for ∆∆G of the MULES mutations of the full 
MULES dataset calculated with the ideal MULES protocol for each residue subset. Polar residue 
mutations were performed with MM-GBSA, non-polar with MM-PBSA and charged with 
MM-GBSA and the stripped mutation protocol. 
Metric MULES validation result 
Regression slope 1.13 ± 0.30 
Regression intercept 0.42 ± 0.25 
Pearson correlation 0.453 
Mean unsigned errora 1.78 
Outliers N/A 
a Value in kcal mol-1 
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Figure 6.12 - Comparison of individual ∆∆G calculated using the optimum MULES protocol for 
polar (dark blue) non-polar (red) and charged residues (light blue). Linear regression of the full 
dataset weighted by the error in each point (solid) and line of perfect y = x prediction (dashed 
line) included for comparison.
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Table 6.11 – Comparison of the Robetta, post-processing and optimal MULES results calculated across the full validation dataset 
Metric Robetta PP PBa PP GBa MULES 
Regression slope 0.70 ± 0.11 1.12 ± 0.41 1.38 ± 0.33 1.13 ± 0.30 
Regression intercept 0.23 ± 0.19 0.70 ± 0.67 0.91 ± 0.57 0.42 ± 0.25 
Pearson correlation 0.673 0.357 0.500 0.453 
Mean unsigned errorb 0.72 2.15 2.15 1.78 
Outliers 1A22 D171A 1A22 D171A 
1VFB D207A 
1JRH K460A 
1A22 D171A N/A 
a PP = Post-processing, b Values in kcal mol-1 
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Overall, the MULES ∆∆G estimates were encouragingly a clear improvement on those of 
post-processing, with lower mean unsigned error to experiment, generally better 
correlation to experiment, regression slopes and intercepts close to ideal and, 
importantly, no statistical outliers. Despite this improvement, MUE with MULES 
remained high, at 1.78 kcal mol-1, and correlation to experiment was far lower than that 
obtained in the initial MULES investigations. Figure 6.12 clearly shows that the residues 
with the largest errors, and hence biggest contributors to MUE, were charged residues. 
Hence the blanket choice of using the stripped approach for mutating charged residues 
was clearly inappropriate in some cases. In an effort to determine exactly why this may 
have been the case, some of the mutations that were poorly estimated with MULES are 
examined in further detail in the following section. 
6.4 Case studies 
6.4.1 The barnase/barstar interface 
The interface between the bacterial ribonuclease barnase and its protein inhibitor 
barstar has been a widely studied protein-protein interaction. Study of the structure of 
the interface and its mutants has resulted in a number of additions to the Protein Data 
Bank, including the 2.0 Å resolution X-ray crystal structure of the complex used for 
MULES validation in this study, with accession code 1BRS. 
Eight mutations of the barnase/barstar interface were included as part of the MULES 
validation dataset, and ∆∆G estimates of each generated with the Robetta, 
post-processing and MULES methods. Individual ∆∆G calculated for each mutation are 
compared in table 6.12. 
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Table 6.12 – Comparison of predicted and experimental ∆∆G for mutations at the 1BRS 
barnase/barstar interface. All values in kcal mol-1, residues numbered sequentially as per Amber 
internal numbering. 
Mutation Robetta PP MM-PBSAa PP MM-GBSAa MULESb Experimental 
D52A -0.04 -4.02 -2.20 -2.33 ± 0.35 -0.80 
N56A -0.03 -0.27 0.24 0.13 ± 0.30 3.10 
E58A 1.65 0.32 -0.33 -0.90 ± 0.69 -0.20 
E71A -0.20 -7.14 -3.02 -1.59 ± 1.19 2.80 
Y137A 3.13 0.60 3.05 1.94 ± 0.38 3.40 
T150A 1.69 1.27 2.74 3.47 ± 0.52 1.80 
E184A 1.54 11.82 9.79 9.87 ± 0.80 1.30 
E188A -0.12 0.18 -0.22 -0.48 ± 0.19 0.50 
a PP = Post-processing. b Mean and 95% confidence interval of 10 independent MULES results 
calculated with optimal MULES protocol of section 6.3.3 - MM-GBSA for polar, MM-PBSA for 
non-polar and MM-GBSA and the stripped mutation protocol for charged residues. 
Clearly, none of the methods performed well in predicting the effects of mutations at the 
barnase/barstar interface. Robetta identified the majority of residues as having almost 
no contribution to binding and falsely identified the E58 residue as being a warm-spot of 
intermediate ∆∆G. Post-processing and MULES suffered from the overestimation of both 
positive and negative mutational effects; E184 was overestimated as virtually abolishing 
binding entirely on mutation to alanine, while D52 and E58 were both estimated to have 
excessively favourable effects as alanine mutants. 
Each of these mutations was ‘correctly’ (± 1.0 kcal mol-1 of experiment) predicted with 
one or more of the computational methods used, indicating problems with false 
predictions lay more with the method chosen rather than the nature of the mutation or 
interface itself. More interestingly, two mutations (N56A and E71A) were falsely 
predicted by all of the techniques. This suggested instead that the mutation itself could 
not be correctly represented by any of the techniques, despite their relatively different 
approaches to structural flexibility and choice of energy functions. 
Both N56 and E71 are residues of the barnase protein partner. Both were 
experimentally measured to be hot-spots but predicted to be neutral or favourable 
alanine mutations computationally. Neither is buried directly at the interface (see figure 
6.13) but both instead interact with barstar through water-mediated hydrogen bonds.314 
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Figure 6.13 – Key interactions of N56 and E71 residues of barnase (light blue) with D143 of 
barstar (magenta) through water-mediated hydrogen bonds (dashed lines). Wat 1 mediates 
interaction between OE2 of E71 and O of D143 (atom not shown). Wat 2 mediates interaction 
between OD1 of N56 and OD2 of D143.314 Image created with UCSF Chimera.258 
The disruption of these solvent-mediated hydrogen bonds on mutation could potentially 
have caused conformational changes in vitro that were not represented correctly with 
the limited structural flexibility of MULES in silico. This possibility was supported by the 
large uncertainty in the E71A ∆∆G estimate, for which values from individual MULES 
simulations varied from -3.99 to +1.09 kcal mol-1. Additionally, although the 
barnase/barstar complex has often been used in protein-protein docking benchmarks 
due to its rigidity on binding,325, 326 a more recent structural study has also shown the 
potential for single mutations to make dramatic differences to structure and interface 
hydration.327 
Enhancing structural differences allowed between native and mutant MULES copies 
may therefore have improved predictions for these residues. As discussed in chapter 5, 
one way of enhancing differences between copies is by the use of implicit solvation 
during simulations. As such, MULES simulations of the N56A and E71A mutations were 
repeated, using ten independent simulations of 1 ns production MD length each and 
identical heating and equilibration methodology to that described in section 5.4.2.2. 
Mean ∆∆G results are shown in table 6.13 and compared with their explicitly solvated 
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counterparts. As with previous implicitly solvated simulations only MM-GBSA free 
energy calculations were performed for consistency with the simulation method. 
Table 6.13 – Comparison of ∆∆G from implicit and explicitly solvated MULES simulations of 
1BRS mutations. All values in kcal mol-1. 
Implicit solvation did not improve ∆∆G estimates for either of the mutations. Although 
this did not discount the possibility that the mutations induced large conformational 
changes, it did suggest that increased flexibility between native and mutant copies alone 
could not solve the problem of these falsely estimated ∆∆G. 
The source of the poor predictions was likely to be more complex. The binding 
interactions of barnase and barstar are predominantly electrostatic, as might be 
expected for an inhibitor of a ribonuclease that is designed to bind strongly to the highly 
negatively charged phosphate groups of RNA molecules.16, 314 The direct interaction 
between the charged E71 residue of barnase and the charged D143 residue of barstar 
should in principle be unfavourable. The removal of this interaction explains the highly 
favourable predicted ∆∆G for the E71A mutation. However, counterintuitively, 
double-mutant cycle experiments focussed on the importance of the E71 residue for 
binding and catalysis revealed the interaction between E71 and D143 to actually be 
favourable, contributing roughly 2.9 kcal mol-1 to binding.328 
Schreiber and Fersht’s hypothesis was that the E71 residue interacted indirectly with 
D143 through neighbouring residues in the barnase active site that were predominantly 
positively charged. E71 was proposed to play a role in pre-orientating these 
neighbouring residues in the unbound barnase structure, stabilising the binding site and 
enhancing binding. Mutation of E71 to alanine destabilised the binding site in the 
unbound barnase, resulting in a corresponding decrease in binding free energy when 
complexed to barstar (particularly interactions with residue D143).328 
Mutation Explicit MULES ∆∆G Implicit MULES ∆∆G Experimental ∆∆G 
N56A 0.13 ± 0.30 -0.46 ± 2.52 3.10 
E71A -1.59 ± 1.19 -3.64 ± 0.52 2.80 
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Similar indirect effects were proposed for the interactions of the N56 residue, which is 
part of the barnase substrate recognition loop. Again, although direct interactions with 
barstar were limited, intramolecular hydrogen bonds between N56 and neighbouring 
residues may have been disrupted on alanine mutation, resulting in changes in loop 
orientation and interactions in both the unbound and bound states.16 For both 
mutations the role (if any) of solvent molecules in the change in binding free energies 
remains unknown. 
In any case, the MULES studies used during validation were unlikely to capture any of 
the possible effects of either of the two mutations on binding. The single trajectory 
MM-PB/GBSA approach did not account for any changes in the unbound states of either 
receptor or ligand, and any information on the contribution of solvent to binding is lost 
on removal of all explicit solvent molecules prior to free energy analysis. It is possible 
that a carefully designed MULES protocol, including specific solvent molecules inside the 
MULES region and an adaptation of the three-trajectory MM-PB/GBSA approach for 
MULES, could successfully recreate the ∆∆G for these challenging residues. However, 
such a protocol could not be developed for mutations whose experimental ∆∆G was not 
known beforehand. 
The failure of all computational methods for predicting the E71A and N56A ∆∆G 
highlights the pitfalls of using a generic approach to predicting the effects of PPI 
mutations. Although MULES has shown an improvement over post-processing, it may be 
more efficiently used in determining the mode or mechanism of binding for mutations 
for which a ∆∆G is already known, but perhaps not fully understood. In particular, 
MULES could be used for making and evaluating ‘mutations’, such as changes in 
solvation or protonation state, that would not be accessible to other predictive models 
without the vast expense of pathway free energy calculations. This would still provide 
valuable information for the understanding of PPIs and protein design, helping to 
explain how and why particular residues contribute to binding rather than simply what 
they contribute. 
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6.4.2 Large residues - the human growth hormone/receptor 
interface 
Following on from the investigation of poorly predicted mutations within the 1BRS 
complex, other challenging residues to be studied in further detail were identified. Bulky 
residues, such as tyrosine, phenylalanine or tryptophan, undergo a large change in 
sidechain volume on mutation to alanine. This change in volume would normally be 
accounted for either by local rearrangements of structure or by changes in solvation. 
These rearrangements likely make some mutations of large residues challenging targets 
for MULES and other ∆∆G prediction methods; tyrosine residues have already been 
discussed as major contributors to the overall errors of the polar residue subset of 
MULES predictions in section 6.3.2.2. 
Similarly to the 1BRS mutations identified in the previous section, the ∆∆G of one large 
residue mutation was particularly poorly estimated by all computational methods 
investigated. The F25A mutation of the human growth hormone/receptor complex (PDB 
accession code 1A22) was incorrectly predicted as a warm- or hot-spot by all 
computational prediction methods (table 6.14). 
Table 6.14 – Comparison of predicted and experimental ∆∆G for the 1A22 F25A mutation. All 
values in kcal mol-1, residues numbered sequentially as per Amber internal numbering. 
Mutation Robetta PP MM-PBSAa PP MM-GBSAa MULESb Experimental 
F25A 1.30 4.72 8.35 1.46 ± 0.40 -0.40 
a PP = Post-processing. b Mean and 95% confidence interval of 10 independent MULES results 
calculated with optimal MULES protocol (MM-PBSA for non-polar residues). 
Experimentally the loss of the phenylalanine sidechain volume resulted in a mild 
increase in binding affinity. Examination of the surroundings of the F25 residue, on both 
sides of the receptor/ligand interface, revealed a number of polar and charged residues 
capable of forming multiple hydrogen bonds (figure 6.14). 
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Figure 6.14 – Neighbouring residues of the F25 phenylalanine residue (red) of the 1A22 human 
growth hormone/receptor complex (cyan). Residues numbered sequentially as per Amber 
internal numbering. Each label corresponds to the position of that residue’s Cα atom. Image 
created with UCSF Chimera.258 
The F25 residue appeared to be a bulky, hydrophobic, aromatic amino acid surrounded 
by a highly polar environment. It was therefore understandable that, experimentally, the 
mutation to the smaller, less hydrophobic alanine residue would be favourable. The lack 
of computational agreement with this suggested again that no computational technique 
had yet correctly captured the effects of the mutation. It was possible that the large loss 
of sidechain volume resulted in a change in solvation at the interface. 
Uniquely amongst the computational approaches investigated, MULES could substitute 
any atoms or molecules in the native copy to become any desired atoms or molecules in 
the mutant copy. This idea had been proven with the development of the charged 
mutation protocols including ionised solvent molecules, but was extended here to 
replace the majority of sidechain volume with neutral water molecules. The F25 residue 
was replaced by A25 and three TIP3P water molecules, as per figure 6.15. 
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Figure 6.15 – Replacement of F25 sidechain volume with water molecules. A) Initial minimised structure of 1A22 residue 25 (Phe) in native copy prior to MULES 
simulation. B) Initial minimised structure of 1A22 residue 25 (Ala + 3 Wat) in mutant copy prior to MULES simulation. 
 
  244 
Ten independent MULES simulations of the 1A22 F25A + 3 Wat mutation were then 
carried out using an identical protocol to the existing F25A mutation MULES 
simulations. Water molecules added in the native copy were weakly restrained in the 
cavity left by the Phe sidechain to avoid substitution with bulk solvent. Binding free 
energy results were calculated with one of two protocols - either treating the additional 
water standardly as bulk solvent and stripping out all three molecules prior to analysis, 
or treating all three molecules as part of the ligand (the mutated protein partner) during 
analysis. Results of both protocols are summarised in table 6.15. 
Table 6.15 – MM-PB/GBSA results of MULES 1A22 F25A + 3 Wat mutations. All values 
in kcal mol-1. 
Although the stripped protocol did improve the magnitude of the estimates slightly, the 
ligand side approach, which included the additional water molecules explicitly in free 
energy calculations, resulted in poorer agreement with experiment. This was likely due 
to the ‘solvent exposed’ nature of the additional water molecules when in the unbound 
state (hence causing inaccuracy by ‘solvating’ explicit water molecules in the ligand with 
implicit PB or GB solvation) rather than any genuine contribution of the water to 
binding. Nevertheless, even the stripped approach, which was the more appropriate 
here, did not correctly identify a mildly negative ∆∆G for F25A. 
It was possible that, rather than direct interactions with the opposite protein partner, 
the F25A mutation improved binding indirectly, similarly to the methods proposed for 
the 1BRS E71A and N56A mutations. A definitive cause of the favourable ∆∆G could not 
be determined without further MULES simulations and other investigations. At the very 
least however, MULES had clearly provided some evidence that the unusual F25A ∆∆G 
was not simply a case of a small, highly localised change in solvation on mutation. 
The case studies presented here do not by any means cover an exhaustive list of reasons 
why individual MULES predictions may have been incorrect, or why the validation of 
Protocol MM-PBSA ∆∆G MM-GBSA ∆∆G Experimental ∆∆G 
Stripped 1.14 ± 0.57 2.46 ± 0.62 -0.40 
Ligand side 4.64 ± 0.77 4.16 ± 0.34 -0.40 
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MULES on a wider set of PPI mutations did not replicate the same levels of accuracy and 
correlation to experiment as the initial investigations of the P2’ series of mutations, 
despite continuing to show improvement over post-processing. However, they do 
suggest that MULES might be better implemented to help explain why other methods 
fail, or to provide new insights into binding mechanisms rather than rapidly predict ∆∆G 
outright. 
This is why one of the key benefits of MULES is its ability to mutate residues to any 
desired structure, in particular to residues other than alanine. The final section of this 
study was designed to demonstrate the method’s potential in this regard. 
6.5 Mutations other than alanine 
6.5.1 The OppA complex 
The oligopeptide binding protein OppA is involved in the uptake of small peptides by E. 
coli bacteria. It binds to a range of substrates between 2 - 5 residues in length, enclosing 
them within a hydrated cavity buried in the protein interior.329, 330 The broad specificity 
and range of affinities shown by OppA for its peptide substrates has caused it to be the 
subject of a variety of structural and computational investigations of binding.330-334 
The small size of the oligopeptide substrates leads to a relatively small receptor-ligand 
interface in OppA, more akin to the tight cavity binding of a protein-small molecule 
interaction than the broad, flat surfaces traditionally found in PPIs. Despite this, the 
OppA-peptide interaction does have specific qualities that enhance its potential for 
investigation with MULES. Firstly, a detailed study by Wilkinson and coworkers has led 
to a wealth of structural and thermodynamic data for closely related substrates; X-ray 
crystal structures and binding affinity measurements exist for trimer peptide substrates 
of the sequence Lys-X-Lys, where X is any of the naturally occurring amino acids.335 
Secondly, these structural studies showed a highly structurally conserved binding 
pocket, with only limited structural differences in protein backbone and sidechain 
orientation on both sides of the interface. Instead, differences in binding affinity (which 
covered a range of up to ~200-fold change in Kd) were proposed to come predominantly 
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from differences in solvation inside the binding pocket. Crystal structures showed 
significant differences in the number and positioning of ordered and well-defined water 
molecules inside the binding cavity. This has led directly to the use of OppA as a 
benchmark for the development and evaluation of computational protocols predicting 
the location and effects of water molecules on binding.333, 334 
Detailed structural data for a series of related peptides, thermodynamic binding data for 
each mutation made and the possibility of investigating known differences in solvation 
led to the choice of OppA as a platform for investigating MULES mutations to residues 
other than alanine. The mutations chosen, their simulation and their results are 
explored in the following section. 
6.5.2 Mutations under investigation 
Although the majority of MULES simulations performed so far had involved the 
mutation of a native residue to alanine, the concept of non-alanine mutations had 
already been proven during the initial MULES studies of the 1SMF P2’Ile residue. With 
OppA this concept was extended further to cover a sample of mutations that differed 
more greatly (either in structure or residue type) between native and mutant, and 
which covered a range of experimentally measured ∆∆G. 
All mutations were performed at the ‘X’ position of the tripeptide OppA ligand Lys-X-Lys 
in the OppA complex. In total, five mutations were performed, covering all initial residue 
types: acidic, basic, polar and non-polar. Table 6.16 shows all five mutations, the PDB 
accession codes of their native structure (used for generation of MULES 
parameter/coordinate files), their mutant structure (used for comparison/information 
only) and their experimentally measured ∆∆G.335 Figure 6.16 compares the initial crystal 
structures of all mutant pairs. 
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Table 6.16 – OppA mutations investigated with MULES. All values in kcal mol-1. 
Native PDB Native residue Mutant residue Mutant PDB Experimental ∆∆G 
1JEU Glu Asp 1B4Z 2.19 
1B5J Gln Asn 1B5I 0.53 
1B58 Tyr Phe 1B40 -0.95 
1QKA Arg Lys 2OLB 0.52 
1JEV Trp His 1B3F 0.00 
 
Figure 6.16 – Comparison of initial crystal structures for OppA mutations studied with MULES 
(see table 6.16 for PDB accession codes). In each case only a selection of key interacting residues 
in the binding cavity are shown in the licorice representation, with crystallographically resolved 
water molecules shown as points. Only residue 2 of the ligand is shown. Native complex structure 
shown in blue, mutant in magenta. A) E2D mutation. B) Q2N mutation. C) Y2F mutation. D) R2K 
mutation. E) W2H mutation. Images created with UCSF Chimera.258 
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∆∆G for mutations were spread between being moderately favourable (Y2F), neutral 
(W2H), moderately unfavourable (Q2N, R2K) or highly unfavourable (E2D). Changes in 
residue type (Y2F, W2H) may also have invoked changes in the interactions of water 
molecules inside the pocket, hence it was of particular interest to determine whether 
MULES could correctly recreate ∆∆G for these mutations. The MULES protocol used to 
perform the OppA mutations is explained below. 
6.5.3 Methods 
Full computational methods are available in section 8.4.3, but are summarised here for 
clarification of the results of the following sections. Each of the mutations identified in 
table 6.16 underwent MULES simulations with one of two protocols. Firstly, simulations 
were performed with MULES regions that included all receptor and ligand residues 
within 5 Å radius of the mutated residue, as well as all residues identified by Wilkinson 
and coworkers as lining the binding pocket335 if they were not otherwise included (E32, 
Y274, H405, G415, T438). Ten independent simulations of each mutation were 
performed using an identical protocol to that of the MULES validation process, with 1 ns 
structural equilibration time and 1 ns of production MD. MM-PB/GBSA calculations 
were performed on snapshots extracted at 10 ps intervals from the production MD 
simulations. 
Secondly, simulations were performed with MULES regions including identical protein 
residues, but also all water molecules inside the binding pocket within 5 Å radius of the 
mutation site. This varied between 4 and 7 individual copied water molecules 
depending on the mutation under investigation. Water molecules in the MULES region 
were weakly restrained inside the binding pocket during simulation. Ten independent 
simulations of each mutation were again carried out, and separate free energy 
calculations performed both including and excluding the explicitly copied water 
molecules during MM-PB/GBSA. 
For both protocols, no neutralisation strategy was required for the mutation of charged 
residues as the overall charge of the system did not change on mutation of Glu to Asp or 
Arg to Lys and was hence maintained throughout. Additionally the histidine residue of 
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the W2H mutation was simulated separately in its delta (Hid) and epsilon (Hie) neutral 
protonation states and ∆∆G generated for both potential mutants. 
6.5.4 ∆∆G estimate results 
6.5.4.1 MULES region excluding solvent 
For an explicitly solvated MULES simulation both copies are solvated identically if no 
water molecules are included in the copied region. The OppA series of mutations were 
hypothesised to have differences in affinity mainly dependent on differences in 
solvation between mutants, but if MULES could correctly recreate ∆∆G while treating 
the solvation of native and mutant structures identically, then this would suggest that 
other factors, possibly subtle structural changes of the receptor and ligand, were more 
important. 
Mean ∆∆G and associated 95% confidence intervals from the ten independent 
simulations of each mutation are summarised in table 6.17 and compared with their 
experimentally measured values. 
Table 6.17 – MULES predicted ∆∆G for OppA mutations, not including water in MULES regions. 
All values in kcal mol-1. 
MULES results not including water molecules inside the copied region were of mixed 
success. Two mutations, E2D and Y2F, showed excellent agreement with experiment. 
The exact accuracy of some of these agreements was perhaps slightly fortuitous, given 
the magnitude of uncertainties in each of the mean results, but agreement trends were 
also very good - E2D was successfully identified as a highly unfavourable mutation and 
Y2F identified as moderately favourable. 
The effects of other mutations were greatly overestimated however. R2K and Q2N were 
both identified as greatly unfavourable mutations, and while there was a clear 
Mutation MM-PBSA ∆∆G MM-GBSA ∆∆G Experimental ∆∆G 
E2D 2.19 ± 1.18 1.32 ± 0.93 2.19 
Q2N 2.96 ± 0.75 2.86 ± 0.62 0.53 
Y2F -1.05 ± 0.57 -0.17 ± 0.39 -0.95 
R2K 5.11 ± 1.11 4.39 ± 0.78 0.52 
W2Hid 4.03 ± 1.02 6.41 ± 0.60 0.00 
W2Hie 3.00 ± 0.80 4.30 ± 0.48 0.00 
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difference between predictions for the epsilon-protonated Hie and delta-protonated Hid 
mutant, neither was correctly identified to be a neutral mutation. 
It was possible that hydration in the binding pocket played a greater role in the binding 
of some residues, such as R, K, W, H, Q or N, than of others. To investigate whether this 
was the case, MULES simulations of each mutation were repeated including specific 
water molecules in the MULES region, as described above in section 6.5.3. 
6.5.4.2 MULES region including solvent 
Copying water molecules as part of the MULES region should, in principle, have allowed 
the solvation of the native and mutant copies to differ slightly, just as their protein 
structures were allowed to differ. However, as discussed during the investigations of 
MULES with implicit solvation (section 5.4.2), copying of more than a few specific 
solvent molecules would have been intractable from the perspective of maintaining 
computational efficiency. Therefore only water molecules inside the binding cavity and 
within 5 Å radius of the mutated residue were included as part of the MULES region for 
each mutation. 
Following simulation, binding free energy calculations for each investigated mutation 
were carried out in two ways; either including the copied water molecules as part of the 
receptor during MM-PB/GBSA (but removing uncopied bulk solvent and counterions as 
normal), or stripping all water molecules from the trajectory prior to free energy 
analysis as is standard with MM-PB/GBSA. Mean ∆∆G results and associated 95% 
confidence intervals for all mutations are shown below in table 6.18. 
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Table 6.18 - MULES predicted ∆∆G for OppA mutations, including water in MULES regions. All values in kcal mol-1. MM-PB/GBSA calculations carried out either 
including copied water molecules as part of the receptor, or after stripping of all solvent from the native and mutant trajectories. 
 MM-PBSA ∆∆G MM-GBSA ∆∆G  
Mutation Including solvent Stripped of solvent Including solvent Stripped of solvent Experimental ∆∆G 
E2D 5.17 ± 0.86 5.12 ± 1.45 3.43 ± 0.88 3.47 ± 0.90 2.19 
Q2N 4.13 ± 1.10 3.54 ± 1.08 4.99 ± 0.67 4.19 ± 0.56 0.53 
Y2F -0.53 ± 0.57 -0.88 ± 0.75 0.30 ± 0.68 0.90 ± 0.61 -0.95 
R2K 4.70 ± 1.35 2.51 ± 1.47 4.38 ± 1.16 3.42 ± 0.99 0.52 
W2Hid 4.38 ± 1.38 4.48 ± 1.13 5.23 ± 0.73 6.06 ± 0.56 0.00 
W2Hie 5.83 ± 1.45 4.05 ± 1.29 5.05 ± 1.02 5.40 ± 0.86 0.00 
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Surprisingly, including specific water molecules inside the MULES region did not 
improve the predictive power of MULES. For the majority of mutations, inclusion of 
water molecules in the MULES region had an adverse effect on ∆∆G estimates whether 
or not these molecules were included in free energy calculations. The effect of the E2D 
mutation was now overestimated whereas it had previously (table 6.17) been predicted 
correctly, the Q2N mutation ∆∆G was similarly overestimated, and the W2Hid/Hie 
mutations now showed similar ∆∆G whereas the Hie mutant had previously been 
calculated as the more favourable of the two. 
The ∆∆G for the Y2F mutation continued to be correctly estimated, but only with 
MM-PBSA rather than MM-GBSA. Only the R2K mutation showed some improvement in 
the agreement of predicted and experimental values, but was nevertheless still falsely 
predicted to be a highly unfavourable mutation. 
Comparison of the initial crystal structures of each of the mutations (figure 6.16) 
revealed very few structural differences between any of the investigated native and 
mutant pairs, even in the placement of interacting water molecules inside the binding 
pocket. Only the W2H mutation (figure 6.17) showed a significant difference in solvation 
on mutation. Two additional water molecules were present in the mutant His structure, 
partially replacing the lost sidechain volume of the tryptophan. 
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Figure 6.17 – Comparison of crystal structures of tryptophan (blue) and histidine (magenta) 
OppA complexes. Only residue 2 of the ligand is shown. Two additional water molecules (circled) 
are present in the histidine structure that are not seen in the tryptophan complex. 
This clear difference in solvation may have affected the binding and of the mutant 
histidine and/or its preference for a particular protonation state. To investigate whether 
this was the case, further MULES simulations were performed in which the native 
tryptophan sidechain was mutated to either a delta-protonated Hid or 
epsilon-protonated Hie, and two additional TIP3P water molecules to replace the Trp 
sidechain volume. All other water molecules within 5 Å of the mutated residue were also 
included in the MULES region and copied. MM-PB/GBSA calculations were again 
performed either including or excluding copied water molecules from the free energy 
analysis. Results are shown in table 6.19. For reference, the experimentally determined 
∆∆G was 0.00 kcal mol-1. 
Table 6.19 - MULES predicted ∆∆G for W2H mutations, including two additional waters in the 
mutant copy. All values in kcal mol-1. MM-PB/GBSA calculations carried out either including 
copied water molecules as part of the receptor, or after stripping of all solvent from the native 
and mutant trajectories. 
 MM-PBSA ∆∆G MM-GBSA ∆∆G 
Mutation Including solvent Stripped Including solvent Stripped 
W2Hid 5.90 ± 1.41 7.64 ± 2.17 9.60 ± 0.90 9.15 ± 1.06 
W2Hie 4.13 ± 1.24 4.19 ± 1.09 7.76 ± 0.70 6.58 ± 0.63 
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Including additional water molecules in the histidine copy to replace the lost tryptophan 
sidechain volume did not allow the mutation ∆∆G to be accurately predicted and in fact 
worsened agreement with experiment overall. Nevertheless, the W2Hie mutation was 
again calculated to be slightly less unfavourable than the W2Hid, suggesting that the 
epsilon-protonated state would be the more likely of the two. From the structural 
comparison of figure 6.17, the Hie mutant would be more capable of forming favourable 
hydrogen bonding interactions with both Thr438 and the additional water molecules in 
the pocket than its Hid counterpart, depending on the exact Hie rotamer conformation. 
Despite the inaccuracy of the predicted ∆∆G to experiment, MULES did identify trends in 
protonation state that seemed intuitively reasonable from the native and mutant 
structures. As with the case studies from the MULES validation dataset discussed in 
section 6.4, this suggested that the MM-PB/GBSA methodology itself may have been the 
cause of the poor estimations, rather than the MULES protocol for generating native and 
mutant trajectories. 
6.5.5 Summary 
The OppA series of mutations have clearly shown the potential for MULES to be 
transferred to mutations other than alanine. Moreover, they have provided access to 
mutations that would not have been possible with existing computational methods. 
Although the latest versions of RosettaDesign do allow point mutations to any of the 
naturally occurring amino acids,72, 336 it may be difficult to extract experimentally 
relevant binding free energy information from the multiple potential conformations 
they provide. Additionally, Rosetta or other techniques are unable to recreate the 
changes in mutant copy solvation that have been investigated here with MULES. 
The OppA studies have again highlighted the difficulty in obtaining quantitative ∆∆G 
estimates, required for any broadly useful protein design method, without being able to 
adequately represent all the effects of mutation, whether structural, solvation-based, or 
otherwise. The fact that MULES successfully predicted ∆∆G for the E2D and Y2F 
mutations, but not for the Q2N, R2K or W2H, suggested potentially different 
contributions and mechanisms of binding for the different mutations, although clearly 
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further computational and experimental studies would be required to confirm this. 
Relative entropic contributions between native and mutant complexes, for example, 
were not evaluated for any of the mutations performed here and may have improved the 
accuracy of individual predictions. 
The results of the MULES validation and the OppA mutations presented here have 
implied that MULES may be more effective when invoked as a tool for investigating the 
mechanisms and modes of binding for specific residues or ligands, rather than as a 
method for rapidly screening large protein interfaces for hot-spots of binding free 
energy. The requirement of dynamics in a MULES simulation means that it can simply 
not be rapid enough to compete with other single structure ∆∆G prediction methods, or 
perhaps even post-processing. However, the diversity of mutations possible with MULES 
can result in detailed rationalisations of observed results. The investigations of the 
OppA mutations here, particularly the E2D, Y2F and W2Hid/Hie simulations, and the 
case studies from the MULES validation dataset presented in the previous section, go 
some way to demonstrating the potential of MULES in this area. 
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7 Summary and outlook 
7.1 Free energy calculations 
7.1.1 Uses of MM-PB/GBSA 
Understanding of the mechanism and rationale of a protein-protein binding process 
often requires details of the underlying free energy change and the contributions of 
individual residues to binding. MM-PBSA and –GBSA are popular endpoint free energy 
calculation methods used for the calculation of either absolute or relative binding free 
energies for protein-protein complexes. As discussed in chapter 2, they have been 
widely used in the investigation of PPIs, both for the evaluation of biological 
mechanisms and for drug discovery purposes. 
The accuracy of any MM-PB/GBSA free energy estimate to its experimental counterpart 
is dependent upon two main factors. Firstly, the methodology itself relies on an 
approximation that the free energy change of the binding process can be accurately 
calculated from the endpoints of that process (namely the bound and unbound states) 
and does not require the evaluation of the full binding pathway. The validity of this 
assumption may vary for different complexes. Secondly, the underlying MD 
simulation(s) should accurately represent the correct thermodynamic equilibrium 
states of the bound and unbound partners. This is where problems with conformational 
sampling, representation of protonation states, structural equilibration of the 
biomolecules or choice of a suitable MM force field may arise. 
The latter source of error is the one that this study has attempted to tackle. In particular, 
it has focussed on the estimation of relative binding free energies, differences between 
the ∆G of native and mutant complexes, whose accuracy often relies on the cancellation 
of errors between the independent calculations for native and mutant complexes. 
Relative free energy calculations have been widely used in the performance of 
computational alanine scanning mutagenesis, identifying hot-spots at protein-protein 
interfaces. This was therefore chosen as the first area of study. 
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7.1.2 Computational alanine scanning mutagenesis 
This study initially sought to test the ability of two simulation methods, full MD and 
post-processing, to perform computational alanine scanning mutagenesis at 
protein-protein interfaces (chapter 2). Using a prototypical PPI between trypsin and a 
synthetic peptide loop of the Mung Bean Trypsin Inhibitor, computational predictions 
were validated against experimentally measured ∆∆G for a set of five alanine mutations. 
Although the accuracy of alanine scanning methods has been assessed before on other 
systems, this, to our knowledge, was the first study that made use of multiple 
independent trajectories to investigate the statistical relevance of results. 
Both methods successfully recreated the ordering of mutant ∆∆G and showed 
impressive correlation with experimental measurements. However, the additional MD 
simulation required in the full MD method resulted in a large increase in computational 
expense over post-processing. Although the size of this increase will reduce with 
improvements in hardware and GPU-accelerated simulation, full MD will remain a 
costlier method due to the additional simulation involved. 
In addition, the range of individual ∆∆G calculated with the full MD approach varied far 
more than that of post-processing, primarily due to varying structural changes seen 
between native and mutant trajectories. Using the rotation of the P2’Ile sidechain as an 
example, differential sampling between trajectories was shown to have a large impact 
on accuracy for full MD, but little for post-processing, where native and mutant 
trajectories stem from the same simulation. The issue with full MD, then, was in 
determining how many simulations of what length were required before results could 
be deemed reliable. 
These results pointed to post-processing as the more attractive choice for a rapid and 
reproducible evaluation of an interface. The approximation that almost all protein 
dynamics remain constant on mutation, and the cancellation of errors this provides, is 
the reason behind the impressive precision and speed of post-processing. However, 
neglecting structural rearrangement and entropic contributions to binding will give 
inaccurate results for some systems, and which systems these are may be difficult to 
  258 
predict. Post-processing is also limited to making mutations to smaller residues - a 
disadvantage compared to the extensive mutational capability of full MD, which can 
adapt the interface through simulation to avoid structural clashes. 
7.1.3 Necessity for novel methodologies 
Neither of the existing methods evaluated here was ideal as a PPI probe therefore, 
although both had their individual advantages. The difference between the two methods 
lay in the treatment of the underlying MD trajectories of the native and mutant 
structures. The development of a technique that combined the speed and cancellation of 
errors of post-processing with structural flexibility at the interface and mutation to any 
desired residue would provide a useful tool with potential for hot-spot analysis and 
protein design. This was the concept behind the development of the MULES approach. 
MULES adapts the Locally Enhanced Sampling technique to include heterogeneous 
copies of a defined region of a simulation. During an MD trajectory, the local structure 
and dynamics of these copies is allowed to diverge, whilst there is only one set of 
dynamics for all atoms outside the central copied region. This in turn allows the local 
structural and dynamical effects of a mutation to be accommodated whilst cancelling 
errors due to changes distal from the interface. To the best of our knowledge, no similar 
heterogeneous LES approach had been attempted prior to the development of MULES 
presented here. 
7.2 Potential of the MULES technique 
7.2.1 Improved correlations with experimental ∆∆G 
As an entirely novel method, MULES required a degree of initial testing and proof of its 
concept prior to any widespread validation. The predictive power of MULES was 
therefore tested using a series of mutations of the prototypical trypsin/MBTI PPI of PDB 
entry 1SMF. Relative binding free energies for these mutations were experimentally 
determined and compared to computational predictions. MULES greatly improved the 
accuracy of predictions at a prototype PPI interface when compared to the existing 
post-processing approach, whilst still maintaining a high degree of precision, 
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reproducibility and robustness of results to changes in dynamics between independent 
simulations. Mean unsigned errors to experiment with MULES were as low as 
0.25 kcal mol-1, indicating impressive near-quantitative accuracy for the new approach. 
This improved accuracy was proposed to be a direct result of the structural flexibility 
allowed by MULES between native and mutant trajectories. By incorporating limited 
structural rearrangement, the unfavourable, high-energy conformations that may be 
generated by the simple deletion of atoms in post-processing are not visited by the 
MULES run. In principle therefore, similar improvement in accuracy would be seen for 
any mutation performed with MULES. 
A far broader validation of the MULES technique, consisting of a total of 57 individual 
mutations across six complexes, resulted in a more complex picture of the potential of 
MULES for alanine scanning and hot-spot prediction purposes. Overall, MULES 
continued to estimate ∆∆G with improved accuracy and correlation to experiment over 
the equivalent estimates performed with post-processing. Nevertheless, there were 
significant differences in accuracy of predictions between subsets of residues divided by 
type – MULES performed particularly well for non-polar residue mutations, but more 
poorly for polar residues, for example. 
It was also noted that MULES could only generate ∆∆G predictions of similar correlation 
to experiment as the popular Robetta online alanine scanning server. MULES 
predictions also included some large overestimations of ∆∆G, resulting in larger mean 
unsigned errors to experiment than Robetta. Given Robetta’s empirically weighted 
energy function and requirement for only a single set of structural coordinates makes it 
several orders of magnitude faster than MULES, it or a similar online technique would 
seem to be a more suitable choice for any widespread analysis of a large number of 
mutations. The strength of MULES instead lies in its versatility. 
7.2.2 Versatility of MULES methodology 
MULES is a far more versatile technique than either post-processing, Robetta and its 
parent Rosetta suite, or many other computational site directed mutagenesis tools. 
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Allowing structural variation means that MULES in principle may be used to investigate 
any desired mutation. This includes changes in solvation, protonation state or other 
experiments that may only currently be performed with time consuming pathway free 
energy methods. 
Additionally, as a molecular dynamics-based technique, the parameters of MULES 
simulations can be entirely flexible between systems; if more structural co-ordinates are 
required for free energy analysis, the complex may be simulated for longer; if more 
flexibility is required between native and mutant copies, the MULES region size may be 
increased, or the system simulated with implicit rather than explicit solvent, and so on. 
This can be seen as either an advantage or disadvantage of MULES depending on the 
objective of the investigation being undertaken. 
Both of these facets of MULES versatility were put to use in the evaluation of why 
MULES falsely estimated ∆∆G for defined case studies, discussed in section 6.4. Changes 
in the MULES methodology to solvate the complex implicitly during the simulation were 
used to investigate the effects of increasing structural differences between native and 
mutant copies for certain mutations of the 1BRS barnase/barstar complex. In a 
complementary fashion, the MULES region was extended to investigate the effects of 
proposed changes in explicit solvation for a mutation of the 1A22 human growth 
hormone/receptor interface. 
Both of these investigations suggested that MULES may be more effectively used to 
perform mutations that other methods cannot, without the need for extensive 
alchemical free energy calculations. MULES may be better focussed on rationalising the 
mechanisms of binding or designing improvements to specific residues whose 
contribution to binding is already known. Continuing the use of MULES for mutations 
inaccessible to other techniques, mutations to residues other than alanine were also 
investigated for an example system - the oligopeptide binding protein OppA bound to 
Lys-X-Lys tripeptides. 
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7.2.3 Mutations other than to alanine 
As the final part of MULES development (section 6.5) MULES simulations were 
performed for a small series of five mutations of OppA/Lys-X-Lys complexes. Agreement 
of ∆∆G estimates with experiment varied, from achieving quantitative accuracy for some 
mutations to vastly overestimating the effects of others. This was despite the 
experimentally determined binding modes being very similar for each of the peptide 
ligands. Experimentally, differences in binding were proposed to be the result of 
differences in solvation of the binding pocket, rather than any structural differences in 
the surrounding protein regions. 
However, because MULES allows any residues to be incorporated inside the copied 
MULES region, these processes could also be investigated, providing information on the 
modes and mechanisms of binding that could not be evaluated with other techniques. In 
this case, allowing changes in solvation did not improve the accuracy of the previously 
incorrectly predicted ∆∆G, suggesting an alternative mechanism of binding for the 
subset of incorrectly predicted mutations. Further computational modelling would be 
required to verify this beyond doubt. However, the OppA mutations and the case studies 
from the MULES validation dataset have both demonstrated the potential of MULES for 
investigating and rationalising the effects of mutations in much greater detail than is 
possible with alternative methods. Notwithstanding the demonstration of its potential, 
MULES remains in its initial stages of development and is still subject to limitations in its 
more widespread use and in its possible accuracy. 
7.3 Limitations 
7.3.1 Accuracy of MM-PB/GBSA 
MULES, at its heart, is simply a way of generating a series of structural snapshots for 
free energy calculations, and so the accuracy of its predictions is inherently linked to the 
accuracy of the ∆G calculation method used - in this case MM-PB/GBSA. As discussed in 
chapter 2, the assumptions on which MM-PB/GBSA are based may be invalid in some 
cases, and the techniques are also subject to some known inaccuracies, such as the 
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overestimation of the effects of electrostatic contributions to binding for charged 
residues. 
Some errors in MULES predictions may therefore have been caused by errors in 
MM-PB/GBSA calculations themselves. The comparison of MULES results with 
post-processing, which uses identical MM-PB/GBSA free energy calculations, goes some 
way to accounting for this, but it remains difficult to extract the magnitude of error 
thanks to MULES methodology and magnitude due to MM-PB/GBSA independently. 
In some cases, the high precision and robustness of MULES predictions to changes in 
methodology (such as in the final investigations of OppA mutations) lend high levels of 
confidence to the MULES predictions themselves and suggest either an underlying 
problem in the representation of the mutation as a whole, or in the free energy 
calculation method. What is clear in every case, however, is the requirement for careful 
choice of MM-PB/GBSA parameters in order to be consistent with other, similar free 
energy studies and avoid the introduction of any unnecessary unforeseen errors. Where 
possible, this should be combined with assessments of the robustness of the MULES ∆∆G 
estimates simply to provide further confidence in predictions. 
7.3.2 Predetermining a successful protocol 
The MULES protocol used in chapter 6 to evaluate the large dataset of alanine mutations 
required the optimisation of numerous MULES parameters, as described in chapter 5. 
Generating MULES estimates of ∆∆G that are both accurate, reproducible and 
computationally efficient is a challenging prospect for future studies, as there is no 
guarantee that the MD run length, structural equilibration time, MULES region size or 
mutation protocols developed and used here will be the most appropriate for other 
studies. 
Being able to predetermine suitable parameters for a MULES study would eliminate the 
necessity of the extensive parameter validation of chapter 5 for every desired mutation. 
The computational cost such a validation would require again suggests that MULES 
studies would be better targeted to rationalising the effects of mutations that other 
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approaches cannot model, rather than use as a large-scale screening tool. However, the 
extensive dataset of mutations investigated here may also provide a starting point for 
the assessment and development of protocols more suitable for specific systems or 
residues. 
Although the MULES validation protocol developed in chapter 6 did generate reliable 
∆∆G for the majority of mutations, some statistical outliers remained. By determining 
whether these outliers, or other over- or underestimated ∆∆G values, have any common 
properties, specific and tailored MULES protocols that were suited to mutations of 
residues or interfaces with particular physical properties could begin to be developed. 
These physical properties may include, but would not necessarily be limited to, 
sidechain volume, sidechain polarity, relative solvent accessibility, number of hydrogen 
bond donors/acceptors, overall charge and sidechain pKa. 
Each residue could first be evaluated for each of these metrics. Performing multiple 
linear regressions to fit calculated ∆∆G to experimental, taking these metrics into 
account, would then provide an indication of which properties had large contributions 
to changes in predicted binding free energies. However, it is possible that a larger 
dataset than the 57 mutations investigated here would be required to observe 
statistically significant trends and correlations in the resulting contributions of 
individual properties, hence this should be viewed as potential for further work 
following further MULES validation. 
7.3.3 Manual parameter manipulation 
MULES is an adaptation of the existing LES methodology and requires the adaptation of 
LES parameter files in order to perform simulations. This study has performed this 
parameter file manipulation manually, according to the procedure outlined in section 
4.4.2.2. This manual process clearly has potential for the introduction of error during 
the file creation process. Although the rigorous comparison of structural and energetic 
properties before and after file manipulations is designed to eliminate any of these 
errors before simulations, the file creation and verification process is still a time 
consuming endeavour. 
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Ideally, MULES parameter file generation should be automated as an addition to the 
Addles module of Amber. This would allow full integration with the existing Amber suite 
and provide flexibility for the future modification and updating of MULES in accordance 
with that of Addles and Amber. However, any future automated MULES procedure 
should take care to preserve the flexibility of the technique in terms of the mutations 
possible. One of the key assets of MULES is its ability to perform a diverse set of 
mutations, restricted only by the use of a suitable MD force field for the desired 
biomolecule or (potentially) small molecule ligand. 
7.4 Outlook 
The development and validation of MULES has shown that it can successfully improve 
the correlation and accuracy to experiment of MM-PB/GBSA relative binding free energy 
estimates, over and above those of the alternative MD-based post-processing approach. 
MULES exists in a niche of versatility, between the inflexible (both in terms of almost 
identical native/mutant protein structures and lack of diversity of potential mutations) 
post-processing technique, and the flexible (in terms of completely independent 
native/mutant protein structures and unbounded range of mutations) full MD technique 
for generating MD trajectories of native and mutant protein complexes. Its range of 
potential mutations also places MULES at distinct advantage over other, rapid, single 
structure mutagenesis techniques. 
In principle, any mutation within a protein structure can be performed and analysed 
with MULES and this has been demonstrated here through the mutation of over 60 
residues across 7 complexes to natural and non-natural amino acids. MULES has also 
allowed the investigation of changes in solvation and residue protonation 
state - mutations that would not otherwise be possible without the use of costly 
alchemical free energy calculations or large numbers of independent MD simulations to 
ensure precision in a full MD + MM-PB/GBSA approach. In this way, MULES would be 
best suited to assessing and rationalising the structural, dynamical and energetic effects 
of any mutation in more reproducible way than existing approximate endpoint free 
energy methods, and faster than existing alchemical methods. 
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However, it should be recognised that MULES is not yet fully ready for widespread 
implementation across research areas, and further work is necessary to validate its 
effects more extensively and increase its ease of use. This work falls into three main 
categories:  
 Continuing MULES validation across further natural and non-natural mutations, 
enlarging the dataset of successful and unsuccessful MULES ∆∆G estimates. 
These estimates should be compared both to experimentally determined ∆∆G 
and, wherever possible, computational ∆∆G predicted with alternative methods, 
either approximate (post-processing, Rosetta, LIE) or exact (FEP, TI) depending 
on the mutation under investigation. For a specific ∆∆G prediction method to be 
useful it should not only agree well with experiment, but do so more accurately, 
more precisely or more quickly than its direct competitors. 
 Analysing MULES validation datasets to identify trends in the agreement or 
disagreement of ∆∆G estimates with experiment. Errors in MULES results have 
already been shown to be lowest for mutations of non-polar residues. The 
identification of further trends, related to residue or interface properties, could 
help in the development of unique MULES protocols for unique residue types. 
This would, in theory, improve the reliability and accuracy of MULES across 
large and varied mutational datasets. 
 Automating the MULES input file production process. Manual file preparation is 
too lengthy and potentially error-prone for any widespread implementation of 
MULES by other researchers. Automation of the process in conjunction with the 
Addles module of Amber would provide a far more convenient method for future 
validation work. However, MULES may also require integration with other 
Amber modules, particularly Leap (for non-LES parameter file generation), in 
order to successfully add parameters for any possible mutation. Maintaining 
diversity in possible mutations is a crucial part of the development of any 
automated MULES strategy. 
  266 
Of these proposed future developments, the latter, automating the parameter file 
production process, is the most pressing and should be attempted first. By making 
MULES easily accessible for use by other researchers and for other purposes, the 
efficiency of its validation would be greatly enhanced. MULES has clearly shown 
potential for widespread use in the rationalisation of binding mechanisms and the 
performance of previously inaccessible mutations, but eventually, the key test of the 
technique will be in its use on novel systems and in answering novel biomedical 
questions. This study has begun to progress MULES down this path, but should now be 
seen as a springboard to allow others to additionally work towards this aim. 
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8 Methods 
8.1 Comparing computational alanine scanning 
techniques 
8.1.1 MD simulations 
All simulation methods and metadata described in the following sections are reported in 
accordance with published standards and recommendations,337 designed to simplify the 
understanding, assessment and reproduction of these results by external researchers as 
much as possible. 
The full MD method required a set of ten independent simulations for the native 
trypsin/MBTI complex and each of its desired mutants. All MD simulations presented in 
this section were performed using the PMEMD module of the Amber 10 suite of 
software262 and the Amber ff99SB force field.163 Initial complex coordinates were taken 
(in the case of the native structure) or modified (in the case of the alanine mutants) from 
RCSB PDB entry 1SMF.256 Initial structures of alanine mutants were created by simple 
deletion of the appropriate sidechain down to the Cβ atom, followed by automated 
placement of the appropriate hydrogen atoms by the Leap module of Amber. 
Crystallographic water molecules present in the crystal structure were kept and a 
calcium ion present was modelled as a +2 charged ion. Acidic (Asp, Glu) and basic (Lys, 
Arg) residues were modelled with charged sidechain protonation states unless 
otherwise stated. Histidine residues were modelled with neutral sidechains, singly 
protonated at the delta position (i.e. ‘Hid’ residue type) unless otherwise stated. Prior to 
simulation, initial structures were charged neutralised with an appropriate number of 
Cl- ions, parameterised with the chloride parameters of Smith and Dang338 as standard in 
the Amber ff99SB force field. A sufficient number of pre-equilibrated TIP3P water 
molecules130 were then added to create a truncated octahedron in which no solute atom 
was closer than 8 Å from the edge of the box. A total of 5531 water molecules were 
added for the native complex using the Leap module of Amber. Periodic boundary 
conditions were imposed and a cutoff of 8 Å used for the explicit calculation of 
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non-bonded interactions, beyond which the PME method was used to treat long range 
interactions.131 
Following solvation, all complexes were energy-minimised in two stages. Initially, 
solvent molecules and chloride counterions were relaxed with 500 steps of steepest 
descent and 500 steps of conjugate gradient minimisation. Solute atoms were restrained 
with 500 kcal mol-1 Å-1 restraints during this minimisation. Following this, restraints 
were removed and the entire system re-minimised with 1000 steps of steepest descent 
and 1500 steps of conjugate gradient minimisation. Energy minimisations were only 
performed once for each complex – the final coordinates of each were then used as 
starting structures for each set of ten independent simulations. 
After structure preparations, MD simulations were performed for each complex using 
the following strategy. Each system was first heated from 0 to 300 K over a time period 
of 50 ps and in the NVT ensemble. This was followed by a further 50 ps of pressure 
equilibration at 1.0 bar in the NPT ensemble, and then by 10 ns of further production 
MD simulation in the NPT ensemble. Structural snapshots were saved at 10 ps intervals 
from production MD simulations, giving a total of 1000 frames in each trajectory. In 
each case a Langevin thermostat339-341 was used to maintain temperature, with a 
collision frequency of 1.0 ps-1, and pressure maintained using a Berendsen weak 
coupling algorithm342, with pressure relaxation time of 2.0 ps. All simulations used a 
timestep of 2 fs, enabled by the use of the SHAKE algorithm343 constraining the bond 
lengths of bonds containing hydrogen atoms. Trajectory independence was achieved 
with the use of a different random number generator seed for the Langevin thermostat 
of each run.263 
8.1.2 Free energy calculations 
The full MD and post-processing approaches followed different methodology for 
generating trajectories of alanine mutant complexes, but both used an identical 
approach for calculating binding free energies. All free energy calculations were 
performed with the mm_pbsa perl scripts in Amber 10. All 1000 frames of each 
trajectory were used in analyses, except during the evaluations of trajectory 
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equilibration, in which only the final 800 snapshots (i.e. 8 ns of simulation) were used as 
stated in sections 3.2.3 and 3.3.2. 
Prior to analysis, each snapshot was stripped of all water molecules and ions. MM 
contributions to ∆G were calculated with a dielectric constant of 1.0 and a non-bonded 
interaction cutoff of 999 Å. GB solvation energies were calculated with an internal 
dielectric constant of 1.0 and an external constant of 80.0. PB solvation energies were 
calculated using the pbsa module of Amber, with a grid spacing of 0.5 Å, internal 
dielectric of 1.0, external dielectric of 80.0 and a solvent radius of 1.4 Å. Non-polar 
contributions to free energy were calculated as              , with γ set to 
0.0072 kcal mol-1 Å-2 and SASA as the Connolly surface calculated with the Molsurf 
program, with a solvent probe radius of 1.4 Å and Bondi atomic radii.145, 344, 345For the 
full MD protocol, 10 ∆G from the native complex trajectories were compared with 10 ∆G 
from the trajectories of each mutant, giving a total of 100 ∆∆G for each mutant and 
solvation method used in free energy calculations. The post-processing protocol used 
the 10 runs of the native structure to generate trajectories of the mutants, giving 10 
individual ∆∆G for each mutation and solvation method. 
8.1.3 Computational hardware 
All MD simulations were performed with the PMEMD module of Amber 10. Simulations 
were performed in parallel across 8 Intel Xeon E5462 CPU cores at 2.80 GHz, whilst 
MM-PB/GBSA calculations were performed in serial on Intel Xeon 5150 processors at 
2.66 GHz. 
8.2 Development of Mutational Locally Enhanced 
Sampling 
8.2.1 Peptide synthesis and inhibition assays 
Measurement of experimental ∆∆G for the series of MBTI mutants at the P2’ position 
required the synthesis, cyclisation, purification and biochemical assay of a series of 
related peptides. Automated solid-phase peptide synthesis (SPPS) was carried out as 
follows: 
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All general laboratory chemicals obtained from chemical suppliers (Novabiochem UK, 
Sigma Aldrich) were used without further purification. N--Fluorenylmethoxycarbonyl 
(N--Fmoc) protected amino acids were obtained from National Diagnostics UK with the 
following protecting groups: Cys(Trt), Thr(tBu), Lys(Boc), Ser(tBu), Glu(tBu). 
Peptides were synthesised using an Intavis Respep SL multiple peptide synthesiser 
(Intavis AG, Germany). Linear peptides were synthesised using standard 
Fmoc-protected solid-phase peptide synthesis: 20 µmol per well of preloaded 
Fmoc-Cys(Trt)-TentaGel™ S PHB resin (Rapp Polymere, Germany) was swelled in 
peptide synthesis grade dimethylformamide (DMF, National Diagnostics UK) for 60 min 
before coupling each cycle. The N--Fmoc protecting group was treated with 20% v/v 
piperidine in DMF for 15 min, and this was repeated two further times. Five equivalents 
of the incoming N--Fmoc-protected amino acid (100 µmol, 200 µL of 0.5 M solution in 
N-methyl pyrrolidone (NMP)) were used for each coupling. Coupling was carried out in 
a mixture of O-benzotriazole-N,N,N’,N’-tetramethyluroniumhexafluorophosphate 
(HBTU, 100 µmol, 200 µL, National Diagnostics UK) and diisopropylethylamine (DIPEA, 
100 µmol, 200 µL, National Diagnostics UK) as 0.5 M solutions in NMP. The resin was 
washed with DMF (3 x 1 ml) between each deprotection and coupling step. The cycle of 
deprotection, DMF wash, coupling and a further DMF wash was continued for each 
amino acid in the peptide sequence. The final N--Fmoc protecting group was removed 
at the end of the synthesis under the usual conditions. Resins were removed from the 
synthesiser, washed with DMF, dichloromethane, methanol and diethylether (3 x 3 ml 
each) and dried under vacuum. 
Synthesised peptides were then cleaved from the resin and deprotected using 3 mL of 
deprotection mixture (88% trifluoroacetic acid, 5% H2O, 5% w/v phenol, 2% 
triisopropylsilane). The mixture was shaken for 3 h at room temperature and then 
filtered. The resin was washed with a small amount of the deprotection mixture and 
washings and filtrate combined. Peptides were precipitated with cold 
tert-butylmethylether (TBME) and centrifuged at 4000 rpm (1431 g) for 15 min. The 
supernatant was discarded and the remaining peptide washed with a fresh aliquot of 
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TBME. This process was repeated three times to ensure the removal of all organic 
impurities. The crude linear peptides were dried overnight in a dessicator to yield white 
solids. 
Following synthesis, the linear peptides were cyclised via the formation of an 
intramolecular disulfide as follows. Prior to cyclisation, crude linear peptides were 
analysed and purified by preparative LC-MS using a Waters LC-MS system consisting of 
a Waters 2767 autosampler, a Waters 515 HPLC pump, an XBridge C18 column (4.6 x 
100 mm for analytical, 19 x 100 mm for preparative LC-MS), a Waters 3100 mass 
spectrometer with ESI and a Waters 2998 photodiode array. For both analytical and 
preparative HPLC, peptides were eluted over a gradient of 5 to 98% methanol in H2O 
over 15 min. All mobile phases contained 0.1% HPLC grade formic acid. For both 
analytical and preparative methods peptide bond absorption was measured at 223 nm. 
Following preparative LC-MS, fractions containing the desired linear peptide were 
combined and freeze dried on a Christ Alpha 2-4 Freeze Dryer (Osterode am Harz, 
Germany) and obtained as white solids. 
Cyclisation of the pure linear peptides was performed by oxidation and crosslinking of 
the two terminal cysteine residues with dimethylsulfoxide (DMSO)-mediated 
oxidation.279 Linear peptide was dissolved, at 5 mg ml-1 concentration, in an aqueous 
solution of 5% v/v DMSO, 5% v/v acetic acid (adjusted to pH 6.0 with ammonium 
bicarbonate) and shaken overnight at room temperature. Crude cyclised peptide was 
diluted to < 1% DMSO with deionised water, freeze dried and then analysed and purified 
via LC-MS using the same method as above. Yields and characterisation data for the pure 
peptides can be found in table 4.1. HPLC chromatograms are available in appendix 3, 
figures S1 to S6. All peptides were also identified by MALDI-TOF spectrometry following 
purification. 
Finally, competitive inhibition assays of the series of peptidic trypsin inhibitors were 
performed as follows. Bovine ß-trypsin (TPCK treated, Sigma UK) concentration was 
standardised by active site titration with p-nitrophenyl-p-guanidinobenzoate HCl prior 
to use in inhibition assays.280 Competitive binding assays were carried out using a 
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SpectraMax M2 microplate reader (Molecular Devices, Wokingham, UK) and Microfluor 
2 microtitration 96-well plates. Trypsin (12.5 nM, 50 µL) was incubated with serial 
dilutions of cyclic peptide in 50 µL buffer (50 mM Tris-HCl, 150 mM NaCl, 0.01% Triton 
X-100, 0.01% sodium azide, pH 7.6) for 40 min at 37˚C. Measurement was started with 
the addition of carbobenzoxy-L-arginine-7-amino-4-methylcoumarin (Z-Arg-AMC, 
75 µM, 100 µL). The initial rate of hydrolysis was monitored by the release of 
fluorescent AMC from the substrate at an excitation wavelength of 360 nm and emission 
of 460 nm. Assays were performed in triplicate. Initial rate data were fitted to determine 
IC50 using the GraFit software package.281  
8.2.2 MD simulations and free energy calculations 
8.2.2.1 Post-processing 
The calculations of ∆∆G with the post-processing method for comparison to MULES 
results used the 10 independent native trypsin/MBTI trajectories that had already been 
performed for the initial comparison of the post-processing and full MD methods in 
chapter 3. MD simulation and free energy calculation protocols can therefore be found 
in section 8.1. 
The mm_pbsa perl scripts in Amber do not have the capability of mutating residues to 
anything other than alanine or glycine. Post-processing calculations were therefore 
performed using the adaptations described in section 4.3.1. 
8.2.2.2 MULES 
MULES simulations were performed using the Sander.LES module of the Amber 11 suite 
of software.346 MULES parameter and coordinate files were prepared manually as 
follows: 
Initial (non-LES) parameter and coordinate files for the native 1SMF trypsin/MBTI 
complex had already been prepared for previous simulations. These were reused for the 
preparation of standard LES parameter files (with two identical, homogeneous copies) 
using the Addles module of Amber 11. A LES region encompassing all residues within 5 Å 
radius of the MBTI P2’Ile residue (i.e. any residue whose Cα atom lay within 5 Å of any 
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atom of the P2’Ile residue) was copied for all simulations, excluding during the 
investigation of the effects of LES region size described in section 4.5.1. This 5 Å radius 
MULES region included residues 22-24, 123, 131 and 174-175 on the receptor (trypsin) 
side of the interaction and residues 226-230 on the ligand (MBTI) side (all residues 
numbered as per internal Amber numbering, where residues 1-223 correspond to 
trypsin and 224-232 comprise the MBTI ligand). 
Having created standard homogeneous LES parameter files, these were transformed 
into heterogeneous MULES files using the protocol described in section 4.4.2.2. MULES 
simulations were then performed using the following protocol. 
Complexes were initially subjected to energy minimisation using an identical two-stage 
procedure to that described for previous simulations in section 8.1.1. Following 
minimisation, complex structures before and after minimisation were compared to 
ensure that the native and mutant copies had structurally diverged, that the mutant 
copy had adopted a visually correct representation of the desired mutant structure and 
that atoms with zero parameters (‘dummy atoms’) in the mutant copy had not moved 
from their initial coordinates (within numerical error) during the minimisation process. 
Standard Locally Enhanced Sampling simulations usually require a different set of 
random initial velocities for atoms in different copies to ensure that they do not feel 
identical forces and undergo identical dynamics during simulations. This means 
simulations should not begin at 0 K, with zero kinetic energy, but rather a small 
temperature above 0 K. MULES should not suffer from this requirement as the initial 
coordinates of the two copies differ after minimisation, but to guarantee that copies 
diverged successfully, MULES simulations nevertheless began at 0.001 K. 
For each MULES mutant, ten independent simulations were then performed as follows. 
Complexes were heated from 0.001 to 300 K over 50 ps in the NVT ensemble, followed 
by 50 ps of pressure equilibration at 1.0 bar in the NPT ensemble. Complexes were then 
subject to a further 1 ns of structural equilibration at 1.0 bar and 300 K, followed by 
10 ns of production MD under identical conditions. Structural snapshots were saved at 
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10 ps intervals from production MD simulations, giving trajectories of 1000 frames in 
total. Thermostat and barostat conditions were identical to those described in section 
8.1.1. The SHAKE algorithm constraining bonds including hydrogen atoms was again 
used to allow a timestep of 2 fs in all simulations. Dummy atoms in the mutant MULES 
copy were excluded from the constraints of SHAKE via the use of the “noshakemask” 
option. This avoided placing inappropriate constraints on atoms that had zero 
parameters, felt zero forces and had zero velocity during simulations. 
Following simulation, trajectories of the native and mutant copies were extracted 
separately for each simulation using the ptraj module of Amber. MM-PB/GBSA binding 
free energy calculations were then performed independently for each trajectory using 
identical methods to those described in section 8.1.2. 
8.2.3 Computational hardware 
MD simulations were performed in parallel across 12 Intel Xeon 5650 CPU cores at 
2.66 GHz, excluding during the comparison of computational timings between different 
MULES region sizes, which were performed in parallel across 8 Intel Xeon E5462 cores 
at 2.80 GHz. All free energy calculations were performed in serial across either Intel 
Xeon E5462 processors at 2.80 GHz or Intel Xeon 5150 cores at 2.66 GHz. 
8.3 Further MULES testing 
8.3.1 MD simulations and free energy calculations 
Additional investigations of explicitly-solvated MULES performed in chapter 5 were 
performed using identical simulation conditions to those described in section 8.2.2.2, 
with additional parameters, changes to mass scaling and changes to simulation or 
equilibration length as described in the appropriate sections of chapter 5. Where MULES 
simulation protocols required the imposition of weak positional restraints (for example 
for simulations including hydroxonium or hydroxide ions due to the mutation of 
charged residues), these were imposed at the level of 0.25 kcal mol-1 Å-1. 
Investigations of MULES performed with GB implicit solvation were performed as 
follows. Parameter files of the native 1SMF complex were prepared afresh using the 
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Leap module of Amber 11, excluding explicit water molecules and all ions and using a 
modified set of Bondi radii designed for use with the Onufriev, Bashford and Case GB 
models.147 Complexes were energy-minimised in a single stage with 1000 steps of 
steepest descent and 1500 steps of conjugate gradient minimisation. Minimised 
structures were then heated from 0.001 to 300 K slowly in multiple stages, and with the 
slow reduction of Cartesian positional restraints on the complex, as described in section 
5.4.2.2 and figure 5.13. The OBC GB model implemented in Amber as igb=5 was used 
throughout, modelled with a salt concentration of 0.15 M to replicate experimental 
conditions.141, 147 No periodic boundary conditions were imposed for implicit solvent 
simulations, hence a non-bonded interaction cutoff of 999 Å was used to ensure that all 
non-bonded interactions were explicitly evaluated throughout. Without periodic 
boundary conditions, no barostat was imposed. All other simulation parameters, 
including timestep, use of SHAKE and thermostat conditions, were identical to those 
described in section 8.2.2.2 or at their default values as defined in Amber 11.346 
Where standard (non-MULES) MD simulations were required for comparison, these 
were performed with the PMEMD module of Amber 11, using identical simulation 
conditions as described in section 8.1.1, with the exception that run lengths were 
extended to 100 ns, giving trajectories of a total of 10 000 frames. 
In all cases, MM-PB/GBSA free energy calculations were performed with identical 
conditions to those described in section 8.1.2. 
8.3.2 Computational hardware 
MULES MD simulations were performed in parallel across 12 Intel Xeon 5650 CPU cores 
at 2.66 GHz or in parallel across 8 Intel Xeon E5462 cores at 2.80 GHz. All free energy 
calculations were performed in serial across either Intel Xeon E5462 processors at 
2.80 GHz or Intel Xeon 5150 cores at 2.66 GHz. Standard MD simulations of 100 ns 
length were performed with the GPU-enabled version of the PMEMD module to enhance 
computational efficiency. PMEMD simulations were therefore performed on single 
Nvidia Tesla C2050 GPU units. Free energy calculations were performed in serial on 
Intel Xeon 5150 processors at 2.66 GHz or Intel Xeon E5462 processors at 2.80 GHz. 
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8.4 Validating MULES 
Experiments in this section are divided into studies of alanine scanning with the Robetta 
dataset and studies of other mutations investigated with the OppA protein. All standard 
MD runs were performed with Amber 10, whilst MULES runs were performed with 
Amber 11. 
8.4.1 The Robetta methodology 
The Robetta alanine scanning server uses an empirically scaled energy function to 
calculate free energies of native and mutant complex structures generated from a single 
set of the native coordinates. Full details of the derivation of this energy function and 
validation of this empirical scaling are available as the supplementary information of 
reference 96, but are summarised here as limitations of the approach are referred to 
throughout this study. 
The Robetta free energy function is a linear combination of the following energetic 
terms, E, each with an associated weight, W. 
                               (     )   (     )
    (     )   (     )                     
    ⁄    ⁄ (  )  ∑       
   
  
    
 
( 8-1 ) 
Here, LJattr is the attractive part of a Lennard-Jones potential, LJrep a linear 
distance-dependent repulsive term, HB(sc-bb) and HB(sc-sc) database derived terms for 
sidechain-backbone and sidechain-sidechain hydrogen bonding respectively, Coul a 
Coulombic electrostatics term, sol an implicit solvation term,   (  )⁄  a term 
dependent on amino acid type phi/psi probabilities and aa an amino acid type and 
number (n) dependent reference energy. 
Details of the exact form of each term, amino acid reference energies and the weights 
derived from fitting results to a training set of mutations are available in the original 
article.96 However, for the purposes of interpreting results from this study it should be 
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noted that the Coulombic electrostatics term was assigned a weight of 0 by the Robetta 
training set; Robetta predictions today rely solely on the hydrogen bonding terms to 
account for electrostatic effects. 
8.4.2 Robetta dataset mutations 
8.4.2.1 Complex preparation 
Validation of MULES required both MULES and standard MD simulations of a series of 
complexes and individual mutations from the Robetta validation dataset. Initial 
structures for these complexes were obtained as X-ray crystal structures from the RCSB 
Protein Data Bank. Accession codes can be found in table 6.2. Crystallographic water 
molecules present in the initial structures were kept. Where individual residues or small 
loop regions were unresolved and missing from crystal structures they were 
reconstructed from sequence information using the Modeller v9.7 software prior to any 
MD simulation.309, 310 Acidic (Asp, Glu) and basic (Lys, Arg) residues were modelled with 
charged sidechain protonation states unless otherwise stated. Histidine residues were 
modelled with neutral sidechains, singly protonated at the delta position (i.e. ‘Hid’ 
residue type) unless otherwise stated. 
All complexes were then parameterised with the Amber ff99SB force field.163 Complexes 
were charge neutralised using an appropriate number of Cl- or Na+338, 347 ions and 
solvated by the addition of a sufficient number of pre-equilibrated TIP3P water 
molecules130 to create either truncated octahedral or cuboid boxes in which no solute 
atom was less than 8 Å from the edge of the box. The choice of solvent box was 
determined by the geometry of the complex to be solvated. Periodic boundary 
conditions were imposed and a cutoff of 8 Å used for the explicit calculation of 
non-bonded interactions, beyond which the PME method was used to treat long range 
interactions.131 MULES parameter files were than prepared with copied MULES regions 
consisting of all residues within a 5 Å radius of the desired mutation and with the ‘omas’ 
option to avoid the scaling of original atomic masses, in accordance with the validation 
protocol of section 5.5.2. 
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8.4.2.2 MD simulations and free energy calculations 
Complexes were energy-minimised and MD simulations performed using the conditions 
of sections 8.1.1 and 8.2.2.2 for standard MD and MULES simulations respectively, with 
one change to simulation length; standard production MD trajectories were run singly 
for each complex (not as 10 individual repeat simulations) for a longer period of 20 ns 
to ensure the equilibration of the larger complexes under investigation, whilst 10 
independent MULES trajectories were run with production MD lengths of 1 ns each in 
accordance with the MULES validation protocol described in section 5.5.2. This led to a 
total of 2000 trajectory frames for free energy analysis for each complex analysed with 
post-processing, and ten trajectories of 100 frames each analysed for MULES. 
Additionally, charged residue mutations that included hydroxonium or hydroxide ions 
included weak positional restraints of weight 0.25 kcal mol-1 Å-1 on these ions. 
MM-PB/GBSA free energy calculations were finally performed with identical conditions 
to those described in section 8.1.2. 
8.4.3 Mutations of OppA 
8.4.3.1 Complex preparation 
MULES mutations of the oligopeptide binding protein OppA required the simulation of a 
series of related complexes. Initial structures for all complexes were taken from the 
RCSB Protein Data Bank. Accession codes are available in table 6.16. All simulations 
were prepared from the structures of the native PDB complex identified in table 6.16. 
Crystallographic water molecules present in the initial structures were kept. Acidic (Asp, 
Glu) and basic (Lys, Arg) residues were modelled with charged sidechain protonation 
states unless otherwise stated. Histidine residues were modelled with neutral 
sidechains, singly protonated at the delta position (i.e. ‘Hid’ residue type), excluding 
His405, which was modelled in its positively charged, doubly protonated form (‘Hip’ 
residue type) in order to recreate a defined salt bridge between Glu32 and His405.335 
All complexes were then parameterised with the Amber ff99SB force field.163 Complexes 
were charge neutralised using an appropriate number of Na+ ions, with parameters from 
Åqvist as standard in the ff99SB force field,347 and solvated by the addition of a sufficient 
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number of pre-equilibrated TIP3P water molecules130 to create truncated octahedral 
boxes in which no solute atom was less than 8 Å from the edge of the box. Periodic 
boundary conditions were imposed and a cutoff of 8 Å used for the explicit calculation of 
non-bonded interactions, beyond which the PME method was used to treat long range 
interactions. Again, MULES parameter files were than prepared with copied MULES 
regions consisting of all residues within a 5 Å radius of the desired mutation and with 
the ‘omas’ option to avoid the scaling of original atomic masses. At minimum, MULES 
regions included receptor residues 32, 274, 405, 415 and 438 as these were specifically 
identified as lining the ligand binding pocket during literature studies.335 
MULES energy minimisations and simulations were then performed identically to those 
described in section 8.2.2.2, except with production MD run lengths of 1 ns. Where 
water molecules were copied as part of MULES regions (section 6.5.4.2) they were 
subject to weak positional restraints of 0.10 kcal mol-1 Å-1 during simulation. 
Finally, MM-PB/GBSA free energy calculations were performed with identical conditions 
to those described in section 8.1.2. 
8.4.4 Computational hardware 
Standard MD simulations of complexes from the Robetta dataset were performed in 
parallel across 8 Intel Xeon E5462 CPU cores at 2.80 GHz or in parallel across 16 Intel 
Xeon 5150 cores at 2.66 GHz. MULES MD simulations were performed in parallel across 
12 Intel Xeon 5650 CPU cores at 2.66 GHz or in parallel across 8 Intel Xeon E5462 CPU 
cores at 2.80 GHz. As in previous sections, free energy calculations were performed in 
serial on Intel Xeon 5150 processors at 2.66 GHz or Intel Xeon E5462 processors at 
2.80 GHz. 
  
  280 
References 
1. B. Alberts, et al., Molecular Biology of the Cell, 4th edn., Garland Science, 2002. 
2. A. Ben-Shem, et al., "The Structure of the Eukaryotic Ribosome at 3.0 Å 
Resolution", Science, 2011, 334, 1524-1529. 
3. D. Figeys, "Mapping the human protein interactome", Cell Res, 2008, 18, 716-
724. 
4. M. P. H. Stumpf, et al., "Estimating the size of the human interactome", Proc. Nat. 
Acad. Sci., 2008, 105, 6959-6964. 
5. K. Venkatesan, et al., "An empirical framework for binary interactome mapping", 
Nat. Meth., 2009, 6, 83-90. 
6. T. Finkel and J. S. Gutkind, Signal transduction and human disease, John Wiley & 
Sons, 2003. 
7. D. P. Ryan and J. M. Matthews, "Protein-protein interactions in human disease", 
Curr. Op. Struct. Biol., 2005, 15, 441-446. 
8. A. M. Spiegel, "Defects in G Protein-Coupled Signal Transduction in Human 
Disease", Annu. Rev. Physiol., 1996, 58, 143-170. 
9. Y. Yarden, "The EGFR family and its ligands in human cancer. signalling 
mechanisms and therapeutic opportunities", Eur. J. Cancer, 2001, 37 Suppl 4, S3-
8. 
10. D. Filmore, "It's a GPCR world", Modern Drug Discovery, 2004, 7, 24-28. 
11. S. L. Ritter and R. A. Hall, "Fine-tuning of GPCR activity by receptor-interacting 
proteins", Nat. Rev. Mol. Cell Biol., 2009, 10, 819-830. 
12. G. Milligan and J. H. White, "Protein protein interactions at G-protein-coupled 
receptors", Trends Pharmacol. Sci., 2001, 22, 513-518. 
13. L. Stryer, J. L. Tymoczko and J. M. Berg, Biochemistry, 5th edn., W.H. Freeman, 
2002. 
14. A. R. M. Bradbury, S. Sidhu, S. Dubel and J. McCafferty, "Beyond natural 
antibodies: the power of in vitro display technologies", Nat. Biotech., 2011, 29, 
245-254. 
15. D. J. Mandell and T. Kortemme, "Computer-aided design of functional protein 
interactions", Nat. Chem. Biol., 2009, 5, 797-807. 
16. G. Schreiber and A. R. Fersht, "Interaction of barnase with its polypeptide 
inhibitor barstar studied by protein engineering", Biochemistry, 1993, 32, 5145-
5150. 
17. R. Shapiro and B. L. Vallee, "Interaction of human placental ribonuclease with 
placental ribonuclease inhibitor", Biochemistry, 1991, 30, 2246-2255. 
18. M. Cemazar and D. J. Craik, "Factors influencing the stability of cyclotides: 
Proteins with a circular backbone and cystine knot motif", Int. J. Peptide Research 
& Therapeutics, 2006, 12, 253-260. 
19. D. J. Craik, M. Cemazar, C. K. L. Wang and N. L. Daly, "The cyclotide family of 
circular miniproteins: Nature's combinatorial peptide template", Biopolymers, 
2006, 84, 250-266. 
  281 
20. D. J. Craik, N. L. Daly and C. Waine, "The cystine knot motif in toxins and 
implications for drug design", Toxicon, 2001, 39, 43-60. 
21. P. Thongyoo, N. Roque-Rosell, R. J. Leatherbarrow and E. W. Tate, "Chemical and 
biomimetic total syntheses of natural and engineered MCoTI cyclotides", Org. 
Biomol. Chem., 2008, 6, 1462-1470. 
22. P. Thongyoo, C. Bonomelli, R. J. Leatherbarrow and E. W. Tate, "Potent Inhibitors 
of beta-Tryptase and Human Leukocyte Elastase Based on the MCoTI-II 
Scaffold", J. Med. Chem., 2009, 52, 6197-6200. 
23. G. Smith, "Filamentous fusion phage: novel expression vectors that display 
cloned antigens on the virion surface", Science, 1985, 228, 1315-1317. 
24. T. Clackson and H. B. Lowman, Phage Display: A Practical Approach, Oxford 
University Press, 2004. 
25. T. Clackson and J. A. Wells, "In vitro selection from protein and peptide 
libraries", Trends Biotech., 1994, 12, 173-184. 
26. S. Fields and O.-k. Song, "A novel genetic system to detect protein–protein 
interactions", Nature, 1989, 340, 245-246. 
27. E. M. Marcotte, et al., "Detecting Protein Function and Protein-Protein 
Interactions from Genome Sequences", Science, 1999, 285, 751-753. 
28. Y. Ofran and B. Rost, "Predicted protein-protein interaction sites from local 
sequence information", FEBS Letters, 2003, 544, 236-239. 
29. C. von Mering, et al., "Comparative assessment of large-scale data sets of protein-
protein interactions", Nature, 2002, 417, 399-403. 
30. G. R. Smith and M. J. E. Sternberg, "Prediction of protein-protein interactions by 
docking methods", Curr. Op. Struct. Biol., 2002, 12, 28-35. 
31. S. J. Wodak and R. Méndez, "Prediction of protein–protein interactions: the 
CAPRI experiment, its evaluation and implications", Curr. Op. Struct. Biol., 2004, 
14, 242-249. 
32. J. Fernández-Recio and M. J. E. Sternberg, "The 4th meeting on the Critical 
Assessment of Predicted Interaction (CAPRI) held at the Mare Nostrum, 
Barcelona", Proteins - Struct. Func. Bioinfo., 2010, 78, 3065-3066. 
33. U. Jönsson, et al., "Real-time Biospecific Interaction Analysis Using Surface 
Plasmon Resonance and a Sensor Chip Technology", Biotechniques, 1991, 11, 
620-627. 
34. E. A. Smith, W. D. Thomas, L. L. Kiessling and R. M. Corn, "Surface Plasmon 
Resonance Imaging Studies of Protein-Carbohydrate Interactions", J. Am. Chem. 
Soc., 2003, 125, 6140-6148. 
35. A. Dagkessamanskaia, et al., "Functional dissection of an intrinsically disordered 
protein: Understanding the roles of different domains of Knr4 protein in 
protein–protein interactions", Prot. Sci., 2010, 19, 1376-1385. 
36. Y. Li, C. A. Lipschultz, S. Mohan and S. J. Smith-Gill, "Mutations of an Epitope Hot-
Spot Residue Alter Rate Limiting Steps of Antigen−Antibody Protein−Protein 
Associations", Biochemistry, 2001, 40, 2011-2022. 
37. M. M. Pierce, C. S. Raman and B. T. Nall, "Isothermal Titration Calorimetry of 
Protein–Protein Interactions", Methods, 1999, 19, 213-221. 
  282 
38. T. S. G. Olsson, J. E. Ladbury, W. R. Pitt and M. A. Williams, "Extent of enthalpy–
entropy compensation in protein–ligand interactions", Prot. Sci., 2011, 20, 1607-
1618. 
39. T. Brandt, et al., "Congeneric but Still Distinct: How Closely Related Trypsin 
Ligands Exhibit Different Thermodynamic and Structural Properties", J. Mol. 
Biol., 2011, 405, 1170-1187. 
40. W. Treesuwan, et al., "A detailed binding free energy study of 2 : 1 ligand-DNA 
complex formation by experiment and simulation", Phys. Chem. Chem. Phys., 
2009, 11, 10682-10693. 
41. N. A. G. Meenan, et al., "The structural and energetic basis for high selectivity in a 
high-affinity protein-protein interaction", Proc. Nat. Acad. Sci., 2010, 107, 10080-
10085. 
42. M. R. Arkin and J. A. Wells, "Small-molecule inhibitors of protein-protein 
interactions: Progressing towards the dream", Nat. Rev. Drug Discov., 2004, 3, 
301-317. 
43. A. V. Veselovsky and A. I. Archakov, "Inhibitors of protein-protein interactions as 
potential drugs", Curr. Comput.-Aided Drug Des., 2007, 3, 51-58. 
44. J. A. Wells and C. L. McClendon, "Reaching for high-hanging fruit in drug 
discovery at protein-protein interfaces", Nature, 2007, 450, 1001-1009. 
45. S. Jones and J. M. Thornton, "Principles of protein-protein interactions", Proc. 
Nat. Acad. Sci., 1996, 93, 13-20. 
46. L. Lo Conte, C. Chothia and J. Janin, "The atomic structure of protein-protein 
recognition sites", J. Mol. Biol., 1999, 285, 2177-2198. 
47. C. Yan, F. Wu, R. Jernigan, D. Dobbs and V. Honavar, "Characterization of Protein–
Protein Interfaces", Protein J., 2008, 27, 59-70. 
48. N. London, D. Movshovitz-Attias and O. Schueler-Furman, "The Structural Basis 
of Peptide-Protein Binding Strategies", Structure, 2010, 18, 188-199. 
49. Y. Ofran and B. Rost, "Analysing Six Types of Protein–Protein Interfaces", J. Mol. 
Biol., 2003, 325, 377-387. 
50. F. Glaser, D. M. Steinberg, I. A. Vakser and N. Ben-Tal, "Residue frequencies and 
pairing preferences at protein–protein interfaces", Proteins - Struct. Func. 
Bioinfo., 2001, 43, 89-102. 
51. I. M. A. Nooren and J. M. Thornton, "Structural Characterisation and Functional 
Significance of Transient Protein–Protein Interactions", J. Mol. Biol., 2003, 325, 
991-1018. 
52. D. Rajamani, S. Thiel, S. Vajda and C. J. Camacho, "Anchor residues in protein-
protein interactions", Proc. Nat. Acad. Sci., 2004, 101, 11287-11292. 
53. T. Clackson and J. A. Wells, "A hot spot of binding energy in a hormone-receptor 
interface", Science, 1995, 267, 383-386. 
54. A. A. Bogan and K. S. Thorn, "Anatomy of hot spots in protein interfaces", J. Mol. 
Biol., 1998, 280, 1-9. 
55. I. S. Moreira, P. A. Fernandes and M. J. Ramos, "Hot spots-A review of the protein-
protein interface determinant amino-acid residues", Proteins - Struct. Func. 
Bioinfo., 2007, 68, 803-812. 
  283 
56. S. Eyrisch and V. Helms, "Transient Pockets on Protein Surfaces Involved in 
Protein−Protein Interaction", J. Med. Chem., 2007, 50, 3457-3464. 
57. L. Zhao and J. Chmielewski, "Inhibiting protein-protein interactions using 
designed molecules", Curr. Op. Struct. Biol., 2005, 15, 31-34. 
58. H. Yin and A. D. Hamilton, "Strategies for targeting protein-protein interactions 
with synthetic agents", Angew. Chem. Int. Ed., 2005, 44, 4130-4163. 
59. D. Kozakov, et al., "Structural conservation of druggable hot spots in protein–
protein interfaces", Proc. Nat. Acad. Sci., 2011, 108, 13528-13533. 
60. B. C. Cunningham and J. A. Wells, "High-resolution epitope mapping of HGH-
receptor interactions by alanine-scanning mutagenesis", Science, 1989, 244, 
1081-1085. 
61. K. L. Morrison and G. A. Weiss, "Combinatorial alanine-scanning", Curr. Op. Chem. 
Biol., 2001, 5, 302-307. 
62. S. K. Avrantinis, R. L. Stafford, X. Tian and G. A. Weiss, "Dissecting the 
streptavidin-biotin interaction by phage-displayed shotgun scanning", 
Chembiochem, 2002, 3, 1229-1234. 
63. G. Pal, A. A. Kossiakoff and S. S. Sidhu, "The Functional Binding Epitope of a High 
Affinity Variant of Human Growth Hormone Mapped by Shotgun Alanine-
scanning Mutagenesis: Insights into the Mechanisms Responsible for Improved 
Affinity", J. Mol. Biol., 2003, 332, 195-204. 
64. K. S. Thorn and A. A. Bogan, "ASEdb: a database of alanine mutations and their 
effects on the free energy of binding in protein interactions", Bioinformatics, 
2001, 17, 284-285. 
65. T. B. Fischer, et al., "The binding interface database (BID): a compilation of 
amino acid hot spots in protein interfaces", Bioinformatics, 2003, 19, 1453-1454. 
66. M. D. S. Kumar and M. M. Gromiha, "PINT: Protein–protein Interactions 
Thermodynamic Database", Nucl. Acids Res., 2006, 34, D195-D198. 
67. N. Tuncbag, G. Kar, O. Keskin, A. Gursoy and R. Nussinov, "A survey of available 
tools and web servers for analysis of protein-protein interactions and 
interfaces", Brief Bioinform, 2009, 10, 217-232. 
68. N. Tuncbag, A. Gursoy and O. Keskin, "Identification of computational hot spots 
in protein interfaces: combining solvent accessibility and inter-residue 
potentials improves the accuracy", Bioinformatics, 2009, 25, 1513-1520. 
69. S. J. Darnell, D. Page and J. C. Mitchell, "An automated decision-tree approach to 
predicting protein interaction hot spots", Proteins - Struct. Func. Bioinfo., 2007, 
68, 813-823. 
70. K.-i. Cho, D. Kim and D. Lee, "A feature-based approach to modeling protein–
protein interaction hot spots", Nucl. Acids Res., 2009, 37, 2672-2687. 
71. X. Zhu and J. C. Mitchell, "KFC2: A knowledge-based hot spot prediction method 
based on interface solvation, atomic density, and plasticity features", Proteins - 
Struct. Func. Bioinfo., 2011, 79, 2671-2683. 
72. K. W. Kaufmann, G. H. Lemmon, S. L. DeLuca, J. H. Sheehan and J. Meiler, 
"Practically Useful: What the Rosetta Protein Modeling Suite Can Do for You", 
Biochemistry, 2010, 49, 2987-2998. 
73. A. J. Wilson, "Inhibition of protein-protein interactions using designed 
molecules", Chem. Soc. Rev., 2009, 38, 3289-3300. 
  284 
74. C. Vita, et al., "Rational engineering of a miniprotein that reproduces the core of 
the CD4 site interacting with HIV-1 envelope glycoprotein", Proc. Nat. Acad. Sci., 
1999, 96, 13091-13096. 
75. J. W. Chin and A. Schepartz, "Design and Evolution of a Miniature Bcl-2 Binding 
Protein", Angew. Chem. Int. Ed., 2001, 40, 3806-3809. 
76. N. London, B. Raveh, D. Movshovitz-Attias and O. Schueler-Furman, "Can self-
inhibitory peptides be derived from the interfaces of globular protein–protein 
interactions?", Proteins - Struct. Func. Bioinfo., 2010, 78, 3140-3149. 
77. S. D. Liang, et al., "Exploring the Molecular Design of Protein Interaction Sites 
with Molecular Dynamics Simulations and Free Energy Calculations", 
Biochemistry, 2009, 48, 399-414. 
78. C. J. Brown, et al., "Rational Design and Biophysical Characterization of 
Thioredoxin-Based Aptamers: Insights into Peptide Grafting", J. Mol. Biol., 2010, 
395, 871-883. 
79. D. S. Lawrence, "Signaling protein inhibitors via the combinatorial modification 
of peptide scaffolds", BBA-Proteins & Proteomics, 2005, 1754, 50-57. 
80. H. Kolmar, "Alternative binding proteins: Biological activity and therapeutic 
potential of cystine-knot miniproteins", FEBS Journal, 2008, 275, 2684-2690. 
81. S. J. Hershberger, S. G. Lee and J. Chmielewski, "Scaffolds for blocking protein-
protein interactions", Curr. Top. Med. Chem., 2007, 7, 928-942. 
82. M. J. P. de Vega, M. Martin-Martinez and R. Gonzalez-Muniz, "Modulation of 
protein-protein interactions by stabilizing/mimicking protein secondary 
structure elements", Curr. Top. Med. Chem., 2007, 7, 33-62. 
83. N. T. Ross, W. P. Katt and A. D. Hamilton, "Synthetic mimetics of protein 
secondary structure domains", Philos. T. Roy. Soc. A, 2010, 368, 989-1008. 
84. L. D. Walensky, et al., "Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled 
BH3 Helix", Science, 2004, 305, 1466-1470. 
85. R. E. Moellering, et al., "Direct inhibition of the NOTCH transcription factor 
complex", Nature, 2009, 462, 182-188. 
86. J. A. Kritzer, J. D. Lear, M. E. Hodsdon and A. Schepartz, "Helical β-Peptide 
Inhibitors of the p53-hDM2 Interaction", J. Am. Chem. Soc., 2004, 126, 9468-
9469. 
87. R. Fasan, et al., "Structure–Activity Studies in a Family of β-Hairpin Protein 
Epitope Mimetic Inhibitors of the p53–HDM2 Protein–Protein Interaction", 
Chembiochem, 2006, 7, 515-526. 
88. H. Yin, et al., "Terphenyl-Based Bak BH3 α-Helical Proteomimetics as Low-
Molecular-Weight Antagonists of Bcl-xL", J. Am. Chem. Soc., 2005, 127, 10191-
10196. 
89. J. M. Rodriguez, L. Nevola, N. T. Ross, G.-i. Lee and A. D. Hamilton, "Synthetic 
Inhibitors of Extended Helix–Protein Interactions Based on a Biphenyl 4,4′-
Dicarboxamide Scaffold", Chembiochem, 2009, 10, 829-833. 
90. P. Maity and B. Konig, "Synthesis and Structure of 1,4-Dipiperazino Benzenes: 
Chiral Terphenyl-type Peptide Helix Mimetics", Org. Lett., 2008, 10, 1473-1476. 
91. D. K. Leung, Z. Yang and R. Breslow, "Selective disruption of protein aggregation 
by cyclodextrin dimers", Proc. Nat. Acad. Sci., 2000, 97, 5050-5053. 
  285 
92. B. A. Rosenzweig, et al., "Multivalent Protein Binding and Precipitation by Self-
Assembling Molecules on a DNA Pentaplex Scaffold", J. Am. Chem. Soc., 2009, 
131, 5020-5021. 
93. D. Gfeller, O. Michielin and V. Zoete, "Expanding molecular modeling and design 
tools to non-natural sidechains", J. Comput. Chem., 2012, 33, 1525-1535. 
94. J. J. Havranek and P. B. Harbury, "Automated design of specificity in molecular 
recognition", Nat. Struct. Mol. Biol., 2003, 10, 45-52. 
95. T. Kortemme and D. Baker, "Computational design of protein-protein 
interactions", Curr. Op. Chem. Biol., 2004, 8, 91-97. 
96. T. Kortemme and D. Baker, "A simple physical model for binding energy hot 
spots in protein-protein complexes", Proc. Nat. Acad. Sci., 2002, 99, 14116-
14121. 
97. T. Kortemme, D. E. Kim and D. Baker, "Computational Alanine Scanning of 
Protein-Protein Interfaces", Sci. STKE, 2004, 219, pl2. 
98. L. A. Joachimiak, T. Kortemme, B. L. Stoddard and D. Baker, "Computational 
Design of a New Hydrogen Bond Network and at Least a 300-fold Specificity 
Switch at a Protein−Protein Interface", J. Mol. Biol., 2006, 361, 195-208. 
99. S. J. Fleishman, et al., "Computational Design of Proteins Targeting the Conserved 
Stem Region of Influenza Hemagglutinin", Science, 2011, 332, 816-821. 
100. J. Karanicolas, et al., "A De Novo Protein Binding Pair By Computational Design 
and Directed Evolution", Mol. Cell, 2011, 42, 250-260. 
101. D. Frenkel and B. Smit, Understanding Molecular Simulation, from Algorithms to 
Applications, 2nd edn., Elsevier, 2002. 
102. A. Einstein, "Über einen die Erzeugung und Verwandlung des Lichtes 
betreffenden heuristischen Gesichtspunkt", Annalen der Physik, 1905, 322, 132-
148. 
103. M. Planck, "Über das Gesetz der Energieverteilung im Normalspectrum", Annalen 
der Physik, 1901, 309, 553-563. 
104. C. Davisson and L. H. Germer, "Diffraction of Electrons by a Crystal of Nickel", 
Phys. Rev., 1927, 30, 705-740. 
105. P. A. M. Dirac, "Quantum Mechanics of Many-Electron Systems", P. Roy. Soc. Lond. 
A, 1929, 123, 714-733. 
106. F. Jensen, Introduction to Computational Chemistry, John Wiley & Sons, 2007. 
107. J. W. Neidigh, R. M. Fesinmeyer and N. H. Andersen, "Designing a 20-residue 
protein", Nat. Struct. Mol. Biol., 2002, 9, 425-430. 
108. D. R. Bowler and T. Miyazaki, "O-N methods in electronic structure calculations", 
Rep. Prog. Phys., 2012, 75, 036503. 
109. C.-K. Skylaris, P. D. Haynes, A. A. Mostofi and M. C. Payne, "Introducing ONETEP: 
Linear-scaling density functional simulations on parallel computers", J. Chem. 
Phys., 2005, 122, 084119-084110. 
110. D. J. Cole, et al., "Interrogation of the Protein-Protein Interactions between 
Human BRCA2 BRC Repeats and RAD51 Reveals Atomistic Determinants of 
Affinity", PLoS Comput. Biol., 2011, 7, e1002096. 
111. S. Fox, H. G. Wallnoefer, T. Fox, C. S. Tautermann and C.-K. Skylaris, "First 
Principles-Based Calculations of Free Energy of Binding: Application to Ligand 
  286 
Binding in a Self-Assembling Superstructure", J. Chem. Theo. Comput., 2011, 7, 
1102-1108. 
112. J. Dziedzic, S. J. Fox, T. Fox, C. S. Tautermann and C.-K. Skylaris, "Large-scale DFT 
calculations in implicit solvent—A case study on the T4 lysozyme L99A/M102Q 
protein", Int. J. Quantum Chemistry, 2012, In Press. 
113. R. W. Hockney, in Methods in Computational Physics, Academic Press, New York, 
1970, vol. 9, pp. 136-211. 
114. L. Verlet, "Computer "Experiments" on Classical Fluids. I. Thermodynamical 
Properties of Lennard-Jones Molecules", Phys. Rev., 1967, 159, 98-103. 
115. K. Henzler-Wildman and D. Kern, "Dynamic personalities of proteins", Nature, 
2007, 450, 964-972. 
116. H. Frauenfelder, S. Sligar and P. Wolynes, "The energy landscapes and motions of 
proteins", Science, 1991, 254, 1598-1603. 
117. D. Xu, M. J. Williamson, R. C. Walker and A. W. Ralph, "Advancements in 
Molecular Dynamics Simulations of Biomolecules on Graphical Processing 
Units", Annu. Rep. Comput. Chem., 2010, 6, 2-19. 
118. M. S. Friedrichs, et al., "Accelerating molecular dynamic simulation on graphics 
processing units", J. Comput. Chem., 2009, 30, 864-872. 
119. A. W. Götz, et al., "Routine Microsecond Molecular Dynamics Simulations with 
AMBER on GPUs. 1. Generalized Born", J. Chem. Theo. Comput., 2012, 8, 1542-
1555. 
120. R. O. Dror, et al., "Pathway and mechanism of drug binding to G-protein-coupled 
receptors", Proc. Nat. Acad. Sci., 2011, 108, 13118-13123. 
121. D. E. Shaw, et al., "Atomic-Level Characterization of the Structural Dynamics of 
Proteins", Science, 2010, 330, 341-346. 
122. Y. Sugita and Y. Okamoto, "Replica-exchange molecular dynamics method for 
protein folding", Chem. Phys. Lett., 1999, 314, 141-151. 
123. D. Hamelberg, J. Mongan and J. A. McCammon, "Accelerated molecular dynamics: 
A promising and efficient simulation method for biomolecules", J. Chem. Phys., 
2004, 120, 11919-11929. 
124. L. C. T. Pierce, R. Salomon-Ferrer, C. Augusto F. de Oliveira, J. A. McCammon and 
R. C. Walker, "Routine Access to Millisecond Time Scale Events with Accelerated 
Molecular Dynamics", J. Chem. Theo. Comput., 2012, 8, 2997-3002. 
125. A. R. Leach, Molecular Modelling, Principles and Applications, 2nd edn., Pearson 
Education, 2001. 
126. R. J. Ellis and A. P. Minton, "Cell biology: Join the crowd", Nature, 2003, 425, 27-
28. 
127. D. D. L. Minh, C.-e. Chang, J. Trylska, V. Tozzini and J. A. McCammon, "The 
Influence of Macromolecular Crowding on HIV-1 Protease Internal Dynamics", J. 
Am. Chem. Soc., 2006, 128, 6006-6007. 
128. S. R. McGuffee and A. H. Elcock, "Diffusion, Crowding & Protein Stability in a 
Dynamic Molecular Model of the Bacterial Cytoplasm", PLoS Comput. Biol., 2010, 
6, e1000694. 
129. R. Harada, Y. Sugita and M. Feig, "Protein Crowding Affects Hydration Structure 
and Dynamics", J. Am. Chem. Soc., 2012, 134, 4842-4849. 
  287 
130. W. L. Jorgensen, J. Chandrasekhar, J. D. Madura, R. W. Impey and M. L. Klein, 
"Comparison of simple potential functions for simulating liquid water", J. Chem. 
Phys., 1983, 79, 926-935. 
131. T. Darden, D. York and L. Pedersen, "Particle mesh Ewald: An N log(N) method 
for Ewald sums in large systems", J. Chem. Phys., 1993, 98, 10089-10092. 
132. T. E. Cheatham, J. L. Miller, T. Fox, T. A. Darden and P. A. Kollman, "Molecular-
dynamics simulations on solvated biomolecular systems - the Particle Mesh 
Ewald method leads to stable trajectories of DNA, RNA, and proteins", J. Am. 
Chem. Soc., 1995, 117, 4193-4194. 
133. I. Klapper, R. Hagstrom, R. Fine, K. Sharp and B. Honig, "Focusing of electric fields 
in the active site of Cu-Zn superoxide dismutase: Effects of ionic strength and 
amino-acid modification", Proteins - Struct. Func. Bioinfo., 1986, 1, 47-59. 
134. B. Honig and A. Nicholls, "Classical electrostatics in biology and chemistry", 
Science, 1995, 268, 1144-1149. 
135. F. Fogolari, A. Brigo and H. Molinari, "The Poisson–Boltzmann equation for 
biomolecular electrostatics: a tool for structural biology", J. Mol. Recog., 2002, 15, 
377-392. 
136. F. Fogolari, P. Zuccato, G. Esposito and P. Viglino, "Biomolecular Electrostatics 
with the Linearized Poisson-Boltzmann Equation", Biophys. J., 1999, 76, 1-16. 
137. M. E. Davis and J. A. McCammon, "Solving the finite difference linearized Poisson-
Boltzmann equation: A comparison of relaxation and conjugate gradient 
methods", J. Comput. Chem., 1989, 10, 386-391. 
138. A. Nicholls and B. Honig, "A rapid finite difference algorithm, utilizing successive 
over-relaxation to solve the Poisson–Boltzmann equation", J. Comput. Chem., 
1991, 12, 435-445. 
139. R. Luo, L. David and M. K. Gilson, "Accelerated Poisson–Boltzmann calculations 
for static and dynamic systems", J. Comput. Chem., 2002, 23, 1244-1253. 
140. J. Wang, Q. Cai, Z.-L. Li, H.-K. Zhao and R. Luo, "Achieving energy conservation in 
Poisson–Boltzmann molecular dynamics: Accuracy and precision with finite-
difference algorithms", Chem. Phys. Lett., 2009, 468, 112-118. 
141. M. Feig, et al., "Performance comparison of generalized born and Poisson 
methods in the calculation of electrostatic solvation energies for protein 
structures", J. Comput. Chem., 2004, 25, 265-284. 
142. J. Wagoner and N. A. Baker, "Solvation forces on biomolecular structures: A 
comparison of explicit solvent and Poisson–Boltzmann models", J. Comput. 
Chem., 2004, 25, 1623-1629. 
143. A. Nicholls, et al., "Predicting Small-Molecule Solvation Free Energies: An 
Informal Blind Test for Computational Chemistry", J. Med. Chem., 2008, 51, 769-
779. 
144. A. Onufriev, D. A. Case and D. Bashford, "Effective Born radii in the generalized 
Born approximation: The importance of being perfect", J. Comput. Chem., 2002, 
23, 1297-1304. 
145. W. C. Still, A. Tempczyk, R. C. Hawley and T. Hendrickson, "Semianalytical 
treatment of solvation for molecular mechanics and dynamics", J. Am. Chem. Soc., 
1990, 112, 6127-6129. 
  288 
146. V. Tsui and D. A. Case, "Molecular Dynamics Simulations of Nucleic Acids with a 
Generalized Born Solvation Model", J. Am. Chem. Soc., 2000, 122, 2489-2498. 
147. A. Onufriev, D. Bashford and D. A. Case, "Exploring protein native states and 
large-scale conformational changes with a modified Generalized Born model", 
Proteins - Struct. Func. Bioinfo., 2004, 55, 383-394. 
148. M. Born, "Volumen und Hydratationswärme der Ionen", Zeitschrift für Physik A, 
1920, 1, 45-48. 
149. A. Onufriev, D. Bashford and D. A. Case, "Modification of the Generalized Born 
Model Suitable for Macromolecules", J. Phys. Chem. B, 2000, 104, 3712-3720. 
150. M. S. Shell, R. Ritterson and K. A. Dill, "A Test on Peptide Stability of AMBER 
Force Fields with Implicit Solvation", J. Phys. Chem. B, 2008, 112, 6878-6886. 
151. V. A. Voelz, G. R. Bowman, K. Beauchamp and V. S. Pande, "Molecular Simulation 
of ab Initio Protein Folding for a Millisecond Folder NTL9(1−39)", J. Am. Chem. 
Soc., 2010, 132, 1526-1528. 
152. G. L. Butterfoss, et al., "De novo structure prediction and experimental 
characterization of folded peptoid oligomers", Proc. Nat. Acad. Sci., 2012, 109, 
14320-14325. 
153. K. M. ElSawy, R. Twarock, C. S. Verma and L. S. D. Caves, "Peptide Inhibitors of 
Viral Assembly: A Novel Route to Broad-Spectrum Antivirals", J. Chem. Info. 
Model., 2012, 52, 770-776. 
154. D. R. Roe, A. Okur, L. Wickstrom, V. Hornak and C. Simmerling, "Secondary 
Structure Bias in Generalized Born Solvent Models:  Comparison of 
Conformational Ensembles and Free Energy of Solvent Polarization from Explicit 
and Implicit Solvation", J. Phys. Chem. B, 2007, 111, 1846-1857. 
155. Y. Shang, H. Nguyen, L. Wickstrom, A. Okur and C. Simmerling, "Improving the 
description of salt bridge strength and geometry in a Generalized Born model", J. 
Mol. Graph. Model., 2011, 29, 676-684. 
156. J. W. Ponder and D. A. Case, in Adv. Prot. Chem., ed. V. Daggett, Academic Press, 
2003, vol. 66, pp. 27-85. 
157. W. D. Cornell, et al., "A 2nd generation force-field for the simulation of proteins, 
nucleic-acids and organic-molecules", J. Am. Chem. Soc., 1995, 117, 5179-5197. 
158. W. D. Cornell, P. Cieplak, C. I. Bayly and P. A. Kollmann, "Application of RESP 
charges to calculate conformational energies, hydrogen bond energies, and free 
energies of solvation", J. Am. Chem. Soc., 1993, 115, 9620-9631. 
159. C. I. Bayly, P. Cieplak, W. Cornell and P. A. Kollman, "A well-behaved electrostatic 
potential based method using charge restraints for deriving atomic charges: the 
RESP model", J. Phys. Chem., 1993, 97, 10269-10280. 
160. T. Fox and P. A. Kollman, "Application of the RESP Methodology in the 
Parametrization of Organic Solvents", J. Phys. Chem. B, 1998, 102, 8070-8079. 
161. S. A. J. Rosen, P. R. J. Gaffney and I. R. Gould, "A theoretical investigation of 
inositol 1,3,4,5-tetrakisphosphate", Phys. Chem. Chem. Phys., 2011, 13, 1070-
1081. 
162. J. Wang, P. Cieplak and P. A. Kollman, "How well does a restrained electrostatic 
potential (RESP) model perform in calculating conformational energies of 
organic and biological molecules?", J. Comput. Chem., 2000, 21, 1049-1074. 
  289 
163. V. Hornak, et al., "Comparison of multiple Amber force fields and development of 
improved protein backbone parameters", Proteins - Struct. Func. Bioinfo., 2006, 
65, 712-725. 
164. K. Lindorff-Larsen, et al., "Improved side-chain torsion potentials for the Amber 
ff99SB protein force field", Proteins - Struct. Func. Bioinfo., 2010, 78, 1950-1958. 
165. B. L. Tembre and J. A. Mc Cammon, "Ligand-receptor interactions", Computers & 
Chemistry, 1984, 8, 281-283. 
166. T. P. Straatsma and J. A. McCammon, "Computational Alchemy", Ann. Rev. Phys. 
Chem., 1992, 43, 407-435. 
167. U. C. Singh, F. K. Brown, P. A. Bash and P. A. Kollman, "An approach to the 
application of free-energy perturbation-methods using molecular-dynamics - 
applications to the transformations of CH3OH - CH3CH3, H3O+ - NH4+, glycine - 
alanine, and alanine - phenylalanine in aqueous-solution and to H3O+(H2O)3 - 
NH4+(H2O)3 in the gas-phase", J. Am. Chem. Soc., 1987, 109, 1607-1614. 
168. P. A. Bash, U. C. Singh, R. Langridge and P. A. Kollman, "Free-energy calculations 
by computer-simulation", Science, 1987, 236, 564-568. 
169. K. M. Merz and P. A. Kollman, "Free-energy perturbation simulations of the 
inhibition of Thermolysin - prediction of the free-energy of binding of a new 
inhibitor", J. Am. Chem. Soc., 1989, 111, 5649-5658. 
170. J. K. Hwang and A. Warshel, "Semiquantitative calculations of catalytic free 
energies in genetically modified enzymes", Biochemistry, 1987, 26, 2669-2673. 
171. T. P. Straatsma and H. J. C. Berendsen, "Free energy of ionic hydration: Analysis 
of a thermodynamic integration technique to evaluate free energy differences by 
molecular dynamics simulations", J. Chem. Phys., 1988, 89, 5876-5886. 
172. R. C. Wade and J. A. McCammon, "Binding of an antiviral agent to a sensitive and 
a resistant human rhinovirus - computer-simulation studies with sampling of 
amino-acid side-chain conformations. 2. Calculation of free-energy differences 
by thermodynamic integration", J. Mol. Biol., 1992, 225, 697-712. 
173. M. Zacharias, T. P. Straatsma, J. A. McCammon and F. A. Quiocho, "Inversion of 
receptor-binding preferences by mutagenesis - free-energy thermodynamic 
integration studies on sugar binding to L-arabinose binding-proteins", 
Biochemistry, 1993, 32, 7428-7434. 
174. R. Zwanzig, "High-Temperature Equation of State by a Perturbation Method. I. 
Nonpolar Gases", J. Chem. Phys., 1954, 22, 1420-1426. 
175. M. R. Shirts, J. W. Pitera, W. C. Swope and V. S. Pande, "Extremely precise free 
energy calculations of amino acid side chain analogs: Comparison of common 
molecular mechanics force fields for proteins", J. Chem. Phys., 2003, 119, 5740-
5761. 
176. R. Zhou, P. Das and A. K. Royyuru, "Single Mutation Induced H3N2 
Hemagglutinin Antibody Neutralization: A Free Energy Perturbation Study", J. 
Phys. Chem. B, 2008, 112, 15813-15820. 
177. P. Das, J. Li, A. K. Royyuru and R. Zhou, "Free energy simulations reveal a double 
mutant avian H5N1 virus hemagglutinin with altered receptor binding 
specificity", J. Comput. Chem., 2009, 30, 1654-1663. 
178. L. Wang, B. J. Berne and R. A. Friesner, "On achieving high accuracy and 
reliability in the calculation of relative protein–ligand binding affinities", Proc. 
Nat. Acad. Sci., 2012, 109, 1937-1942. 
  290 
179. D. Bucher, B. J. Grant and J. A. McCammon, "Induced Fit or Conformational 
Selection? The Role of the Semi-closed State in the Maltose Binding Protein", 
Biochemistry, 2011, 50, 10530-10539. 
180. F. R. Beierlein, G. G. Kneale and T. Clark, "Predicting the Effects of Basepair 
Mutations in DNA-Protein Complexes by Thermodynamic Integration", Biophys. 
J., 2011, 101, 1130-1138. 
181. J. D. Chodera, et al., "Alchemical free energy methods for drug discovery: 
progress and challenges", Curr. Op. Struct. Biol., 2011, 21, 150-160. 
182. J. Michel and J. Essex, "Prediction of protein–ligand binding affinity by free 
energy simulations: assumptions, pitfalls and expectations", J. Comput.-Aided 
Mol. Des., 2010, 24, 639-658. 
183. M. Zacharias, T. P. Straatsma and J. A. McCammon, "Separation-shifted scaling, a 
new scaling method for Lennard-Jones interactions in thermodynamic 
integration", J. Chem. Phys., 1994, 100, 9025-9031. 
184. T. C. Beutler, A. E. Mark, R. C. van Schaik, P. R. Gerber and W. F. van Gunsteren, 
"Avoiding singularities and numerical instabilities in free energy calculations 
based on molecular simulations", Chem. Phys. Lett., 1994, 222, 529-539. 
185. W. Jiang and B. Roux, "Free Energy Perturbation Hamiltonian Replica-Exchange 
Molecular Dynamics (FEP/H-REMD) for Absolute Ligand Binding Free Energy 
Calculations", J. Chem. Theo. Comput., 2010, 6, 2559-2565. 
186. M. Lawrenz, R. Baron and J. A. McCammon, "Independent-Trajectories 
Thermodynamic-Integration Free-Energy Changes for Biomolecular Systems: 
Determinants of H5N1 Avian Influenza Virus Neuraminidase Inhibition by 
Peramivir", J. Chem. Theo. Comput., 2009, 5, 1106-1116. 
187. M. Lawrenz, R. Baron, Y. Wang and J. A. McCammon, "Effects of Biomolecular 
Flexibility on Alchemical Calculations of Absolute Binding Free Energies", J. 
Chem. Theo. Comput., 2011, 7, 2224-2232. 
188. D. L. Mobley, J. D. Chodera and K. A. Dill, "Confine-and-Release Method: 
Obtaining Correct Binding Free Energies in the Presence of Protein 
Conformational Change", J. Chem. Theo. Comput., 2007, 3, 1231-1235. 
189. H. Paliwal and M. R. Shirts, "A Benchmark Test Set for Alchemical Free Energy 
Transformations and Its Use to Quantify Error in Common Free Energy 
Methods", J. Chem. Theo. Comput., 2011, 7, 4115-4134. 
190. J. Åqvist, C. Medina and J.-E. Samuelsson, "A new method for predicting binding 
affinity in computer-aided drug design", Prot. Eng., 1994, 7, 385-391. 
191. B. A. Tounge and C. H. Reynolds, "Calculation of the Binding Affinity of ß-
Secretase Inhibitors Using the Linear Interaction Energy Method", J. Med. Chem., 
2003, 46, 2074-2082. 
192. M. Almlöf, B. O. Brandsdal and J. Åqvist, "Binding affinity prediction with 
different force fields: Examination of the linear interaction energy method", J. 
Comput. Chem., 2004, 25, 1242-1254. 
193. W. Wang, J. Wang and P. A. Kollman, "What determines the van der Waals 
coefficient beta in the LIE (linear interaction energy) method to estimate binding 
free energies using molecular dynamics simulations?", Proteins, 1999, 34, 395-
402. 
  291 
194. M. Almlöf, J. Åqvist, A. O. Smalas and B. O. Brandsdal, "Probing the effect of point 
mutations at protein-protein interfaces with free energy calculations", Biophys. 
J., 2006, 90, 433-442. 
195. J. Marelius, T. Hansson and J. Åqvist, "Calculation of ligand binding free energies 
from molecular dynamics simulations", Int. J. Quantum Chemistry, 1998, 69, 77-
88. 
196. H. A. Carlson and W. L. Jorgensen, "An Extended Linear Response Method for 
Determining Free Energies of Hydration", J. Phys. Chem., 1995, 99, 10667-10673. 
197. M. Almlöf, J. Carlsson and J. Åqvist, "Improving the Accuracy of the Linear 
Interaction Energy Method for Solvation Free Energies", J. Chem. Theo. Comput., 
2007, 3, 2162-2175. 
198. N. Singh and A. Warshel, "Absolute binding free energy calculations: on the 
accuracy of computational scoring of protein-ligand interactions", Proteins, 
2010, 78, 1705-1723. 
199. J. Srinivasan, T. E. Cheatham, P. Cieplak, P. A. Kollman and D. A. Case, "Continuum 
Solvent Studies of the Stability of DNA, RNA, and Phosphoramidate-DNA 
Helices", J. Am. Chem. Soc., 1998, 120, 9401-9409. 
200. H. Gohlke and D. A. Case, "Converging free energy estimates: MM-PB(GB)SA 
studies on the protein-protein complex Ras-Raf", J. Comput. Chem., 2004, 25, 
238-250. 
201. J. M. J. Swanson, R. H. Henchman and J. A. McCammon, "Revisiting Free Energy 
Calculations: A Theoretical Connection to MM/PBSA and Direct Calculation of 
the Association Free Energy", Biophys. J., 2004, 86, 67-74. 
202. S.-R. Tzeng and C. G. Kalodimos, "Protein activity regulation by conformational 
entropy", Nature, 2012, 488, 236-240. 
203. J. M. Ward, N. M. Gorenstein, J. Tian, S. F. Martin and C. B. Post, "Constraining 
Binding Hot Spots: NMR and Molecular Dynamics Simulations Provide a 
Structural Explanation for Enthalpy-Entropy Compensation in SH2-Ligand 
Binding", J. Am. Chem. Soc., 2010, 132, 11058-11070. 
204. M. Karplus and J. N. Kushick, "Method for estimating the configurational entropy 
of macromolecules", Macromolecules, 1981, 14, 325-332. 
205. C.-E. Chang, W. Chen and M. K. Gilson, "Evaluating the Accuracy of the 
Quasiharmonic Approximation", J. Chem. Theo. Comput., 2005, 1, 1017-1028. 
206. R. Baron, P. H. Hunenberger and J. A. McCammon, "Absolute Single-Molecule 
Entropies from Quasi-Harmonic Analysis of Microsecond Molecular Dynamics: 
Correction Terms and Convergence Properties", J. Chem. Theo. Comput., 2009, 5, 
3150-3160. 
207. A. Weis, K. Katebzadeh, P. Söderhjelm, I. Nilsson and U. Ryde, "Ligand Affinities 
Predicted with the MM/PBSA Method: Dependence on the Simulation Method 
and the Force Field", J. Med. Chem., 2006, 49, 6596-6606. 
208. C. S. Page and P. A. Bates, "Can MM-PBSA calculations predict the specificities of 
protein kinase inhibitors?", J. Comput. Chem., 2006, 27, 1990-2007. 
209. B. Kuhn and P. A. Kollman, "Binding of a diverse set of ligands to avidin and 
streptavidin: An accurate quantitative prediction of their relative affinities by a 
combination of molecular mechanics and continuum solvent models", J. Med. 
Chem., 2000, 43, 3786-3791. 
  292 
210. J. Kongsted and U. Ryde, "An improved method to predict the entropy term with 
the MM/PBSA approach", J. Comput.-Aided Mol. Des., 2009, 23, 63-71. 
211. S. Genheden, O. Kuhn, P. Mikulskis, D. Hoffmann and U. Ryde, "The Normal-Mode 
Entropy in the MM/GBSA Method: Effect of System Truncation, Buffer Region, 
and Dielectric Constant", J. Chem. Info. Model., 2012, 52, 2079-2088. 
212. T. Hou, J. Wang, Y. Li and W. Wang, "Assessing the Performance of the MM/PBSA 
and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations 
Based on Molecular Dynamics Simulations", J. Chem. Info. Model., 2011, 51, 69-
82. 
213. D. L. Mobley and K. A. Dill, "Binding of Small-Molecule Ligands to Proteins: 
"What You See" Is Not Always "What You Get"", Structure, 2009, 17, 489-498. 
214. M. K. Gilson and H.-X. Zhou, "Calculation of Protein-Ligand Binding Affinities", 
Annu. Rev. Biophys. Biomol. Struct., 2007, 36, 21-42. 
215. D. A. Pearlman, "Evaluating the Molecular Mechanics Poisson-Boltzmann Surface 
Area Free Energy Method Using a Congeneric Series of Ligands to p38 MAP 
Kinase", J. Med. Chem., 2005, 48, 7796-7807. 
216. T. Yang, et al., "Virtual screening using molecular simulations", Proteins - Struct. 
Func. Bioinfo., 2011, 79, 1940-1951. 
217. C. R. W. Guimaraes and M. Cardozo, "MM-GB/SA Rescoring of Docking Poses in 
Structure-Based Lead Optimization", J. Chem. Info. Model., 2008, 48, 958-970. 
218. D. C. Thompson, C. Humblet and D. Joseph-McCarthy, "Investigation of MM-PBSA 
Rescoring of Docking Poses", J. Chem. Info. Model., 2008, 48, 1081-1091. 
219. T. Hou, J. Wang, Y. Li and W. Wang, "Assessing the performance of the molecular 
mechanics/Poisson Boltzmann surface area and molecular 
mechanics/generalized Born surface area methods. II. The accuracy of ranking 
poses generated from docking", J. Comput. Chem., 2011, 32, 866-877. 
220. S. Genheden and U. Ryde, "How to obtain statistically converged MM/GBSA 
results", J. Comput. Chem., 2009, 31, 837-846. 
221. I. Stoica, S. K. Sadiq and P. V. Coveney, "Rapid and Accurate Prediction of Binding 
Free Energies for Saquinavir-Bound HIV-1 Proteases", J. Am. Chem. Soc., 2008, 
130, 2639-2648. 
222. S. Z. Wan and P. V. Coveney, "Rapid and accurate ranking of binding affinities of 
epidermal growth factor receptor sequences with selected lung cancer drugs", J. 
R. Soc. Interface, 2011, 8, 1114-1127. 
223. S. K. Sadiq, D. W. Wright, O. A. Kenway and P. V. Coveney, "Accurate Ensemble 
Molecular Dynamics Binding Free Energy Ranking of Multidrug-Resistant HIV-1 
Proteases", J. Chem. Info. Model., 2010, 50, 890-905. 
224. A. Gutteridge and J. Thornton, "Conformational Changes Observed in Enzyme 
Crystal Structures upon Substrate Binding", J. Mol. Biol., 2005, 346, 21-28. 
225. K. A. Henzler-Wildman, et al., "Intrinsic motions along an enzymatic reaction 
trajectory", Nature, 2007, 450, 838-U813. 
226. E. Z. Eisenmesser, D. A. Bosco, M. Akke and D. Kern, "Enzyme dynamics during 
catalysis", Science, 2002, 295, 1520-1523. 
227. E. Z. Eisenmesser, et al., "Intrinsic dynamics of an enzyme underlies catalysis", 
Nature, 2005, 438, 117-121. 
  293 
228. D. L. Mobley, et al., "Predicting Absolute Ligand Binding Free Energies to a 
Simple Model Site", J. Mol. Biol., 2007, 371, 1118-1134. 
229. S. Genheden and U. Ryde, "A comparison of different initialization protocols to 
obtain statistically independent molecular dynamics simulations", J. Comput. 
Chem., 2011, 32, 187-195. 
230. L. Monticelli, E. J. Sorin, D. P. Tieleman, V. S. Pande and G. Colombo, "Molecular 
simulation of multistate peptide dynamics: A comparison between microsecond 
timescale sampling and multiple shorter trajectories", J. Comput. Chem., 2008, 
29, 1740-1752. 
231. D. G. Covell and A. Wallqvist, "Analysis of protein-protein interactions and the 
effects of amino acid mutations on their energetics. The importance of water 
molecules in the binding epitope", J. Mol. Biol., 1997, 269, 281-297. 
232. C. Barillari, J. Taylor, R. Viner and J. W. Essex, "Classification of Water Molecules 
in Protein Binding Sites", J. Am. Chem. Soc., 2007, 129, 2577-2587. 
233. Z. Li and T. Lazaridis, "Water at biomolecular binding interfaces", Phys. Chem. 
Chem. Phys., 2007, 9, 573-581. 
234. S. Wong, R. E. Amaro and J. A. McCammon, "MM-PBSA Captures Key Role of 
Intercalating Water Molecules at a Protein-Protein Interface", J. Chem. Theo. 
Comput., 2009, 5, 422-429. 
235. C. Combelles, J. Gracy, A. Heitz, D. J. Craik and L. Chiche, "Structure and folding of 
disulfide-rich miniproteins: Insights from molecular dynamics simulations and 
MM-PBSA free energy calculations", Proteins - Struct. Func. Bioinfo., 2008, 73, 87-
103. 
236. Q. Z. Cui, et al., "Molecular dynamics-solvated interaction energy studies of 
protein-protein interactions: The MP1-p14 scaffolding complex", J. Mol. Biol., 
2008, 379, 787-802. 
237. H. Gohlke, C. Kiel and D. A. Case, "Insights into Protein-Protein Binding by 
Binding Free Energy Calculation and Free Energy Decomposition for the Ras-Raf 
and Ras-RalGDS Complexes", J. Mol. Biol., 2003, 330, 891-913. 
238. R. T. Bradshaw, B. H. Patel, E. W. Tate, R. J. Leatherbarrow and I. R. Gould, 
"Comparing experimental and computational alanine scanning techniques for 
probing a prototypical protein-protein interaction", Prot. Eng. Des. Sel., 2011, 24, 
197-207. 
239. D. Bowman, "Differentiation of soybean antitryptic factors", P. Soc. Expt. Biol. 
Med., 1946, 63, 547-550. 
240. Y. Birk, A. Gertler and S. Khalef, "A pure Trypsin inhibitor from soybeans", 
Biochem. J., 1963, 87, 281-284. 
241. S. Norioka and T. Ikenaka, "Amino Acid Sequences of Trypsin-Chymotrypsin 
Inhibitors (A-I, A-II, B-I, and B-II) from Peanut (Arachis hypogaea)1: A 
Discussion on the Molecular Evolution of Legume Bowman-Birk Type 
Inhibitors", J. Biochem., 1983, 94, 589-598. 
242. J. D. McBride and R. J. Leatherbarrow, "Synthetic Peptide Mimics of the Bowman-
Birk Inhibitor Protein", Curr. Med. Chem., 2001, 8, 909-917. 
243. J. D. McBride, E. M. Watson, A. B. E. Brauer, A. M. Jaulent and R. J. Leatherbarrow, 
"Peptide mimics of the Bowman-Birk inhibitor reactive site loop", Biopolymers, 
2002, 66, 79-92. 
  294 
244. T. Gariani, J. D. McBride and R. J. Leatherbarrow, "The role of the P2' position of 
Bowman-Birk proteinase inhibitor in the inhibition of trypsin: Studies on P2' 
variation in cyclic peptides encompassing the reactive site loop", BBA-Prot. 
Struct. Mol. Enzymol., 1999, 1431, 232-237. 
245. A. B. E. Brauer and R. J. Leatherbarrow, "The conserved P1' Ser of Bowman-Birk-
type proteinase inhibitors is not essential for the integrity of the reactive site 
loop", Biochem. Biophys. Res. Comm., 2003, 308, 300-305. 
246. A. B. E. Brauer, M. Nievo, J. D. McBride and R. J. Leatherbarrow, "The structural 
basis of a conserved P2 threonine in canonical serine proteinase inhibitors", J. 
Biomol. Struct. Dynamics, 2003, 20, 645-655. 
247. R. F. Qi, Z. W. Song and C. W. Chi, "Structural features and molecular evolution of 
Bowman-Birk protease inhibitors and their potential application", Acta 
Biochimica Et Biophysica Sinica, 2005, 37, 283-292. 
248. S. Odani and T. Ono, "Chemical Substitutions of the Reactive Site Leucine Residue 
in Soybean Bowman-Birk Proteinase Inhibitor with Other Amino Acids", J. 
Biochem., 1980, 88, 1555-1558. 
249. J. D. McBride, H. N. M. Freeman and R. J. Leatherbarrow, "Selection of human 
elastase inhibitors from a conformationally-constrained combinatorial peptide 
library", Eur. J. Biochem., 1999, 266, 403-412. 
250. D. Scarpi, J. D. McBride and R. J. Leatherbarrow, "Inhibition of human beta-
tryptase by Bowman-Birk inhibitor derived peptides: creation of a new tri-
functional inhibitor", Bioorg. & Med. Chem., 2004, 12, 6045-6052. 
251. E. Zablotna, et al., "Design of serine proteinase inhibitors by combinatorial 
chemistry using trypsin inhibitor SFTI-1 as a starting structure", J. Pept. Sci., 
2007, 13, 749-755. 
252. J. R. Costa and S. N. Yaliraki, "Role of Rigidity on the Activity of Proteinase 
Inhibitors and Their Peptide Mimics", J. Phys. Chem. B, 2006, 110, 18981-18988. 
253. A. B. E. Brauer, G. J. Domingo, R. M. Cooke, S. J. Matthews and R. J. Leatherbarrow, 
"A Conserved cis Peptide Bond Is Necessary for the Activity of Bowman-Birk 
Inhibitor Protein", Biochemistry, 2002, 41, 10608-10615. 
254. B. H. Patel, R. J. Leatherbarrow and I. R. Gould, Imperial College London MSci 
report, 2008. 
255. I. Schechter and A. Berger, "On the size of the active site in proteases. I. Papain", 
Biochem. Biophys. Res. Comm., 1967, 27, 157-162. 
256. Y. Li, et al., "Studies on an Artificial Trypsin Inhibitor Peptide Derived from the 
Mung Bean Trypsin Inhibitor: Chemical Synthesis, Refolding, and 
Crystallographic Analysis of Its Complex with Trypsin", J. Biochem., 1994, 116, 
18-25. 
257. E. Krissinel and K. Henrick, "Inference of Macromolecular Assemblies from 
Crystalline State", J. Mol. Biol., 2007, 372, 774-797. 
258. E. Pettersen, et al., "UCSF Chimera - A visualization system for exploratory 
research and analysis", J. Comput. Chem., 2004, 25, 1605-1612. 
259. I. Massova and P. A. Kollman, "Computational Alanine Scanning To Probe 
Protein-Protein Interactions: A Novel Approach To Evaluate Binding Free 
Energies", J. Am. Chem. Soc., 1999, 121, 8133-8143. 
  295 
260. S. Huo, I. Massova and P. A. Kollman, "Computational alanine scanning of the 1 : 1 
human growth hormone-receptor complex", J. Comput. Chem., 2002, 23, 15-27. 
261. P. A. Kollman, et al., "Calculating structures and free energies of complex 
molecules: Combining molecular mechanics and continuum models", Acc. Chem. 
Res., 2000, 33, 889-897. 
262. D. A. Case, et al., AMBER 10, (2008) University of California, San Francisco. 
263. D. S. Cerutti, R. Duke, P. L. Freddolino, H. Fan and T. P. Lybrand, "A Vulnerability 
in Popular Molecular Dynamics Packages Concerning Langevin and Andersen 
Dynamics", J. Chem. Theo. Comput., 2008, 4, 1669-1680. 
264. R. T. Bradshaw, E. W. Tate, R. J. Leatherbarrow and I. R. Gould, Imperial College 
London MRes thesis, 2009. 
265. G. Rastelli, A. Del Rio, G. Degliesposti and M. Sgobba, "Fast and accurate 
predictions of binding free energies using MM-PBSA and MM-GBSA", J. Comput. 
Chem., 2009, 31, 797-810. 
266. B. Kuhn, P. Gerber, T. Schulz-Gasch and M. Stahl, "Validation and use of the MM-
PBSA approach for drug discovery", J. Med. Chem., 2005, 48, 4040-4048. 
267. I. S. Moreira, P. A. Fernandes and M. J. Ramos, "Computational alanine scanning 
mutagenesis - An improved methodological approach", J. Comput. Chem., 2007, 
28, 644-654. 
268. I. S. Moreira, P. A. Fernandes and M. J. Ramos, "Hot Spot Occlusion from Bulk 
Water:‚Äâ a Comprehensive Study of the Complex between the Lysozyme HEL 
and the Antibody FVD1.3", J. Phys. Chem. B, 2007, 111, 2697-2706. 
269. I. S. Moreira, P. A. Fernandes and M. J. Ramos, "Protein-protein recognition: a 
computational mutagenesis study of the MDM2-P53 complex", Theor. Chem. Acc., 
2008, 120, 533-542. 
270. V. M. Krishnamurthy, B. R. Bohall, V. Semetey and G. M. Whitesides, "The 
Paradoxical Thermodynamic Basis for the Interaction of Ethylene Glycol, 
Glycine, and Sarcosine Chains with Bovine Carbonic Anhydrase II:  An 
Unexpected Manifestation of Enthalpy/Entropy Compensation", J. Am. Chem. 
Soc., 2006, 128, 5802-5812. 
271. J. D. Chodera and D. L. Mobley, "Entropy-Enthalpy Compensation: Role and 
Ramifications in Biomolecular Ligand Recognition and Design", Annu. Rev. 
Biophys., 2012. 
272. R. T. Bradshaw, P. G. A. Aronica, E. W. Tate, R. J. Leatherbarrow and I. R. Gould, 
"Mutational Locally Enhanced Sampling (MULES) for quantitative prediction of 
the effects of mutations at protein-protein interfaces", Chem. Sci., 2012, 3, 1503-
1511. 
273. R. Elber and M. Karplus, "Enhanced sampling in molecular dynamics: use of the 
time-dependent Hartree approximation for a simulation of carbon monoxide 
diffusion through myoglobin", J. Am. Chem. Soc., 1990, 112, 9161-9175. 
274. A. Roitberg and R. Elber, "Modeling side-chains in peptides and proteins - 
application of the locally enhanced sampling and the simulated annealing 
methods to find minimum energy conformations", J. Chem. Phys., 1991, 95, 9277-
9287. 
275. C. Simmerling, J. L. Miller and P. A. Kollman, "Combined locally enhanced 
sampling and Particle Mesh Ewald as a strategy to locate the experimental 
structure of a nonhelical nucleic acid", J. Am. Chem. Soc., 1998, 120, 7149-7155. 
  296 
276. C. Simmerling, T. Fox and P. A. Kollman, "Use of Locally Enhanced Sampling in 
Free Energy Calculations: Testing and Application to the a - ß Anomerization of 
Glucose", J. Am. Chem. Soc., 1998, 120, 5771-5782. 
277. V. Hornak and C. Simmerling, "Generation of accurate protein loop 
conformations through low-barrier molecular dynamics", Proteins - Struct. Func. 
Genet., 2003, 51, 577-590. 
278. A. J. Scheidig, T. R. Hynes, L. A. Pelletier, J. A. Wells and A. A. Kossiakoff, "Crystal 
structures of bovine chymotrypsin and trypsin complexed to the inhibitor 
domain of alzheimer's amyloid β-protein precursor (APPI) and basic pancreatic 
trypsin inhibitor (BPTI): Engineering of inhibitors with altered specificities", 
Prot. Sci., 1997, 6, 1806-1824. 
279. J. P. Tam, C. R. Wu, W. Liu and J. W. Zhang, "Disulfide bond formation in peptides 
by dimethyl sulfoxide. Scope and applications", J. Am. Chem. Soc., 1991, 113, 
6657-6662. 
280. T. Chase Jr and E. Shaw, in Methods in Enzymology, eds. G. E. Perlmann and L. 
Lorand, Academic Press, New York, 1970, vol. 19, pp. 20-27. 
281. R. J. Leatherbarrow, GraFit Version 7, Erithacus Software Ltd., Horley, UK, 2010. 
282. B. Kuhn and P. A. Kollman, "A Ligand That Is Predicted to Bind Better to Avidin 
than Biotin: Insights from Computational Fluorine Scanning", J. Am. Chem. Soc., 
2000, 122, 3909-3916. 
283. P. Bonnet and R. A. Bryce, "Molecular dynamics and free energy analysis of 
neuraminidase–ligand interactions", Prot. Sci., 2004, 13, 946-957. 
284. P. Bonnet and R. A. Bryce, "Scoring binding affinity of multiple ligands using 
implicit solvent and a single molecular dynamics trajectory: Application to 
Influenza neuraminidase", J. Mol. Graph. Model., 2005, 24, 147-156. 
285. S. F. Chowdhury, et al., "Design of Noncovalent Inhibitors of Human Cathepsin L. 
From the 96-Residue Proregion to Optimized Tripeptides", J. Med. Chem., 2002, 
45, 5321-5329. 
286. J. Torras, et al., "Correlation between symmetry breaker position and the 
preferences of conformationally constrained homopeptides: A molecular 
dynamics investigation", Pept. Sci., 2008, 90, 695-706. 
287. Schrodinger, LLC, The PyMOL Molecular Graphics System, Version 1.3r1, (2010). 
288. I. S. Moreira, P. A. Fernandes and M. J. Ramos, "Unraveling the importance of 
protein-protein interaction: Application of a computational alanine-scanning 
mutagenesis to the study of the IgG1 streptococcal protein G (C2 fragment) 
complex", J. Phys. Chem. B, 2006, 110, 10962-10969. 
289. M. Heinig and D. Frishman, "STRIDE: a web server for secondary structure 
assignment from known atomic coordinates of proteins", Nucl. Acids Res., 2004, 
32, W500-W502. 
290. W. Kabsch and C. Sander, "Dictionary of protein secondary structure: Pattern 
recognition of hydrogen-bonded and geometrical features", Biopolymers, 1983, 
22, 2577-2637. 
291. R. P. Joosten, et al., "A series of PDB related databases for everyday needs", Nucl. 
Acids Res., 2011, 39, D411-D419. 
292. C. Chothia, "The nature of the accessible and buried surfaces in proteins", J. Mol. 
Biol., 1976, 105, 1-12. 
  297 
293. K. Ravindranathan, J. Tirado-Rives, W. L. Jorgensen and C. R. W. Guimaraes, 
"Improving MM-GB/SA Scoring through the Application of the Variable 
Dielectric Model", J. Chem. Theo. Comput., 2011, 7, 3859-3865. 
294. D. Seeliger and B. L. de Groot, "Protein Thermostability Calculations Using 
Alchemical Free Energy Simulations", Biophys. J., 2010, 98, 2309-2316. 
295. S. Bogusz, T. E. Cheatham III and B. R. Brooks, "Removal of pressure and free 
energy artifacts in charged periodic systems via net charge corrections to the 
Ewald potential", J. Chem. Phys., 1998, 108, 7070-7084. 
296. B. R. Morgan and F. Massi, "Accurate Estimates of Free Energy Changes in Charge 
Mutations", J. Chem. Theo. Comput., 2010, 6, 1884-1893. 
297. R. Anandakrishnan, B. Aguilar and A. V. Onufriev, "H++ 3.0: automating pK 
prediction and the preparation of biomolecular structures for atomistic 
molecular modeling and simulations", Nucl. Acids Res., 2012, 40, W537-W541. 
298. M. Baaden, M. Burgard and G. Wipff, "TBP at the Water-Oil Interface: The Effect 
of TBP Concentration and Water Acidity Investigated by Molecular Dynamics 
Simulations", J. Phys. Chem. B, 2001, 105, 11131-11141. 
299. N. London, B. Raveh, E. Cohen, G. Fathi and O. Schueler-Furman, "Rosetta 
FlexPepDock web server - high resolution modeling of peptide-protein 
interactions", Nucl. Acids Res., 2011, 39, W249-W253. 
300. C. Simmerling, B. Strockbine and A. E. Roitberg, "All-Atom Structure Prediction 
and Folding Simulations of a Stable Protein", J. Am. Chem. Soc., 2002, 124, 11258-
11259. 
301. J. L. Miller and P. A. Kollman, "Theoretical Studies of an Exceptionally Stable RNA 
Tetraloop: Observation of Convergence from an Incorrect NMR Structure to the 
Correct One Using Unrestrained Molecular Dynamics", J. Mol. Biol., 1997, 270, 
436-450. 
302. D. J. Williams and K. B. Hall, "Unrestrained Stochastic Dynamics Simulations of 
the UUCG Tetraloop Using an Implicit Solvation Model", Biophys. J., 1999, 76, 
3192-3205. 
303. X. Cheng, V. Hornak and C. Simmerling, "Improved Conformational Sampling 
through an Efficient Combination of Mean-Field Simulation Approaches", J. Phys. 
Chem. B, 2004, 108, 426-437. 
304. M. D. Brazas, D. Yim, W. Yeung and B. F. F. Ouellette, "A decade of web server 
updates at the bioinformatics links directory: 2003-2012", Nucl. Acids Res., 2012, 
40, W3-W12. 
305. I. H. Moal and J. Fernández-Recio, "SKEMPI: a Structural Kinetic and Energetic 
database of Mutant Protein Interactions and its use in empirical models", 
Bioinformatics, 2012, 28, 2600-2607. 
306. P. L. Kastritis, et al., "A structure-based benchmark for protein–protein binding 
affinity", Prot. Sci., 2011, 20, 482-491. 
307. J. Schymkowitz, et al., "The FoldX web server: an online force field", Nucl. Acids 
Res., 2005, 33, W382-W388. 
308. R. Guerois, J. E. Nielsen and L. Serrano, "Predicting Changes in the Stability of 
Proteins and Protein Complexes: A Study of More Than 1000 Mutations", J. Mol. 
Biol., 2002, 320, 369-387. 
  298 
309. M. A. Martí-Renom, et al., "Comparative protein structure modeling of genes and 
genomes", Annu. Rev. Biophys. Biomol. Struct., 2000, 29, 291-325. 
310. N. Eswar, et al., in Current Protocols in Bioinformatics, John Wiley & Sons, Inc., 
2006. 
311. D. J. Diller, C. Humblet, X. Zhang and L. M. Westerhoff, "Computational alanine 
scanning with linear scaling semiempirical quantum mechanical methods", 
Proteins - Struct. Func. Bioinfo., 2010, 78, 2329-2337. 
312. T. Clackson, M. H. Ultsch, J. A. Wells and A. M. de Vos, "Structural and functional 
analysis of the 1:1 growth hormone:receptor complex reveals the molecular 
basis for receptor affinity", J. Mol. Biol., 1998, 277, 1111-1128. 
313. B. C. Cunningham and J. A. Wells, "Comparison of a Structural and a Functional 
Epitope", J. Mol. Biol., 1993, 234, 554-563. 
314. A. M. Buckle, G. Schreiber and A. R. Fersht, "Protein-protein recognition: Crystal 
structural analysis of a barnase-barstar complex at 2.0-Å resolution", 
Biochemistry, 1994, 33, 8878-8889. 
315. G. Schreiber and A. R. Fersht, "Energetics of protein-protein interactions: 
Analysis of the Barnase-Barstar interface by single mutations and double mutant 
cycles", J. Mol. Biol., 1995, 248, 478-486. 
316. L. Mosyak, et al., "The bacterial cell-division protein ZipA and its interaction with 
an FtsZ fragment revealed by X-ray crystallography", EMBO J, 2000, 19, 3179-
3191. 
317. S. Sogabe, et al., "Neutralizing epitopes on the extracellular interferon y-receptor 
(IFNyR) a-chain characterized by homolog scanning mutagenesis and X-ray 
crystal structure of the A6 Fab-IFNyR1-108 complex", J. Mol. Biol., 1997, 273, 
882-897. 
318. S. Lang, et al., "Analysis of Antibody A6 Binding to the Extracellular Interferon y-
Receptor a-Chain by Alanine-Scanning Mutagenesis and Random Mutagenesis 
with Phage Display", Biochemistry, 2000, 39, 15674-15685. 
319. K. Hofstädter, F. Stuart, L. Jiang, J. W. Vrijbloed and J. A. Robinson, "On the 
importance of being aromatic at an antibody-protein antigen interface: 
mutagenesis of the extracellular interferon [gamma] receptor and recognition by 
the neutralizing antibody A6", J. Mol. Biol., 1999, 285, 805-815. 
320. T. N. Bhat, et al., "Bound water molecules and conformational stabilization help 
mediate an antigen-antibody association", Proc. Nat. Acad. Sci., 1994, 91, 1089-
1093. 
321. W. Dall'Acqua, E. R. Goldman, E. Eisenstein and R. A. Mariuzza, "A Mutational 
Analysis of the Binding of Two Different Proteins to the Same Antibody", 
Biochemistry, 1996, 35, 9667-9676. 
322. W. Dall'Acqua, et al., "A Mutational Analysis of Binding Interactions in an 
Antigen-Antibody Protein-Protein Complex", Biochemistry, 1998, 37, 7981-7991. 
323. R. E. Hawkins, S. J. Russell, M. Baier and G. Winter, "The Contribution of Contact 
and Non-contact Residues of Antibody in the Affinity of Binding to Antigen: The 
Interaction of Mutant D1.3 Antibodies with Lysozyme", J. Mol. Biol., 1993, 234, 
958-964. 
324. UniProtKB/TrEMBL Release Statistics, 
http://www.ebi.ac.uk/uniprot/TrEMBLstats/, accessed on 1st Dec 2012 
  299 
325. R. Chen, J. Mintseris, J. Janin and Z. Weng, "A protein–protein docking 
benchmark", Proteins - Struct. Func. Bioinfo., 2003, 52, 88-91. 
326. J. Mintseris, et al., "Protein–protein docking benchmark 2.0: An update", Proteins 
- Struct. Func. Bioinfo., 2005, 60, 214-216. 
327. Y. Urakubo, T. Ikura and N. Ito, "Crystal structural analysis of protein–protein 
interactions drastically destabilized by a single mutation", Prot. Sci., 2008, 17, 
1055-1065. 
328. G. Schreiber, C. Frisch and A. R. Fersht, "The role of glu73 of barnase in catalysis 
and the binding of barstar", J. Mol. Biol., 1997, 270, 111-122. 
329. C. A. Guyer, D. G. Morgan and J. V. Staros, "Binding specificity of the periplasmic 
oligopeptide-binding protein from Escherichia coli", J. Bacteriology, 1986, 168, 
775-779. 
330. Tame, et al., "The structural basis of sequence-independent peptide binding by 
OppA protein", Science, 1994, 264, 1578-1581. 
331. M. M. Klepsch, et al., "Escherichia coli Peptide Binding Protein OppA Has a 
Preference for Positively Charged Peptides", J. Mol. Biol., 2011, 414, 75-85. 
332. F. Tian, L. Yang, F. Lv, X. Luo and Y. Pan, "Why OppA protein can bind sequence-
independent peptides? A combination of QM/MM, PB/SA, and structure-based 
QSAR analyses", Amino Acids, 2011, 40, 493-503. 
333. D. J. Huggins and B. Tidor, "Systematic placement of structural water molecules 
for improved scoring of protein–ligand interactions", Prot. Eng. Des. Sel., 2011, 
24, 777-789. 
334. G. A. Ross, G. M. Morris and P. C. Biggin, "Rapid and Accurate Prediction and 
Scoring of Water Molecules in Protein Binding Sites", PLoS ONE, 2012, 7, e32036. 
335. S. H. Sleigh, P. R. Seavers, A. J. Wilkinson, J. E. Ladbury and J. R. H. Tame, 
"Crystallographic and Calorimetric Analysis of Peptide Binding to OppA Protein", 
J. Mol. Biol., 1999, 291, 393-415. 
336. Y. Liu and B. Kuhlman, "RosettaDesign server for protein design", Nucl. Acids 
Res., 2006, 34, W235-W238. 
337. S. E. Murdock, et al., "Quality Assurance for Biomolecular Simulations", J. Chem. 
Theo. Comput., 2006, 2, 1477-1481. 
338. D. E. Smith and L. X. Dang, "Computer simulations of NaCl association in 
polarizable water", J. Chem. Phys., 1994, 100, 3757-3766. 
339. R. W. Pastor, B. R. Brooks and A. Szabo, "An analysis of the accuracy of Langevin 
and Molecular Dynamics algorithms", Mol. Phys., 1988, 65, 1409-1419. 
340. R. J. Loncharich, B. R. Brooks and R. W. Pastor, "Langevin dynamics of peptides - 
The frictional dependence of isomerisation rates of N-acetylalanyl-N'-
methylamide", Biopolymers, 1992, 32, 523-535. 
341. J. A. Izaguirre, D. P. Catarello, J. M. Wozniak and R. D. Skeel, "Langevin 
stabilization of molecular dynamics", J. Chem. Phys., 2001, 114, 2090-2098. 
342. H. J. C. Berendsen, J. P. M. Postma, W. F. van Gunsteren, A. DiNola and J. R. Haak, 
"Molecular dynamics with coupling to an external bath", J. Chem. Phys., 1984, 81, 
3684-3690. 
  300 
343. J. P. Ryckaert, G. Ciccotti and H. J. C. Berendsen, "Numerical integration of 
Cartesian equations of motion of a system with constraints - Molecular 
Dynamics of N-alkanes", J. Comput. Phys., 1977, 23, 327-341. 
344. A. Bondi, "van der Waals Volumes and Radii", J. Phys. Chem., 1964, 68, 441-451. 
345. M. L. Connolly, "Analytical Molecular Surface Calculation", J. App. Crystallogr., 
1983, 16, 548 - 558. 
346. D. A. Case, et al., AMBER 11, (2010) University of California, San Francisco. 
347. J. Åqvist, "Ion-water interaction potentials derived from free energy 
perturbation simulations", J. Phys. Chem., 1990, 94, 8021-8024. 
 
 
